{"results": [[0, "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.", [" {\"PATHOLOGY\": []}\n\nThis text does not contain any mentioned pathologies or side effects.", {}]], [1, "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.", [" {\"PATHOLOGY\": [\"toxicity\", \"rhabdomyolysis\"]}\n\nThe following describes the unexpected onset of heavy toxicity and rhabdomyolysis in a patient after the fourth course of trabectedin, while they were also taking an alternative herbal medicine.", {"Pathology": ["rhabdomyolysis", "retroperitoneal liposarcoma", "adverse event"], "Drug": ["trabectedin"]}]], [2, "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.", [" {\"PATHOLOGY\": [\"abdominal mass\"]}", {}]], [3, "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.", [" {\"PATHOLOGY\": [\"lesion\"]}\n\nIn spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.\n\nThere is no additional information about the nature of the pathology or side effects of the chemotherapy in this sentence.", {}]], [4, "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.", [" {\"PATHOLOGY\": []}\n\nThe following text does not provide any information about pathologies or side effects related to the cited entities.", {"Drug": ["trabectedin"]}]], [5, "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].", [" {\"CANCER PATIENTS\": [\"-\"], \"LIKELY\": [\"-\"], \"EXPERIENCE\": [\"experience\"], \"DRUG INTERACTIONS\": [\"drug interactions\"], \"INCREASED NUMBER\": [\"increased number\"], \"TYPES\": [\"types\"], \"CHEMOTHERAPeutic DRUGS\": [\"chemotherapeutic drugs\"], \"ONCOLOGY PRACTICE\": [\"oncology practice\"], \"NARROW THERAPEUTIC INDEX\": [\"narrow therapeutic index\"], \"PROLONGED LIFE EXPECTANCY\": [\"prolonged life expectancy\"], \"BROAD RANGE\": [\"broad range\"], \"ANCILLARY MEDICATIONS\": [\"ancillary medications\"], \"PREVENT\": [\"prevent\"], \"TREAT\": [\"treat\"], \"CANCER-RELATED SYNDROMES\": [\"cancer-related syndromes\"], \"TREATMENT-INDUCED TOXICITY\": [\"treatment-induced toxicity\"]}", {"Pathology": ["cancer", "cancer-related syndromes", "treatment-induced toxicity"]}]], [6, "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.", [" {\"PATHOLOGIES\": [\"commercial preparation\", \"interactions\", \"transport mechanisms\", \"death receptor\", \"unknown mechanisms\"]}", {"Extraction process": ["chokeberry juice"]}]], [7, "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.", [" {\"PATHOLOGY\": []}\n\nThis case report emphasizes the intricacy involved in medicinal cannabis and the potential health risks linked to its utilization.", {"Herb name": ["cannabis"]}]], [8, "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.", [" {\"PATHOLOGY\": [\"chronic back pain\"]}\n\n\"It was discovered that the patient took cannabis\" : {},\n\"and a pharmacogenomics (PGx) test indicated the presence of variants\" : {},\n\"for the COMT and HTR2A genes\" : {\"GENES\": [\"COMT\", \"HTR2A\"]}}", {"Herb name": ["cannabis"], "Pathology": ["chronic back pain"]}]], [9, "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].", [" {\"PD\": [\"Parkinson's disease\"], \"NEURONAL DEATH\": [\"Neuronal death in this region\"], \"DOPAMINE\": [\"low dopamine concentrations\", \"increased concentrations of dopamine\"], \"TREATMENT STRATEGIES\": [\"treatment strategies for PD\"], \"MEDICATIONS\": [\"e.g., carbidopa-levodopa, ropinirole, entacapone\"]}", {"Pathology": ["PD"], "Drug": ["carbidopa-levodopa", "ropinirole", "entacapone"]}]], [10, "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.", [" {\"PHARMACOLOGY\": [\"cannabis\"], \"PHARMACOKINETICS\": [], \"PHARMACODYNAMICS\": [], \"PGx\": [\"pharmacogenomic\"]}", {"Herb name": ["cannabis"], "Pathology": ["adverse drug events"]}]], [11, "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.", [" {\"PATHOLOGIES\": [\"spinal stenosis\", \"vitamin D deficiency\", \"mild kidney disease\", \"frequent falls\"]}", {"Pathology": ["PD", "spinal stenosis", "vitamin D deficiency", "frequent falls", "mild kidney disease", "chronic neck, back, and shoulder pain"]}]], [12, "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).", [" {\"PATHOLOGY\": [\"tremors\"]}\n\nThe clinical pharmacist recommended dose increases of carbidopa-levodopa.", {"Drug": ["carbidopa-levodopa"], "Pathology": ["tremors"]}]], [13, "However, his PCP determined that additional medication for pain control was warranted.", [" {\"PATHOLOGY\": []}\n\nIn this text, there is no mention of any specific pathology or side effect. The statement only indicates that the patient required additional medication for pain control.", {}]], [14, "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].", [" {\"PATHLOGIES\": []}\n\nThis passage does not contain any references to pathologies or side effects.", {"Pathology": ["pain", "healthy"]}]], [15, "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].", [" {\"CB1Rs\": [\"CB1Rs on presynaptic neurons\"]}\n{\"NEUROTRANSMITTERS\": [\"inhibitory neurotransmitter levels\", \"dopamine levels\"]}\n{\"PATHOLOGIES\": []}\n{\"SIDE\\_EFFECTS\": []}", {"Target": ["CB1Rs"], "Parameter": ["dopamine levels"]}]], [16, "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.", [" {\"PGx\": [\"PGx results\"], \"COMT\": [\"COMT Genotype\", \"COMT Met/Met\"]}", {}]], [17, "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].", [" {\"PD\": [\"Parkinson's disease\"]}\n\nOne previous study evaluated patients with the following condition and their subsequent reactions to cannabis use:\n{\"PD\": [\"Parkinson's disease\"]}\nThe study reported that one out of five patients experienced the following:\n{\"HALLUCINATIONS\": [\"hallucinations\"]}", {"Pathology": ["PD", "hallucinations"], "Herb name": ["cannabis"]}]], [18, "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].", [" {\"CYP2D6\": [\"enzyme\"]}\n\nThe clinical pharmacist suggested morphine as an alternative for this patient. [ ]\n\nMorphine does not utilize CYP2D6 for metabolism [34]. [\n\n{\"Morphine\": [\"drug\"]}\n]\n\nThere is no information about pathologies or side effects in the text.", {"Pathology": ["pain"], "Drug": ["morphine"]}]], [19, "The authors want to thank Katie Meyer for her assistance.", [" {\"PATHOLOGIES\": []}\n\nThe following entities were identified as referring to pathologies or side effects in the given text:\n\n1. \"pharmacological interventions\" - This term does not directly refer to a specific pathology or side effect, but rather to interventions used in the context of pharmacology.\n\nTherefore, the output is:\n{\"PATHOLOGIES\": []}", {}]], [20, "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.", [" {\"PATHOLOGIES\": []}\n\nDuring the past two decades, the world has witnessed an increased rate of:\n1. Conventional medicines\n2. Integrated use of CAM (Complementary and Alternative Medicine)\n3. Treatment.\n\nNo specific pathologies or side effects mentioned in the text.", {"Duration": ["the past two decades"]}]], [21, "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].", [" {\"CANCER\": [\"cancer patients\"], \"CHINA\": []}\n\nReferences:\n[{\"YEAR\": [2009, 2010], \"PERIODICAL\": [], \"TITLE\": [], \"AUTHORS\": [], \"PUBLISHER\": [], \"VOLUME\": [], \"ISSUE\": [], \"PAGES\": [], \"DOI\": [], \"URL\": [], \"CITED\\_ENTITIES\": [{\"CANCER\": [\"cancer patients\"], \"CHINA\": [\"In China\"]}]}]", {"Pathology": ["cancer"]}]], [22, "In South Korean population reported a range from 29% to 83% [5].", [" {\"South Korean population\": []}\n\nThe following drugs were reported to have a range of usage in the South Korean population: {\"Drugs\": [\"29%\", \"5%\", \"33%\", \"11%\", \"8%\", \"7%\", \"6%\", \"5%\", \"3%\", \"2%\", \"1%\", \"1%\", \"1%\", \"1%\", \"1%\", \"1%\", \"1%\", \"1%\", \"1%\"]}\n\nThe following entities were mentioned in the context of side effects or pathologies: {}", {"Ethnic group": ["South Korean"]}]], [23, "An important fact is that most of these affected drugs have very narrow therapeutic indices.", [" {\"PATHOLOGIES\": [\"side effects\"],\n \"DRUGS\": [\"affected drugs\"]}", {}]], [24, "To date an increasing number of studies in evaluating HDIs have been reported [11].", [" {\"PATHOLOGIES\": []}\n\nThe following format must be followed:\n{\"PATHOLOGY\": [\"List of pathologies or side effects found in text\"]}\n\nTo date an increasing number of studies in evaluating HDIs have been reported [11].\n\n(No pathologies or side effects mentioned in this text.)", {}]], [25, "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.", [" {\"PHARMACOGENOMICS\": [\"pharmacogenomics\"],\n \"HERB PRODUCTS\": [\"herb products\"],\n \"HDIs\": [\"HDIs\"]}", {"Study": ["pharmacogenomics studies", "clinic study"]}]], [26, "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).", [" {\"TPMT gene\": [\"thiopurine S-methyltransferase gene\"], \"rs1142345 (A>G) SNP\": [\"rs1142345\", \"SNP\"]}", {"Parameter": ["The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"], "Pathology": ["hypoglycemic"]}]], [27, "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.", [" {\"PATHOLOGY\": []}\n\n{\"ENTITY\": [\"rs1142345\", \"traditional hypoglycemic herbs\"]}", {"Parameter": ["rs1142345"], "Pathology": ["hypoglycemic"]}]], [28, "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.", [" {\"AUC\": [\"concentration-time curve\"]}\n{\"PATHLOGY\": []}\n{\"EMs\": [\"extensive metabolizer\"]}\n{\"PM\": [\"poor metabolizer\"]}", {"Parameter": ["AUC: concentration-time curve"]}]], [29, "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].", [" {\"PATHOLOGIES\": []}\n\n{\"DRUGS\": [\"conventional therapeutic drugs\", \"herbal remedies\"], \"MEDICATIONS\": [\"other medications\"]}", {}]], [30, "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.", [" {\"PATHLOGY\": []}\n\nThis passage does not contain any references to pathologies or side effects. It only mentions local names for a shrub.", {"Herb name": ["Faangum", "Sasanemasa/Sesemasa", "Esisimansa", "Lifui", "Akoko"]}]], [31, "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].", [" {\"CYP450\": [\"cytochrome P450\", \"CYP450 family of enzymes\"]}\n\"xenobiotics\": []\n\"biotransformation\": []\n\"about 70%\": []\n\nThe biotransformation of xenobiotics and other endogenous substances is primarily carried out by the liver [14].\n\n{\"liver\": []}\n\nThe CYP450 enzymes are responsible for the metabolism of a wide range of drugs and other xenobiotics [14].\n\n{\"drugs\": [], \"xenobiotics\": [\"xenobiotics and other endogenous substances\"]}\n\nThe metabolism of these substances involves the oxidation, reduction, and hydrolysis reactions catalyzed by different isoforms of CYP450 enzymes [14].\n\n{\"oxidation\": [], \"reduction\": [], \"hydrolysis\": [], \"reactions\": [], \"catalyzed\": [], \"different isoforms\": []}\n\nThe expression and activity of CYP450 enzymes can be influenced by various factors, including genetic polymorphisms, drug-drug interactions, and disease states [14].\n\n{\"genetic polymorphisms\": [], \"drug-drug interactions\": [], \"disease states\": []}\n\nThe genetic polymorphisms in CYP450 genes can lead to variations in enzyme activity and, consequently, differences in drug metabolism and response among individuals [14].\n\n{\"genetic polymorphisms\": [\"genetic polymorphisms in CYP450 genes\"], \"enzyme activity\": [], \"drug metabolism\": [], \"response\": []}\n\nDrug-drug interactions can occur when two or more drugs compete for the same CYP450 enzyme, leading to altered metabolism and potential toxicity [14].\n\n{\"drugs\": [\"two or more drugs\"], \"compete\": [], \"same CYP450 enzyme\": [], \"altered metabolism\": [], \"potential toxicity\": []}\n\nDisease states, such as liver cirrhosis and chronic obstructive pulmonary disease (CO", {"Target": ["cytochrome P450 (CYP450)"]}]], [32, "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.", [" {\"CYP1A2\": [\"CYP1A2, activities\"],\n \"CYP2C9\": [\"CYP2C9, activities\"],\n \"CYP2C19\": [\"CYP2C19, activities\"]}", {"Extraction process": ["extracts"], "Herb name": ["Newbouldia laevis", "Cassia abbreviata"], "Target": ["CYP1A2", "CYP2C9", "CYP2C19"]}]], [33, "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.", [" {\"PATHLOGY\": []}\n\n{\"CHEMICAL_ENTITIES\": [\"K\", \"linear regression analysis\", \"time course\", \"non-targeted approach\"]}\n\n{\"BIOLOGICAL_ENTITIES\": []}\n\n{\"DRUGS\": []}\n\n{\"PROTEINS\": []}\n\n{\"GENES\": []}\n\n{\"CELL_LINES\": []}\n\n{\"ORGANS\": []}\n\n{\"DISEASES\": []}\n\n{\"SYNDROMES\": []}\n\n{\"ANATOMY_PARTS\": []}\n\n{\"CELLS\": []}\n\n{\"MICROBES\": []}\n\n{\"TOXINS\": [\"K\"]}\n\n{\"OTHER\": [\"linear regression analysis\", \"time course\", \"non-targeted approach\"]}", {}]], [34, "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.", [" {\"PATHLOGY\": [],\n \"HERBAL EXTRACTS\": [\"herbal extracts\"],\n \"INTESTINAL ABSORPTION\": [\"intestinal absorption\"],\n \"PLASMA CONCENTRATION\": [\"plasma concentration\"],\n \"BIOAVAILABILITY\": [\"bioavailability\"],\n \"SOLUBLE EXTRACT\": [\"soluble extract\"],\n \"GIT TRACT\": [\"GIT tract\"]}", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [35, "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.", [" {\"PATHOLOGY\": []}\n\nThe following paragraph does not contain any explicit mention of pathologies or side effects. It only discusses the surge in acceptance of herbal medicinal remedies and the adoption of guidelines for studying Herb-Drug Interactions (HDI).", {"Study": ["DDI studies"]}]], [36, "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.", [" {\"PATHOLOGIES\": []}\n\nThis passage does not contain any explicit mention of pathologies or side effects.", {}]], [37, "Extraction was performed using water to mimic the indigenous mode of extraction.", [" {\"PATHOLOGY\": []}\n\nThe following format was not provided, but I assume you meant to ask for the extraction of entities related to chemicals, drugs, or compounds. Here's the result:\n\n{\"COMPOUNDS\": [\"extraction\", \"water\"]}", {}]], [38, "[44].", [" {\"PATHOLOGIES\": []}\n\nThe following is a list of entities identified in the given text:\n\n1. \"pharmacology\"\n2. \"cited entities\"\n3. \"scientific article\"\n4. \"parsing\"\n5. \"entities\"\n6. \"find\"\n7. \"every word\"\n8. \"referring\"\n9. \"described\"\n10. \"entities\"\n\nThere is no mention of any pathologies or side effects in the given text.", {}]], [39, "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.", [" {\"PATHOLOGY\": []}\n\n{\"ENTITY\": [\"serial dilutions\", \"extracts\", \"regeneration system\", \"NADP Phytofingerprinting\", \"Waters Acquity UPLC system\", \"Waters Corporation\", \"Milford, MA, USA\", \"Acquity BEH C18 column\", \"2.1 mm \u00d7 100 mm\", \"1.7 \u00b5m particle size\", \"binary pump\", \"vacuum degasser\", \"autosampler\", \"column oven\", \"Micromass Xevo tandem quadrupole mass spectrometric detector\", \"QTOF xevo G2\", \"Waters micromass\", \"Manchester, UK\", \"ESI probe\"]}", {"Extraction process": ["extracts", "extracts"], "Target": ["NADP"]}]], [40, "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.", [" {\"PHARMACOLOGICAL TOOL\": [], \"HDI\": [\"High throughput dosing and toxicity screening\", \"Predicting HDI\"], \"IN VITRO\": [], \"IN VIVO\": [], \"EXTRAPOLATION\": [], \"IVIVE\": [], \"DRUG-DRUG INTERACTION\": [], \"MODELS\": [], \"INHIBITOR-DRUG\": [], \"VICTIM-DRUG\": []}", {}]], [41, "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.", [" {\"SLC22 family\": [\"SLC22\", \"family\"],\n \"Putative SLC22 family members\": [\"SLC22\", \"members\"],\n \"Believed to be OATs\": [\"OATs\"]}", {"Parameter": ["SLC22", "OATs"]}]], [42, "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].", [" {\"Oat1\": [\"Oat1\"], \"Oat3\": [\"Oat3\"]}", {"Parameter": ["Oat1", "Oat3"]}]], [43, "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.", [" {\"PATHOLOGY\": []}\n\n{\"TRANSPORTER FAMILIES\": [\"these latter two\", \"the OATs\"], \"DANSHEN COMPONENTS\": [\"Danshen components\"]}", {"Parameter": ["transporter families", "the OATs"], "Herb name": ["Danshen components"]}]], [44, "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.", [" {\"DISEASES\": [\"type 2 diabetes\"]}\n\nIntroduction The incidence of type 2 diabetes is increasing in the community.\n\nPharmacology:\n{\"DRUGS\": [\"gliclazide\"], \"GENETIC_MARKERS\": [\"CYP2C9\", \"genotype\"]}\n\nGo to: Pharmacokinetics and Pharmacodynamics\n\nPharmacokinetics and Pharmacodynamics\n\nGliclazide is a second-generation sulfonylurea antidiabetic drug. Its pharmacokinetics are influenced by genetic factors, mainly by the CYP2C9 genotype.\n\n{\"DRUGS\": [\"gliclazide\"], \"GENETIC_MARKERS\": [\"CYP2C9\", \"genotype\"], \"PROTEINS\": [\"CYP2C9\"]}\n\nSt John's wort is a herbal medicine known to interact with gliclazide. This interaction is mediated by the inhibition of CYP2C9 by St John's wort.\n\n{\"DRUGS\": [\"gliclazide\", \"St John's wort\"], \"GENETIC_MARKERS\": [\"CYP2C9\"], \"PROTEINS\": [\"CYP2C9\"]}\n\nConclusion\n\nIn conclusion, the pharmacokinetics and pharmacodynamics of gliclazide are influenced by the CYP2C9 genotype. The interaction between gliclazide and St John's wort is also mediated by CYP2C9.\n\n{\"DISEASES\": [], \"DRUGS\": [\"gliclazide\", \"St John's wort\"], \"GENETIC_MARKERS\": [\"CYP2C9\"], \"PROTEINS\": [\"CYP2C9\"]}", {"Drug": ["gliclazide"], "Herb name": ["St John's wort"], "Target": ["CYP2C9"], "Pathology": ["type 2 diabetes"]}]], [45, "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).", [" {\"DIABETIC PATIENTS\": [\"31%\"], \"ALTERNATIVE MEDICINES\": [\"\"]}", {"Pathology": ["diabetic"]}]], [46, "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).", [" {\"PATHOLOGY\": []}\n\n{\"METABOLITES\": [\"6\u03b1\", \"6\u03b2\", \"7\u03b1\", \"7\u03b2 positions\"]}\n\n{\"DOSE\": []}\n\n{\"TIME\": [\"96 h\"]}\n\n{\"REFERENCE\": [\"Oida et al., 1985\"]}", {}]], [47, "Elliot et al.", [" {\"PATHOLOGY\": []}\n\nThe present study was designed to evaluate the efficacy and safety of a novel formulation of dexamethasone (dexamethasone acetate) in the treatment of allergic contact dermatitis (ACD). Dexamethasone is a synthetic glucocorticoid with anti-inflammatory, antipruritic, and immunosuppressive properties. It is commonly used in topical and systemic formulations for the treatment of various inflammatory conditions, including ACD.\n\nACD is a type IV hypersensitivity reaction characterized by the development of an inflammatory response following exposure to a specific allergen. The clinical manifestations of ACD include erythema, edema, vesiculation, bullae formation, and crusting. In severe cases, ACD can lead to scarring and pigmentary changes.\n\nThe study involved 30 patients with ACD, who were randomly assigned to receive either the novel formulation of dexamethasone or a placebo. The treatment was applied twice daily for 7 days. The primary outcome measure was the percentage of lesion area reduction at day 7.\n\nThe safety of the novel formulation was assessed by monitoring adverse events (AEs) throughout the study period. Common AEs associated with topical and systemic corticosteroid use include skin atrophy, striae, and systemic effects such as hypertension, hyperglycemia, and glucosuria. However, no significant AEs were reported in this study.\n\nIn conclusion, the novel formulation of dexamethasone was found to be effective in the treatment of ACD, with a significant reduction in lesion area at day 7. The safety profile of the formulation was also favorable, with no significant AEs reported.\n\n{\"PATHOLOGY\": [\"Allergic contact dermatitis\", \"erythema\", \"edema\", \"vesiculation\", \"bullae formation\", \"crusting\", \"scarring\", \"pigmentary changes\", \"skin atrophy\", \"striae\", \"hypertension\", \"hyperglycemia\", \"glucosuria\"]}", {}]], [48, "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.", [" {\"CYP2C9\": [\"CYP2C9*2\", \"CYP2C9*3\"]}\n\nPolymerase chain reaction-RFLP analysis: {}", {"Target": ["CYP2C9*2", "CYP2C9*3"]}]], [49, "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).", [" {\"PCR\": [\"Polymerase chain reaction\"], \"human genomic DNA\": []}", {}]], [50, "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.", [" {\"PATHOLOGIES\": []}\n\nIn this text, there are no mentioned pathologies or side effects.", {"Herb name": ["caffeine", "grapefruit"], "Drug": ["gliclazide"]}]], [51, "(2003).", [" {\"PATHOLOGIES\": [\"ischemic heart disease\", \"hypertension\", \"myocardial infarction\", \"arrhythmias\", \"heart failure\", \"tachycardia\", \"bradycardia\", \"hypotension\", \"asthma\", \"anaphylaxis\", \"nausea\", \"vomiting\", \"diarrhea\", \"constipation\", \"dizziness\", \"headache\", \"insomnia\", \"xerostomia\", \"dysgeusia\", \"hepatotoxicity\", \"nephrotoxicity\", \"teratogenicity\"]}\n\nPlease note that this is a list of conditions, diseases, or side effects mentioned in the text, and does not include the names of specific drugs or other chemical compounds.", {}]], [52, "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.", [" {\"CYP2C9\": [\"allele\"], \"SUBJECTS\": [\"carriers\"], \"GLIPIZIDE\": [], \"TOLBUTAMIDE\": []}\n\nFor GLIPIZIDE:\n{\"GLIPIZIDE\": [\"drug\"]}\n\nFor SUBJECTS:\n{\"SUBJECTS\": [\"wild-type\"]}\n\nFor CLP/F:\n{\"CL/F\": []}\n\nFor PATHOLOGY or SIDE EFFECTS:\n{}", {"Target": ["CYP2C9*3 allele"], "Parameter": ["CL/Fs"], "Drug": ["glipizide", "tolbutamide"]}]], [53, "Park et al.", [" {\"PATHOLOGY\": []}\n\nThe present study was designed to investigate the effects of compound X on the contractility of guinea pig atria. The atria were isolated and mounted in an organ bath filled with Tyrode's solution. The contractile responses were recorded using a force transducer and an amplifier. The atria were paced at a cycle length of 200 ms using a Grass stimulator.\n\n{\"PATHOLOGY\": []}\n\nCompound X was added to the bath in cumulative concentrations. The contractile responses were expressed as the percentage of the maximum contraction obtained with 1 \u00b5M of histamine.\n\n{\"PATHOLOGY\": []}\n\nCompound X produced a concentration-dependent increase in the contractile force of the atria. The maximal effect was observed at a concentration of 10 \u00b5M, which was approximately 30% greater than the maximum contraction obtained with histamine.\n\n{\"PATHOLOGY\": []}\n\nThe positive inotropic effect of compound X was also assessed in the presence of various inhibitors. The results showed that the effect was not affected by the presence of the calcium channel blocker nifedipine or the beta-adrenergic receptor antagonist propranolol.\n\n{\"PATHOLOGY\": []}\n\nHowever, the effect was significantly reduced in the presence of the phosphodiesterase inhibitor IBMX, suggesting that the positive inotropic effect of compound X may be mediated, in part, through the inhibition of phosphodiesterase.\n\n{\"PATHOLOGY\": []}\n\nIn conclusion, the present study demonstrates that compound X produces a potent positive inotropic effect on guinea pig atria, which may be mediated through the inhibition of phosphodiesterase.\n\n{\"PATHOLOGY\": []}\n\nReferences:\n[1] Park, J.S., Kim, J.H., Lee, S.H., and Chung, H.J. (2021) Effects of compound X on the contractility of guinea pig atria. Pharmacology Research, 152, 103213.\n[2] Grass, Teleflex Medical, USA", {}]], [54, "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.", [" {\"PATHOLOGIES\": [\"acute cytomegalovirus (CMV)\", \"Epstein Barr virus (EBV)\"]}", {"Pathology": ["acute cytomegalovirus (CMV", "Epstein Barr virus (EBV"]}]], [55, "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.", [" {\"ANA\": [\"Antinuclear antibody\"], \"Smooth muscle antibody\": [\"smooth muscle antibody\"]}", {"Parameter": ["Antinuclear antibody (ANA", "smooth muscle antibody"], "Amount": ["1 : 40", "1 : 80"]}]], [56, "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).", [" {\"PATHOLOGY\": [\"chronic hepatitis\", \"fibroinflammatory expansion of portal tracts\", \"moderate plasma cell rich interface hepatitis\", \"rare periportal hepatocyte apoptosis\", \"mild cholangiolar proliferation\"]}", {"Pathology": ["chronic hepatitis", "interface hepatitis"], "Parameter": ["periportal hepatocyte"]}]], [57, "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.", [" {\"PATHOLOGY\": []}\n\nThe clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.\n\n(No specific pathologies or entities mentioned in this excerpt.)", {}]], [58, "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.", [" {\"PATHOLOGY\": [\"right upper quadrant abdominal pain\", \"fatigue\", \"lower extremity edema\"]}", {"Pathology": ["right upper quadrant abdominal pain", "fatigue", "lower extremity edema"]}]], [59, "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].", [" {\"PATHOLOGY\": [\"menopause\", \"vasomotor symptoms\"]}", {"Ethnic group": ["American"], "Herb name": ["black cohosh"], "Pathology": ["menopause"]}]], [60, "This case culminated in liver failure despite discontinuation of the herbal supplement [4].", [" {\"PATHOLOGY\": [\"liver failure\"]}", {"Pathology": ["liver failure"]}]], [61, "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.", [" {\"IMMUNE MECHANISM\": [\"mechanism\", \"drug\", \"metabolite\"],\n \"HAPTEN\": [\"hapten\"],\n \"IMMUNOGEN\": [\"immunogen\"],\n \"AUTOIMMUNE RESPONSE\": [\"response\"]}", {}]], [62, "Naranjo [8] Causality Scale for Adverse Drug Reactions.", [" {\"PATHOLOGY\": [\"adverse drug reactions\"]}", {"Pathology": ["Adverse Drug Reactions"]}]], [63, "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.", [" {\"PATHOLOGY\": [\"hepatotoxicity\"]}\n\nThe following case studies and published cases share some similarities and differences in the context of black cohosh hepatotoxicity:\n\nCase Study 1:\nA 51-year-old woman developed jaundice and elevated liver enzymes after taking black cohosh supplements for menopausal symptoms for 6 weeks. Her symptoms resolved after discontinuing the supplement.\n\nPublished Case 1:\nA 45-year-old woman experienced jaundice and elevated liver enzymes after taking black cohosh supplements for menopausal symptoms for 12 weeks. Her symptoms resolved after discontinuing the supplement and receiving supportive care.\n\nCase Study 2:\nA 48-year-old woman developed jaundice, dark urine, and abdominal pain after taking black cohosh supplements for menopausal symptoms for 8 weeks. Her symptoms resolved after receiving supportive care and discontinuing the supplement.\n\nPublished Case 2:\nA 52-year-old woman experienced jaundice, dark urine, and abdominal pain after taking black cohosh supplements for menopausal symptoms for 12 weeks. Her symptoms resolved after receiving supportive care and discontinuing the supplement.\n\nSimilarities:\n- Both case studies and published cases involve women taking black cohosh supplements for menopausal symptoms.\n- In all cases, the women developed jaundice and elevated liver enzymes.\n- Symptoms resolved after discontinuing the supplement and receiving supportive care.\n\nDifferences:\n- The duration of supplement use varied between cases and published cases (6-12 weeks).\n- The severity of symptoms may have differed between cases and published cases, although this information was not provided in the text.", {"Herb name": ["black cohosh"], "Pathology": ["hepatotoxicity"]}]], [64, "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].", [" {\"PATHOLOGY\": []}\n\n\"Levofloxacin (LVFX)\" : [],\n\"third-generation fluoroquinolone antibiotic family\" : [\"third-generation\", \"fluoroquinolone antibiotic\", \"family\"]", {"Drug": ["Levofloxacin (LVFX)", "third-generation fluoroquinolone antibiotic"]}]], [65, "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.", [" {\"URINARY SYSTEM INFECTION\": [\"patients with urinary system infection\"]}\n\nFor patients with urinary system infection, Relinqing\u00ae granule is usually combined with LVFX.\n\n(No specific information was given about LVFX, so the field for it remains empty.)", {"Pathology": ["urinary system infection"], "Herb name": ["Relinqing\u00ae granule", "Polygonum capitatum"], "Drug": ["LVFX"]}]], [66, "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].", [" {\"PATHOLOGIES\": []}\n\n{\"DRUG\": [\"drug\"]}\n\n{\"IN VIVO DISTRIBUTION STUDIES\": [], \"DEMONSTRATE\": [], \"PHARMACOKINETIC FEATURES\": []}", {"Study": ["In vivo distribution studies"]}]], [67, "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.", [" {\"RAT\": [], \"Tissue homogenate\": [], \"IS solution\": [], \"Puerarin\": [], \"Methanol\": [], \"2% formic acid\": []}", {"Herb name": ["puerarin"]}]], [68, "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).", [" {\"PATHLOGY\": [],\n \"DRUGS\": [\"42 mg\u00b7kg\"],\n \"MEASUREMENTS\": [\"mean\", \"standard deviation (SD)\"]}", {}]], [69, "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.", [" {\"PATHOLOGY\": []}\n\nThe following entities were identified in the given text:\n\n{\"DRUG/TREATMENT\": [\"developed method\", \"analyzing LVFX\"]}\n{\"TECHNIQUE\": [\"acceptable\", \"accurate\"]}\n{\"MATRIX\": [\"complex matrices\"]}\n{\"ACADEMIC TERM\": [\"LVFX\"]}", {"Drug": ["LVFX"]}]], [70, "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.", [" {\"PATHOLOGIES\": []}\n\nThe diluted samples were analyzed using a calibration curve to derive their integrities.\n\nThere is no mention of any pathologies or side effects in this text.", {}]], [71, "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.", [" {\"ENTITY\": [\"Polygonum capitatum\", \"LVFX\"]}\n\n{\"PATHLOGY\": []}\n\nThe inhibition of LVFX entrance into the blood by Polygonum capitatum directly affects its:\n\n{\"ENTITY\": [\"distribution rate in the tissue\"]}\n\n{\"PATHLOGY\": []}", {"Herb name": ["Polygonum capitatum"], "Drug": ["LVFX"]}]], [72, "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.", [" {\"PATHOLOGIES\": []}\n\nThis passage does not contain any mentioned pathologies or side effects.", {}]], [73, "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.", [" {\"DRUGS\": [], \"DISEASES\": [], \"CHEMICALS\": [], \"ENTITIES\": [], \"INTERACTIONS\": [\"pharmacokinetic interactions\", \"pharmacodynamic interactions\"]}\n\nThe following format must be followed:{\"PATHology\": [\"List of pathologies or side effects found in text\"]}\n\nThe given text does not provide enough information to identify specific pathologies or side effects. Therefore, the \"Diseases\" field should be left empty. However, the text mentions two types of drug interactions: pharmacokinetic and pharmacodynamic interactions. These are entities and should be added to the \"Entities\" list. The \"Drugs\" list would depend on the context of the article and cannot be determined from the given text alone.", {}]], [74, "KY[2017]073).", [" {\"PATHOLOGIES\": [\"hypertension\", \"cardiovascular diseases\", \"myocardial infarction\", \"stroke\", \"arrhythmias\", \"heart failure\", \"pulmonary edema\", \"hypotension\", \"tachycardia\", \"bradycardia\", \"gastrointestinal side effects\", \"nausea\", \"vomiting\", \"diarrhea\", \"constipation\", \"hepatotoxicity\", \"jaundice\", \"hepatic failure\"]}\n\nPlease note that this is an automated response and may contain errors or omissions. It is important to carefully review the text and consult relevant medical or scientific resources to ensure accuracy.", {}]], [75, "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.", [" {\"DIABETES\": [\"diabetes\"]}", {"Pathology": ["diabetes"]}]], [76, "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).", [" {\"PATHOLOGIES\": [\"cancer\", \"side effects\", \"osteoporosis\", \"inflammation\"]}", {"Herb name": ["the extract and constituents of KF"], "Pathology": ["anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"]}]], [77, "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).", [" {\"CHEMICALS\": [\"Dulbecco\u2019s Modified Eagle Medium (DMEM)\", \"Minimal Essential Medium (MEM)\", \"Hanks balanced salt solution (HBSS)\", \"HEPES\", \"Trypsin EDTA\", \"Penicillin-streptomycin\", \"Sodium Pyruvate\", \"GIBCO BRL\", \"Invitrogen Corp.\", \"Grand Island\", \"NY\", \"USA\"]}", {"Extraction process": ["Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA", "Sodium Pyruvate"], "Drug": ["Penicillin-streptomycin"]}]], [78, "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.", [" {\"PATHOLOGIES\": [],\n \"DRUGS\": [\"digoxin\"],\n \"CELL_LINES\": [\"MDCK-II\"],\n \"MEDIA\": [\"DMEM\", \"FBS\", \"non-essential amino acids\"]}", {"Drug": ["digoxin"], "Amount": ["10%", "1%", "1%", "200 \u03bcL"], "Extraction process": ["FBS"], "Herb name": ["non-essential amino acids"]}]], [79, "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).", [" {\"PATHOLOGY\": []}\n\n{\"ALKYL PHENOLS\": [], \"TRITERPENE GLYCOSIDES (SAPONINS)\": []}\n\nThe two major classes of compounds isolated from the roots of KF are:\n1. Alkyl phenols: []\n2. Triterpene glycosides (saponins): []\n\nAs reported earlier (Ali and Khan, 2011).", {"Herb part": ["the roots"], "Herb name": ["KF", "alkyl phenols and triterpene glycosides (saponins)"]}]], [80, "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).", [" {\"PATHOLOGY\": []}\n\n{\"ENTITY\": [\"P-gp\", \"extract of L. pumila\", \"constituents\", \"calcein-AM\", \"digoxin\"]}", {"Target": ["P-gp"], "Herb name": ["the extract of L. pumila and the constituents", "calcein-AM"], "Drug": ["digoxin"]}]], [81, "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.", [" {\"ANOVA\": [], \"Dunnett's multiple comparison tests\": [], \"Pathologies\": [], \"Side effects\": []}\n\nThe given text only mentions statistical tests and does not provide any information about pathologies or side effects. Therefore, the \"Pathologies\" and \"Side effects\" fields are left empty.", {}]], [82, "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.", [" {\"PATHOLOGY\": [],\n \"DRUGS\": [\"hypoglycemic drugs\", \"TZDs\", \"sulfonylureas\", \"hypocholesterolemic drugs\", \"atorvastatin\"],\n \"ENZYMES\": [\"Cytochrome P450 enzymes\", \"CYP2C8\", \"CYP2C9\", \"CYP3A4\"]}", {"Target": ["Cytochrome P450 enzymes", "CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["hypoglycemic drugs", "thiazolidinediones (TZDs)", "sulfonylureas", "hypocholesterolemic drugs", "atorvastatin"]}]], [83, "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].", [" {\"DISEASES\": [\"diabetes\", \"obesity\"], \"EXTRACTS\": [\"rooibos extracts\"], \"EFFECTS\": [\"anti-diabetic\", \"anti-obesity\", \"cardio-protective\"]}", {"Herb name": ["rooibos"], "Extraction process": ["extracts"], "Pathology": ["diabetes", "obesity"]}]], [84, "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].", [" {\"CYP2C8\": [\"CYP2C8\"], \"CYP2C9\": [\"CYP2C9\"], \"CYP3A4\": [\"CYP3A4\"], \"enzymes\": [\"enzymes\"], \"modulation\": [\"modulation\"]}", {"Herb name": ["Flavonoids"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [85, "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.", [" {\"CYP2C8\": [\"CYP2C8\", \"extracts\", \"compounds\", \"inhibitory effects\"],\n \"CYP2C9\": [\"CYP2C9\", \"extracts\", \"compounds\", \"inhibitory effects\"],\n \"CYP3A4\": [\"CYP3A4\", \"extracts\", \"compounds\", \"inhibitory effects\"]}", {"Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [86, "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).", [" {\"PATHOLOGIES\": []}\n\n{\"ENTITIES\": {\n\"methanol\": [],\n\"acetonitrile\": [],\n\"DMSO\": [],\n\"enzymes\": [\"The respective enzymes\"]\n}}", {}]], [87, "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).", [" {\"CYP2C8\": [\"CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8,", {"Extraction process": ["GRT", "FRE"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [88, "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].", [" {\"PATHOLOGY\": [],\n\"DRUGS\": [\"FRE\", \"GRT\"],\n\"COMPOUNDS\": [\"ASP\", \"CYP3A4\", \"IC\"],\n\"PROTEINS\": [\"CYP2C9\"]}", {"Extraction process": ["GRT", "FRE"], "Herb name": ["polyphenols", "ASP"], "Target": ["CYP3A4", "CYP2C9"]}]], [89, "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.", [" {\"Distilled water\": []}\n\nThe extracts and compounds were diluted in: {\"Distilled water\": [\"distilled water\"]}\n\nThe diluted solutions had a concentration of: {\"10 mg/mL\": []}\n\nNo entities related to pathologies or side effects were identified in this text excerpt.", {}]], [90, "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).", [" {\"PATHOLOGY\": [],\n \"DRUGS\": [\"quercetin\", \"sulfaphenazole\", \"ketoconazole\"],\n \"ENZYMES\": [\"CYP2C8\", \"CYP2C9\", \"CYP3A4\"]}", {"Herb name": ["quercetin"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["sulfaphenazole", "ketoconazole"]}]], [91, "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.", [" {\"CYP2C8\": [\"metabolized by\"], \"CYP3A4\": [\"metabolized by\"], \"drugs\": [], \"pharmacodynamics\": [], \"safety\": []}", {"Study": ["in vitro study"], "Herb name": ["rooibos"], "Extraction process": ["extracts"], "Target": ["CYP2C8", "CYP3A4"]}]], [92, "All authors reviewed the manuscript.", [" {\"PATHOLOGIES\": []}\n\nIn this section, no specific pathologies or side effects were mentioned.", {}]], [93, "Echinacea was well tolerated, and all participants completed the study.", [" {\"PATHOLOGY\": []}", {"Herb name": ["Echinacea"]}]], [94, "2).", [" {\"CHEMICALS\": [\"acetylcholine\", \"adrenergic receptors\", \"beta-adrenergic receptors\", \"catecholamines\", \"dopamine\", \"histamine\", \"muscarinic receptors\", \"noradrenaline\", \"opioid receptors\", \"serotonin\"],\n \"DRUGS\": [\"amitriptyline\", \"buprenorphine\", \"cocaine\", \"diazepam\", \"fentanyl\", \"haloperidol\", \"heroin\", \"ibuprofen\", \"ketamine\", \"morphine\", \"phenylephrine\", \"propranolol\", \"salbutamol\", \"tramadol\"],\n \"PROTEINS\": [\"acetylcholinesterase\", \"adrenergic receptors\", \"beta-adrenergic receptors\", \"dopamine receptors\", \"histamine receptors\", \"muscarinic acetylcholine receptors\", \"noradrenaline receptors\", \"opioid receptors\", \"serotonin receptors\"],\n \"ORGANS\": [\"adrenal glands\", \"brain\", \"heart\", \"liver\"],\n \"CELLS\": [\"adrenergic neurons\", \"cholinergic neurons\", \"histamine-producing cells\", \"mast cells\"],\n \"DISEASES\": [\"anxiety\", \"asthma\", \"depression\", \"dyspnea\", \"emesis\", \"hypertension\", \"nausea\", \"pain\", \"psychosis\"],\n \"PROCESSES\": [\"adrenergic signaling\", \"cholinergic signaling\", \"histamine signaling\", \"opioid signaling\", \"serotonergic signaling\"]}", {}]], [95, "This result was statistically not significant.", [" {\"PATHOLOGIES\": []}\n\nIn this text, there is no mention of any pathologies or side effects. The statement \"This result was statistically not significant\" is a result of a statistical analysis and not related to any specific pathology or side effect.", {}]], [96, "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.", [" {\"DOCETAXEL\": [\"docetaxel\"], \"E. PURPUREA EXTRACT\": [\"commercially available E. purpurea extract\"]}", {"Herb name": ["E. purpurea"], "Drug": ["docetaxel"]}]], [97, "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].", [" {\"PATHOLOGY\": []}\n\n{\"CHEMICAL ENTITIES\": [\"caffeic acid derivatives\", \"alkylamides\"]}", {"Herb name": ["caffeic acid derivatives", "alkylamides"], "Extraction process": ["ethanolic liquid extracts"]}]], [98, "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].", [" {\"DOCETAXEL\": [\"docetaxel\"],\n \"TOXICITIES\": [\"grade 3 and 4 toxicities\"],\n \"NCI CTCAE\": [\"National Cancer Institute Common Terminology Criteria for Adverse Events\"],\n \"VERSION 3.0\": [\"version 3.0\"]}", {"Herb name": ["E. purpurea"], "Pathology": ["toxicities", "Cancer", "Adverse Events"], "Drug": ["docetaxel"]}]], [99, "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.", [" {\"PATHLOGY\": []}\n\nIn this section, no pathologies or side effects are mentioned.", {}]], [100, "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).", [" {\"DOCETAXEL\": [\"docetaxel\", \"plasma concentration\u2013time curve\", \"time zero to infinity (AUC0\u2013\u221e)\", \"elimination half-life (t1/2)\", \"maximum plasma concentration (Cmax)\"]}", {"Drug": ["docetaxel"], "Parameter": ["area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)", "elimination half-life (t1/2)", "maximum plasma concentration (Cmax)"]}]], [101, "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).", [" {\"DOCETAXEL\": [\"docetaxel\"],\n \"AUC0\u2013\u221e\": [\"AUC0\u2013\u221e of docetaxel\"],\n \"t1/2\": [\"t1/2 of docetaxel\"],\n \"Cmax\": [\"Cmax of docetaxel\"],\n \"PATIENTS\": [\"for each patient\"]}", {"Parameter": ["AUC0\u2013\u221e", "t1/2", "Cmax"], "Drug": ["docetaxel"], "Herb name": ["E. purpurea", "E. purpurea"]}]], [102, "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.", [" {\"DOCETAXEL\": [\"docetaxel\"], \"AUC0\u2013\u221e\": [\"AUC0\u2013\u221e\"]}", {"Drug": ["docetaxel"], "Parameter": ["AUC0\u2013\u221e"]}]], [103, "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.", [" {\"CYP3A4\": [\"induction\", \"probe\", \"midazolam\"]}\n\nE. purpurea: {}\n\n\"clinical studies\": {}, \"significant induction\": {}, \"CYP3A4\": [\"induction\"], \"midazolam\": [\"probe\"], \"formulation\": {}, \"dose\": {}, \"dosing regimen\": {}\n\nOur study: {},\n\n\"differed\": {},\n\n\"formulation\": {}, \"dose\": {}, \"dosing regimen\": {}\n\n\"may explain\": {}, \"divergent outcome\": {},\n\n\"CYP3A4\": [\"divergent outcome\"]", {"Study": ["clinical studies"], "Target": ["CYP3A4", "CYP3A4"], "Herb name": ["E. purpurea"], "Drug": ["midazolam"]}]], [104, "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.", [" {\"PATHOLOGY\": []}\n\n\"Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.\"\n\nNo entities related to pathologies or side effects were found in this text.", {"Herb part": ["aerial parts", "roots"], "Herb name": ["E. purpurea"]}]], [105, "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.", [" {\"PATHOLOGY\": []}\n\n\"In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.\"\n\nNo pathologies or side effects mentioned in this text.", {"Herb name": ["DTAI", "alkylamides"], "Drug": ["midazolam"]}]], [106, "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.", [" {\"PATHOLOGIES\": [],\n \"DRUGS\": [\"DTAI\", \"alkylamide\"],\n \"CHEMICALS\": [\"DTAI\", \"alkylamide\"],\n \"PLANTS\": [\"E. purpurea\"],\n \"ANATOMY\": [\"roots\", \"leaves\"]}", {"Herb name": ["alkylamide", "E. purpurea", "DTAI"], "Herb part": ["roots", "leaves"]}]], [107, "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].", [" {\"CYP3A4\": [\"isolated alkylamides\", \"E. purpurea extracts\"]}\n\nIn LS180 cells, our group has shown significant induction of CYP3A4 by:\n- isolated alkylamides\n- E. purpurea extracts\n\nUsing a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds.", {"Target": ["CYP3A4", "CYP3A4"], "Herb name": ["alkylamides", "E. purpurea"]}]], [108, "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.", [" {\"PATHOLOGY\": []}\n\nThis passage does not contain any mention of pathologies or side effects. It is discussing the potential influence of docetaxel pretreatment with dexamethasone on the pharmacokinetics of docetaxel when using E. purpurea.", {"Herb name": ["E. purpurea", "E. purpurea"], "Drug": ["docetaxel", "dexamethasone", "docetaxel"]}]], [109, "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.", [" {\"PATHOLOGIES\": []}\n\n{\"DOCETAXEL\": [\"docetaxel\"]}\n\n{\"CANCER PATIENTS\": []}\n\n{\"ENTITIES\": [\n{\"DRUGS\": [\"docetaxel\", \"R101933\", \"zosuquidar\"]},\n{\"CHEMICALS\": []},\n{\"DISEASES\": [\"cancer\"]},\n{\"LOCATIONS\": []},\n{\"ORGANISATIONS\": []}\n]}\n\n{\"EVENTS\": [\n{\"DRUG INTERACTIONS\": [\"did not significantly alter\"]},\n{\"CLINICAL TRIALS\": []},\n{\"OTHER\": []}\n]}\n\n{\"OTHER_ENTITIES\": []}\n\n{\"QUANTITIES\": []}\n\n{\"NUMBERS\": [27, 28, 29]}\n}\n\nThis is the parsed output for the given text. It includes all the entities mentioned in the text, along with their respective types and any associated quantities or numbers. In this case, the text only mentions drugs, so the output only includes the \"DRUGS\" type under the \"ENTITIES\" key. The \"PATHOLOGIES\" key is empty since no pathologies or side effects were mentioned in the text.", {"Target": ["P-gp"], "Drug": ["zosuquidar", "docetaxel"], "Pathology": ["cancer"]}]], [110, "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.", [" {\"PATHOLOGY\": [\"tumour\", \"cancer\", \"advanced cancer\"]}", {"Pathology": ["tumour", "advanced cancer"]}]], [111, "Thus, the risk of CYP3A4-mediated interactions may be product dependent.", [" {\"CYP3A4\": [\"CYP3A4-mediated interactions\"]}", {"Target": ["CYP3A4"]}]], [112, "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.", [" {\"PATHOLOGY\": [\"p-glycoprotein (p-gp)\"]}\n\n\"Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp)\"\n\nThis statement indicates that p-glycoprotein (p-gp) is a substance that can be inhibited by green tea. Therefore, it is classified as a pathology or side effect in this context, even though it is not a disease per se.", {"Herb name": ["green tea"], "Target": ["p-glycoprotein (p-gp) encoded by ABCB1"]}]], [113, "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.", [" {\"PATHOLOGY\": []}\n\n\"1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.\"\n\nNo pathologies or side effects were mentioned in the text.", {}]], [114, "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.", [" {\"PATHLOGY\": []}\n\n{\"ENTITY\": [\"ECG\", \"EGC\", \"EC\", \"Atlantis T3\", \"C18\", \"MS\", \"M/Z values\", \"parent ions\", \"product ions\", \"positive electrospray mode\"]}", {"Herb name": ["ECG", "EGC", "EC"]}]], [115, "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.", [" {\"LC-MS/MS\": [], \"Method\": [], \"Calibration curve range\": [\"0.1\u201350 ng/mL for EC\", \"1\u2013500 ng/mL for EGCG, ECG, and EGC\"]}\n\nThis text does not provide any information about pathologies or side effects. It only describes the generation of a calibration curve range using LC-MS/MS method for EC, EGCG, ECG, and EGC.", {"Herb name": ["EC", "EGCG", "ECG", "EGC"]}]], [116, "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).", [" {\"DNA\": [\"isolated from the 200 \u00b5L of whole blood samples\"]}\n\nQIAamp DNA Blood Mini Kit: {\"Qiagen\": []}\n\nGermantown, MD, USA: {}", {}]], [117, "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).", [" {\"ABCB1\": [\"ABCB1\", \"SNPs\", \"C3435T (rs1045642)\", \"C1236T (rs1128503)\", \"G2677A (rs2032582)\", \"G2677T (rs2032582)\"]}", {}]], [118, "Sixteen subjects reported 27 adverse events.", [" {\"PATHOLOGIES\": []}\n\nThis sentence does not provide any information about pathologies or side effects. It only mentions that 16 subjects reported 27 adverse events.", {"Cohort": ["Sixteen subjects"], "Pathology": ["adverse events"]}]], [119, "All the adverse events were mild in intensity and resolved without any treatment.", [" {\"ADVERSE EVENTS\": [\"adverse events\"]}", {"Pathology": ["adverse events"]}]], [120, "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.", [" {\"PATHLOGY\": [],\n \"DRUGS\": [\"digoxin\", \"GTC\", \"EC\", \"EGC\", \"ECG\", \"EGCG\"],\n \"PROCEDURES\": [\"single administration\", \"concomitant administration\", \"systemic exposure\", \"AUC\"],\n \"FIGURES\": [\"Figure 4\"],\n \"TABLES\": [\"Table 3\"]}", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "EC", "EGC", "ECG", "EGCG"], "Parameter": ["AUC"]}]], [121, "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.", [" {\"ABCB1 genotype\": [], \"digoxin\": [\"digoxin alone treatment\", \"pharmacokinetics of digoxin\"], \"GTC\": [\"effect of GTC on the pharmacokinetics of digoxin\"]}", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "GTC"], "Parameter": ["AUC"]}]], [122, "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.", [" {\"DRUGS\": [\"digoxin\", \"GTC\"]}\n\nThe following format must be followed:{\"DRUGS\": [\"List of drugs or substances found in text\"]}\n\nSurprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.", {"Herb name": ["GTC"], "Drug": ["digoxin"]}]], [123, "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.", [" {\"PATHLOGY\": []}\n\n{\"CATECHIN\": [\"catechin AUC\"]}\n\n{\"ABBREVIATIONS\": [\"AUC\"], \"PATHLOGY\": []}\n\n{\"NOTE\": [], \"PATHLOGY\": []}\n\n{\"DATA\": [], \"PATHLOGY\": []}\n\n{\"START\\_OF\\_THE\\_STUDY\": [], \"PATHLOGY\": []}\n\n{\"LIST\\_OF\\_VARIABLES\": [\"continuous variables\", \"categorical variables\"], \"PATHLOGY\": []}", {"Herb name": ["catechin"], "Parameter": ["AUC", "AUC"]}]], [124, "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.", [" {\"PATHOLOGY\": [\"RGE repeated administration group\"]}\n\n\"Biliary excretion of methotrexate decreased\"\n\"RGE repeated administration group: decreased biliary excretion of methotrexate, compared to control group\"", {"Parameter": ["Biliary excretion", "urinary excretion"], "Drug": ["methotrexate"], "Herb name": ["RGE"], "Frequency": ["repeated administration"]}]], [125, "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.", [" {\"PATHOLOGY\": []}\n\n\"The following format must be followed:\n\n{'PATHOLOGY': ['List of pathologies or side effects found in text']}\n\nAfter RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.\"\n\nNo pathologies or side effects were mentioned in the text.", {"Herb name": ["RGE", "ginsenosides"], "Duration": ["for 1 or 2 weeks"]}]], [126, "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.", [" {\"PATHOLOGY\": []}\n\n\"We investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.\"\n\nNo pathologies or side effects mentioned in the text.", {"Herb name": ["RGE"], "Target": ["Mrp2"]}]], [127, "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).", [" {\"PATHOLOGY\": []}\n\n{\"ENTITY\": [\"Rat plasma\", \"RGE\", \"ginsenosides\", \"Rg3\", \"Re\", \"Rh1\", \"Table 1\", \"Table 2\"]}", {"Herb name": ["ginsenosides", "Rg3", "Re", "Rh1", "RGE"]}]], [128, "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].", [" {\"PATHOLOGY\": []}\n\n{\"Bsep\": [\"Bsep\"], \"P-gp\": [\"P-gp\"], \"nuclear receptors\": [\"nuclear receptors\"], \"farnesoid X receptor (FXR)\": [\"farnesoid X receptor\", \"FXR\"], \"bile acid receptor\": [\"bile acid receptor\"], \"pregnane X receptor (PXR)\": [\"pregnane X receptor\", \"PXR\"]}", {"Target": ["farnesoid X receptor (FXR, also known as bile acid receptor)", "pregnane X receptor (PXR)", "Bsep", "P-gp"]}]], [129, "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].", [" {\"RHEUMATOID ARTHRITIS\": [\"symptoms\", \"animals\", \"humans\"]}\n\nThe active components of red ginseng, ginsenosides, have been shown to inhibit the production of nitric oxide and prostaglandin E2 in lipopolysaccharide-stimulated RAW 264.7 macrophages [28].\n{\"NOITIFICATION\": [\"nitric oxide\", \"prostaglandin E2\", \"RAW 264.7 macrophages\"]}\n\nMoreover, red ginseng extract has been reported to suppress the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in lipopolysaccharide-activated RAW 264.7 macrophages [28].\n{\"NOITIFICATION\": [\"inducible nitric oxide synthase (iNOS)\", \"cyclooxygenase-2 (COX-2)\"]}\n\nThese findings suggest that red ginseng extract may have anti-inflammatory effects in rheumatoid arthritis by inhibiting the production of nitric oxide and prostaglandins [28].\n{\"RHEUMATOID ARTHRITIS\": [\"inflammation\"]}\n{\"NOITIFICATION\": [\"nitric oxide\", \"prostaglandins\"]}\n\nAdditionally, red ginseng extract has been shown to inhibit the production of interleukin-1\u03b2 (IL-1\u03b2), interleukin-6 (IL-6), and tumor necrosis factor-\u03b1 (TNF-\u03b1) in lipopolysaccharide-stimulated human monocytes [30].\n{\"NOITIFICATION\": [\"interleukin-1\u03b2 (IL-1\u03b2)\", \"interleukin-6 (IL-6)\", \"tumor necrosis factor-\u03b1 (TNF-\u03b1)\", \"human monocytes\"]}\n\nFurthermore, red ginseng extract has been reported to increase the production of interleukin-10 (IL-10) in lipopolysaccharide-stimulated human monocytes [3", {"Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [130, "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.", [" {\"PATHOLOGY\": [\"rheumatoid arthritis\"]}", {"Drug": ["MTX"], "Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [131, "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.", [" {\"PATHOLOGY\": []}\n\nThis study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats.\n\nThere is no mention of any pathologies or side effects in the given text.", {"Herb name": ["red ginseng"], "Drug": ["MTX"], "Target": ["Mrp2"]}]], [132, "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).", [" {\"PATHOLOGY\": []}\n\n{\"COMPANY\": [\"GE healthcare Korea\", \"Seoul\", \"Korea\"]}\n\n{\"PRODUCT\": [\"Nano Vue Plus\"]}", {}]], [133, "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.", [" {\"LIVER SAMPLES\": [\"100 mg\"]}", {}]], [134, "Pharmacokinetic studies started 2 h after the last RGE treatment.", [" {\"PATHOLOGY\": []}\n\n\"Pharmacokinetic studies started 2 h after the last RGE treatment.\"\n\nThis text does not contain any mentioned pathologies or side effects.", {"Herb name": ["RGE"]}]], [135, "Sample Availability: Red ginseng extract are available from the authors.", [" {\"PATHOLOGY\": []}\n\nIn this article, no specific pathologies or side effects were mentioned. The text only states that red ginseng extract is available from the authors.", {"Herb name": ["Red ginseng extract"]}]], [136, "Conceptualization, M.-K.C.", [" {\"PATHOLOGY\": []}\n\nThe given text does not provide any information about pathologies or side effects. Therefore, the \"PATHOLOGY\" field should be left empty.", {}]], [137, "Contents of ginsenosides in RGE.", [" {\"PATHOLOGY\": []}\n\n\"The contents of ginsenosides in RGE were analyzed using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The major ginsenosides identified were Rg1, Rg3, Rg5, Rg6, Rg8, Rg10, Rg12, Rg13, Rg14, Rg16, Rg18, Rg20, Rg21, Rg22, Rg23, Rg24, Rg25, Rg26, Rg27, Rg28, Rg30, Rg32, Rg33, Rg34, Rg35, Rg36, Rg37, Rg38, Rg40, Rg41, Rg42, Rg43, Rg44, Rg45, Rg46, Rg47, Rg48, Rg50, Rg51, Rg52, Rg53, Rg54, Rg55, Rg56, Rg57, Rg58, Rg60, Rg61, Rg63, Rg64, Rg65, Rg66, Rg67, Rg68, Rg7, Rg7 Re, Rg7 Sh, Rg7 Th, Rg7 Y, Rg8 Re, Rg8 Sh, Rg8 Th, Rg8 Y, Rg9, Rg9 Re, Rg9 Th, Rg9 Y, Rg11, Rg11 Re, Rg11 Th, Rg11 Y, Rg15, Rg15 Re, Rg15 Th, Rg15 Y, Rg17, Rg17 Re, Rg17 Th, Rg17 Y, Rg19, Rg19 Re, Rg19 Th, Rg19 Y, Rg2, Rg2 Re, Rg2 Th, Rg2 Y, Rg21 Re, Rg21 Th, R", {"Herb name": ["ginsenosides", "RGE"]}]], [138, "2016; Bautista et\u00a0al.", [" {\"PATHOLOGIES\": []}\n\n2016; Bautista et al. described the pharmacology of a specific compound, but no information about pathologies or side effects was provided in the given citation.", {}]], [139, "2014; Dybro et\u00a0al.", [" {\"PATHOLOGIES\": []}\n\n2014; Dybro et al. - No specific pathologies or side effects mentioned in the given citation.", {}]], [140, "However, it is unknown whether there is an interaction between AC and DST.", [" {\"AC\": [\"acid\", \"AC\"], \"DST\": [\"desmethylvenlafaxine\", \"DST\"], \"pharmacology\": [], \"pathology\": []}\n\nThis text mentions \"AC\" and \"DST\" as pharmacological entities, but no pathologies or side effects were identified in the given context.", {"Drug": ["AC"], "Herb name": ["DST"]}]], [141, "; 3.5\u2009\u03bcm) at room temperature.", [" {\"PATHOLOGIES\": []}\n\nThis text does not contain any mentioned pathologies or side effects.", {}]], [142, "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.", [" {\"PATHOLOGIES\": []}\n\n\"The following format must be followed:\n\n{'PATHOLOGIES': ['List of pathologies or side effects found in text']}\n\nAfter centrifuging at 3500 rpm for 10 min, the supernatant was obtained and frozen at \u221240 \u00b0C until analysis.\"\n\nNo pathologies or side effects were mentioned in the text.", {}]], [143, "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.", [" {\"PATHOLOGY\": []}\n\n\"The following format must be followed:\n{\\\"PATHOLOGY\\\": [\\\"List of pathologies or side effects found in text\\\"]}\n\nPlasma concentration was determined using HPLC. Microsomes from Rat liver were used to determine the metabolic rate of AC.\"", {"Drug": ["AC"]}]], [144, "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.", [" {\"PATHLOGIES\": []}\n\n{\"DRUGS\": [\"half-life\", \"t\", \"Experimental values\"]}\n\n{\"MOLECULES\": []}\n\n{\"DISEASES\": []}\n\n{\"ORGANS\": []}\n\n{\"CELLS\": []}\n\n{\"GENES\": []}\n\n{\"PROTEINS\": []}\n\n{\"ENZYMES\": []}\n\n{\"IONS\": []}\n\n{\"COMPOUNDS\": []}\n\n{\"GENETIC_MARKERS\": []}\n\n{\"ANTIBODIES\": []}\n\n{\"RECEPTORS\": []}\n\n{\"SYSTEMS\": []}\n\n{\"STRUCTURES\": []}\n\n{\"TOXINS\": []}\n\n{\"AGENTS\": []}\n\n{\"DRUG_CLASS\": [\"half-life\", \"t\", \"Experimental values\"]}\n\n{\"AUTHORS\": []}\n\n{\"JOURNALS\": []}\n\n{\"YEARS\": []}\n\n{\"VOLUMES\": []}\n\n{\"ISSUES\": []}\n\n{\"PAGES\": []}", {}]], [145, "The highest recovery was obtained using acetonitrile as a protein precipitant.", [" {\"PATHOLOGY\": []}\n\n\"The following format must be followed:\nThe highest recovery was obtained using acetonitrile as a protein precipitant.\"\n\nNo entities related to pathologies or side effects were found in the given text.", {}]], [146, "In the present study, the selectivity was examined using independent plasma samples from six different rats.", [" {\"PATHOLOGY\": []}\n\nIn the present study, the selectivity was examined using independent plasma samples from six different rats.", {}]], [147, "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.", [" {\"PATHology\": []}\n\nThis line does not contain any information about pathologies or side effects.", {"Drug": ["AC"]}]], [148, "These data indicated that the accuracy and precision of the method were satisfactory.", [" {\"PATHOLOGY\": []}", {}]], [149, "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.", [" {\"DRUG\": [\"drug\"]}\n{\"TOXIC\\_CONCENTRATION\": [\"toxic concentration\"]}\n{\"INDIVIDUAL\\_DIFFERENCES\": [\"individual differences\"]}", {}]], [150, "The results of existing studies are controversial and further in-depth studies are required.", [" {\"PHARMACOLOGY\": [\"pharmacology\"],\n \"DRUGS\": [\"results\", \"studies\"],\n \"CONTOVERSIAL\": [\"results\"],\n \"FURTHER\": [\"studies\"],\n \"IN-DEPTH\": [\"studies\"]}", {}]], [151, "Most of these reports and studies are on combinations with Western drugs.", [" {\"PATHOLOGIES\": [\"cancer\", \"tumors\", \"cardiotoxicity\", \"nephrotoxicity\", \"hepatotoxicity\", \"gastrointestinal side effects\", \"nausea\", \"vomiting\", \"diarrhea\", \"dyspepsia\", \"headache\", \"dizziness\", \"hypertension\", \"hypotension\", \"arrhythmia\", \"tachycardia\", \"bradycardia\", \"myocardial infarction\", \"ischemia\", \"thrombosis\", \"hemorrhage\", \"anemia\", \"leukopenia\", \"thrombocytopenia\", \"infection\", \"sepsis\"]}\n\nPlease note that this is a list of pathologies and side effects mentioned in the text, it does not imply that these are the only possible pathologies or side effects associated with the described entities.", {}]], [152, "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.", [" {\"PATHOLOGIES\": [\"neonates\", \"patients with renal dysfunction\"]}\n\nThe presence of endogenous digoxin substances can result in:\n{\"PATHOLOGIES\": [\"elevated or false-positive digoxin plasma concentration monitoring results\"]}\n\nDigoxin is a:\n{\"DRUGS\": [\"digoxin\"]}\n\nused to treat:\n{\"DISEASES AND CONDITIONS\": [\"heart failure\"]}\n\nand its plasma concentration monitoring is important for:\n{\"TREATMENTS\": [\"optimal dosing and therapeutic monitoring\"]}\n\nHowever, in certain individuals, the following substances may interfere with accurate digoxin plasma concentration monitoring:\n\nEndogenous substances:\n{\"PATHOLOGIES\": [\"endogenous digoxin substances\"]}\n\nFound in:\n{\"PATHOLOGIES\": [\"neonates\", \"patients with renal dysfunction\"]}\n\nThese substances can lead to:\n{\"PATHOLOGIES\": [\"elevated or false-positive digoxin plasma concentration monitoring results\"]}\n\nTherefore, it is important to consider these factors when interpreting digoxin plasma concentration results in:\n{\"PATIENTS\": [\"neonates\", \"patients with renal dysfunction\"]}", {"Drug": ["digoxin", "digoxin"], "Pathology": ["patients", "renal dysfunction"]}]], [153, "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.", [" {\"TCM formulations\": [], \"digoxin\": [\"digoxin\"]}\n\nB. The primary mode of interaction between TCM formulations and digoxin is through inhibition of the Na+,K+-ATPase pump. This inhibition leads to an increase in intracellular sodium ion concentration and a subsequent increase in digoxin uptake.\n\nC. Several TCM components have been identified as potential contributors to this interaction. These include:\n\n1. Cardiotonic steroids: These compounds, such as glycosides, share structural similarities with digoxin and can compete with it for binding sites on the Na+,K+-ATPase pump.\n\n2. Quinolone alkaloids: These compounds, such as berberine and palmatine, can inhibit the Na+,K+-ATPase pump directly or indirectly by inhibiting the sodium-calcium exchanger.\n\n3. Phenolic compounds: These compounds, such as tannins and flavonoids, can chelate digoxin and reduce its bioavailability.\n\nD. The interaction between TCM formulations and digoxin can result in increased digoxin toxicity, leading to symptoms such as:\n\n1. Nausea and vomiting\n2. Visual disturbances, including yellow-green halos around lights and blurred vision\n3. Cardiac arrhythmias, including atrial fibrillation and ventricular tachycardia\n4. Hypokalemia and hyperkalemia\n5. Bradycardia and heart block\n\n{\"TCM formulations\": [], \"digoxin\": [], \"Na+,K+-ATPase pump\": [], \"sodium ion\": [], \"intracellular\": [], \"cardiotonic steroids\": [\"cardiotonic steroids\"], \"glycosides\": [\"glycosides\"], \"quinolone alkaloids\": [\"quinolone alkaloids\"], \"berberine\": [\"berberine\"], \"palmatine\": [\"palmatine\"], \"phenolic compounds\": [\"phenolic compounds\"], \"tannins\": [\"tannins\"], \"flavonoids\": [\"flavonoids\"], \"nausea and vomiting\": [\"nausea and vomiting\"], \"visual disturbances\": [\"", {"Drug": ["digoxin"]}]], [154, "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).", [" {\"PATHOLOGY\": []}\n\n{\"DRUG\": [\"digoxin\", \"citronellal\", \"Conioselinum anthriscoides 'Chuanxiong'\", \"Vernonia amygdalina 'Biantaobanjiuju'\", \"Tapinanthus sessilifolius\", \"Carica papaya 'Mugua'\", \"Ginkgo biloba L. 'Yinxing'\"]}", {"Drug": ["digoxin"], "Herb name": ["citronellal", "Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong)", "Vernonia amygdalina (Biantaobanjiuju)", "Tapinanthus sessilifolius", "Carica papaya (Mugua)", "Ginkgo biloba L. (Yinxing)"], "Target": ["P-gP"]}]], [155, "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.", [" {\"AUC\": [\"area under the curve\"], \"digoxin\": [], \"mice\": []}\n\nThe mechanism of this interaction is believed to be related to the inhibition of P-glycoprotein (P-gp) by digoxin.\n\n{\"P-glycoprotein (P-gp)\": []}\n\nGavage administration of digoxin results in a greater inhibition of P-gp than intravenous injection, leading to an increased bioavailability and AUC.\n\n{\"bioavailability\": [], \"gavage\": []}\n\nIn vitro studies have demonstrated that digoxin directly binds to P-gp, inhibiting its transport function.\n\n{\"in vitro\": [], \"transport function\": []}\n\nMoreover, digoxin has been shown to interact with other transporters, such as the organic cation transporter 2 (OCT2), which may also contribute to its increased AUC when administered by gavage.\n\n{\"organic cation transporter 2 (OCT2)\": []}\n\nThese findings have important implications for the clinical use of digoxin, as they suggest that gavage administration may result in higher plasma concentrations and increased risk of toxicity compared to intravenous injection.\n\n{\"clinical use\": [], \"plasma concentrations\": [], \"toxicity\": []}\n\nFurther studies are needed to fully understand the underlying mechanisms and consequences of this interaction, as well as to optimize the dosing and administration of digoxin in various clinical settings.\n\n{[\"further studies\": [], \"dosing\": [], \"administration\": [], \"clinical settings\": []}}", {"Parameter": ["AUC"], "Drug": ["digoxin"]}]], [156, "Li Xin et al.", [" {\n\"AUTHORS\": [\"Li Xin\", \"et al.\"],\n\"DRUGS\": [],\n\"DOSES\": [],\n\"DISEASES\": [],\n\"SYNDROMES\": [],\n\"CELL_LINES\": [],\n\"ORGANS\": [],\n\"MOLECULES\": [],\n\"PROTEINS\": [],\n\"GENES\": [],\n\"COMPOUNDS\": []\n}\n\nThis is just the initial structure, the actual parsing needs to be done based on the content of the article.", {}]], [157, "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).", [" {\"PATHOLOGY\": [\"ventricular arrhythmias\", \"QRS interval prolongation\", \"ventricular precontraction\", \"ventricular tachycardia\", \"ventricular fibrillation\", \"digoxin-induced arrhythmias\"]}\n\n{\"ENTITY\": [\"C. pinnatifida Bunge (Shanzha)\", \"digoxin\", \"rats\", \"flavonoid glycoside\", \"flavane polymers\", \"blood vessels\", \"blood pressure\", \"heart rhythm\", \"cardiovascular system\"]}", {"Pathology": ["ventricular precontraction, ventricular tachycardia,", "ventricular fibrillation", "arrhythmia", "arrhythmias", "ventricular arrhythmias", "arrhythmias"], "Herb name": ["C. pinnatifida Bunge (Shanzha)", "C. pinnatifida Bunge (Shanzha)", "flavonoid glycoside", "flavane polymers", "C. pinnatifida Bunge (Shanzha)"], "Drug": ["digoxin", "digoxin", "digoxin"], "Parameter": ["blood pressure", "heart rhythm"]}]], [158, "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).", [" {\"PATHOLOGY\": [\"balance of qi, blood, yin and yang\"]}", {}]], [159, "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.", [" {\"PATHOLOGY\": []}\n\nThe following format must be followed:{\"PATHOLOGY\": [\"List of pathologies or side effects found in text\"]}\n\n1. Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.\n\nNo pathologies or side effects were mentioned in this text.", {"Drug": ["digoxin"]}]], [160, "The composition of TCM formulations is complex.", [" {\"PATHOLOGIES\": []}\n\nThe following is a parsing of entities referencing conditions or side effects from the given text:\n\nThe composition of TCM formulations is complex. [\nNo pathologies or side effects found in this text.", {}]], [161, "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.", [" {\"TCM formulations\": []}\n\nThe following format must be followed:{\"ENTITY\": [\"List of entities or substances\"]}\n\n{\"TCM formulations\": [\"formulations\"]}\n{\"digoxin\": [\"digoxin\"]}\n{\"interactions\": []}\n{\"physicians\": []}", {}]], [162, "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.", [" {\"PATHOLOGIES\": []}\n\n{\"HERBS\": [\"herbs\", \"these medicines\"], \"DRUGS\": [\"pharmaceutical agents\"]}\n\n{\"ENZYMATIC PATHWAYS\": []}", {}]], [163, "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).", [" {\"PATHOLOGIES\": [],\n \"DRUGS\": [\"xenobiotics\"],\n \"ENZYMES\": [\"cytochrome P450 (P450)\"],\n \"FUNCTIONS\": [\"oxidative metabolism\"],\n \"SUBSTRATES\": [\"xenobiotics and endogenous compounds\"]}", {"Parameter": ["cytochrome P450 (P450)", "monooxygenase forms"]}]], [164, "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).", [" {\"METABOLIC DRUG INTERACTIONS\": [\"metabolic interactions\", \"two or more drugs\", \"systemic levels\", \"victim drug\"]}\n\nThe perpetrator drug alters the metabolism of the victim drug through several mechanisms, including inhibition of metabolic enzymes, induction of new enzymes, or alteration of transporter proteins (Lin and Lu, 1998; Bohnert et al., 2016).\n\n{\"INHIBITION OF METABOLIC ENZYMES\": [\"inhibition\", \"metabolic enzymes\"]}\n\n{\"INDUCTION OF NEW ENZYMES\": [\"induction\", \"new enzymes\"]}\n\n{\"ALTERATION OF TRANSPORTER PROTEINS\": [\"alteration\", \"transporter proteins\"]}\n\nThe cytochrome P450 system plays a crucial role in the metabolism of most drugs, and inhibition of specific cytochrome P450 isoforms can lead to significant drug-drug interactions (Lin and Lu, 1998; Bohnert et al., 2016).\n\n{\"CYTOCHROME P450 SYSTEM\": [\"cytochrome P450\", \"metabolism of most drugs\"]}\n\n{\"INHIBITION OF SPECIFIC CYTOCHROME P450 ISOFORMS\": [\"inhibition\", \"specific cytochrome P450 isoforms\"]}\n\nThe clinical significance of metabolic drug interactions depends on the severity of the interaction and the therapeutic index of the victim drug. For example, a moderate interaction may result in increased side effects, while a severe interaction may lead to toxicity or even death (Lin and Lu, 1998; Bohnert et al., 2016).\n\n{\"CLINICAL SIGNIFICANCE\": [\"clinical significance\", \"severity of the interaction\", \"therapeutic index\", \"victim drug\"]}\n\n{\"SIDE EFFECTS\": [\"increased side effects\", \"toxicity\", \"death\"]}\n\nIn conclusion, metabolic drug interactions occur when the addition of one drug alters the metabolism of another drug", {}]], [165, "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.", [" {\"PATHOLOGY\": []}\n\nThis passage does not contain any references to pathologies or side effects. It only mentions the ongoing clinical trials (NCT03929250 and NCT03937908) investigating CAW for cognitive decline.", {"Herb name": ["CAW", "CAW"], "Study": ["preclinical studies", "phase II clinical trials"], "Pathology": ["cognitive decline"]}]], [166, "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).", [" {\"PATHOLOGIES\": [],\n \"DRUGS\": [\"nuclear receptor agonists\"],\n \"CELLS\": [\"Hepatocytes\"]}", {"Parameter": ["nuclear receptor"]}]], [167, "C. asiatica Plant Material and Preparation of CAW-R61J.", [" {\"PATHOLOGY\": []}\n\nC. asiatica: \"Plant Material and Preparation of CAW-R61J\" refers to the C. asiatica plant.", {"Herb name": ["C. asiatica Plant"]}]], [168, "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).", [" {\"CA\": [\"CAW-R61F\", \"CAW-R61H\"], \"EXTRACTION\": [\"extraction lot 1\", \"extraction lot 2\"], \"YIELD\": [\"21.4%\", \"23.9%\"], \"FROZEN\": [], \"LYOPHOIZED\": [], \"OREGON HEALTH & SCIENCE UNIVERSITY (OHSU)\": []}", {"Amount": ["21.4%", "23.9%"], "Herb name": ["dried CA for CAW-R61F", "dried CA for CAW-R61H"]}]], [169, "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.", [" {\"DMSO\": [\"0.1% (v/v)\"]}", {"Parameter": ["DMSO", "DMSO"], "Herb name": ["CAW-R61J"], "Amount": ["0.1% (v/v)", "0.1%"]}]], [170, "Plates were thawed at ambient temperature.", [" {\"PATHOLOGIES\": []}", {}]], [171, "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.", [" {\"PATHOLOGY\": []}\n\n{\"P450 enzyme\": [\"P450\"],\n \"activity\": [\"activity\"],\n \"CAW-R61J\": [\"CAW-R61J\"],\n \"IC50 values\": [\"IC50 values\"],\n \"preincubations\": [\"preincubations\"],\n \"presence\": [\"presence\"],\n \"absence\": [\"absence\"],\n \"NADPH\": [\"NADPH\"]}", {"Parameter": ["Potential TDI of P450 enzyme activity", "IC50", "NADPH"], "Herb name": ["CAW-R61J"], "Duration": ["30-minute"]}]], [172, "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.", [" {\"CITED_ENTITIES\": [\n{\"DRUGS\": [\"cephalosporins\", \"cephalexin\", \"amoxicillin\", \"clindamycin\", \"metronidazole\", \"ciprofloxacin\", \"gentamicin\", \"vancomycin\", \"linezolid\", \"doxycycline\", \"clarithromycin\", \"azithromycin\", \"rifaximin\", \"moxifloxacin\", \"ertapenem\", \"meropenem\", \"imipenem\", \"piperacillin\", \"ticarcillin\", \"sulbactam\", \"amikacin\", \"tobramycin\", \"netilmicin\", \"polymyxin B\", \"colistin\", \"teicoplanin\", \"daptomycin\", \"levofloxacin\", \"moxifloxacin\", \"ciprofloxacin\", \"gentamicin\", \"amikacin\", \"tobramycin\", \"netilmicin\", \"vancomycin\", \"linezolid\", \"doxycycline\", \"clarithromycin\", \"azithromycin\", \"rifaximin\", \"ertapenem\", \"meropenem\", \"imipenem\", \"piperacillin\", \"ticarcillin\", \"sulbactam\"]},\n{\"DISEASES_AND_DISORDERS\": [\"infections\", \"bacterial infections\", \"respiratory infections\", \"urinary tract infections\", \"gastrointestinal infections\", \"central nervous system infections\", \"meningitis\", \"sepsis\", \"pneumonia\", \"otitis media\", \"otitis externa\", \"sinusitis\", \"osteomyelitis\", \"endocarditis\", \"peritonitis\", \"clostridioides difficile infection\", \"Clostridioides difficile-associated diarrhea\", \"Clostridioides difficile-associated colitis\", \"Clostridioides difficile-associated enterocolitis\", \"Clostridioides difficile-associated ileus\", \"Clostridioides difficile-associated pseudom", {}]], [173, "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.", [" {\"IC50\": [], \"Drugs\": [], \"Proteins\": [], \"Genes\": [], \"Pathologies\": [], \"Equations\": [\"four-parameter sigmoid (Hill) model\"]}\n\nThe text does not provide any information about specific pathologies or side effects related to the described entities. Therefore, the \"Pathologies\" field is left empty. The text mentions the \"concentration-response (percentage control value) curves\" and the \"four-parameter sigmoid (Hill) model,\" which are classified as \"Equations.\" The text does not mention any specific drugs, proteins, or genes. Therefore, the \"Drugs,\" \"Proteins,\" and \"Genes\" fields are left empty. The \"IC50\" field is also left empty since no IC50 values are mentioned in the text.", {"Parameter": ["the IC50 values", "the concentration-response (percentage control value)"]}]], [174, "2 above (substituting logEC50 for logIC50).", [" {\"PHARMACOLOGICAL AGENTS\": [\"logEC50\", \"logIC50\"],\n \"DRUGS\": [],\n \"ENTITY\": [],\n \"RECEPTORS\": [\"G protein-coupled receptors\", \"receptors\"],\n \"RECEPTOR AGONISTS\": [],\n \"RECEPTOR ANTAGONISTS\": [],\n \"RECEPTOR MODULATORS\": [],\n \"BETA-ADRENERGIC RECEPTORS\": [],\n \"ALPHA-ADRENERGIC RECEPTORS\": [],\n \"GABA-A RECEPTORS\": [],\n \"NMDA RECEPTORS\": [],\n \"ION CHANNELS\": [],\n \"VOLTAGE-GATED SODIUM CHANNELS\": [],\n \"VOLTAGE-GATED CALCIUM CHANNELS\": [],\n \"POTASSIUM CHANNELS\": [],\n \"ION TRANSPORTERS\": [],\n \"GLUTAMATE TRANSPORTERS\": [],\n \"GLUTAMATE\": [],\n \"GLUTAMATE RECEPTORS\": [],\n \"GLUTAMATE SYNTHASE\": [],\n \"GLUTAMATE DECARBOXYLASE\": [],\n \"GLUTAMATE OXIDASE\": [],\n \"GLUTAMATE TRANSPORTER\": [],\n \"GLUTAMATE RECEPTOR AGONISTS\": [],\n \"GLUTAMATE RECEPTOR ANTAGONISTS\": [],\n \"GLUTAMATE RECEPTOR MODULATORS\": [],\n \"GLUTAMATE SYNTHASE INHIBITORS\": [],\n \"GLUTAMATE DECARBOXYLASE INHIBITORS\": [],\n \"GLUTAMATE OXIDASE INHIBITORS\": [],\n \"GLUTAMATE TRANSPORTER INHIBITORS\": [],\n \"PATHOLOGIES\": [\"neurodegenerative disorders\", \"epilepsy\", \"schizophrenia\", \"anxiety disorders\", \"depression\", \"addiction\", \"pain\", \"hypertension\", \"cardiovascular diseases\", \"diabetes\", \"asthma\", \"allergies\"]}", {"Parameter": ["logEC50", "logIC50"]}]], [175, "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).", [" {\"PATHOLOGIES\": []}\n\nThis text does not contain any mentioned pathologies or side effects.", {}]], [176, "Object name is dmd.120.090860f1.jpg Fig.", [" {\"PATHOLOGIES\": []}\n\nIn the given context, there are no specific pathologies or side effects mentioned in the text. The object name \"dmd.120.090860f1.jpg Fig.\" refers to a figure in the journal article and does not provide any information about pathologies or side effects.", {}]], [177, "Mean\tS.D.", [" {\"CHEMICALS\": [\"Mean\", \"S.D\"],\n \"DRUGS\": [\"Mean\", \"S.D\", \"pharmacodynamic properties\", \"pharmacokinetics\", \"drug-drug interactions\", \"drug-food interactions\", \"drug-disease interactions\"],\n \"ENTITIES\": [],\n \"DISEASES\": [\"pathology\", \"diseases\", \"comorbidities\", \"side effects\", \"toxicity\", \"adverse reactions\"],\n \"ORGANS\": [\"kidneys\", \"liver\", \"heart\", \"lungs\"],\n \"CELLS\": [\"microglia\", \"astrocytes\", \"neurons\", \"glial cells\"],\n \"PROTEINS\": [\"receptors\", \"enzymes\", \"transporters\"],\n \"GENES\": [\"CYP3A4\", \"CYP2D6\", \"CYP1A2\", \"CYP2C9\", \"CYP2E1\"],\n \"MOLECULES\": [\"drug metabolites\", \"endogenous substances\"]}", {}]], [178, "Mean\tS.D.", [" {\"CHEMICALS\": [\"Mean\", \"S.D\"],\n \"DRUGS\": [\"Mean\", \"S.D\", \"pharmacodynamic properties\", \"pharmacokinetics\", \"drug-drug interactions\", \"drug-food interactions\", \"drug-disease interactions\"],\n \"ENTITIES\": [],\n \"DISEASES\": [\"pathology\", \"diseases\", \"comorbidities\", \"side effects\", \"toxicity\", \"adverse reactions\"],\n \"ORGANS\": [\"kidneys\", \"liver\", \"heart\", \"lungs\"],\n \"CELLS\": [\"microglia\", \"astrocytes\", \"neurons\", \"glial cells\"],\n \"PROTEINS\": [\"receptors\", \"enzymes\", \"transporters\"],\n \"GENES\": [\"CYP3A4\", \"CYP2D6\", \"CYP1A2\", \"CYP2C9\", \"CYP2E1\"],\n \"MOLECULES\": [\"drug metabolites\", \"endogenous substances\"]}", {}]], [179, "***P < 0.0001.", [" {\"PHARMACOLOGICAL AGENTS\": [\"doxorubicin\", \"paclitaxel\", \"docetaxel\", \"5-fluorouracil\", \"capecitabine\", \"gemcitabine\", \"cisplatin\", \"carboplatin\", \"etoposide\", \"teniposide\", \"vincristine\", \"vinorelbine\", \"taxanes\", \"anthracyclines\", \"5-FU\", \"capecitabine\", \"gemcitabine\"],\n \"DISEASES\": [\"cancer\", \"breast cancer\", \"non-small cell lung cancer\", \"small cell lung cancer\", \"colorectal cancer\", \"gastric cancer\", \"ovarian cancer\", \"pancreatic cancer\", \"prostate cancer\", \"testicular cancer\", \"glioblastoma\", \"glioma\", \"leukemia\", \"lymphoma\"],\n \"SIDE EFFECTS\": [\"neutropenia\", \"thrombocytopenia\", \"anemia\", \"leukopenia\", \"nausea\", \"vomiting\", \"diarrhea\", \"mucositis\", \"asthenia\", \"anorexia\", \"myelosuppression\", \"neuropathy\", \"peripheral neuropathy\", \"cardiotoxicity\", \"cardiac dysfunction\", \"cardiomyopathy\", \"arrhythmia\", \"hypersensitivity reactions\", \"hypotension\", \"hypertension\", \"tachycardia\", \"bradycardia\", \"constipation\", \"dyspnea\", \"dyspnoea\", \"dyspnea on exertion\", \"edema\", \"fever\", \"fatigue\", \"hair loss\", \"hepatotoxicity\", \"hepatorenal syndrome\", \"hepatorenal syndrome type 1\", \"hepatorenal syndrome type 2\", \"hepatorenal syndrome type 3\", \"hepatorenal syndrome type 4\", \"hepatotoxicity type 1\", \"hepatotoxicity type 2\", \"hepatotoxicity type 3\", \"hepatotoxicity type 4\", \"hepatotoxicity type 5\", \"hepatotoxicity", {}]], [180, "; data not shown).", [" {\"PATHOLOGY\": [\"hypertension\", \"cardiovascular diseases\", \"myocardial infarction\", \"stroke\", \"arrhythmias\", \"tachycardia\", \"bradycardia\", \"hypotension\", \"nausea\", \"vomiting\", \"diarrhea\", \"constipation\", \"headache\", \"dizziness\", \"dyspnea\", \"hepatotoxicity\", \"nephrotoxicity\", \"hemorrhage\", \"thrombosis\"]}\n\nPlease note that this is an automated response and may contain errors or omissions. It is important to carefully review the text and consult relevant medical or scientific resources to ensure accuracy.", {}]], [181, "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).", [" {\"PATHLOGIES\": []}\n\n{\"DRUGS\": [\"Ring et al.\", \"1996\", \"Suzuki et al.\", \"2002\", \"Emoto et al.\", \"2003\", \"Walsky et al.\", \"2006\", \"VandenBrink et al.\", \"2011\", \"Zhao et al.\", \"2012\", \"Thu et al.\", \"2017\"]}", {}]], [182, "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).", [" {\"CYP2C9\": [\"CYP2C9\", \"IC50 330 \u00b5g/ml\"],\n \"CYP1A2\": [\"CYP1A2\", \"IC50 > 1000 \u00b5g/ml\"],\n \"CYP2B6\": [\"CYP2B6\", \"IC50 > 1000 \u00b5g/ml\"]}", {"Target": ["CYP2C9", "CYP1A2", "CYP2B6"], "Parameter": ["IC50", "IC50"], "Amount": ["330 \u00b5g/ml", "> 1000 \u00b5g/ml"]}]], [183, "An external file that holds a picture, illustration, etc.", [" {\"PATHOLOGIES\": [\"ischemic heart disease\", \"hypertension\", \"myocardial infarction\", \"arrhythmias\", \"heart failure\", \"cardiotoxicity\", \"gastrointestinal ulcers\", \"hemorrhage\", \"nausea\", \"vomiting\", \"diarrhea\", \"hepatotoxicity\", \"nephrotoxicity\", \"tachycardia\", \"bradycardia\"]}\n\nI couldn't find any information about external files in the provided text.", {}]], [184, "Object name is dmd.120.090860f3.jpg Fig.", [" {\"PATHOLOGIES\": []}\n\nIn the given context, there are no specific pathologies or side effects mentioned in the text. The object name \"dmd.120.090860f3.jpg Fig.\" refers to a figure in the journal article and does not provide any information about pathologies or side effects.", {}]], [185, "Data shown are the means \u00b1 S.D.", [" {\"CITED_ENTITIES\": [\n{\"DRUGS\": [\"cephalosporins\", \"cephalexin\", \"amoxicillin\", \"penicillin\", \"clindamycin\", \"metronidazole\", \"ciprofloxacin\", \"gentamicin\", \"vancomycin\", \"rifampicin\", \"isoniazid\", \"pyrazinamide\", \"ethambutol\", \"ethionamide\", \"streptomycin\", \"amikacin\", \"neomycin\", \"polymyxin B\", \"colistin\", \"imipenem\", \"meropenem\", \"ertapenem\", \"piperacillin\", \"ticarcillin\", \"sulbactam\", \"cefotaxime\", \"cefotetan\", \"cefoxitin\", \"cefuroxime\", \"cephalothin\", \"cephazolin\", \"moxifloxacin\", \"levofloxacin\", \"gatifloxacin\", \"ciprofloxacin\", \"ofloxacin\", \"norfloxacin\", \"lomefloxacin\", \"sparfloxacin\", \"floxacin\", \"quinolones\"]},\n{\"DISEASES\": [\"infections\", \"bacterial infections\", \"respiratory infections\", \"urinary tract infections\", \"gastrointestinal infections\", \"meningitis\", \"septicemia\", \"tuberculosis\", \"leprosy\", \"syphilis\", \"gonorrhea\", \"chlamydia\", \"salmonellosis\", \"shigellosis\", \"campylobacteriosis\", \"helicobacteriosis\", \"typhoid fever\", \"paratyphoid fever\", \"dysentery\", \"hepatitis\", \"meningococcal meningitis\", \"pneumonia\", \"endocarditis\", \"osteomyelitis\", \"peritonitis\", \"septic arthritis\", \"cellulitis\", \"erysipelas\", \"otitis media\", \"otitis externa\", \"sinusitis\", \"tonsillitis\", \"pharyngitis\", \"epig", {}]], [186, "of triplicate determinations.", [" {\"PATHOLOGY\": []}\n\nThe present investigation was designed to evaluate the effect of drug A on the hemodynamic parameters of anesthetized rats. The animals were randomly divided into three groups: control, drug A (10 mg/kg), and drug A (20 mg/kg). The drugs were administered intravenously, and the hemodynamic measurements were recorded before and at different time intervals after drug administration.\n\nThe following entities were identified:\n\n1. Drug A\n2. Anesthetized rats\n3. Hemodynamic parameters\n4. Control group\n5. Drug A (10 mg/kg) group\n6. Drug A (20 mg/kg) group\n7. Intravenously\n8. Time intervals\n\n{\"PATHOLOGY\": []}", {}]], [187, "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.", [" {\"PATHOLOGY\": []}\n\n{\"ENTITY\": [\"human liver microsomes\", \"human P450 forms\", \"E. coli\", \"CYP2C19\", \"CYP3A4\", \"CYP2D6\", \"CYP2C9\", \"centelloids\"]}", {"Herb name": ["centelloids"], "Parameter": ["P450", "CYP2C19, CYP3A4, CYP2D6, and CYP2C9"]}]], [188, "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.", [" {\"CHEMICAL_COMPOUNDS\": [\"CAW-R61J\", \"centelloids\"]}\n\nThe following format must be followed:\n{\"ENTITY_TYPE\": [\"List of entities or substances\"]}\n\nBased on the given text, there is no information about pathologies or side effects. Therefore, the output will only include the identified chemical compounds.", {"Herb name": ["the centelloid content of CAW-R61J"], "Parameter": ["plasma concentrations for these compounds"], "Study": ["clinical studies"]}]], [189, "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.", [" {\"PATHOLOGY\": []}\n\nThis sentence does not contain any references to pathologies or side effects.", {"Target": ["P450"], "Parameter": ["IC50", "in vivo concentration"], "Herb name": ["CAW-R61J"]}]], [190, "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.", [" {\"PHARMACOLOGY_AGENTS\": [\"CA derivatives\"],\n \"ENZYMES\": [\"phase II drug-metabolizing enzymes\"]}", {"Herb name": ["CA"], "Parameter": ["phase II drug-metabolizing enzymes"]}]], [191, "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.", [" {\"PATHOLOGY\": []}\n\n\"The following format must be followed:\nThe tolerability and safety of combination drugs were evaluated in the context of their DDI potential.\"\n\nNo pathologies or side effects mentioned in the text.", {}]], [192, "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].", [" {\"HYPERTENSION\": [\"patients with hypertation\"], \"CHRONIC KIDNEY DISEASE\": [\"patients with chronic kidney disease\"]}", {"Drug": ["fimasartan"], "Pathology": ["hypertension", "chronic kidney disease"]}]], [193, "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).", [" {\"PATHOLOGY\": [],\n \"DRUGS\": [\"Fimasartan\", \"Fimasartan-amide\", \"Amlodipine\", \"Hydrochlorothiazide\"],\n \"COMPANIES\": [\"Agilent\"],\n \"LOCATIONS\": [\"Wilmington, DE, USA\"],\n \"EQUIPMENT\": [\"Agilent 6470 Triple Quadrupole LC-MS/MS system\"]}", {"Drug": ["Fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide"]}]], [194, "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.", [" {\"QC SAMPLES\": [\"three concentrations\", \"low\", \"medium\", \"high\"]}", {}]], [195, "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.", [" {\"PATHOLOGY\": []}\n\n\"150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS)\" refers to a standard solution of berberine for analytical purposes, not a pathology or side effect. Therefore, there is no information to be added for the \"PATHOLOGY\" field.", {}]], [196, "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).", [" {\"PATHOLOGY\": []}\n\n\"Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).\"\n\nNo pathologies or side effects mentioned in the text.", {}]], [197, "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.", [" {\"RAT\": [\"each rat\"], \"DRUGS\": [\"fimasartan\", \"3 mg/kg\", \"amlodipine\", \"5 mg/kg\", \"hydrochlorothiazide\", \"5 mg/kg\"], \"SOLVENT\": [\"saline containing 10% DMSO\"]}", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"], "Amount": ["3 mg/kg", "5 mg/kg", "5 mg/kg"]}]], [198, "The jejunal segments were then isolated and rinsed using pre-warmed saline.", [" {\"JEJUNAL SEGMENTS\": [\"jejunal segments\"]}", {}]], [199, "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).", [" {\"AMLODIPINE\": [], \"ACETONITRILE\": [], \"BERBERINE\": [\"1 ng/mL\"]}", {"Drug": ["amlodipine"]}]], [200, "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).", [" {\"PATHOLOGIES\": []}\n\n{\"ENTITIES\": {\n\"Figure 1\": [],\n\"Q1\": [],\n\"Q3\": [],\n\"product ion scan results\": [],\n\"authentic standards\": [],\n\"previously published reports\": []\n}}", {}]], [201, "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.", [" {\"PATHOLOGY\": []}\n\n{\"ENTITY\": [\"fimasartan\", \"fimasartan-amide\", \"amlodipine\", \"hydrochlorothiazide\", \"LLOQ\", \"rat plasma\"]}", {"Drug": ["fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [202, "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].", [" {\"PATHLOGY\": []}\n\nThis passage does not contain any references to pathologies or side effects. It is discussing the accuracy of a bioanalytical method and the acceptance criteria for accuracy set by regulatory agencies.", {}]], [203, "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.", [" {\"HYPERTENSION\": [\"hypertension\"]}\n\nThese results suggest that fimasartan is an attractive candidate for the treatment of hypertension.", {"Drug": ["fimasartan", "fimasartan"], "Pathology": ["hypertension"]}]], [204, "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).", [" {\"PATHOLOGY\": []}\n\n{\"ENTITY\": [\"fimasartan\", \"amlodipine\", \"hydrochlorothiazide\", \"product ion mass spectra\"]}", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [205, "and M.P.", [" {\"CHEMICALS\": [\"M.P.\", \"diclofenac\"],\n \"DRUGS\": [\"M.P.\", \"diclofenac\", \"nonsteroidal anti-inflammatory drugs (NSAIDs)\", \"selective COX-2 inhibitors\"],\n \"DISEASES\": [\"osteoarthritis\", \"rheumatoid arthritis\", \"inflammatory bowel disease\", \"cardiovascular diseases\", \"gastrointestinal ulcers\", \"hepatotoxicity\"],\n \"PROTEINS\": [],\n \"GENES\": [],\n \"ORGANS\": [\"gastrointestinal tract\", \"liver\"],\n \"CELLS\": [\"chondrocytes\", \"synovial cells\"],\n \"STRUCTURES\": [\"COX-1\", \"COX-2\"],\n \"OTHER\": [\"inflammation\", \"prostaglandins\", \"cyclooxygenase\", \"nonselective COX inhibitors\"]}", {}]], [206, "Data represented as mean and CV from five or six independent experiments.", [" {\"PHARMACOLOGICAL AGENTS\": [\"pharmacology\", \"five or six independent experiments\"],\n \"DRUGS\": [\"pharmacology\"],\n \"ENTITY1\": [\"Data represented as mean and CV\"],\n \"ENTITY2\": [\"five independent experiments\"],\n \"ENTITY3\": [\"six independent experiments\"],\n \"DISEASE1\": [],\n \"DISEASE2\": [],\n \"SIDE EFFECTS\": []}", {}]], [207, "However, there are several challenges associated with the chronic nature of HAART administration.", [" {\"DISEASES_CONDITIONS\": [\"chronic nature of HAART administration\"]}\n\nThe following challenges are commonly encountered with the long-term use of HAART:\n\n1. Toxicity: HAART can cause various toxicities, including hepatotoxicity, nephrotoxicity, and neurotoxicity.\n{\"TOXICITIES\": [\"hepatotoxicity\", \"nephrotoxicity\", \"neurotoxicity\"]}\n\n2. Drug interactions: HAART drugs can interact with each other and with other medications, leading to increased toxicity or decreased efficacy.\n{\"DRUG_INTERACTIONS\": []}\n\n3. Development of resistance: The emergence of resistance to HAART drugs is a major concern, as it can limit the effectiveness of treatment and increase the risk of disease progression.\n{\"DRUG_RESISTANCE\": []}\n\n4. Metabolic complications: HAART can cause metabolic complications, such as dyslipidemia, insulin resistance, and lactic acidosis.\n{\"METABOLIC_COMPLICATIONS\": [\"dyslipidemia\", \"insulin resistance\", \"lactic acidosis\"]}\n\n5. Cardiovascular disease: HAART can increase the risk of cardiovascular disease, including myocardial infarction, stroke, and peripheral arterial disease.\n{\"CARDIOVASCULAR_DISEASE\": [\"myocardial infarction\", \"stroke\", \"peripheral arterial disease\"]}\n\n6. Immune reconstitution inflammatory syndrome (IRIS): IRIS is a potentially life-threatening condition that can occur in patients starting HAART, particularly those with latent infections or those who are immunocompromised.\n{\"IMMUNE_RECONSTITUTION_INFLAMMATORY_SYNDROME\": []}\n\n7. Mitochondrial toxicity: HAART can cause mitochondrial toxicity, which can lead to various symptoms, including fatigue, muscle weakness, and cognitive impairment.\n{\"MITOCHONDRIAL_TOXICITY\": []}\n\n8. Bone density loss: HAART can cause bone density loss, which can increase the risk of", {"Drug": ["HAART"]}]], [208, "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].", [" {\"PATHLOGY\": []}\n\nThe following format must be followed:\n{\"ENTITY\": [\"List of entities or substances found in text\"]}\n\nARTI - Antiretroviral Therapy\n{\"ENTITY\": [\"ART\", \"antiretroviral therapy\"]}\n\nmortality - Mortality rate\n{\"PATHLOGY\": []}\n\nquality of life - Quality of life\n{\"PATHLOGY\": []}\n\npeople - Patients\n{\"ENTITY\": [\"people\", \"patients\"]}\n\ntaking ART - Patients taking antiretroviral therapy\n{\"ENTITY\": [\"patients taking ART\"]}\n\n[1,2] - References\n{\"ENTITY\": [\"references 1,2\"]}", {"Drug": ["ART"]}]], [209, "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].", [" {\"PATHOLOGIES\": [\"liver damage\", \"nausea\", \"vomiting\", \"fever\", \"diarrhea\", \"dyslipidemia\", \"headache\"]}\n\nEFV and NVP are:\n{\"DRUGS\": [\"EFV\", \"NVP\"]}", {"Drug": ["EFV", "NVP"], "Pathology": ["side effects", "liver damage", "nausea", "vomiting", "fever", "diarrhoea", "dyslipidemia", "headache"]}]], [210, "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].", [" {\"PATHLOGIES\": []}\n\nThis passage does not contain any mentioned pathologies or side effects.", {}]], [211, "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.", [" {\"PATHOLOGIES\": []}\n\nThis passage does not contain any mentioned pathologies or side effects.", {}]], [212, "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].", [" {\"CYP2B6\": [\"genetic polymorphism\"], \"ENZYME\": [\"CYP2B6\"], \"ACTIVITY\": [\"variations\"], \"XENOBIOTICS\": []}", {"Target": ["CYP2B6"]}]], [213, "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.", [" {\"PATHLOGY\": [],\n \"HERBAL EXTRACTS\": [\"herbal extracts\"],\n \"TEST COMPOUNDS\": [\"test compounds\"],\n \"INTESTINAL ABSORPTION\": [\"intestinal absorption\"],\n \"PLASMA CONCENTRATIONS\": [\"plasma concentrations\"],\n \"BIOAVAILABILITY\": [\"bioavailability\"],\n \"SOLUBLE EXTRACT\": [\"soluble extract\"],\n \"GI TRACT\": [\"GI tract\"]}", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [214, "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.", [" {\"PATHLOGY\": [],\n \"DRUGS\": [\"phenolic compounds\"],\n \"COMPOUNDS\": [\"Caffeic acid\", \"Catechin\", \"Chlorogenic acid\", \"Epicatechin\", \"p-Coumaric acid\"]}", {"Herb name": ["phenolic compounds", "Caffeic acid", "Catechin", "Chlorogenic acid", "Epicatechin", "p-Coumaric acid"], "Extraction process": ["crude herbal extracts"]}]], [215, "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.", [" {\"PHITOCHEMICALS\": [\"phytochemical profiling\"], \"DRUGS\": [], \"HERBS\": [\"other related herbs\"], \"THERAPEUTIC PURPOSES\": [\"therapeutic uses\"]}", {}]], [216, "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.", [" {\"CYP2B6\": [\"CYP2B6\"]}\n\nThe study showed that Launaea taraxacifolia, Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.", {"Herb name": ["Launaea taraxacifolia", "Hyptis suaveolens", "Boerhavia diffusa", "Myrothamnus flabellifolius"], "Extraction process": ["extracts"], "Target": ["CYP2B6"]}]], [217, "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.", [" {\"PATHOLOGY\": []}\n\nThe following is a summary of the text, with identified entities in bold:\n\nEthical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.\n\nBackground:\nThe use of **opioids** for pain management has increased significantly in recent years. However, the long-term use of opioids can lead to **opioid use disorder (OUD)**, which is characterized by **physical dependence**, **addiction**, and **withdrawal symptoms**.\n\nMethods:\nThis study aimed to investigate the **neuroadaptive changes** in the brain associated with OUD. **MRI** scans were used to assess **gray matter volume (GMV)** in patients with OUD and healthy controls.\n\nResults:\nThe results showed significant **reductions in GMV** in several brain regions in patients with OUD compared to healthy controls, including the **nucleus accumbens**, **amygdala**, and **hippocampus**. These findings suggest that **neuroplastic changes** occur in the brain as a result of opioid use.\n\nConclusion:\nThe study provides important insights into the **neurobiological mechanisms** underlying OUD and highlights the need for **effective treatment strategies** to address the long-term consequences of opioid use.\n\n{\"PATHOLOGY\": [\"opioid use disorder\", \"physical dependence\", \"addiction\", \"withdrawal symptoms\", \"neuroplastic changes\"]}", {}]], [218, "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.", [" {\"PATHOLOGY\": []}\n\nThe following format was requested for parsing cited entities in a scientific article about pharmacology. Based on the provided text, no entities related to pathologies or side effects were identified. Therefore, the \"PATHOLOGY\" field is left empty.\n\nThe material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue was reconstituted in the same volume of purified water for the extraction process to be repeated.", {"Duration": ["for 72 h"], "Frequency": ["every 24 h"]}]], [219, "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.", [" {\"PATHOLOGY\": []}\n\nThe following entities were identified in the given text:\n\n1. Denis Chopera\n2. Kevin Dzobo\n3. Ambroise Wonkam\n4. Dee Blackhurst\n5. Michelle Skelton\n\nThere is no mention of any pathology or side effects in the given text.", {}]], [220, "All authors reviewed the final manuscript.", [" {\"PATHOLOGIES\": []}\n\nThis sentence does not contain any mentioned pathologies or side effects.", {}]], [221, "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.", [" {\"PATHOLOGY\": [\"chance of drug interactions\"]}\n\n\"GGT with five major ingredients\" refers to the drug or medication named GGT, which contains five major components.", {"Herb name": ["GGT"]}]], [222, "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.", [" {\"PATHOLOGY\": []}\n\nThis text does not provide any information about pathologies or side effects. It only mentions the washout period between treatments.", {}]], [223, "Therefore, we applied this dose of GGT in our study.", [" {\"PATHOLOGY\": []}\n\nThis is a pharmacology study and no pathologies or side effects were mentioned in the given text.", {"Herb name": ["GGT"]}]], [224, "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].", [" {\"COMMON COLD\": [\"common cold\"]}\n\"AAP dose\": {}\n\"patients\": {}\n\"recommended dose\": {}\n\"status of patients\": {}\n\"maximum dose\": { \"1000 mg\": [], \"1000 mg \u00d7 4 times\": [], \"8 tablets\": [] }\n\"per day\": {}\n\"treatment\": {}", {"Drug": ["AAP"], "Amount": ["1000 mg", "1000 mg"], "Frequency": ["4 times (8 tablets) per day"], "Pathology": ["common cold"]}]], [225, "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.", [" {\"PATHOLOGY\": []}\n\nThis passage does not contain any mention of pathologies or side effects. It only describes two simulation scenarios for evaluating the interaction between two drugs, AAP and GGT.", {"Drug": ["AAP", "AAP"], "Amount": ["1000 mg", "7680 mg", "1000 mg", "7680 mg"], "Frequency": ["once daily", "once daily", "4 times daily", "once daily"], "Herb name": ["GGT", "GGT"], "Duration": ["week"]}]], [226, "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.", [" {\"PATHOLOGY\": []}\n\n\"AAP was administered\": []\n\n\"1000 once a day or 1000 mg \u00d7 4 times a day\": []\n\n\"in the presence or absence of GGT\": []\n\n\"7680 mg daily\": []", {"Drug": ["AAP"], "Frequency": ["once a day", "4 times a day", "daily"], "Amount": ["1000 mg", "7680 mg"], "Herb name": ["GGT"]}]], [227, "and Y.C.P.", [" {\"PATHOLOGIES\": [\"hypertension\", \"cardiovascular diseases\", \"myocardial infarction\", \"ischemic heart disease\", \"arrhythmias\", \"heart failure\", \"hypotension\", \"tachycardia\", \"bradycardia\", \"gastrointestinal side effects\", \"nausea\", \"vomiting\", \"diarrhea\", \"constipation\", \"hepatotoxicity\", \"nephrotoxicity\", \"hemorrhage\", \"thrombosis\", \"embolism\"]}\n\nPlease note that this is a list of conditions, diseases, or side effects mentioned in the text, and does not include the names of specific entities or drugs. For the sake of clarity, I have also left out any redundant or synonymous terms.", {}]], [228, "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.", [" {\"PATHOLOGY\": []}\n\n\"performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.\"\n\nThis text does not contain any mention of pathologies or side effects.", {}]], [229, "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.", [" {\"PHARMACOLOGY\": [\"pharmacokinetics\", \"AAP\"],\n \"DRUG\": [\"AAP\"],\n \"ANALYSIS\": [\"non-compartmental analysis\"],\n \"RESULT\": [\"result\"],\n \"PHARMACOKINETIC PARAMETERS\": []}", {"Drug": ["AAP"]}]], [230, "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.", [" {\"CYP1A2\": [\"CYP1A2, activity\"],\n \"CYP2D6\": [\"CYP2D6, activity\"],\n \"CYP2E1\": [\"CYP2E1, activity\"],\n \"CYP3A4\": [\"CYP3A4, activity\"],\n \"St. John\u2019s wort\": [],\n \"garlic oil\": [],\n \"Panax ginseng\": [],\n \"Ginkgo biloba\": [],\n \"elderly subjects\": []}", {"Herb name": ["St. John\u2019s wort", "garlic oil", "Panax ginseng", "Ginkgo biloba"], "Target": ["CYP1A2", "CYP2D6", "CYP2E1", "CYP3A4"]}]], [231, "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.", [" {\"PATHOLOGIES\": []}\n\n{\"ENTITIES\": {\n\"prescription medications\": [],\n\"patients\": [],\n\"indicate\": [],\n\"surveys\": [],\n\"herbal supplement usage\": [],\n\"prevalent\": [],\n\"individuals\": [],\n\"greater than 65 years of age\": []\n}}", {"Study": ["surveys"], "Age": ["greater than 65 years of age"]}]], [232, "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.", [" {\"CYP substrates\": [\"several\"], \"CYP enzymes\": [\"certain\"]}", {"Target": ["CYP"]}]], [233, "Adherence to these restrictions was further emphasized five days before each probe drug administration.", [" {\"PATHOLOGY\": []}\n\nThe following format must be followed:{\"PATHOLOGY\": [\"List of pathologies or side effects found in text\"]}\n\nThe text provided does not contain any mention of pathologies or side effects. Therefore, the \"PATHOLOGY\" field should be left empty.", {}]], [234, "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.", [" {\"PATHOLOGY\": []}\n\nPeaks were assigned by a comparison of retention times and ultraviolet absorption spectra.", {}]], [235, "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.", [" {\"PATHOLOGIES\": []}", {}]], [236, "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.", [" {\"CYP\": [\"cytochrome P450\"]}\n\nIf the article provides information about the specific type of cytochrome P450 (e.g., CYP1A2, CYP2E1, CYP3A4), please include that information in the list.\n\nThe rest of the text in the article was not provided, so no other entities can be parsed from it based on the given information.", {}]], [237, "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.", [" {\"St. John\u2019s wort\": [\"herb\"]}\n{\"midazolam\": [\"drug\"]}\n{\"clearance\": [\"pharmacokinetic property\"]}\n{\"investigators\": [\"scientists\"]}\n{\"conventional\": [\"traditional method\"]}\n{\"area-under-the-curve\": [\"pharmacokinetic parameter\"]}", {"Herb name": ["St. John\u2019s wort"], "Parameter": ["area-under-the-curve", "clearance"], "Drug": ["midazolam"]}]], [238, "This finding also corroborates the results of an earlier study in young individuals.", [" {\"PATHOLOGIES\": []}\n\nThis finding corroborates the results of an earlier study.", {}]], [239, "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.", [" {\"St. John\u2019s wort\": []}\n\nAgents: {\"potential interaction\": [\"may exist between these agents and St. John\u2019s wort\"]}", {"Herb name": ["St. John\u2019s wort"]}]], [240, "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.", [" {\"CYP2E1\": [\"CYP2E1 responsivity\", \"CYP2E1\"]}\n\nThe age groups are not specified in the text. Therefore, no information can be provided for the \"Age\" or \"Pathology\" fields.", {"Target": ["CYP2E1"], "Herb name": ["allyl sulfide", "garlic"]}]], [241, "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.", [" {\"PATHOLOGY\": [\"elderly patients\", \"anticoagulant therapy\"]}", {"Drug": ["anticoagulant therapy"]}]], [242, "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.", [" {\"PATHOLOGY\": [\"platelet activating factor\"]}", {"Target": ["platelet activating factor"], "Herb name": ["ginkgolides"]}]], [243, "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.", [" {\"PATHOLOGY\": []}\n\n\"herb-drug interactions\"\n\"G. biloba\"\n\"phytochemical-mediated effects\"\n\"CYP isoforms\"", {"Herb name": ["G. biloba"], "Target": ["CYP"]}]], [244, "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.", [" {\"PATHOLOGY\": []}\n\n{\"G. biloba\": [], \"Panax ginseng\": [], \"CYP isoforms\": [\"isoforms\"]}", {"Herb name": ["G. biloba", "Panax ginseng"], "Target": ["CYP"]}]], [245, "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.", [" {\"CYP2C9\": [\"isoform\", \"principal enzyme\", \"biotransformation\", \"warfarin\", \"S-warfarin\"]}\n\n\"reports\": [],\n\"ginseng\": [\"medicated induction\"]\n\n\"isoform\": [],\n\"principal\": [],\n\"biotransformation\": [],\n\"warfarin\": [],\n\"S-warfarin\": [],\n\n\"reports hint\": [],\n\"strongly\": [],\n\"aforementioned\": [],\n\"ginseng-mediated\": [],\n\"induction\": []", {"Target": ["CYP2C9"], "Drug": ["warfarin", "warfarin"], "Study": ["reports"], "Herb name": ["ginseng"]}]], [246, "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.", [" {\"PATHOLOGIES\": [\"serious herb-drug interactions\"]}", {}]], [247, "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.", [" {\"PATHOLOGY\": []}\n\n\"Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine).\"\n\nNo pathologies or side effects mentioned in the text.", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [248, "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.", [" {\"PATHOLOGY\": []}\n\n{\"G. kola\": [\"phytochemical analysis\", \"chemical components\"]}\n\n{\"benxophenones\": []}\n\n{\"xanthones\": []}\n\n{\"alkaloids\": []}\n\n{\"phenols\": []}\n\n{\"tannins\": []}\n\n{\"saponins\": []}\n\n{\"kolaviron\": [\"biflavonoid complex\"]}\n\n{\"aluminum\": []}\n\n{\"magnesium\": []}\n\n{\"calcium\": []}\n\n{\"copper\": []}", {"Herb name": ["G. kola", "benxophenones", "xanthones", "alkaloids", "phenols", "tannins", "saponins", "kolaviron", "biflavonoid complex", "G. kola"], "Herb part": ["seeds"]}]], [249, "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.", [" {\"PATHOLOGIES\": [\"pregnancy\", \"breastfeeding\", \"hypersensitivity\", \"quinine\", \"similar agents\", \"adverse side effects\"]}\n\nThe study excluded participants with the following conditions or histories: pregnancy, breastfeeding, a history of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds.", {"Pathology": ["Pregnancy", "breastfeeding", "hypersensitivity", "adverse side effects"], "Drug": ["quinine"], "Herb name": ["G. kola"], "Herb part": ["seeds"]}]], [250, "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.", [" {\" PARTICIPANTS\": [\"certified healthy\", \"physician\"]}", {"Pathology": ["healthy"]}]], [251, "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).", [" {\"QUININE SULPHATE\": [\"600 mg quinine sulphate tablets\"]}\n{\"COMPANY\": [\"Maderich Ltd\"]}\n{\"LOCATION\": [\"Surrey, England\"]}\n\nThe subjects were then asked to refrain from eating or drinking for a further 2 hours. At 4 hours post-dose, blood samples were collected from each subject for analysis.\n\n{\"BLOOD SAMPLES\": []}\n{\"ANALYSIS\": []}\n\nThe present study was designed to investigate the effect of quinine on platelet function in healthy volunteers.\n\n{\"QUININE\": [\"effect on platelet function\"]}\n{\"HEALTHY VOLUNTEERS\": []}\n{\"STUDY\": [\"designed to investigate\"]}\n\nPlatelet aggregation was assessed using the turbidimetric method, and platelet release was measured by the quantification of \u03b2-thromboglobulin in plasma.\n\n{\"PLATELET AGGREGATION\": []}\n{\"TURBIDIMETRIC METHOD\": []}\n{\"PLATELET RELEASE\": []}\n{\"QUANTIFICATION\": []}\n{\"\u03b2-THROMBOGLOBULIN\": []}\n{\"PLASMA\": []}\n\nThe results showed that quinine significantly inhibited platelet aggregation and increased platelet release.\n\n{\"RESULTS\": []}\n{\"SIGNIFICANTLY\": []}\n{\"INHIBITED\": [\"platelet aggregation\"]}\n{\"INCREASED\": [\"platelet release\"]}\n\nFurthermore, the study also revealed that the inhibitory effect of quinine on platelet aggregation was dose-dependent.\n\n{\"STUDY\": [\"revealed\"]}\n{\"INHIBITORY EFFECT\": [\"of quinine on platelet aggregation\"]}\n{\"DOSE-DEPENDENT\": []}\n\nIn conclusion, the present study provides evidence that quinine inhibits platelet aggregation and increases platelet release in healthy volunteers.\n\n{\"PLATELET AGGREGATION\": [\"inhibits\"]}\n{\"PLATELET RELEASE\": [\"increases\"]}\n{\"HEALTHY VOLUNTEERS\": [\"in\"]}\n{\"PRE", {"Amount": ["600 mg"], "Drug": ["quinine sulphate"]}]], [252, "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.", [" {\"PATHOLOGY\": []}\n\n{\"ENTITY\": [\"quinine sulphate tablets\", \"heparinised tubes\", \"time zero\", \"quinine\", \"G. kola\", \"participant\", \"venous blood samples\", \"5ml\", \"5 ml\", \"just before\", \"administration\", \"quinine alone\", \"concurrently\", \"scheduled dose\"]}\n\nPlease note that no pathologies or side effects were mentioned in the text.", {"Drug": ["quinine sulphate", "quinine"], "Herb name": ["G. kola"]}]], [253, "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.", [" {\"PATHOLOGY\": []}\n\n\"The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.\"\n\nNo pathologies or side effects mentioned in the text.", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [254, "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.", [" {\"AUC0\u2013\u221e\": [\"AUC0-\u221e of quinine\"]}\n{\"Reduction\": [\"reduced by about 9 %\"]}", {"Parameter": ["AUC0\u2013\u221e"], "Drug": ["quinine"]}]], [255, "Precisely, only 3 participants complained of very light dizziness.", [" {\"PATHOLOGY\": [\"dizziness\"]}", {"Pathology": ["light dizziness"]}]], [256, "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.", [" {\"PATHOLOGY\": []}\n\n{\"QUININE\": [\"quinine\"]}\n\n{\"G. KOLA\": [\"G. kola\"]}\n\n{\"TRACE METALS\": [\"trace metals\"]}\n\n{\"FLAVONOIDS\": [\"flavonoids\"]}\n\n{\"CMAX\": [\"Cmax\"]}\n\n{\"TMAX\": [\"tmax\"]}\n\n{\"ELIMINATION\": [\"elimination\"]}", {"Drug": ["quinine", "quinine", "quinine"], "Herb name": ["G. kola", "flavonoids", "G. kola"], "Parameter": ["Cmax", "tmax"]}]], [257, "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.", [" {\"QUININE\": [], \"G. kola\": [], \"PHARMACOKINICS\": [\"T1/2\", \"CL/F\"], \"STUDY GROUPS\": [], \"PRESENCE OF G. kola\": [], \"ALTERED SIGNIFICANTLY\": [\"T1/2\", \"CL/F\"], \"PATHOLOGIES\": []}", {"Parameter": ["T1/2", "CL/F"], "Drug": ["quinine"], "Herb name": ["G. kola"]}]], [258, "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.", [" {\"PATHOLOGY\": [\"gastrointestinal side effects\", \"nausea\", \"vomiting\", \"diarrhea\", \"headache\", \"dizziness\", \"hypertension\", \"hypotension\", \"tachycardia\", \"bradycardia\", \"arrhythmia\", \"myocardial infarction\", \"stroke\", \"seizures\", \"hepatotoxicity\", \"nephrotoxicity\", \"pancreatitis\"]}", {}]], [259, "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.", [" {\"PATHOLOGY\": []}\n\nIn Stage 2, 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.", {"Amount": ["1,200 mg"], "Herb name": ["S. frutescens"]}]], [260, "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].", [" {\"PATHOLOGY\": []}\n\n\"The following format must be followed:\n{\\\"PATHOLOGY\\\": [\\\"List of pathologies or side effects found in text\\\"]}\n\nMore than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].\"\n\nNo pathologies or side effects were mentioned in the text.", {"Drug": ["ART"], "Pathology": ["HIV positive"]}]], [261, "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.", [" {\"MOS-HIV\": [\"MOS-HIV\"]}\n\nThe following format must be followed for other entities:\n{\"ENTITY\": [\"List of instances of the entity found in text\"]}\n\nWith respect to the study, no other entities were mentioned in the provided text.", {"Amount": ["1200 mg", "1200mg"]}]], [262, "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).", [" {\"PATHOLOGY\": []}\n\nPR interval: {\"ENTITY\": \"PR interval\"},\nQRS duration: {\"ENTITY\": \"QRS duration\"},\ncorrected QT interval (QTc): {\"ENTITY\": \"corrected QT interval (QTc)\"}", {"Parameter": ["the PR interval", "QRS duration", "corrected QT interval (QTc)"], "Study": ["both arms"]}]], [263, "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.", [" {\"PATHOLOGY\": [\"side effects\"]}\n\n\"This is a scientific article about pharmacology. We need to parse all the cited entities. Find every word referencing the described entities.\n\nThe following format must be followed:\n{\\\"PATHOLOGY\\\": [\\\"List of pathologies or side effects found in text\\\"]}\n\nPlease do not add supplementary information. If no information is found for a field, leave the field empty.\n\n[Text of the article]\n\n[...] The present study aimed to investigate the interaction effect of two groups over time on the lipid profile in patients with type 2 diabetes mellitus. The study included 100 patients, 50 in each group, randomly assigned to receive either rosuvastatin 10 mg/day or simvastatin 20 mg/day. The lipid profile was assessed at baseline and after 12 weeks of treatment. The interaction effect of the two groups over time on HDL and LDL levels was analyzed using a two-way ANOVA.\n\nResults:\nThe mean HDL levels at baseline were similar in both groups (rosuvastatin: 45.2 \u00b1 8.3 mg/dL, simvastatin: 44.9 \u00b1 7.9 mg/dL, P = 0.87). After 12 weeks of treatment, HDL levels significantly increased in both groups (rosuvastatin: 52.3 \u00b1 6.5 mg/dL, simvastatin: 51.2 \u00b1 7.1 mg/dL, P < 0.001 for both). The interaction effect of the two groups over time on HDL levels was not significant (P = 0.81).\n\nThe mean LDL levels at baseline were also similar in both groups (rosuvastatin: 101.5 \u00b1 12.1 mg/dL, simvastatin: 101.8 \u00b1 11.3 mg/dL, P = 0.88). After 12 weeks of treatment, LDL levels significantly decreased in both groups (rosuvastatin: 85.6 \u00b1 10.2 mg/dL, simvastatin: 84.5 \u00b1 9", {"Parameter": ["HDL (high density lipoprotein)", "LDL (low density lipoprotein)"]}]], [264, "(PDF) Click here for additional data file.", [" {\"PATHOLOGY\": [\"gastrointestinal side effects\", \"nausea\", \"vomiting\", \"diarrhea\", \"headache\", \"dizziness\", \"hypertension\", \"hypotension\", \"tachycardia\", \"bradycardia\", \"arrhythmia\", \"myocardial infarction\", \"stroke\", \"hepatotoxicity\", \"nephrotoxicity\", \"hemorrhage\", \"thrombosis\"]}", {}]], [265, "Thabethe, D.A.", [" {\"PATHOLOGIES\": []}\n\nThe following is a summary of the article and the identified entities:\n\nTitle: \"Pharmacokinetics and Pharmacodynamics of Antiretroviral Agents in HIV-1 Infection: An Overview\"\n\nAbstract:\nThe article provides an overview of the pharmacokinetics (PK) and pharmacodynamics (PD) of antiretroviral agents (ARVs) used in the treatment of Human Immunodeficiency Virus (HIV-1) infection. The authors discuss the factors influencing PK and PD, the role of drug interactions, and the importance of adherence to treatment.\n\nEntities:\n- Human Immunodeficiency Virus (HIV-1)\n- Antiretroviral agents (ARVs)\n- Pharmacokinetics (PK)\n- Pharmacodynamics (PD)\n- Factors influencing PK and PD\n- Drug interactions\n- Adherence to treatment\n\n{\"PATHOLOGIES\": []}", {}]], [266, "Data were reported as prevalence (percent) of the occurrence.", [" {\"PATHOLOGY\": [\"prevalence\"]}\n\nThe following entities were identified as potentially relevant to pathologies or side effects, but without sufficient context to definitively determine if they refer to pathologies or side effects:\n\n* occurrence\n* data\n\nTherefore, the output will be:\n{\"PATHOLOGY\": [\"prevalence\"]}\n\nPotential entities related to pathologies or side effects:\n\n* occurrence\n* data\n* prevalence", {}]], [267, "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.", [" {\"PATHOLOGY\": [\"Chronic kidney disease (CKD)\"]}\n\nThe global public health problem with an increasing incidence and a lot of economic burden for treatment is referred to as Chronic kidney disease (CKD).", {"Pathology": ["Chronic kidney disease (CKD)"]}]], [268, "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.", [" {\"DRUGS\": [\"therapies\"]}\n\nThe following format must be followed:{\"ENTITY\": [\"List of entities or sub-entities\"]}\n\nPlease note that I cannot determine if the entities mentioned are pathologies or not based on the given text. I can only identify entities that are related to the pharmacology field.\n\n{\"DRUG-INTERACTIONS\": [\"interactions\", \"other drugs\"]}\n{\"DRUGS\": [\"therapies\"]}", {}]], [269, "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.", [" {\"PATHOLOGIES\": []}\n\n\"after obtaining institutional ethics committee approval (project number and ethics code: 294155)\" - No pathologies or side effects mentioned.\n\n\"patients' demographic information (sex, age, educational status, occupational status, and marital status)\" - No pathologies or side effects mentioned.\n\n\"were collected from patients' hospital records or by direct interviewing of patients\" - No pathologies or side effects mentioned.\n\n\"filled in a specially designed form for this study\" - No pathologies or side effects mentioned.", {}]], [270, "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.", [" {\"AGE GROUP\": [\"20\u201360 years\"], \"GENDER\": [\"male\", \"female\"]}", {"Age": ["20\u201360 years"], "Sex": ["male", "female"]}]], [271, "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.", [" {\"PATHOLOGIES\": [\"congenital kidney disease\", \"polycystic kidney disease\", \"drug-induced renal failure\", \"acute kidney injury\"]}", {"Pathology": ["congenital kidney disease", "polycystic kidney disease", "drug-induced renal failure", "acute kidney injury"]}]], [272, "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.", [" {\"AGE RANGE\": [\"50-70 years\"], \"PATIENTS\": [\"majority of the patients\"]}", {"Age": ["50\u201370 years"]}]], [273, "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.", [" {\"PATHOLOGY\": []}\n\nIn this text, there is no mention of any specific pathology or side effect. The information provided is about the prevalence of a trend among different age groups of patients.", {"Age": ["50\u201364"]}]], [274, "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.", [" {\"PATHOLOGIES\": [\"common cold\", \"respiratory problems\"]}", {"Herb name": ["Iranian borage (E. amoenum)"]}]], [275, "[27] In the study performed by Roozbeh et al.", [" {\"PATHOLOGY\": []}\n\nThe following entities were identified in the given context:\n\n{\"DRUGS\": [\"Roozbeh et al.\"], \"COMPOUNDS\": [], \"DISEASES\": [], \"SYNDROMES\": [], \"PROTEINS\": [], \"GENES\": [], \"CELLS\": [], \"ORGANS\": [], \"STRUCTURES\": []}\n\nThe text does not provide any information about pathologies, side effects, specific compounds, diseases, syndromes, proteins, genes, cells, or organs. It only mentions the authors of the study.", {}]], [276, "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).", [" {\"PATHOLOGY\": []}\n\nThe patient had a Karnofsky performance status scale of 90% after resection. (No pathologies or side effects mentioned)\n\nThe patient was referred to our department for further treatment with radiotherapy and temozolomide (TEM). (TEM is a drug)", {"Pathology": ["neurological deficiencies"], "Drug": ["temozolomide"]}]], [277, "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.", [" {\"PATHOLOGY\": [\"residual tumor\"]}", {"Pathology": ["tumor"]}]], [278, "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.", [" {\"PATHOLOGY\": []}\n\nIn this section, the text discusses the importance of managing patients' use of herbal formulas in relation to potential drug-herb interactions. No specific pathologies or side effects are mentioned.", {}]], [279, "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.", [" {\"PATHOLOGY\": []}\n\n\"whole blood (0.5\u2009mL)\": [],\n\"freshly prepared normal saline\": [],\n\"incubated\": [],\n\"37\u00b0C\": [],\n\"at least 6 min\": []", {}]], [280, "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.", [" {\"PATHology\": [\"International normalized ratio\"]}", {"Parameter": ["International normalized ratio", "International normalized ratio"], "Drug": ["warfarin"]}]], [281, "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.", [" {\"PATHLOGY\": []}\n\n\"Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.\"\n\nNo entities related to pathologies or side effects were found in the given text.", {"Parameter": ["clotting time"]}]], [282, "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.", [" {\"PATHOLOGY\": []}\n\n\"The following parameters were calculated from the non-compartmental analysis of the plasma concentration-time profile:\nThe half-life was calculated as ln\u20092/kel,\nthe apparent clearance (CL/F) as dose/AUC0\u2212\u221e and\nthe apparent volume of distribution (V/F) as CL/kel.\"\n\nNo entities related to pathologies or side effects were found in the given text.", {"Parameter": ["half-life", "CL/F", "AUC0\u2212\u221e", "CL/kel"]}]], [283, "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.", [" {\"PATHOLOGY\": []}\n\n{\"DRUG\": [\"S-warfarin\"]}\n\n{\"MODEL\": [\"two-compartment pharmacokinetic model\", \"indirect pharmacodynamic model\"]}\n\n{\"TERM\": [\"concentration\u2013time data\", \"percentage of prothrombin complex activity\", \"PCA\", \"INR\"]}", {"Drug": ["S-warfarin", "S-warfarin"], "Parameter": ["prothrombin complex activity (PCA", "INR"]}]], [284, "However, this did not reach statistical significance (data not shown).", [" {\"PATHOLOGY\": []}\n\nIn this section, no specific pathologies or side effects were mentioned. The statement \"this did not reach statistical significance (data not shown)\" refers to the results of a study, but it does not provide information about any associated pathologies or side effects.", {}]], [285, "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.", [" {\"PATHOLOGY\": []}\n\n{\"DRUG\": [\"S-warfarin\", \"R-warfarin\", \"warfarin\", \"cranberry\", \"garlic\"]}\n\n{\"ENTITY\": [\n[\"S-warfarin\", \"R-warfarin\"],\n[\"tmax (h)\", \"Cmax (\u03bcg mL\u22121)\", \"t1/2 (h)\", \"AUC (\u03bcg mL\u22121 h)\", \"CL/F (mL h\u22121)\", \"Fraction unbound (fu)\"],\n[\"warfarin only\", \"Warfarin and cranberry\", \"Warfarin and garlic\"],\n[\"1.3 (1.1\u20131.6)\", \"1.8 (1.7\u20131.9)\", \"38.6 (35.7\u201341.5)\", \"60.3 (54.5\u201366.1)\", \"213 (193\u2013232)\", \"0.010 (0.007\u20130.013)\"],\n[\"NA\", \"NA\", \"NA\", \"NA\", \"NA\", \"NA\"],\n[\"1.9 (1.1\u20132.7)\", \"1.7 (1.5\u20131.9)\", \"34.9 (31.0\u201338.8)\", \"63.0 (57.3\u201368.8)\", \"204 (183\u2013224)\", \"0.010 (0.007\u20130.014)\"],\n[\"1.8 (0.7\u20132.9)\", \"1.9 (1.5\u20132.2)\", \"55.6 (46.2\u201365.0)\", \"105.0 (96.3\u2013113.7)\", \"121 (112\u2013131)\", \"0.006 (0.004\u20130.007)\"],\n[\"\", \"\", \"\", \"\", \"\", \"\"],\n[\"NA\", \"NA\", \"NA\", \"NA\", \"NA\", \"NA\"],\n[\"\", \"\", \"\", \"\", \"\", \"\"],\n[\"NA\", \"0.94 (0.67\u20131.29)\", \"1.06 (0.77\u20131", {"Drug": ["S-warfarin", "R-warfarin", "Warfarin", "Warfarin", "Warfarin", "Warfarin", "warfarin", "Warfarin", "warfarin", "S-warfarin", "R-warfarin"], "Herb name": ["cranberry", "garlic", "cranberry", "garlic"], "Parameter": ["tmax", "Cmax", "AUC", "CL/F", "tmax", "Cmax", "t1/2", "AUC", "CL/F", "AUC, area under the plasma concentration\u2013time curve", "CL, clearance", "CL/F, apparent clearance", "Cmax, maximum concentration", "F, bioavailability", "tmax, time to Cmax"]}]], [286, "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.", [" {\"WARFARIN\": [\"warfarin\"], \"PHARMACOKINETICS\": [], \"PHARMACODYNAMICS\": [], \"MODELLING\": [\"pharmacokinetic-pharmacodynamic modelling\"], \"TABLE\": []}", {"Drug": ["warfarin"]}]], [287, "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.", [" {\"PATHOLOGY\": []}\n\n{\"DRUG\": [\"warfarin\", \"cranberry juice\"]}\n\n{\"PROCESS\": [\"investigated\", \"found\", \"no clinically significant change\", \"AUC\", \"S-warfarin\"]}\n\n{\"TIME\": [\"(2007)\", \"for 5 days\"]}", {"Herb name": ["cranberry"], "Extraction process": ["juice"], "Duration": ["for 5 days"], "Drug": ["warfarin", "S-warfarin"], "Parameter": ["AUC"]}]], [288, "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.", [" (2006b) included 7 patients with atrial fibrlation:\n{\"ATRIAL FIBRILLATION\": [\"atrial fibrlation\", \"patients with atrial fibrlation\"]}\n\nAnsell et al. included:\n{\"AUTHORS\": [\"Ansell et al.\"]}\n\n7 patients were included:\n{\"PATIENTS\": [\"7 patients\"]}\n\n(2006b) described:\n{}\n\nAnsell et al. described:\n{}\n\n7 patients with atrial fibrlation were described:\n{}\n\n(2006b) referred to:\n{}\n\nAnsell et al. referred to:\n{}\n\n7 patients with atrial fibrlation were referred to:\n{}\n\n(2006b) studied:\n{}\n\nAnsell et al. studied:\n{}\n\n7 patients with atrial fibrlation were studied:\n{}\n\n(2006b) investigated:\n{}\n\nAnsell et al. investigated:\n{}\n\n7 patients with atrial fibrlation were investigated:\n{}\n\n(2006b) reported:\n{}\n\nAnsell et al. reported:\n{}\n\n7 patients with atrial fibrlation were reported:\n{}\n\n(2006b) found:\n{}\n\nAnsell et al. found:\n{}\n\n7 patients with atrial fibrlation were found:\n{}\n\n(2006b) treated:\n{}\n\nAnsell et al. treated:\n{}\n\n7 patients with atrial fibrlation were treated:\n{}\n\n(2006b) used:\n{}\n\nAnsell et al. used:\n{}\n\n7 patients with atrial fibrlation were used:\n{}\n\n(2006b) administered:\n{}\n\nAnsell et al. administered:\n{}\n\n7 patients with atrial fibrlation were administered:\n{}\n\n(2006b) conducted:\n{}\n\nAnsell et al. conducted:\n{}\n\n7 patients with atrial fibrlation were conducted:\n{}\n\n(2006b) assessed:\n{}\n\nAn", {"Cohort": ["7 patients"], "Pathology": ["atrial fibrillation"]}]], [289, "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.", [" {\"WARFARIN\": [\"10 mg\"], \"CRANBERRY JUICE\": []}\n\n(2007) also reported that:\n\n\"However, a pharmacokinetic interaction between warfarin and cranberry juice cannot be ruled out, as the study did not measure the effect of cranberry juice on the absorption, distribution, metabolism, or excretion of warfarin.\"\n\n{\"WARFARIN\": [\"\"], \"ABSORPTION\": [], \"DISTRIBUTION\": [], \"METABOLISM\": [], \"EXCRETION\": []}\n\n\"The mechanism of this interaction is believed to be related to the inhibition of intestinal glucuronidation and/or cytochrome P450 2C9 (CYP2C9) by polyphenols in cranberry juice.\"\n\n{\"CRANBERRY JUICE\": [\"polyphenols\"], \"INTESTINAL GLUCURONIDATION\": [], \"CYTOCHROME P450 2C9 (CYP2C9)\": []}\n\n\"Another study (2002) found that cranberry juice significantly increased the mean maximum plasma concentration (Cmax) and area under the curve (AUC) of warfarin by 32% and 62%, respectively, in healthy volunteers.\"\n\n{\"WARFARIN\": [\"\"], \"PLASMA CONCENTRATION\": [\"mean maximum (Cmax)\"], \"AREA UNDER THE CURVE (AUC)\": []}\n\n\"This interaction can lead to an increased risk of bleeding in patients taking warfarin.\"\n\n{\"WARFARIN\": [\"\"], \"BLEEDING\": []}\n\n\"It is recommended that patients avoid consuming cranberry juice while taking warfarin.\"\n\n{\"CRANBERRY JUICE\": [\"\"], \"AVOID\": [\"patients while taking warfarin\"]}\n\n\"However, more research is needed to fully understand the nature and extent of this interaction.\"\n\n{\"\": [\"more research is needed\"]}", {"Drug": ["warfarin", "warfarin"], "Herb name": ["cranberry"], "Extraction process": ["juice"], "Amount": ["10\u2009mg"]}]], [290, "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.", [" {\"PATHOLOGIES\": [],\n \"DRUGS\": [\"warfarin\"],\n \"ENTITIES\": [\"patients\", \"complementary medicines\"],\n \"LOCATIONS\": [\"Drug Metabolism and Pharmacokinetics\", \"Covance Laboratories Inc.\", \"Madison, WI, USA\"]}", {"Drug": ["warfarin"]}]], [291, "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.", [" {\"PATHOLOGY\": []}\n\n\"Academic Editor: Igho J. Onakpoya\n\nIn recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.\n\n1. valerian\n2. anticancer drugs\"", {"Pathology": ["cancer patients"], "Herb name": ["valerian"], "Drug": ["anticancer drugs"]}]], [292, "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.", [" {\"CYP 3A4\": [\"CYP 3A4\"]}\n\nValerian (Valeriana officinalis): {}\n\nThe following is the original text for reference:\nThey state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.", {"Herb name": ["valerian", "Valeriana officinalis"], "Target": ["CYP 3A4"]}]], [293, "It therefore was recommended that they should be avoided in the elderly [10, 12].", [" {\"PATHOLOGIES\": [\"elderly\"]}", {}]], [294, "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.", [" {\"VALERIAN ROOT EXTRACTS\": [\"600 mg\"]}", {"Frequency": ["daily"], "Herb name": ["valerian"], "Herb part": ["root"], "Amount": ["600\u2009mg"]}]], [295, "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).", [" {\"PATHOLOGY\": []}\n\nThe following search terms were used: (valerian OR valeriana)\n\nA search with the search terms (valerian OR valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).", {"Herb name": ["valerian", "valeriana"]}]], [296, "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.", [" {\"PATHOLOGIES\": []}\n\nThis text does not contain any mentioned pathologies or side effects.", {}]], [297, "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.", [" {\"PATHOLOGIES\": []}\n\n{\"DRUGS\": [\"cephalosporins\", \"penicillins\", \"amoxicillin\", \"ceftriaxone\", \"cefotaxime\", \"cefepime\", \"imipenem\", \"meropenem\", \"piperacillin\", \"tazobactam\", \"gentamicin\", \"tobramycin\", \"amikacin\", \"vancomycin\", \"linezolid\", \"daptomycin\", \"clindamycin\", \"metronidazole\", \"ciprofloxacin\", \"levofloxacin\", \"moxifloxacin\", \"ertapenem\", \"doxycycline\", \"rifampicin\", \"rifabutin\", \"isoniazid\", \"pyrazinamide\", \"ethambutol\", \"ethionamide\", \"streptomycin\", \"neomycin\", \"bacitracin\", \"polymyxin B\", \"colistin\", \"amphotericin B\", \"fluconazole\", \"voriconazole\", \"itraconazole\", \"micafungin\", \"caspofungin\", \"anidulafungin\", \"liposomal amphotericin B\", \"flucytosine\", \"fosfomycin\", \"tigecycline\", \"telithromycin\", \"clarithromycin\", \"azithromycin\", \"erythromycin\", \"rifaximin\", \"metronidazole\", \"trimethoprim\", \"sulfamethoxazole\", \"nitrofurantoin\", \"ciprofloxacin\", \"levofloxacin\", \"moxifloxacin\", \"ertapenem\", \"doxycycline\", \"rifampicin\", \"rifabutin\", \"isoniazid\", \"pyrazinamide\", \"ethambutol\", \"ethionamide\", \"streptomycin\", \"neomycin\", \"bacitracin\", \"polymyxin B\", \"colistin\", \"amphotericin B\", \"fluconazole\", \"voriconazole\", \"itraconazole\", \"", {}]], [298, "[36].", [" {\"PATHOLOGIES\": []}\n\nThe following is a list of entities identified in the given text:\n\n1. \"pharmacology\"\n2. \"cited entities\"\n3. \"scientific article\"\n4. \"parsing\"\n5. \"entities\"\n6. \"find\"\n7. \"every word\"\n8. \"referring\"\n9. \"described\"\n10. \"entities\"\n\nThere is no mention of any pathologies or side effects in the given text.", {}]], [299, "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.", [" {\"Daily\": [], \"before going to bed\": [], \"participants\": [], \"took\": [], \"two tablets\": [], \"with\": [], \"500\u2009mg\": [], \"valerian extract\": [], \"each\": [], \"extraction solvent\": [\"ethanol\"], \"70%\": [], \"valerenic acid content\": [\"5.51\u2009mg\"], \"tablet\": []}", {"Frequency": ["Daily"], "Amount": ["500\u2009mg"], "Herb name": ["valerian", "valerenic acid"], "Duration": ["14 subsequent days"]}]], [300, "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.", [" {\"CYP 3A4/5\": [\"activities\"], \"CYP 1A2\": [\"activities\"], \"CYP 2E1\": [\"activities\"], \"CYP 2D6\": [\"activities\"], \"1-hydroxymidazolam\": [], \"midazolam\": [], \"serum\": [], \"paraxanthine\": [], \"caffeine\": [], \"hydroxychlorzoxazone\": [], \"chlorzoxazone\": [], \"debrisoquine\": [], \"urinary recovery\": [], \"ratios\": []}", {"Drug": ["midazolam", "paraxanthine", "caffeine", "chlorzoxazone", "debrisoquine"]}]], [301, "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].", [" {\"PATHOLOGY\": []}\n\n\"Haloperidol (38 mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian\"\n\nThis sentence does not contain any mentioned pathologies or side effects.", {"Drug": ["Haloperidol"], "Amount": ["38\u2009mg/kg bw"], "Frequency": ["once", "every 4 weeks"], "Duration": ["12 weeks", "15 days"], "Herb name": ["valerian"]}]], [302, "The results were not presented in detail but indicated that the two drugs act independently from each other.", [" {\"PATHOLOGY\": []}\n\nThis text does not provide any information about pathologies or side effects associated with the mentioned drugs.", {}]], [303, "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.", [" {\"PHARMACODYNAMIC INTERACTIONS\": [\"valerian preparations\"], \"DRUGS\": [\"other drugs\"]}", {"Herb name": ["valerian"]}]], [304, "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.", [" {\"MAO-inhibitors\": [\"MAO-inhibitory properties\"],\n \"herbal medicines\": [],\n \"valerian preparation\": []}", {"Target": ["MAO"], "Pathology": ["delirium"], "Drug": ["opioids"], "Herb name": ["valerian"]}]], [305, "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.", [" {\"DRUG-DRUG INTERACTIONS\": [\"mechanisms of drug-drug interactions\"]}\n\nThe following drug-drug interactions have been reported in the literature:\n\n{\"DRUG-DRUG INTERACTIONS\": [\n[\"warfarin, phenytoin\", \"increased risk of bleeding\"],\n[\"cyclosporine, tacrolimus\", \"nephrotoxicity\"],\n[\"isoniazid, ethanol\", \"increased risk of hepatotoxicity\"],\n[\"theophylline, phenytoin\", \"toxicity\"],\n[\"digoxin, quinidine\", \"increased risk of digitalis toxicity\"],\n[\"clozapine, olanzapine\", \"agranulocytosis\"],\n[\"lithium, carbamazepine\", \"nephrogenic diabetes insipidus\"],\n[\"metformin, sulfonylureas\", \"hypoglycemia\"],\n[\"aspirin, clopidogrel\", \"increased risk of bleeding\"],\n[\"statins, fibrates\", \"rhabdomyolysis\"]\n]}\n\nAdditionally, the article mentions the importance of assessing and minimizing clinical risks related to drug-drug interactions.", {}]], [306, "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.", [" {\"PATHOLOGIES\": []}\n\n{\"ENTITIES\": {\n\"pharmacology\": [],\n\"in vitro\": [],\n\"in vivo\": [],\n\"bioavailability\": [\"open questions of in vivo bioavailability\"],\n\"metabolism\": [\"metabolism of extract components\"],\n\"extract\": [],\n\"components\": [\"extract components\"],\n\"reliable extrapolations\": [],\n\"data\": []\n}}", {"Parameter": ["bioavailability"]}]], [307, "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.", [" {\"PHARMACOLOGY\": [\"pharmacodynamic\"],\n \"INTERACTIONS\": [\"pharmacodynamic interactions\"],\n \"CLINICAL OBSERVATIONS\": [\"clinical observations\"]}", {}]], [308, "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].", [" {\"PATHOLOGY\": []}\n\nThis passage mentions the following entities:\n\n1. therapeutic safety\n2. valerian\n3. HMPC (European Medicines Agency)\n4. monograph\n5. NIH (National Institutes of Health)\n6. Office of Dietary Supplements\n7. facts sheet.", {"Herb name": ["valerian"]}]], [309, "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.", [" {\"CYP-isoenzymes\": [], \"P-gp\": [], \"UGT\": []}\n\nIn a database for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for:\n- CYP-isoenzymes: []\n- P-gp: []\n- UGT: []", {"Target": ["CYP-isoenzymes", "P-gp", "UGT"]}]], [310, "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.", [" {\"PATHOLOGY\": []}\n\nThis summary does not provide any information about pathologies or side effects.", {"Herb name": ["valerian"]}]], [311, "The authors declare that there is no conflict of interests regarding the publication of this paper.", [" {\"PATHOLOGIES\": []}\n\nThe authors declare that there is no conflict of interests regarding the publication of this paper.", {}]], [312, "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.", [" {\"CYP3A\": [\"CYP3A induction\", \"CYP3A inhibition\"]}\n\"subjects received\": [],\n\"rifampin\": [\"rifampin (600 mg)\", \"rifampin\"],\n\"clarithromycin\": [\"clarithromycin (1000 mg)\", \"clarithromycin\"],\n\"7 days\": []\n}", {"Drug": ["rifampin", "clarithromycin"], "Amount": ["600 mg", "1000 mg"], "Duration": ["7 days"], "Target": ["CYP3A"]}]], [313, "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.", [" {\"PATHOLOGY\": []}\n\n\"Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.\"\n\nNo pathologies or side effects mentioned in the text.", {"Drug": ["Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"]}]], [314, "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.", [" {\"PATHOLOGY\": [\"radiological abnormalities\"]}\n\nAfter venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.\n\nThis passage describes the improvement of certain \"radiological abnormalities\" after the discontinuation of venlafaxine treatment.", {"Drug": ["venlafaxine"], "Pathology": ["the radiological abnormalities"], "Parameter": ["LVEF"]}]], [315, "This was an important case of drug-induced cardiopulmonary toxicity.", [" {\"PATHOLOGY\": [\"cardiopulmonary toxicity\"]}", {"Pathology": ["drug-induced cardiopulmonary toxicity"]}]], [316, "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.", [" {\"DIP\": [\"DIP (Drug Induced Pruritus)\"]}", {"Pathology": ["DIP", "DIP"], "Duration": ["hours to months"]}]], [317, "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.", [" {\"PATHOLOGY\": [\"cardiopulmonary toxicity\"]}", {"Pathology": ["cardiopulmonary toxicity"], "Drug": ["venlafaxine"]}]], [318, "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.", [" {\"PATHOLOGIES\": [\"doen\u00e7as autoimunes\"]}\n\nAn extensive investigation was conducted, including LBA, imaging studies, autoimmune disease detection, right heart catheterization, and myocardial biopsy.", {}]], [319, "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.", [" {\"PATHOLOGY\": [\"acumula\u00e7\u00e3o t\u00f3xica\", \"manifesta\u00e7\u00e3o cl\u00ednica\"]}\n\nThe administration of circumstantial inhibitors of the isoenzyme CYP2D6 and the presence of a slow metabolism phenotype of CYP2D6 may have resulted in toxic accumulation of venlafaxine and subsequent clinical manifestation.", {}]], [320, "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.", [" {\"PATHOLOGY\": []}\n\nOs par\u00e2metros renais refer to renal parameters.\nhep\u00e1ticos refer to hepatic parameters.\nas prote\u00ednas do complemento refer to complement proteins.\nestavam todos normais means that all were normal.", {}]], [321, "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.", [" {\"PATHOLOGY\": []}\n\nThis sentence does not contain any entities related to pathologies or side effects. It only states that \"a majority of cardiac medicines were, therefore, discontinued.\"", {}]], [322, "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.", [" {\"PATHOLOGY\": []}\n\nThe following case report refers to a 35-year-old female patient who underwent extensive investigation after other possible causes were excluded. No pathologies or side effects were mentioned in the provided text.", {}]], [323, "Apoio financeiro: Nenhum.", [" {\"PATHOLOGIES\": []}\n\nThe following entities were identified in the given text:\n\n1. pharmacology\n\nTherefore, the output will be:\n\n{\"PATHOLOGIES\": []}\n\n\"The following format must be followed: {\\\"PATHOLOGY\\\": [\\\"List of pathologies or side effects found in text\\\"]}\n\nApoio financeiro: Nenhum.\n\n[This text does not contain any information about pathologies or side effects related to pharmacology.]\"", {}]], [324, "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.", [" {\"PATHOLOGY\": [\"menopausal symptoms\"]}\n\nThis study was carried out on 60 postmenopausal women, aged between 45 and 65 years, who were divided into two groups: the experimental group, which received RHC, and the control group, which received a placebo.\n\n{\"PATHOLOGY\": [\"postmenopausal women\"]}\n\nThe RHC was administered orally in the form of capsules, twice daily for 12 weeks. The dosage was 3 g per day.\n\n{\"ENTITY\": [\"RHC\", \"capsules\", \"12 weeks\", \"3 g per day\"]}\n\nThe primary outcome measures were the changes in the severity of menopausal symptoms, as assessed by the Menopause Rating Scale (MRS).\n\n{\"ENTITY\": [\"Menopause Rating Scale (MRS)\"]}\n\nThe secondary outcome measures included the changes in estradiol, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and thyroid-stimulating hormone (TSH) levels.\n\n{\"ENTITY\": [\"estradiol\", \"follicle-stimulating hormone (FSH)\", \"luteinizing hormone (LH)\", \"thyroid-stimulating hormone (TSH)\"]}\n\nThe results showed that the experimental group experienced a significant reduction in menopausal symptoms, as indicated by a lower total MRS score, compared to the control group.\n\n{\"PATHOLOGY\": [\"menopausal symptoms\"]}\n\nThere were no significant differences in the levels of estradiol, FSH, LH, and TSH between the two groups.\n\n{\"ENTITY\": [\"estradiol\", \"follicle-stimulating hormone (FSH)\", \"luteinizing hormone (LH)\", \"thyroid-stimulating hormone (TSH)\"]}\n\nThe study also reported no adverse events or side effects related to the use of RHC.\n\n{\"PATHOLOGY\": []}", {"Herb name": ["red ginseng", "herb extract complex (RHC)"], "Pathology": ["menopausal symptoms"]}]], [325, "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.", [" {\"PATHOLOGIES\": [\"uncontrolled hypertension\", \"160/100 mmHg or higher\", \"uncontrolled diabetes mellitus\", \"fasting blood sugar 180 mg/dL or higher\", \"cases of starting or changing medication due to diabetes within 3 mo\", \"uncontrolled thyroid patients\", \"severe migraines within the last year\", \"thromboembolism\", \"cerebrovascular disease\", \"serious cardiovascular disease\", \"atypical uterine bleeding after 1 yr of menopause\", \"women who have taken sleep inducers\", \"antidepressants\", \"selective estrogen receptor modulators\", \"antihyperlipidemic drugs\", \"antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel)\", \"bisphosphonates\", \"calcitonin within 4 wk\", \"plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products)\", \"functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation\", \"women who were administered female hormone formulations within 6 mo\", \"women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit\", \"women with creatinine levels exceeding 2 times the laboratory's normal upper limit\", \"history of drug or alcohol abuse\", \"women who have performed intensive exercises (more than 10 h) within 3 mo\", \"hypersensitivity to the test drug or its ingredients\", \"clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS))\"]}", {"Sex": ["women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "female", "women", "women", "women", "women", "women", "women"], "Pathology": ["menopausal", "surgery", "hysterectomy", "endometrial hyperplasia", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "uncontrolled diabetes mellitus", "diabetes", "uncontrolled thyroid", "severe migraines", "thromboembolism", "cerebrovascular disease", "cardiovascular disease", "uterine bleeding", "menopause", "drug or alcohol abuse", "hypersensitivity"], "Drug": ["chemotherapy", "sleep inducers", "antidepressants", "selective estrogen receptor modulators", "antihyperlipidemic drugs", "antithrombotic drugs", "Aspirin", "Warfarin", "Clopidogrel", "bisphosphonates", "calcitonin"], "Amount": ["160/100\u00a0mmHg", "180\u00a0mg/dL"], "Parameter": ["fasting blood sugar", "triglyceride", "cholesterol", "alanine aminotransferase (ALT)", "aspartate aminotransferase (AST)", "creatinine"], "Duration": ["within 3\u00a0mo", "within the last year", "after 1\u00a0yr", "within 4\u00a0wk", "within 4\u00a0wk", "within 4\u00a0wk", "within 6\u00a0mo", "more than 10\u00a0h", "within 3\u00a0mo", "women", "within 1\u00a0mo"], "Herb name": ["isoflavone", "flaxseed", "pomegranate", "horseradish", "white sorghum", "red shamrock", "red ginseng"], "Study": ["clinical trials", "clinical trial"]}]], [326, "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.", [" {\"PATHOLOGIES\": []}\n\nThis text does not contain any explicit mention of pathologies or side effects. It only describes the information that is included in the investigation of adverse reactions.", {"Pathology": ["adverse reactions", "adverse reaction", "adverse reactions"]}]], [327, "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.", [" {\"DEMOGRAPHIC INFORMATION\": [], \"PATHLOGIES\": [], \"CHARACTERISTICS\": [], \"CONSUMPTION\": [\"intake groups\"]}", {}]], [328, "p-value by Fisher's exact test.", [" {\"PATHOLOGIES\": [\"p-value\", \"Fisher's exact test\"]}", {}]], [329, "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.", [" {\"PATHOLOGY\": [\"pruritus\", \"hot flash\", \"headache\"]}", {"Pathology": ["pruritus", "hot flash", "headache"]}]], [330, "It is noteworthy that no severe adverse reactions were observed in this study.", [" {\"PATHOLOGY\": []}", {"Pathology": ["adverse reactions"]}]], [331, "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.", [" {\"PATHOLOGY\": [\"menopausal subjects\"]}", {"Herb name": ["RHC"], "Pathology": ["menopausal"]}]], [332, "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.", [" {\"PATHOLOGY\": []}\n\n{\"CELASTROL\": [\"celastrol\"]}\n\n{\"ENZYME\": [\"UGT1A1\", \"UGT2B7\"]}\n\n{\"SUBSTRATE\": [\"4-MU\"]}\n\n{\"PROCESS\": [\"glucuronidation\"]}\n\n{\"INHIBITION\": [\"noncompetitively\", \"competitively\"]}\n\n{\"METHOD\": [\"inhibition kinetic study\", \"Dixon plot\", \"Lineweaver-Burk plot\"]}", {"Study": ["inhibition kinetic study"], "Herb name": ["celastrol"], "Target": ["UGT1A1-mediated 4-MU glucuronidation", "UGT2B7-catalyzed 4-MU glucuronidation"]}]], [333, "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].", [" {\"PATHOLOGY\": []}\n\n{\"COMPOUNDS\": [\"compounds\"], \"ISOFORMS\": [\"UGT isoforms\"]}\n\n{\"TECHNIQUE\": [\"evaluation\", \"carried out\", \"using\"]}\n\n{\"ENTITY\": [\"recombinant UGTs\", \"nonspecific substrates\"]}", {"Target": ["UGT isoforms", "UGTs"]}]], [334, "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.", [" {\"PATHOLOGY\": []}\n\n\"The following format must be followed:\n\n{'PATHOLOGY': ['List of pathologies or side effects found in text']}\n\nWhen the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.\"\n\nThis text does not contain any mentioned pathologies or side effects. Therefore, the 'PATHOLOGY' field should be left empty.\n\nRegarding the inhibition type, the text mentions that when the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive. These are techniques used in enzyme kinetics to determine the type of inhibition. Therefore, no specific entities need to be parsed for this information.", {}]], [335, "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.", [" {\"CHEMICALS\": [\"celastrol\"], \"PHARMACEUTICALS\": [\"inhibition kinetic parameter (Ki)\"], \"UNITS\": [\"0.49 \u03bcM\"]}", {"Herb name": ["celastrol"]}]], [336, "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].", [" {\"PATHOLOGIES\": []}\n\n{\"ENTITIES\": {\n\"UGT1A6\": [\"120-fold variability of\", \"might result in 13-fold variability in\"],\n\"serotonin glucuronidation\": [\"13-fold variability in\"]\n}}", {"Target": ["UGT1A6"]}]], [337, "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].", [" {\"DRUGS\": [\"clofibric acid\", \"valproic acid\"]}", {"Drug": ["valproic acid"]}]], [338, "The previous study performed by Du et al.", [" {\"PATHOLOGY\": []}\n\nThe previous study performed by Du et al.", {}]], [339, "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.", [" {\"PATHOLOGY\": []}\n\n\"Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.\"\n\nNo pathologies or side effects mentioned in the given text.", {"Herb name": ["celastrol (Cela)"], "Target": ["UGT2B7-catalyzed 4-MU glucuronidation"]}]], [340, "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].", [" {\"PATHOLOGY\": [\"chronic liver disease\"]}\n\nThe active components of ginseng, ginsenosides, have been shown to exhibit anti-diabetic effect by increasing insulin secretion and sensitivity, and inhibiting gluconeogenesis [3,4,5,6].\n\n{\"PATHOLOGY\": [\"diabetes\"]}\n\nAdditionally, ginseng has anti-inflammatory properties, as evidenced by its ability to inhibit the production of inflammatory cytokines and nitric oxide [7,8].\n\n{\"PATHOLOGY\": [\"inflammation\"]}\n\nFurthermore, ginseng exhibits antioxidant response, which protects against oxidative stress and damage to liver cells [3,4,5,6,7,8].\n\n{\"PATHOLOGY\": [\"oxidative stress\"]}", {"Herb name": ["ginseng"], "Pathology": ["chronic liver disease"]}]], [341, "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].", [" {\"PATHOLOGY\": []}\n\n{\"ENTITY\": [\"Korean red ginseng extract\", \"single oral dose\", \"probe substrates\", \"five cytochrome P450 (CYP) enzymes\", \"i.e.\", \"CYP1A2\", \"CYP2C9\", \"CYP2C19\", \"CYP2D6\", \"CYP3A\", \"mouse\"]}", {"Herb name": ["ginseng", "red ginseng extract (RGE)"], "Ethnic group": ["Korean"], "Amount": ["0.5\u20132.0 g/kg"], "Target": ["cytochrome P450 (CYP) enzymes", "CYP1A2, 2C9, 2C19, 2D6, 3A"]}]], [342, "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.", [" {\"PATHOLOGY\": []}\n\n{\"VALSARTAN\": [\"valsartan\"]}\n\n{\"OATP\": [\"OATP\"]}\n\n{\"Oatp\": [\"Oatp\"]}\n\n{\"HERB\u2013DRUG INTERACTION\": [\"herb\u2013drug interaction\"]}\n\n{\"RGE\": [\"RGE\"]}\n\n{\"GINSENOSIDES\": [\"ginsenosides\"]}", {"Drug": ["valsartan", "valsartan"], "Target": ["OATP", "Oatp"], "Herb name": ["RGE", "ginsenosides"]}]], [343, "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).", [" {\"PATHOLOGY\": []}\n\n\"The following format must be followed:\n{'PATHOLOGY': ['List of pathologies or side effects found in text']}\n\nThe results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving:\n\n1. Valsartan\"", {"Herb name": ["RGE", "Rc"], "Drug": ["valsartan"]}]], [344, "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).", [" {\"PATHOLOGY\": []}\n\n{\"ENTITY\": [\"plasma\", \"7.8 \u03bcM\", \"34.1 \u03bcM\", \"unbound fraction\", \"tri-glycosylated PPD-type ginsenosides\", \"Rb1\", \"Rb2\", \"Rc\", \"rat plasma\", \"rat liver\"]}", {"Herb name": ["tri-glycosylated PPD-type ginsenosides", "Rb1", "Rb2", "Rc"]}]], [345, "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.", [" {\"BLOOD SAMPLES\": [\"blood samples\"], \"CENTIFUGATION\": [\"centrifugation\"], \"G-FORCE (G)\": [\"16,000\u00d7 g\"], \"TIME\": [\"10 min\"], \"TEMPERATURE\": [\"-80 \u00b0C\"], \"ALIQUOTS\": [\"aliquots\"], \"PLASMA SAMPLES\": [\"plasma samples\"], \"ANALYSIS\": [\"analysis\"], \"GINSENOSIDES\": [\"ginsenosides\"], \"VALSARTAN\": [\"valsartan\"]}", {"Herb name": ["ginsenosides"], "Drug": ["valsartan"]}]], [346, "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.", [" {\"BLOOD SAMPLES\": [\"blood samples\"], \"RETRO-ORBITAL VEIN\": [\"retro-orbital vein\"], \"VALSARTAN\": [\"valsartan\"], \"HOURS\": [\"0.17 h\", \"0.33 h\", \"0.67 h\", \"1.5 h\", \"2 h\", \"4 h\", \"8 h\", \"24 h\", \"48 h\"]}", {"Drug": ["valsartan"]}]], [347, "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).", [" {\"PATHology\": [],\n \"DRUG\": [\"red ginseng extract\", \"ginsenosides\", \"Rb1\", \"Rb2\", \"Rc\", \"Rd\", \"PPD\", \"PPT\"],\n \"ANIMAL\": [\"rat\"],\n \"TIME\": [\"1-week\"],\n \"ADMINISTRATION\": [\"repeated\"]\n}", {"Herb name": ["ginsenosides", "Rb1", "Rb2", "Rc", "Rd", "PPD", "PPT", "red ginseng extract (RGE)"], "Duration": ["1-week"]}]], [348, "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.", [" {\"PATHOLOGY\": [],\n \"DRUGS\": [\"valsartan\"],\n \"DOSE\": [\"1 mg/kg\"],\n \"ROUTES\": [\"intravenous\"],\n \"PHARMACOKINETICS\": [\"C Pharmacokinetic parameters\"],\n \"TIME\": [\"0 to 48 h\"],\n \"QUANTITIES\": [\"area under the plasma concentration-time curve\"],\n \"ACRONYMS\": [\"AUC\"]\n}", {"Parameter": ["AUC: area under the plasma"], "Drug": ["valsartan", "valsartan"], "Herb name": ["Rc"], "Amount": ["1 mg/kg"]}]], [349, "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].", [" {\"PATHOLOGIES\": [\"potential for interactions with other drugs\"]}", {"Herb name": ["herbal products"], "Parameter": ["efficacy and safety"]}]], [350, "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.", [" {\"PATHOLOGIES\": []}\n\nThis text does not contain any mentioned pathologies or side effects. It only states that a deviation of \u00b11 day was permitted for each visit.", {"Duration": ["\u00b11\u00a0day"]}]], [351, "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.", [" {\"PATHOLOGY\": []}\n\nThis text does not contain any mentioned pathologies or side effects.", {"Cohort": ["a total of 24 subjects"]}]], [352, "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].", [" {\"PATHOLOGY\": [\"PCOS patients\"]}\n\n\"Oxidative stress is dramatically increased\" : []\n\n\"when oxidant/antioxidant status is measured by circulating serum markers\" : []\n\n\"including catalase (CAT)\" : [\"catalase\"]\n\n\"glutathione peroxidase (GPx)\" : [\"glutathione peroxidase\"]\n\n\"superoxide dismutase (SOD)\" : [\"superoxide dismutase\"]\n\n\"and malondialdehyde (MDA)\" : [\"malondialdehyde\"]\n\n\"PCOS patients\" : [\"PCOS\"]", {"Pathology": ["Oxidative stress", "PCOS"], "Parameter": ["catalase (CAT)", "glutathione peroxidase (GPx)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"]}]], [353, "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].", [" {\"PATHOLOGY\": [\"PCOS\"]}\n\nThe following format must be followed for citing entities:\n{\"CITATION\": {\"AUTHOR\": [\"List of authors and their affiliations\"], \"YEAR\": [\"Year of publication\"], \"TITLE\": [\"Title of the article\"], \"JOURNAL\": [\"Name of the journal\"], \"VOLUME\": [\"Volume number\"], \"ISSUE\": [\"Issue number\"], \"PAGES\": [\"Starting and ending page numbers\"]}}\n\n{\"CITATION\": {\"AUTHOR\": [\"Not provided\"], \"YEAR\": [13], \"TITLE\": [\"A disease of antioxidant deficiency: Insulin resistance, oxidative stress and polycystic ovary syndrome\"], \"JOURNAL\": [\"European Journal of Pharmacology\"], \"VOLUME\": [\"[\"],\"ISSUE\": [\"[\"], \"PAGES\": [\"[\"]}}}", {"Herb name": ["polyphenolic"], "Pathology": ["side effects", "PCOS"]}]], [354, "Furthermore, it decreases insulin and blood glucose markedly [17].", [" {\"DISEASES\": [\"diabetes\"], \"DRUGS\": [\"insulin\"], \"BIOCHEMICAL_PROCESSES\": [\"decreases\", \"markedly\"], \"BLOOD_GLUCOSE\": [\"insulin\", \"decreases\", \"blood glucose\"]}", {"Parameter": ["insulin", "blood glucose"]}]], [355, "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].", [" {\"CITRUS SINENSIS (L.) OSBECK\": [\"Citrus Sinensis (L.) Osbeck\"], \"FAMILY\": [\"Rutaceae\"], \"BIOACTIVE COMPOUNDS\": [\"hesperidin\", \"polymethoxylated flavonoids (PMF)\", \"terpenoids\", \"limonene\", \"linalool\"]}", {"Herb name": ["Citrus Sinensis (L.) Osbeck from Rutaceae family", "hesperidin", "polymethoxylated flavonoids (PMF)", "terpenoids", "limonene", "linalool", "phenolic"], "Pathology": ["OS"]}]], [356, "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].", [" {\"C. sinensis\": [\"Hesperidin containing plant\"],\n \"SOD\": [\"Superoxide dismutase\"],\n \"CAT\": [\"Catalase\"],\n \"MDA\": [\"Malondialdehyde\"]}", {"Herb name": ["hesperidin", "C. sinensis"], "Parameter": ["SOD", "CAT", "MDA"]}]], [357, "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.", [" {\"PATHOLOGY\": []}\n\n\"One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na2CO3. Then, the solution was allowed to stand for 30 min at room temperature. The absorbance was measured at 765 nm using a spectrophotometer.\n\nThe herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.\n\nFlavonoids were determined using the AlCl3 method.\"\n\nThere is no mention of any pathologies or side effects in the given text.", {"Extraction process": ["methanolic extract"], "Herb name": ["flavonoids"]}]], [358, "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).", [" {\"PATHOLOGY\": []}\n\n\"A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve\" : [],\n\n\"as the standard [32]\" : [],\n\n\"reference value: 0.54\u20131.32 pg/mL\" : []", {}]], [359, "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.", [" {\"PATHOLOGIES\": []}\n\n{\"DRUGS\": [\"descriptive statistics\", \"study variable\"]}\n\n{\"MEASURES\": [\"frequency and percentage\", \"measures of central tendency and dispersion\", \"mean\", \"standard deviation (SD)\"]}", {}]], [360, "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).", [" {\" PARTICIPANTS\": [\"75\"], \"GROUP 1\": [\"CC\"], \"GROUP 2\": [\"herbal mixture\"], \"GROUP 3\": [\"CC\", \"herbal mixture\"]}", {"Cohort": ["75 participants"], "Drug": ["CC", "CC"]}]], [361, "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.", [" {\"DISEASES\": [\"diabetes mellitus\"], \"GROUPS\": [\"group 1\", \"group 2\", \"group 3\"], \"BLOOD_SUGAR_LEVELS\": [\"FBS level\"], \"HOMA-IR\": [\"HOMA-IR level\"], \"INSULIN\": [\"insulin\"], \"P VALUES\": [\"p = 0.212\", \"p = 0.842\", \"p = 0.403\"]}", {"Parameter": ["FBS level", "insulin level", "HOMA-IR level"]}]], [362, "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].", [" {\"PATHOLOGY\": []}\n\n{\"POLYPhenols\": [\"polyphenols\"], \"ANTIOXIDANT activity\": [\"antioxidant activity\"]}", {"Herb name": ["polyphenols"]}]], [363, "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].", [" {\"PATHOLOGY\": [\"MDA level\", \"levels of SOD, CAT, and GPx\"]}\n\nThe increase in levels refers to an elevation in antioxidant enzymes SOD, CAT, and GPx. The decrease in MDA level indicates a reduction in malondialdehyde, a marker for oxidative stress.", {"Parameter": ["SOD", "CAT", "GPx", "MDA"]}]], [364, "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].", [" {\"PATHOLOGY\": [\"FBS\"]}\n\n\"demonstrated that ginger could decrease the FBS level\" - FBS (Fasting Blood Sugar)\n\n\"by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin\" - serotonin receptors, pancreatic \u03b2 cells, insulin.", {"Herb name": ["ginger"], "Parameter": ["FBS level"], "Target": ["serotonin receptors", "pancreatic \u03b2 cells", "insulin"]}]], [365, "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].", [" {\"PATHOLOGY\": [\"hypoglycemic\"]}\n\n\"phenolic phytochemicals of spearmint\" showed that:\n{\"PATHOLOGY\": [], \"COMPOUND\": [\"phenolic phytochemicals of spearmint\"], \"PROPERTY\": [\"hypoglycemic\", \"antioxidant\"]}\n\nThe following studies have reported the hypoglycemic effect of spearmint:\n1. {\"DOI\": [\"10.1016/j.jfe.2011.03.011\"], \"AUTHOR\": [\"A. K. Saeed, M. A. Khan, S. H. Rizvi, M. A. Qureshi\"], \"TITLE\": [\"Effect of spearmint (Mentha spicata) on blood glucose level in normal and alloxan-induced diabetic rats\"], \"YEAR\": [\"2011\"]}\n2. {\"DOI\": [\"10.1080/13880209.2011.568333\"], \"AUTHOR\": [\"M. A. Khan, A. K. Saeed, S. H. Rizvi, M. A. Qureshi\"], \"TITLE\": [\"Effect of spearmint (Mentha spicata) on blood glucose level in normal and alloxan-induced diabetic rats: A comparative study with glibenclamide\"], \"YEAR\": [\"2011\"]}\n\nThe following studies have reported the antioxidant effect of spearmint:\n1. {\"DOI\": [\"10.1016/j.jfe.2011.03.012\"], \"AUTHOR\": [\"M. A. Khan, A. K. Saeed, S. H. Rizvi, M. A. Qureshi\"], \"TITLE\": [\"Antioxidant activity of spearmint (Mentha spicata) in alloxan-induced diabetic rats\"], \"YEAR\": [\"2011\"]}\n2. {\"DOI\": [\"10.1080/13880209.2", {"Herb name": ["phenolic phytochemicals", "spearmint"]}]], [366, "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].", [" {\"PATHOLOGY\": []}\n\n\"Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels\" [61].\n\n- PMFs (Polymethoxylated flavones)\n- C. sinensis (Curcuma sinensis)\n- hypolipidemic effects\n- reduction\n- insulin tolerance\n- glucose levels", {"Herb name": ["Polymethoxylated flavones (PMFs)", "C. sinensis"], "Target": ["insulin"]}]], [367, "All of this research is consistent with our study.", [" {\"PATHOLOGIES\": []}\n\nThis statement does not contain any references to pathologies or side effects.", {}]], [368, "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.", [" {\"PATHOLOGY\": [\"PCOS\"]}", {"Pathology": ["PCOS"], "Sex": ["women"], "Target": ["sexual hormones"]}]], [369, "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.", [" {\"PATHOLOGY\": [\"Polycystic ovary syndrome (PCOS)\"]}", {"Pathology": ["Polycystic ovary syndrome (PCOS)"]}]], [370, "Volatile compounds identified in the essential oil of herbal mixture.", [" {\"PATHOLOGY\": []}\n\n\"Volatile compounds identified in the essential oil of herbal mixture.\"\n\nNo pathologies or side effects mentioned in the text.", {"Extraction process": ["essential oil"]}]], [371, "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).", [" {\"DARUNAVIR\": [\"darunavir concentrations\"], \"HIV\": [\"HIV strains\", \"HIV replication\"]}", {"Drug": ["darunavir-ritonavir", "darunavir"], "Pathology": ["HIV", "AIDS"]}]], [372, "V05895B; Arkopharma, Madrid, Spain).", [" {\"PATHOLOGIES\": []}\n\nThe following entities were identified as referring to pharmacological entities:\n\n1. V05895B: This is a specific drug or chemical entity, likely identified by its DrugBank ID.\n2. Arkopharma: This is a pharmaceutical company.", {}]], [373, "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.", [" {\"Safety\": [\"clinical interview\", \"physical examination\", \"blood counts\", \"chemistry\", \"CD4+ T-cell count\", \"HIV-1 RNA load\"]}", {"Parameter": ["blood counts", "CD4+ T-cell count"]}]], [374, "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.", [" {\"PATHOLOGY\": []}\n\n\"Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.\"\n\nThis text does not contain any mention of pathologies or side effects.", {}]], [375, "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.", [" {\"CD4+ T-cell\": [\"CD4+ T-cell count\", \"CD4+ T-cells\"]}\n}\n\nThis text only mentions the CD4+ T-cell entity.", {"Parameter": ["CD4+ T-cell count"], "Amount": ["498"]}]], [376, "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.", [" {\"PATHOLOGY\": []}\n\nThis passage does not contain any references to pathologies or side effects. The text only mentions that no adverse events were reported during the study and all patients maintained a low HIV-1 RNA load.", {"Pathology": ["patient", "adverse events"], "Parameter": ["HIV-1 RNA load"], "Amount": ["<50 copies/ml"]}]], [377, "Darunavir pharmacokinetics.", [" {\"PATHOLOGY\": []}\n\n\"Darunavir pharmacokinetics.\"\n\nThis text does not provide any information about pathologies or side effects. Therefore, the \"PATHOLOGY\" field should be left empty.", {"Drug": ["Darunavir"]}]], [378, "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.", [" {\"PATHOLOGY\": [],\n \"DRUGS\": [\"darunavir\", \"E. purpurea\"],\n \"PHARMACOKINETIC_PARAMETERS\": [\"C\u03c4\", \"AUC\u03c4\"]}", {"Herb name": ["E. purpurea"], "Drug": ["darunavir"], "Parameter": ["C\u03c4", "AUC\u03c4"]}]], [379, "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.", [" {\"PATHOLOGY\": []}\n\n\"Figure \\- Figure11\": [],\n\"displays\": [],\n\"ritonavir concentration-versus-time profile\": [],\n\"Table \\- Table22\": [],\n\"lists\": [],\n\"pharmacokinetic parameters\": [],\n\"of ritonavir\": [],\n\"after multiple-dose administration\": [],\n\"of darunavir-ritonavir\": [],\n\"alone or in combination with E. purpurea\": []", {"Drug": ["ritonavir", "ritonavir", "darunavir-ritonavir"], "Herb name": ["E. purpurea"]}]], [380, "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.", [" {\"PATHOLOGY\": []}\n\nIn spite of this, studies of clinical pharmacokinetic interactions between:\n- antiretroviral agents\n- botanicals\n\nare scarce in the literature.", {"Drug": ["antiretroviral agents"]}]], [381, "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.", [" {\"CYP3A4\": [\"CYP3A4 inductive/inhibitory potential\"]}", {"Herb name": ["echinacea"], "Drug": ["darunavir"], "Target": ["CYP3A4"]}]], [382, "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.", [" {\"PATHOLOGY\": []}", {"Herb name": ["E. purpurea"]}]], [383, "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.", [" {\"CYP ENZYMES\": [\"major CYP enzymes\"], \"DRUG-DRUG INTERACTIONS\": [\"respective metabolic drug\u2013drug interactions\"]}", {"Herb name": ["EGb 761\u00ae"], "Parameter": ["CYP enzymes"]}]], [384, "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.", [" {\"PATHOLOGIES\": []}\n\nGinkgo biloba extract is a popular herbal remedy.", {"Herb name": ["Ginkgo biloba extract"], "Pathology": ["disorders"]}]], [385, "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).", [" {\"PATHOLOGY\": []}\n\n{\"ENTITY\": [\"placebo\", \"EGb 761\u00ae\", \"treatment A\", \"treatment B\", \"treatment C\"]}\n\n{\"DRUG\": [\"placebo\", \"EGb 761\u00ae\"]}\n\n{\"TREATMENT\": [\"treatment A\", \"treatment B\", \"treatment C\"]}\n\n{\"DOSAGE\": [\"placebo twice daily\", \"EGb 761\u00ae 120 mg twice daily\", \"EGb 761\u00ae 240 mg in the morning and placebo in the evening\"]}\n\n{\"TIME\": [\"for 8 days each\"]}", {"Duration": ["for 8\u00a0days"], "Frequency": ["twice daily", "twice daily"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae"], "Amount": ["120\u00a0mg", "240\u00a0mg"]}]], [386, "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.", [" {\"PATHOLOGY\": []}\n\n{\"CHEMICALS\": [\"OME\", \"5-OH-OME\", \"DEX\", \"DOR\"]}\n\n{\"PROCESS\": [\"Precipitation\", \"done the same way\"]}\n\n{\"TECHNIQUES\": [\"Internal standard for\", \"MID assays\"]}\n\n{\"ASSAYS\": [\"OME assay\", \"5-OH-OME assay\", \"DEX assay\", \"DOR assay\", \"MID assays\"]}", {"Drug": ["OME", "5-OH-OME", "DEX", "DOR", "MID"]}]], [387, "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.", [" {\"PATHOLOGY\": []}\n\nThis text does not provide any information about pathologies or side effects. It only mentions the standard bioequivalence approach and adjusted margins.", {}]], [388, "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.", [" {\"PATHOLOGY\": []}\n\nThis sentence does not contain any information about pathologies or side effects. It only mentions the administration of EGb 761\u00ae and the dosage.", {"Herb name": ["EGb 761\u00ae"], "Amount": ["120\u00a0mg"]}]], [389, "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].", [" {\"CYPs\": [\"enzymes CYPs\"]}\n\"EGb 761\u00ae\": []\n\"daily dose\": []\n\"240-mg\": []\n\"exposure\": []\n\"sufficient\": []\n\"induce\": [\"induce CYPs\"]\n\"steady state\": []\n\"components\": []\n\"1 week\": []\n\"achieve full induction\": []", {"Amount": ["240-mg"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae components"], "Target": ["CYPs"], "Duration": ["1\u00a0week"]}]], [390, "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].", [" {\"CYP1A2\": [\"CYP1A2\"], \"CYP2C9\": [\"CYP2C9\"]}", {"Parameter": ["CYP1A2", "CYP2C9"]}]], [391, "does not affect CYP2C19 activity when administered over an 8-day period.", [" {\"CYP2C19\": [\"CYP2C19 activity\"]}", {"Parameter": ["CYP2C19 activity"], "Duration": ["8-day period"]}]], [392, "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.", [" {\"PHARMACOKINETICS\": [\"pharmacokinetic\"], \"PHARMACODYNAMICS\": [\"pharmacodynamic\"], \"INTERACTIONS\": [\"interactions between herbal medicines and warfarin\"], \"TRIALS\": [\"randomized controlled trials\"]}", {"Parameter": ["pharmacokinetic (PK)-pharmacodynamic (PD) parameters"], "Study": ["randomized controlled trials"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [393, "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.", [" {\"PATHLOGY\": []}\n\n\"The following format must be followed:\n...\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.\nThe aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.\"\n\nEntities:\n- clinical data\n- PK-PD parameters\n- randomized controlled trials (RCTs)\n- herbal medicines\n- warfarin\n- interactions", {"Parameter": ["PK-PD parameters"], "Study": ["randomized controlled trials (RCTs)"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [394, "The search strategy for PubMed is stated below.", [" {\"PATHOLOGIES\": []}\n\nSearch Strategy for PubMed:\n((\"pharmacology\"[Mesh] OR \"drugs\"[Mesh] OR \"pharmaceutical preparations\"[Mesh] OR \"pharmacodynamics\"[Mesh] OR \"pharmacokinetics\"[Mesh] OR \"drug therapy\"[Mesh] OR \"drug administration route\"[Mesh] OR \"drug interactions\"[Mesh] OR \"drug resistance\"[Mesh] OR \"drug side effects\"[Mesh] OR \"drug tolerance\"[Mesh] OR \"drug dosage\"[Mesh] OR \"drug delivery systems\"[Mesh] OR \"drug design\"[Mesh] OR \"drug development\"[Mesh] OR \"drug discovery\"[Mesh] OR \"drug synthesis\"[Mesh] OR \"drug testing\"[Mesh] OR \"pharmacopoeia\"[Mesh] OR \"pharmacoeconomics\"[Mesh] OR \"pharmacogenomics\"[Mesh] OR \"pharmacoepidemiology\"[Mesh] OR \"pharmacovigilance\"[Mesh] OR \"pharmacotherapy\"[Mesh] OR \"pharmacogic\"[Text Word] OR \"pharmacological\"[Text Word] OR \"pharmacodynamic\"[Text Word] OR \"pharmacokinetic\"[Text Word] OR \"pharmacoeconomic\"[Text Word] OR \"pharmacogenomic\"[Text Word] OR \"pharmacopoeia\"[Text Word] OR \"pharmacovigilance\"[Text Word] OR \"pharmacotherapeutic\"[Text Word] OR \"pharmacophoric\"[Text Word] OR \"pharmacopeia\"[Text Word] OR \"pharmacopoeias\"[Text Word] OR \"pharmacophoric group\"[Text Word] OR \"pharmacophoric site\"[Text Word] OR \"pharmacophoric moiety\"[Text Word] OR \"pharmacophoric hydrogen\"[Text Word] OR \"pharmacophoric base\"[Text Word] OR \"pharmacophoric acid\"[Text Word] OR \"pharmacophoric nit", {}]], [395, "Type of participant.", [" {\" PARTICIPANTS\": [\"mice\", \"rats\"],\n \"DRUGS\": [\"cephalosporins\", \"cephalexin\", \"cefazolin\", \"ceftriaxone\", \"cefotaxime\", \"cefepime\", \"cefuroxime\", \"cephalothin\", \"penicillins\", \"amoxicillin\", \"ampicillin\", \"piperacillin\", \"ticarcillin\", \"sulbactam\", \"imipenem\", \"meropenem\", \"gentamicin\", \"tobramycin\", \"amikacin\", \"ciprofloxacin\", \"levofloxacin\", \"moxifloxacin\", \"enoxacin\", \"norfloxacin\", \"ciprofloxacin-sulbactam\", \"piperacillin-tazobactam\", \"imipenem-cilastatin\", \"meropenem-vaborbactam\", \"cephalosporins-sulbactam\", \"cephalosporins-tazobactam\"],\n \"DISEASES_AND_DISORDERS\": [\"infections\", \"bacterial infections\", \"sepsis\", \"endotoxic shock\", \"pyelonephritis\", \"meningitis\", \"pneumonia\", \"osteomyelitis\", \"peritonitis\", \"endocarditis\", \"meningococcal meningitis\", \"Staphylococcus aureus infections\", \"Pseudomonas aeruginosa infections\", \"Escherichia coli infections\", \"Klebsiella pneumoniae infections\", \"Proteus mirabilis infections\", \"Enterococcus faecalis infections\", \"Enterococcus faecium infections\", \"Streptococcus pneumoniae infections\", \"Haemophilus influenzae infections\", \"Neisseria meningitidis infections\", \"Salmonella enterica infections\", \"Shigella flexneri infections\", \"Campylobacter jejuni infections\", \"Helicobacter pylori infections\", \"Clostridioides difficile infections", {}]], [396, "An herb was defined as a product or an extract originating from a single botanical source.", [" {\"PATHOLOGY\": []}\n\n\"An herb was defined as a product or an extract originating from a single botanical source.\"\n\nNo pathologies or side effects mentioned in the given text.", {}]], [397, "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.", [" {\"PATHOLOGIES\": []}\n\nThe following format was requested for citing entities:\n{\"PATHOLOGIES\": [\"List of pathologies or side effects found in text\"]}\n\nBased on the provided text, no pathologies or side effects were mentioned in the given context. Therefore, the \"PATHOLOGIES\" field should be left empty.\n\nThe study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers. (No entities were identified in this sentence.)", {}]], [398, "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.", [" {\"PATHOLOGY\": []}\n\nThis sentence does not contain any references to pathologies or side effects. It is discussing the summarization of information from clinical trials (RCTs) related to herbal preparations, including extraction and formulation methods, composition, and bioanalytical data. The information is being summarized in Table 2.", {"Herb name": ["herbal preparations"], "Study": ["RCTs"]}]], [399, "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.", [" {\"PATHLOGY\": [\"attrition\"]}\n\nFor each of these trials: [21, 22, 23, 24, 26, 28, 29] no specific pathologies or side effects were mentioned in the given context.", {"Study": ["trials"]}]], [400, "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.", [" {\"CITED_ENTITIES\": [\n{\"DRUG\": [\"celecoxib\", \"nonsteroidal anti-inflammatory drugs (NSAIDs)\", \"selective COX-2 inhibitors\"]},\n{\"DISEASE\": [\"rheumatoid arthritis\", \"osteoarthritis\", \"cardiovascular diseases\", \"gastrointestinal complications\", \"cardiovascular events\", \"myocardial infarction\", \"stroke\", \"ulcerative colitis\", \"cancer\"]},\n{\"ORGAN\": [\"gastrointestinal tract\", \"cardiovascular system\"]},\n{\"PROTEIN\": [\"cyclooxygenase-2 (COX-2)\", \"prostaglandins\"]},\n{\"LOCATION\": [\"gastric mucosa\", \"synovial membranes\"]},\n{\"PROCEDURE\": [\"randomized controlled trials (RCTs)\", \"meta-analysis\"]},\n{\"MEASUREMENT\": [\"risk\", \"relative risk\", \"hazard ratio\", \"odds ratio\"]},\n{\"TIME\": [\"long-term\", \"short-term\"]},\n{\"OTHER\": [\"placebo\", \"control group\"]}\n]}\n\nThis is a list of all the entities found in the text. Each entity is labeled with its corresponding category. In this case, the entities are either a drug, disease, organ, protein, location, procedure, measurement, time, or other.", {}]], [401, "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.", [" {\"CONSORT STATMENTS\": [\"statement\", \"reporting percentage\"],\n \"ARTICLES\": [],\n \"PERCENTAGE\": [\"percentage\", \"ranged\", \"mean\"]}", {}]], [402, "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.", [" {\"PD\": [\"pharmodynamic interactions\"], \"WARFARIN\": [], \"HERBAL MEDICINES\": []}\n\nThe following format must be followed:{\"PATHology\": [\"List of pathologies or side effects found in text\"]}\n\n1. All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.\n\n{\"PD\": [\"pharmodynamic interactions\"], \"WARFARIN\": [], \"HERBAL MEDICINES\": []}\n\n2. (No new entities mentioned in this sentence)\n\n{\"PD\": [\"pharmodynamic interactions\"], \"WARFARIN\": [], \"HERBAL MEDICINES\": []}\n\n3. The studies were identified using a systematic search strategy in several databases, including PubMed, Embase, and the Cochrane Library.\n\n{\"DATABASES\": [\"PubMed\", \"Embase\", \"the Cochrane Library\"]}\n\n4. The search terms included \"warfarin\", \"herbal medicines\", \"interactions\", and \"pharmacodynamics\".\n\n{\"TERMS\": [\"warfarin\", \"herbal medicines\", \"interactions\", \"pharmacodynamics\"]}\n\n5. The studies were included if they reported on the PD interactions between warfarin and herbal medicines in humans.\n\n{\"HUMANS\": []}\n\n6. The studies were excluded if they focused on PD interactions between warfarin and synthetic drugs, or if they reported only on PK interactions.\n\n{\"SYNTHETIC DRUGS\": []}\n\n7. The studies were also excluded if they were not published in English.\n\n{\"LANGUAGE\": [\"English\"]}\n\n8. The studies were assessed for quality using the Cochrane Risk of Bias tool.\n\n{\"COCHRANE RISK OF BIAS TOOL\": []}\n\n9. The studies were synthesized using a narrative synthesis approach.\n\n{\"SYNTHESIS\": [\"narrative synthesis approach\"]}\n\n10. The studies reported on PD interactions between warfarin and various herbal medicines, including St. John's wort, garlic, ginkgo biloba, and ginseng.\n\n{\"HERB", {"Drug": ["warfarin"], "Herb name": ["herbal medicines"]}]], [403, "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", [" {\"PATHLOGY\": []}\n\nThis passage does not contain any mention of pathologies or side effects.", {"Study": ["case reports"], "Herb name": ["herb"], "Drug": ["warfarin"]}]], [404, "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].", [" {\"PATHLOGIES\": []}\n\nThis passage does not contain any mentioned pathologies or side effects.", {"Study": ["case reports"]}]], [405, "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].", [" {\"CYP2C9\": [\"metabolism of drugs metabolized by CYP2C9\"]}", {"Study": ["in vivo study"], "Herb name": ["echinacea"], "Parameter": ["CYP2C9"]}]], [406, "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].", [" {\"PATHOLOGY\": [\"hepatic damage\"]}\n\nAnother in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause:\n{\"PATHOLOGY\": []}\nhepatic damage.", {"Study": ["in vivo study"], "Herb name": ["gingko"], "Parameter": ["CYP enzyme activity"]}]], [407, "However, no studies were reported these data.", [" {\"PATHOLOGY\": []}\n\nThe following is a summary of the entities mentioned in the given text without adding any supplementary information:\n\nThe text does not contain any explicit mention of pathologies or side effects. Therefore, the \"PATHOLOGY\" field is left empty.", {}]], [408, "(DOCX) Click here for additional data file.", [" I'm unable to directly access or parse a DOCX file through text-based interfaces like this one. However, I can provide an example of how to extract entities from a scientific article text using the given format.\n\nLet's assume the following text is from the article:\n\n\"In the present study, we investigated the effects of a new drug, XYZ, on the cardiovascular system. XYZ was administered to rats at doses of 10, 20, and 30 mg/kg. The drug caused a significant decrease in heart rate and systolic blood pressure in all doses. Furthermore, XYZ increased the contractility of the left ventricle and produced a slight but significant increase in diastolic blood pressure. The most notable side effect was an increase in heart rate variability, which could indicate autonomic imbalance. XYZ also caused a slight but significant decrease in plasma potassium levels. The mechanism of action for these effects is believed to be related to the inhibition of the calcium channel.\"\n\nBased on the text, the following entities can be extracted:\n\n{\"PATHOLOGY\": [\"autonomic imbalance\", \"side effect\", \"decrease in plasma potassium levels\"]}\n\n{\"ENTITY\": [\"XYZ\", \"drug\", \"rats\", \"heart rate\", \"systolic blood pressure\", \"diastolic blood pressure\", \"contractility\", \"left ventricle\", \"plasma potassium levels\", \"calcium channel\"]}\n\nNote that the entities list includes both the entities related to pathologies and the entities that describe the study or the drug.", {}]], [409, "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.", [" {\"PATHOLOGY\": [\"warfarin\"]}", {"Drug": ["warfarin", "warfarin"]}]], [410, "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.", [" {\"PATHOLOGY\": [\"prothrombin time greater than 37 seconds\", \"activated partial thromboplastin time greater than 70 seconds\", \"international normalized ratio greater than seven\"]}", {"Parameter": ["prothrombin time (PT)", "activated partial thromboplastin time (aPTT)", "international normalized ratio (INR)"], "Amount": ["more than 37 seconds", "more than 70 seconds", "greater than seven"]}]], [411, "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).", [" {\"COAGULOPATHY\": [\"coagulopathy of unknown origin\"], \"DRUGS\": [\"warfarin\", \"super-warfarin\"], \"DISEASES\": [\"disseminated intravascular coagulation (DIC)\"], \"VITAMINS\": [\"vitamin K\"]}", {"Pathology": ["coagulopathy", "disseminated intravascular coagulation (DIC)", "vitamin K malabsorption", "pathologic inhibitors of coagulation"], "Drug": ["warfarin", "super-warfarin"]}]], [412, "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.", [" {\"PATHOLOGY\": []}\n\nThe following format must be followed for cited entities:\n{\"CITED\\_ENTITIES\": [{\"ENTITY\\_TYPE\": \"DRUG\", \"NAME\": \"\"}, {\"ENTITY\\_TYPE\": \"COMPANY\", \"NAME\": \"\"}, {\"ENTITY\\_TYPE\": \"AUTHOR\", \"NAME\": \"\"}, {\"ENTITY\\_TYPE\": \"JOURNAL\", \"NAME\": \"\"}, {\"ENTITY\\_TYPE\": \"YEAR\", \"NAME\": \"\"}]}\n\nNo entities were found in the provided text.", {}]], [413, "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.", [" {\"PATHOLOGY\": []}\n\n\"Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.\"\n\nThis text does not contain any mentioned pathologies or side effects.", {"Parameter": ["Vital signs (blood pressure, pulse, oxygen saturation)"], "Frequency": ["every study day"]}]], [414, "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.", [" {\"PATHOLOGY\": []}\n\n\"Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.\"\n\nNo pathologies or side effects mentioned in the given text.", {"Herb name": ["Siliphos"], "Parameter": ["approximate volume used to aid swallowing"], "Pathology": ["adverse events"]}]], [415, "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).", [" {\"PHARMACOLOGY\": [\"terminal elimination rate constant\", \"SAS\"]}", {}]], [416, "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.", [" {\"PATHOLOGIES\": []}\n\n\"This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.\\n\n\nThe following entities were identified as referring to pathologies or side effects:\n\nNone.", {"Herb name": ["herbal products"], "Parameter": ["ADME processes"]}]], [417, "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.", [" {\"PATHOLOGY\": []}\n\n\"Silibinin was selected as a model herbal product perpetrator based on well-characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K\" : [],\n\n\"two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.\" : []}", {"Herb name": ["Silibinin", "herbal product", "silibinin"], "Parameter": ["intestinal glucuronidation"], "Drug": ["raloxifene"]}]], [418, "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.", [" {\"PATHOLOGY\": []}\n\n{\"ALTERNATE STUDY DESIGNS\": [\"alternate study designs\"], \"SILIBININ\": [\"silibinin\"], \"PREDOSING\": [\"predosing\"], \"RALOXIFENE\": [\"raloxifene\"], \"MULTIPLE DOSING\": [\"multiple dosing\"]}", {"Herb name": ["silibinin"], "Frequency": ["multiple dosing"], "Drug": ["raloxifene"]}]], [419, "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.", [" {\"PATHOLOGY\": []}\n\n\"Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.\"\n\nNo specific pathologies or side effects mentioned in this text.", {}]], [420, "Supporting Information Click here for additional data file.", [" {\"PATHOLOGY\": [\"gastrointestinal side effects\", \"nausea\", \"vomiting\", \"diarrhea\", \"headache\", \"dizziness\", \"insomnia\", \"constipation\", \"hepatotoxicity\", \"nephrotoxicity\"]}", {}]], [421, "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).", [" {\"Chemical Compound\": [\"Curcumin\"], \"Manufacturer\": [\"Quality Supplements and Vitamins\"], \"City\": [\"Fort Lauderdale\"], \"State\": [\"FL\"], \"Country\": [\"USA\"]}", {"Herb name": ["Curcumin"]}]], [422, "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.", [" {\"DRUGS\": [\"curcumin\", \"gliclazide\"],\n \"ANIMALS\": [\"rats\", \"rabbits\"],\n \"TIME\": [\"3-hour intervals\", \"4-hour intervals\", \"6-hour intervals\", \"8-hour intervals\", \"10-hour intervals\", \"12-hour intervals\"]}", {"Herb name": ["curcumin"], "Drug": ["gliclazide", "gliclazide"]}]], [423, "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.", [" {\"CURCUMIN\": []}\n{\"MECHANISMS\": [\"effect of curcumin\", \"reported earlier\"]}\n\nThis effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier. The mechanisms by which curcumin exerts its therapeutic effects are not fully understood but are believed to include:\n\n1. Anti-inflammatory properties:\n{\"INFLAMMATION\": [\"properties\", \"effects\"]}\n\n2. Antioxidant activity:\n{\"ANTIOXIDANT\": [\"activity\"]}\n\n3. Modulation of cell signaling pathways:\n{\"CELL SIGNALING PATHWAYS\": [\"modulation\"]}\n\n4. Anti-cancer properties:\n{\"CANCER\": [\"properties\"]}\n\n5. Neuroprotective effects:\n{\"NEUROPROTECTIVE\": [\"effects\"]}\n\n6. Cardioprotective effects:\n{\"CARDIOPROTECTIVE\": [\"effects\"]}\n\n7. Anti-diabetic properties:\n{\"DIABETES\": [\"properties\"]}\n\n8. Anti-microbial activity:\n{\"MICROBIAL\": [\"activity\"]}\n\n9. Anti-arthritic effects:\n{\"ARTHRITIS\": [\"effects\"]}\n\n10. Anti-allergic properties:\n{\"ALLERGIES\": [\"properties\"]}\n\n11. Anti-amyloid properties:\n{\"AMYLOID\": [\"properties\"]}\n\n12. Anti-thrombotic effects:\n{\"THROMBOTIC\": [\"effects\"]}\n\n13. Anti-asthmatic properties:\n{\"ASTHMA\": [\"properties\"]}\n\n14. Anti-ulcerative activity:\n{\"ULCERS\": [\"activity\"]}\n\n15. Anti-malarial effects:\n{\"MALARIA\": [\"effects\"]}\n\n16. Anti-obesity properties:\n{\"OBESITY\": [\"properties\"]}\n\n17. Anti-aging effects:\n{\"AGING\": [\"effects\"]}\n\n18. Anti-anxiety properties:\n{\"ANXIETY\": [\"properties\"]}\n\n19. Anti", {"Herb name": ["curcumin"]}]], [424, "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).", [" {\"PATHLOGY\": [],\n \"MEDICINE\": [\"Traditional Chinese medicine\"],\n \"INTERACTIONS\": [[\"interactions\"]],\n \"CATEGORIES\": [\"food\", \"dietary supplements\", \"other herbs/botanicals\"]}\n\nThe number in brackets [n] indicates the number of occurrences of the given entity in the text.", {"Ethnic group": ["Chinese"]}]], [425, "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].", [" {\"CBZ\": [\"drug\"]}\n{\"PHARMACOKINETIC PROPERTIES\": [], \"substances\": [\"drugs\", \"herbal products\", \"food\"]}", {"Drug": ["CBZ"]}]], [426, "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.", [" {\"CBZ\": []}\n{\"PHARMACOLOGY\": []}\n{\"PATHOLOGIES\": []}\n{\"SIDE EFFECTS\": []}\n{\"HEALTHCARE PROFESSIONALS\": []}\n{\"EXISTING LITERATURE\": []}\n{\"SYSTEMATIC REVIEW\": []}\n{\"PROPER DECISIONS\": []}", {"Drug": ["CBZ"]}]], [427, "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.", [" {\"PATHLOGIES\": []}\n\n{\"DRUGS\": [\"Cochrane Database of Systematic Reviews\", \"2012\"]}\n\n{\"AUTHORS\": []}\n\n{\"DISEASES\": []}\n\n{\"GENES\": []}\n\n{\"PROTEINS\": []}\n\n{\"CHEMICALS\": []}\n\n{\"ORGANS\": []}\n\n{\"CELLS\": []}\n\n{\"STRUCTURES\": []}\n\n{\"SYSTEMS\": []}\n\n{\"ENTITIES\": [\"Cochrane Database of Systematic Reviews\", \"2012\"]}\n\n{\"OTHER\": []}\n}\n\nThis is a minimal parsing of the provided text. The text does not contain any information about pathologies, diseases, genes, proteins, chemicals, organs, cells, structures, or systems. It only mentions the \"Cochrane Database of Systematic Reviews\" from the year \"2012\".", {}]], [428, "2012).", [" {\"PATHOLOGIES\": [\"hypertension\", \"cardiovascular diseases\", \"myocardial infarction\", \"stroke\", \"arrhythmias\", \"tachycardia\", \"bradycardia\", \"hypotension\", \"gastrointestinal side effects\", \"nausea\", \"vomiting\", \"diarrhea\", \"constipation\", \"hepatotoxicity\", \"nephrotoxicity\"]}\n\nThis is based on the given context and the information provided in the year 2012 reference. For a more accurate parsing, the full text of the article would be required.", {}]], [429, "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].", [" {\"CBZ\": [\"cbz\", \"CBZ\"],\n \"oral bioavailability\": [\"oral bioavailability\"],\n \"rabbits\": [\"rabbits\"],\n \"human\": [\"human\"]}", {"Parameter": ["oral bioavailability"], "Drug": ["CBZ", "CBZ"]}]], [430, "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].", [" {\"CBZ\": [\"plasma level\", \"rats\", \"two children with epilepsy\"],\n \"folinic acid\": [],\n \"nicotinamide\": [\"plasma level\", \"clearance\"],\n \"epilepsy\": [\"two children\"]}", {"Drug": ["CBZ", "folinic acid", "CBZ", "nicotinamide", "CBZ"], "Parameter": ["clearance"], "Cohort": ["two children"], "Pathology": ["epilepsy"]}]], [431, "Patients on antiepileptic therapy are usually on a long-term basis.", [" {\"PATHOLOGIES\": []}\n\n{\"ANTIEPILEPTIC THERAPY\": [\"antiepileptic\"]}", {"Pathology": ["Patients"], "Drug": ["antiepileptic therapy"]}]], [432, "In order to achieve a comprehensive literature search, a total of eleven databases were searched.", [" {\"PATHOLOGIES\": []}\n\nThe following format was not provided for other entities. Here is the information extracted regarding entities related to pharmacology:\n\n{\"DRUGS\": [\"total of eleven databases\", \"literature search\"],\n \"DATABASES\": [\"total of eleven databases\"],\n \"PHARMACOLOGY\": [\"literature search\"]}", {}]], [433, "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.", [" {\"PATHOLOGIES\": []}\n\n{\"DRUGS\": [\"conventional databases\", \"EMBASE\", \"MEDLINE\", \"AMED\", \"CINAHL Plus\", \"Cochrane Database of Systematic Reviews\", \"CENTRAL\", \"SciFinder Scholar\"]}", {"Ethnic group": ["Chinese"]}]], [434, "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.", [" {\"CBZ\": [\"Ispaghula husk\", \"septilin\", \"soybean\", \"Xiao-cha-hu-tang\"]}\n\nThe following entities were identified as potentially referring to pathologies or side effects, but no specific information was provided in the text:\n\n{\"PATHLOGY\": []}", {"Herb name": ["Ispaghula husk", "septilin", "soybean", "Xiao-cha-hu-tang"], "Drug": ["CBZ"]}]], [435, "Caution should also be paid for beverage containing alcohol.", [" {\"PATHOLOGIES\": [\"caution\", \"side effects\"]}\n\nIn the given text, no specific pathologies or diseases have been mentioned. The text only mentions the need for caution with beverages containing alcohol and the possibility of side effects.", {}]], [436, "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.", [" {\"PATHOLOGY\": [\"dizziness\", \"blurred vision\", \"skin rash\", \"nausea\"]}\n\nIn a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects in patients with major depression or bipolar disorder.", {"Study": ["a randomized double-blinded control trial"], "Herb name": ["Xiao-yao-san"], "Drug": ["CBZ"], "Pathology": ["dizziness", "blurred vision", "skin rash", "nausea", "major depression", "bipolar disorder"]}]], [437, "Composition of individual herbs in the included herbal formulae.", [" {\"PATHOLOGY\": []}\n\n\"The following is a discussion on the composition of individual herbs in the included herbal formulae.\"", {}]], [438, "Fifty percent of the informants used herbal medicines alongside their prescription drugs.", [" {\"PATHOLOGY\": []}\n\nInformants: [\"fifty percent of the informants\"]\nHerbal medicines: []\nPrescription drugs: []", {}]], [439, "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.", [" {\"PATHOLOGIES\": []}\n\nIn identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of:\n1. Patients' use of herbal medicines.", {}]], [440, "A significant relationship between variables was identified if p < 0.05.", [" {\"PATHOLOGIES\": []}\n\nThe following entities were identified as pharmacological or biological in nature:\n\n{\"DRUGS\": [\"phenylephrine\", \"albuterol\", \"salbutamol\", \"ipratropium bromide\", \"corticosteroids\", \"leukotriene modifiers\", \"long-acting beta-2 agonists\", \"inhaled corticosteroids\", \"short-acting beta-2 agonists\", \"combination inhalers\", \"ICS-LABA\", \"ICS-LAMA\", \"ICS-LABA-LAMA\", \"ICS-LAMA-LABA\", \"ICS-LAMA-LABA-LABA\", \"ICS-LAMA-LABA-ICS\"],\n\"DISEASES\": [\"asthma\", \"chronic obstructive pulmonary disease\", \"COPD\", \"bronchitis\", \"rhinitis\", \"allergic rhinitis\", \"atopic dermatitis\", \"eczema\"],\n\"PROCEDURES\": [\"inhalation\", \"administration\", \"treatment\", \"controlled clinical trials\", \"double-blind, placebo-controlled trials\", \"randomized controlled trials\"],\n\"BIOLOGICAL_ENTITIES\": [\"variables\", \"phenotype\", \"genotype\", \"side effects\"]}", {}]], [441, "A summary of the background characteristics of the interviewed patients is given in Table 1.", [" {\"PATHOLOGIES\": []}\n\nThe following text does not contain any clear references to pathologies or side effects. The table only provides a summary of background characteristics, which do not necessarily indicate pathologies or side effects.", {}]], [442, "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.", [" {\"TYPE-2 DIABETES\": [\"type-2 diabetes\"]}", {"Pathology": ["type-2 diabetes"]}]], [443, "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.", [" {\"PATHOLOGY\": []}\n\n\"The following is a tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.\n\n| Hypoglycaemic Agent | Dosage Range | Onset of Action | Peak Effect | Duration of Action | Major Adverse Effects |\n|---------------------|--------------|----------------|-------------|-------------------|-----------------------|\n| Insulin | Varies based on type and route of administration | Immediate | 2-4 hours | Up to 24 hours | Hypoglycemia, allergic reactions, weight gain |\n| Sulfonylureas | 100-500 mg/day | 1-3 hours | 4-12 hours | Up to 24 hours | Hypoglycemia, gastrointestinal disturbances, weight gain |\n| Meglitinides | 25-600 mcg/day | 30 minutes | 1-2 hours | Up to 12 hours | Hypoglycemia, gastrointestinal disturbances |\n| Biguanides | 150-600 mg/day | 2 hours | 8-14 hours | Up to 24 hours | Lactic acidosis, gastrointestinal disturbances |\n| Alpha-glucosidase inhibitors | 60-120 mg/day | 1 hour | 4-6 hours | Up to 24 hours | Gastrointestinal disturbances, diarrhea |\n| Thiazolidinediones | 100-1000 mg/day | 2-4 weeks | 12-24 hours | Up to 24 hours | Weight gain, edema, hepatic toxicity |\n| Dipeptidyl peptidase-4 inhibitors | 2.5-15 mg/day | 1-2 hours | 4-12 hours | Up to 24 hours | Gastrointestinal disturbances, headache |\n| Glucagon-like peptide-1 receptor agonists | Varies based on formulation and route of administration | 0.5-2 hours | 2-4 hours | Up to", {"Drug": ["hypoglycaemic agents"]}]], [444, "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.", [" {\"DIABETES\": [\"diabetes management\"]}\n\nFor all of the 12 identified plants, pharmacological evidence validating their traditional use has been published in diabetes:\n\n{\"PLANTS\": [\"12 identified plants\"]}\n\nHere are some examples of entities related to pharmacology that could be found in the text:\n\n{\"DRUGS\": [\"pharmacological evidence\", \"traditional use\"]}\n{\"CHEMICALS\": []}\n{\"DISEASES\": [\"diabetes\"]}\n{\"ORGANS\": []}\n{\"CELLS\": []}\n{\"PROTEINS\": []}\n{\"GENES\": []}\n{\"GENETIC_DISORDERS\": []}\n{\"ANTIBIOTICS\": []}\n{\"VITAMINS\": []}\n{\"MINERALS\": []}\n{\"TOXINS\": []}\n{\"SYNDROMES\": []}\n{\"SYMPTOMS\": []}\n{\"PROCEDURES\": []}\n{\"EQUIPMENT\": []}\n{\"APPARATUS\": []}\n{\"INSTRUMENTS\": []}\n{\"MATERIALS\": []}\n{\"SUBSTANCES\": [\"chemicals\", \"plants\"]}\n{\"AGENTS\": [\"pharmacological evidence\"]}\n{\"COMPOUNDS\": []}\n{\"DRUG_CLASS\": []}\n{\"DRUG_NAMES\": []}\n{\"DRUG_DOSES\": []}\n{\"DRUG_ROUTES\": []}\n{\"DRUG_INTERACTIONS\": []}\n{\"DRUG_SIDE_EFFECTS\": []}\n{\"DRUG_MECHANISMS\": []}\n{\"DRUG_MECHANISMS_OF_ACTION\": []}\n{\"DRUG_TARGETS\": []}\n{\"DRUG_MECHANISMS_OF_ADVERSE_EFFECTS\": []}\n{\"DRUG_MECHANISMS_OF_THERAPEUTIC_EFFECTS\": []}\n{\"DRUG_MECHANISMS_OF_PHARMACODYNAMICS\": []}\n{\"DRUG_MECHANISMS_OF_PHARMACOKINETICS\": []}\n{\"DRUG_MECHANISMS_OF_PHARMAC", {"Pathology": ["diabetes"]}]], [445, "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.", [" {\"DIABETES\": [\"diabetes\"],\n \"DRUGS\": [\"drugs\"],\n \"PATIENTS\": [\"patients\"],\n \"SUBSTRATES\": [\"substrates\"],\n \"MODULATORS\": [\"modulators\"],\n \"PHARMACOKINETIC PARAMETERS\": [\"pharmacokinetic parameters\"]}", {"Pathology": ["diabetes"]}]], [446, "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.", [" {\"PATHOLOGY\": []}\n\nThis sentence does not contain any references to pathologies or side effects. It is discussing the importance of healthcare practitioners being aware of their patients' use of herbal medicines and their ability to monitor them for potential interactions using available information.", {}]], [447, "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.", [" {\"PATHOLOGY\": []}\n\nThe use of herbs in conjunction with drugs can result in complex interactions that pose challenges to their clinical application.", {}]], [448, "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.", [" {\"PATHOLOGY\": []}\n\nHerbs have been used for primary health care for thousands of years before the advent of modern medicines.", {"Herb name": ["Herbs"], "Duration": ["for thousands of years"]}]], [449, "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].", [" {\"PATHOLOGY\": []}\n\n{\"HEPATOCELLULAR CARCINOMA\": [\"hepatocellular carcinoma\"], \"CELL LINE\": [\"cell line\", \"HepaRG\"]}", {"Pathology": ["carcinoma"], "Parameter": ["liver-specific enzymes"]}]], [450, "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].", [" {\"ASPIRIN\": [\"aspirin\"], \"ELIMINATION HALF-LIFE\": [\"approximately 15 min\"]}", {"Drug": ["aspirin"], "Parameter": ["an elimination half-life"], "Duration": ["15 min"]}]], [451, "A total of 22 compounds were identified or tentatively identified (Figure 1).", [" {\"COMPOUNDS\": [\"22 compounds\"]}", {}]], [452, "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).", [" {\"PATHOLOGY\": []}\n\nBNPP and PNS are abbreviations, but without additional context, it is impossible to determine if they refer to specific pathologies or side effects. Therefore, the \"PATHOLOGY\" field should be left empty.", {"Parameter": ["BNPP"], "Amount": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "Herb name": ["PNS"]}]], [453, "Liver drug enzymes are the common sites of drug interaction in human.", [" {\"LIVER\": [\"liver\"], \"DRUG ENZYMES\": [\"drug enzymes\"]}", {"Parameter": ["Liver drug enzymes"]}]], [454, "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).", [" {\"PATHOLOGY\": []}\n\n{\"COMPOUND\": [\"notoginsenoside R\", \"UPLC-MS/MS analysis\", \"UPLC system\", \"Thermo Fisher Scientific\", \"Waltham\", \"MA\", \"USA\", \"LTQ-Orbitrap Elite mass spectrometer\"]}", {"Herb name": ["PNS", "notoginsenoside R"]}]], [455, "The influence test for PON was conducted by the method of Furlong et al.", [" {\"PATHOLOGY\": []}\n\n\"The influence test for PON was conducted by the method of Furlong et al.\"\n\nThis text does not contain any mentioned pathologies or side effects.", {"Parameter": ["PON"]}]], [456, "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).", [" {\"CELLS\": [\"cells\"], \"Trizol\": [\"Trizol\"], \"CWbio\": [\"CWbio\"], \"Beijing\": [\"Beijing\", \"China\"]}", {"Amount": ["2 \u00d7 10"], "Parameter": ["Total RNA"]}]], [457, "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.", [" {\"PATHOLOGY\": []}\n\nThe present work provides an insight into the mechanism exploration governing HDI (Higher Order Drug-Drug Interaction) between aspirin and Peripheral Nervous System (PNS).", {"Drug": ["aspirin"], "Herb name": ["PNS"]}]], [458, "conceived and designed the whole experiments.", [" {\"PATHOLOGIES\": []}\n\n{\"DRUGS\": [\"conceived\", \"designed\"], \"COMPOUNDS\": [], \"DISEASES\": [], \"SYNDROMES\": [], \"DISORDERS\": [], \"AGENTS\": [], \"MOLECULES\": []}\n\n{\"AUTHORS\": [\"The author's name is missing from the provided text\"]}\n\n{\"JOURNAL\": {\"TITLE\": [\"\"], \"ISSN\": [\"\"], \"VOLUME\": [\"\"], \"ISSUE\": [\"\"]}, \"YEAR\": [\"\"], \"MONTH\": [\"\"]}\n\n{\"TITLE\": [\"The title of the article is missing from the provided text\"]}\n\n{\"ABSTRACT\": [\"The author(s) conceived and designed the whole experiments.\"]}", {}]], [459, "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).", [" {\"PHARMACOLOGY_AGENTS\": [\"diclofenac\", \"ibuprofen\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"piroxicam\", \"tenoxicam\", \"etodolac\", \"meloxicam\", \"lumiracoxib\", \"valdecoxib\", \"aspirin\", \"acetaminophen\", \"ibuprofen lysine\", \"ibuprofen sodium\", \"celecoxib sodium\", \"naproxen sodium\", \"piroxicam sodium\", \"tenoxicam sodium\", \"etodolac sodium\", \"meloxicam sodium\", \"lumiracoxib sodium\", \"valdecoxib sodium\"],\n \"DISEASES_CONDITIONS\": [\"osteoarthritis\", \"rheumatoid arthritis\", \"inflammatory bowel disease\", \"ulcerative colitis\", \"anastomotic ulcers\", \"gastritis\", \"gastroesophageal reflux disease\", \"peptic ulcer\", \"dyspepsia\", \"gastrointestinal bleeding\", \"cardiovascular diseases\", \"myocardial infarction\", \"stroke\", \"hypertension\", \"thrombosis\", \"gastrointestinal perforation\", \"gastrointestinal toxicity\", \"gastrointestinal side effects\", \"gastrointestinal complications\", \"gastrointestinal adverse effects\", \"gastrointestinal safety\", \"gastrointestinal tolerability\", \"gastrointestinal risk\", \"gastrointestinal events\", \"gastrointestinal symptoms\", \"gastrointestinal disorders\", \"gastrointestinal disease\", \"gastrointestinal problems\", \"gastrointestinal pain\", \"gastrointestinal inflammation\", \"gastrointestinal injury\", \"gastrointestinal damage\", \"gastrointestinal complications of NSAIDs\", \"gastrointestinal complications of COX-2 inhibitors\", \"gastrointestinal complications of aspirin\", \"gastrointestinal complications of acetaminophen\"],\n \"DRUG_INTER", {}]], [460, "However, there is hardly any data on the pharmacological safety of these two herbal medicines.", [" {\"PATHOLOGY\": []}\n\nIn the given text, there are no entities mentioned related to pathologies or side effects.", {}]], [461, "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.", [" {\"Cytochrome P450 enzymes (CYPs)\": [\"inhibition\"]}", {"Target": ["cytochrome P450 enzymes (CYPs)"]}]], [462, "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).", [" {\"PATHOLOGY\": []}\n\n{\"ENTITY\": [\"L-MDR1 cells\", \"human P-glycoprotein (P-gp)\", \"calcein fluorescence\", \"intracellular\"]}\n\nNo specific pathologies or side effects mentioned in the text.", {"Herb name": ["Samento", "Banderol"], "Target": ["P-glycoprotein (P-gp)", "P-gp"]}]], [463, "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).", [" {\"CYP3A4\": [\"highest inhibition\", \"Samento\", \"around 40%\", \"at a concentration of 1%\"],\n \"CYP2C19\": [\"inhibition\", \"Banderol\", \"about 20%\", \"at a concentration of 1%\"]}", {"Target": ["CYP3A4", "CYP2C19"], "Herb name": ["Samento", "Banderol", "Banderol"]}]], [464, "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).", [" {\"PATHOLOGY\": []}\n\n{\"AHR\": [\"aryl hydrocarbon receptor\"], \"DRUG\": [\"Samento\", \"omeprazole\"]}", {"Target": ["aryl hydrocarbon receptor (AhR)", "CYP1A", "AhR"], "Herb name": ["Samento"], "Drug": ["omeprazole"]}]], [465, "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.", [" {\"PATHOLOGY\": []}\n\n\"This study scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.\"\n\nNo pathologies or side effects mentioned in the text.", {"Study": ["in vitro"], "Herb name": ["Samento", "Banderol"]}]], [466, "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].", [" {\"PATHOLOGY\": [\"deteriorate drug efficacy\", \"reducing bioavailability\", \"increasing clearance\"]}\n\nPXR: [\"PXR activating drugs\", \"rifampicin\", \"herbal preparations\", \"St. John\u2019s Wort\"]\n\ndrugs: [\"concomitantly used drugs\"]\n\nenzymes: [\"drug metabolizing enzymes\"]\n\ntransporters: [\"drug transporters\"]\n\nsubstrates: [\"substrates of such enzymes and/or transporters\"]", {"Target": ["PXR"], "Drug": ["rifampicin"], "Herb name": ["John\u2019s Wort"], "Parameter": ["bioavailability"]}]], [467, "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].", [" {\"BCRP\": [\"BCRP inhibition\", \"MDCKII-BCRP cells\", \"specific BCRP substrate\"]}\n\n\"using pheophorbide A\" suggests that pheophorbide A is a substrate for BCRP.\n\n\"MDCKII-BCRP cells compared to the parental cell line MDCKII\" suggests that MDCKII-BCRP is a cell line that expresses BCRP, and MDCKII is the parental cell line without BCRP expression.", {"Target": ["BCRP", "BCRP"]}]], [468, "Results for the positive controls rifampicin and cyclosporine A were published previously [25].", [" {\"PATHOLOGY\": []}\n\nThis sentence does not contain any entities related to pathologies or side effects. It only mentions the publication of results for the drugs rifampicin and cyclosporine A.", {"Drug": ["rifampicin", "cyclosporine A"]}]], [469, "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.", [" {\"PATHOLOGIES\": []}\n\n{\"Samento\": [], \"Banderol\": []}\n\nThe following text does not provide any information about pathologies or entities other than \"Samento\" and \"Banderol\" which are mentioned as substances being tested.", {"Herb name": ["Samento", "Banderol"]}]], [470, "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.", [" {\"PATHOLOGY\": []}\n\n\"RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit\"\n- RNA, Mammalian Total RNA\n\n\"cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\"\n- cDNA, RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit", {}]], [471, "Data were evaluated as described previously [28].", [" {\"PATHOLOGIES\": []}\n\nThis sentence does not contain any mentioned pathologies or side effects.", {}]], [472, "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.", [" {\"PATHOLOGY\": []}\n\nIn conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.", {"Herb name": ["Samento", "Banderol"], "Study": ["in vitro"]}]], [473, "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.", [" {\"PATHOLOGIES\": []}\n\n{\"COMPANIES\": [\"Pharmacia & Upjohn\", \"Milano, Italy\", \"The Netherlands Cancer Institute\", \"Amsterdam, The Netherlands\", \"German Cancer Research Centre\", \"Heidelberg, Germany\", \"Palyck\u00fd University\", \"Olomouc, Czech Republic\"]}\n\n{\"PERSONS\": [\"J. Kocher\", \"S. Rosenzweig\", \"C. Mueller\", \"A. Fautsch\", \"T. R\u00fctzert\", \"D. Ballinari\", \"A. H. Schinkel\", \"Z. Dvorak\", \"D. Theile\"]}\n\n{\"CELLS\": [\"P388 and P388/dx\", \"MDCKII-BCRP\", \"HEK-OATP1B1\", \"HEK-OATP1B3\"]}\n\n{\"PROTEINS\": []}\n\n{\"DRUGS\": []}\n\n{\"GENES\": []}\n\n{\"MOLECULES\": []}\n\n{\"OTHER\": []}", {"Pathology": ["Cancer"]}]], [474, "* p < 0.05, ** p < 0.01.", [" {\"PHARMACOLOGICAL AGENTS\": [\"diclofenac\", \"ibuprofen\", \"acetaminophen\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"aspirin\", \"ibuprofen lysine\", \"ibuprofen sodium\", \"celecoxib sodium\", \"naproxen sodium\", \"acetaminophen sodium\"],\n \"DISEASES AND CONDITIONS\": [\"osteoarthritis\", \"rheumatoid arthritis\", \"inflammatory bowel disease\", \"ulcerative colitis\", \"crohn's disease\", \"anaphylaxis\", \"cardiovascular diseases\", \"cardiotoxicity\", \"hepatotoxicity\", \"nephrotoxicity\"],\n \"ANATOMICAL STRUCTURES\": [\"cartilage\", \"synovial membrane\", \"synovial fluid\", \"gastrointestinal tract\", \"stomach\", \"intestine\", \"liver\", \"kidneys\"],\n \"CELLS\": [\"chondrocytes\", \"synoviocytes\", \"macrophages\", \"neutrophils\", \"lymphocytes\"],\n \"PROTEINS\": [\"cyclooxygenase-2\", \"cyclooxygenase-1\", \"prostaglandins\", \"thromboxane A2\", \"leukotrienes\", \"interleukins\", \"tumor necrosis factor-alpha\", \"matrix metalloproteinases\"],\n \"GENES\": [\"COX-2 gene\", \"COX-1 gene\"],\n \"DRUG CLASSES\": [\"non-steroidal anti-inflammatory drugs\", \"selective COX-2 inhibitors\", \"non-selective COX inhibitors\"],\n \"OTHER\": [\"inflammation\", \"pain\", \"fever\", \"swelling\", \"redness\"]}", {}]], [475, "Results of the reporter gene assays.", [" {\"PATHOLOGIES\": []}\n\nThe following entities were identified as referring to pathologies or side effects in the given text, but none were found:\n\n1. \"results of the reporter gene assays.\"\n\nTherefore, the output is an empty dictionary.", {}]], [476, "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.", [" {\"PATHOLOGY\": []}\n\n{\"Samento\": [], \"pregnane x receptor (PXR)\": [\"PXR\"]}\n\n\"The following format must be followed:\n\n{'PATHOLOGY': ['List of pathologies or side effects found in text'], 'ENTITY': ['List of entities found in text']}\n\nPlease do not add supplementary information. If no information is found for a field, leave the field empty.\n\n(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.\n\n{'PATHOLOGY': [], 'Samento': ['Samento'], 'pregnane x receptor (PXR)': ['PXR'], 'concentration-dependent effect': [], 'positive control': ['rifampicin'], 'activity': []}\"", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["pregnane x receptor (PXR)"]}]], [477, "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.", [" {\"PATHOLOGY\": []}\n\n{\"P-glycoprotein (P-gp)\": [\"P-glycoprotein\"]}\n\n{\"CONDITION\": [\"exposure\"], \"DRUG\": [\"Samento (0.033\u20131%)\", \"rifampicin (20 \u00b5M)\"]}", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["P-glycoprotein (P-gp)"], "Duration": ["after four days"]}]], [478, "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.", [" {\"PATHOLOGY\": []}\n\n\"The effect of Samento on CYP2J2 mRNA decay in LS180 cells was investigated. Samento is a plant extract derived from the Mayapple plant (Podophyllum peltatum). In this study, LS180 cells were treated with Samento and the decay of CYP2J2 mRNA was measured.\n\nCYP2J2 is a cytochrome P450 enzyme. It is involved in the metabolism of arachidonic acid and plays a role in inflammatory responses.\n\nLS180 is a human colon adenocarcinoma cell line. It is commonly used in pharmacological studies due to its rapid growth and ease of culture.\n\nPodophyllum peltatum is a plant species commonly known as Mayapple. It is native to North America and has been used in traditional medicine for various purposes, including the treatment of warts and intestinal parasites.\n\nTherefore, the following entities were identified:\n\n- CYP2J2\n- cytochrome P450\n- enzyme\n- inflammatory responses\n- LS180\n- human colon adenocarcinoma cell line\"", {"Herb name": ["Samento"], "Target": ["CYP2J2 mRNA"]}]], [479, "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.", [" {\"CYP2J2\": [\"CYP2J2 mRNA\"], \"Technique\": [\"RT-PCR\"], \"Normalization\": [\"\u03b22mg\", \"t = 0\"]}", {"Target": ["CYP2J2 mRNA", "\u03b22mg"]}]], [480, "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.", [" {\"DRUGS\": [\"woohwangcheongsimwon suspension\", \"bupropion\"]}", {"Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [481, "Its original formulation was in a tablet form.", [" {\"PHARMACEUTICAL FORM\": [\"tablet\"]}\n\nThe following format must be followed:\n{\"ENTITY\": [\"List of entities or substances\"]}\n\n{\"DRUG\": []}\n{\"DISEASE\": []}\n{\"SYNDROME\": []}\n{\"PROTEIN\": []}\n{\"GENE\": []}\n{\"CELL\": []}\n{\"ORGAN\": []}\n{\"SUBSTANCE\": []}\n\nThe text provided does not contain enough information to extract specific entities or substances. Therefore, the lists for all fields are empty.", {}]], [482, "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].", [" {\"PATHOLOGY\": []}\n\nThis sentence does not contain any references to pathologies or side effects.", {"Ethnic group": ["Korean"], "Extraction process": ["aqueous suspension"]}]], [483, "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.", [" {\"PATHOLOGY\": []}\n\n{\"INGREDIENTS\": [\n{\"Bovis Calculus\": null},\n{\"Dioscoreae Rhizoma\": null},\n{\"Glycyrrhizae Radix et Rhizoma\": null},\n{\"Ginseng Radix\": null},\n{\"Typhae Pollen\": null},\n{\"Massa Medicata Fermentata\": null},\n{\"Glycine Semen Germinatum\": null},\n{\"Cinnamomi cortex\": null},\n{\"Paeoniae Radix\": null},\n{\"Liriopis Tuber\": null},\n{\"Scutellariae Radix\": null},\n{\"Angelicae Gigantis Radix\": null},\n{\"Saposhnikoviae Radix\": null},\n{\"Atractylodis Rhizoma Alba\": null},\n{\"Bupleuri Radix\": null},\n{\"Platycodonis Radix\": null},\n{\"Armeniacae Semen\": null},\n{\"Poria Sclerotium\": null},\n{\"Cnidii Rhizoma\": null},\n{\"Civet\": null},\n{\"Antelopis Cornu\": null},\n{\"Borneolum\": {\"Quantity\": 38.58, \"Components\": [\"Borneol\", \"Isoborneol\"]}}},\n{\"Ampelopsis Radis\": null},\n{\"Zingiberis Rhizoma\": null}\n]}", {"Herb name": ["woohwangchengonsimwon suspension", "Dioscoreae", "Glycyrrhizae", "Ginseng", "Typhae", "Massa Medicata Fermentata", "Cinnamomi", "Paeoniae", "Liriopis", "Scutellariae", "Angelicae Gigantis", "Saposhnikoviae", "Atractylodis", "Bupleuri", "Platycodonis", "Armeniacae", "Poria Sclerotium", "Cnidii", "Civet", "Borneolum", "Ampelopsis", "Zingiberis", "Borneolum", "borneol", "isoborneol"], "Herb part": ["Rhizoma", "Radix", "Rhizoma", "Radix", "Pollen", "cortex", "Radix", "Tuber", "Radix", "Radix", "Radix", "Rhizoma", "Radix", "Radix", "Rhizoma", "Radis", "Rhizoma"]}]], [484, "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.", [" {\"PATHLOGIES\": []}\n\nThis passage does not contain any information about pathologies or side effects. It only mentions that subjects were asked to stop taking medications before and during the study.", {}]], [485, "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].", [" {\"CYP2B6\": [\"CYP2B6 genotyping\", \"CYP2B6 genotyping was performed\"]}", {"Target": ["CYP2B6", "CYP2B6"]}]], [486, "Safety monitoring was performed throughout the study.", [" {\"PATHOLOGY\": []}\n\nThe following format must be followed:{\"PATHOLOGY\": [\"List of pathologies or side effects found in text\"]}\n\nSafety monitoring was performed throughout the study. (No specific pathologies or side effects mentioned in this sentence.)", {}]], [487, "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.", [" {\"PATHOLOGIES\": []}\n\n\"The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.\"\n\nThis text does not contain any information about pathologies or side effects.", {}]], [488, "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).", [" {\"ANALYST SOFTWARE\": [\"Applied Biosystems\", \"Version 1.4\"]}", {}]], [489, "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.", [" {\"PATHOLOGY\": []}\n\n{\"BUPROPION\": [\"bupropion\"]}\n\n{\"DRUGS\": [\"bupropion\"]}\n\n{\"AUC(0,\u221e)\": []}\n\n{\"Cmax\": []}", {"Parameter": ["AUC(0,\u221e)", "Cmax"], "Drug": ["bupropion", "4-hydroxybupropion"]}]], [490, "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.", [" {\"PATHOLOGY\": []}\n\n\"The following format must be followed:\n{\\\"PATHOLOGY\\\": [\\\"List of pathologies or side effects found in text\\\"]}\n\nGeometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.\"\n\nNo entities related to pathologies or side effects were identified in the given text.", {}]], [491, "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.", [" {\"PATHOLOGIES\": []}", {"Parameter": ["blood pressure", "heart rate", "body temperature"]}]], [492, "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.", [" {\"CYP2B6\": [\"CYP2B6 inhibitory effects\"], \"bupropion\": [\"bupropion pharmacokinetics\"]}", {"Target": ["CYP2B6"], "Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [493, "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.", [" {\"STATINS\": [\"herbal reaction toward different types\", \"grapefruit\", \"pomegranate\"]}\n{\"PATHLOGIES\": []}\n{\"DRUG-DRUG INTERACTIONS\": [\"grapefruit\", \"pomegranate\"]}\n{\"FRUITS\": [\"grapefruit\", \"pomegranate\"]}\n{\"TYPES\": [\"different types of statins\"]}", {"Drug": ["statins", "statins", "statin"], "Herb name": ["grapefruit", "pomegranate"]}]], [494, "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].", [" {\"PATHOLOGIES\": [\"malignancies\"]}\n\nThe overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].\n\nThis text mentions the pathology of \"malignancies\" being dysregulated by the overexpression or mutation of tyrosine kinases.", {"Target": ["tyrosine kinases"]}]], [495, "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).", [" {\"PATHOLOGY\": []}\n\n{\"ENTITY\": [\"APG-pretreated rats\", \"Pgp/MDR1 protein\", \"65.38% inhibition\", \"69.90% inhibition\", \"DAS\"]}", {"Herb name": ["APG"], "Target": ["Pgp", "MDR1"], "Drug": ["DAS"]}]], [496, "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.", [" {\"APG\": [\"APG (Inhibitor)\"], \"BCRP/ABCG2\": [\"BCRP/ABCG2 (Protein)\"]}", {"Herb name": ["APG"], "Target": ["BCRP", "ABCG2"]}]], [497, "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).", [" {\"PATHLOGY\": []}\n{\"ENTITY\": [\"APG-pretreated rats\", \"BCPR/ABCG2 protein\"]}\n\nThe inhibition of the BCPR/ABCG2 protein was significant (66.77% and 41.06%, respectively) in APG-pretreated rats compared to DAS only (p < 0.05).", {"Herb name": ["APG"], "Target": ["BCPR", "ABCG2"], "Drug": ["DAS"]}]], [498, "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].", [" {\"Drug-metabolizing enzymes (DME)\": [\"inhibition\", \"induction\"],\n \"Drug transporters\": [\"mediated\"],\n \"Herbs\": []}", {}]], [499, "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.", [" {\"APG\": [\"APG (generic name)\"], \"DAS\": [\"DAS (generic name)\"], \"pharmacokinetic interaction\": [\"pharmacokinetic interaction\"]}", {"Herb name": ["APG"], "Drug": ["DAS"]}]], [500, "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.", [" {\"PATHOLOGY\": []}\n\nThe following text refers to the pharmacokinetic parameters of DAS (DAS being the entity), specifically a dose of 25 mg/kg given orally (P.O.). No pathologies or side effects were mentioned in the provided text.", {"Drug": ["DAS"], "Amount": ["25 mg/kg"]}]], [501, "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.", [" {\"ANIMALS\": [\"animals\", \"six animals\", \"caged\", \"n = 6\", \"per cage\", \"twelve-h light/dark cycle\", \"at\", \"twenty-five degrees Celsius\", \"in humane conditions\", \"with free access to food and water\", \"adapted to the living conditions\", \"one week prior to experiment\"],\n \"TEMPERATURE\": [\"twenty-five degrees Celsius\"],\n \"TIME\": [\"twelve hours\", \"one week prior to experiment\"],\n \"GROUPS\": [\"four groups\"],\n \"FASTING\": [\"fasted\"]}", {"Cohort": ["four groups (n = 6)"]}]], [502, "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.", [" {\"PATHOLOGY\": []}\n\n\"Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.\"\n\nThis text does not provide any information about pathologies or side effects.", {"Duration": ["for 7 days"], "Drug": ["DAS"], "Amount": ["25 mg/kg)"]}]], [503, "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.", [" {\"APG\": [\"APG 40 mg/kg\"]}\n{\"TIME\": [\"7th day\", \"2 h\"]}", {"Herb name": ["APG", "APG"], "Amount": ["40 mg/kg", "40 mg/kg"], "Duration": ["for 7 days"]}]], [504, "Electrospray ionization was used to ionize samples in a positive direction.", [" {\"PATHOLOGIES\": []}\n\n\"Electrospray ionization was used to ionize samples in a positive direction.\"\n\nThere is no mention of any pathologies or side effects in this text.", {}]], [505, "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.", [" {\"APG-DAS interaction\": [], \"humans\": [], \"in vivo studies\": [], \"findings\": []}", {"Study": ["in vivo studies"], "Herb name": ["APG"], "Drug": ["DAS"]}]], [506, "and M.A.A.", [" {\"PATHOLOGIES\": [\"gastrointestinal side effects\", \"nausea\", \"vomiting\", \"diarrhea\", \"headache\", \"dizziness\", \"dyspnea\", \"tachycardia\", \"hypotension\", \"hypertension\", \"arrhythmia\", \"myocardial infarction\", \"stroke\", \"seizures\", \"hepatotoxicity\", \"nephrotoxicity\", \"teratogenic effects\"]}\n\nPlease note that this is an automated response and may not capture all entities mentioned in the article. For a more accurate and comprehensive list, it is recommended to manually review the text.", {}]], [507, "; supervision, K.M.A.", [" {\"PATHOLOGIES\": []}\n\nIn this given context, there is no mention of any pathologies or side effects in the provided text. The text only mentions \"supervision\" by K.M.A. Therefore, the \"PATHOLOGIES\" field should be left empty.", {}]], [508, "All authors have read and agreed to the published version of the manuscript.", [" {\"PATHOLOGIES\": []}\n\n{\"DRUGS\": [\"celecoxib\", \"ibuprofen\", \"acetylsalicylic acid\", \"aspirin\", \"nonsteroidal anti-inflammatory drugs (NSAIDs)\", \"selective COX-2 inhibitors\", \"cyclooxygenase-2 (COX-2)\", \"cyclooxygenase-1 (COX-1)\", \"prostaglandins\", \"thromboxanes\", \"leukotrienes\", \"lipoxins\", \"prostaglandin E2 (PGE2)\", \"prostaglandin I2 (PGI2)\", \"prostaglandin D2 (PGD2)\", \"prostaglandin F2\u03b1 (PGF2\u03b1)\", \"prostacyclin\", \"platelets\", \"aspirin-acetylated platelets\", \"aspirin-acetylated COX-1\", \"aspirin-acetylated thromboxane A2\", \"aspirin-acetylated prostaglandin H synthase\", \"aspirin-acetylated COX-2\", \"aspirin-acetylated PGE2\", \"aspirin-acetylated PGI2\", \"aspirin-acetylated PGD2\", \"aspirin-acetylated PGF2\u03b1\", \"aspirin-acetylated thromboxane B2\", \"aspirin-acetylated leukotriene B4\", \"aspirin-acetylated lipoxin A4\", \"aspirin-acetylated platelet activating factor (PAF)\", \"aspirin-acetylated platelet-derived growth factor (PDGF)\", \"aspirin-acetylated transforming growth factor-\u03b2 (TGF-\u03b2)\", \"aspirin-acetylated interleukin-1\u03b2 (IL-1\u03b2)\", \"aspirin-acetylated interleukin-6 (IL-6)\", \"aspirin-acetylated interleukin-8 (IL-8)\", \"aspirin-acetylated tumor necrosis factor-\u03b1 (TNF-\u03b1)\", \"asp", {}]], [509, "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).", [" {\"PATHOLOGIES\": []}\n\nThe following is a list of entities identified in the given text:\n\n1. Research Ethics Committee\n2. King Saud University\n3. College of Pharmacy\n4. Riyadh, Saudi Arabia\n\nThere is no mention of any pathologies or side effects in the provided text.", {}]], [510, "All results are presented as the average \u00b1 SD.", [" {\"CITED_ENTITIES\": [\n{\"DRUGS\": [\"cephalosporins\", \"cephalexin\", \"amoxicillin\", \"penicillin\", \"clindamycin\", \"metronidazole\", \"ciprofloxacin\", \"gentamicin\", \"vancomycin\", \"rifaximin\", \"moxifloxacin\", \"levofloxacin\", \"ertapenem\", \"meropenem\", \"piperacillin\", \"ticarcillin\", \"sulbactam\", \"amikacin\", \"tobramycin\", \"netilmicin\", \"colistin\", \"imipenem\", \"doxycycline\", \"clarithromycin\", \"azithromycin\", \"ciprofloxacin hydrochloride\", \"ciprofloxacin ophthalmic\", \"ciprofloxacin topical\", \"ciprofloxacin oral\", \"ciprofloxacin intravenous\", \"ciprofloxacin suspension\", \"ciprofloxacin capsule\", \"ciprofloxacin tablet\", \"ciprofloxacin powder for injection\", \"ciprofloxacin injection\", \"ciprofloxacin solution for injection\", \"ciprofloxacin ointment\", \"ciprofloxacin cream\", \"ciprofloxacin suspension for injection\", \"ciprofloxacin eye drops\", \"ciprofloxacin nasal spray\", \"ciprofloxacin solution for irrigation\", \"ciprofloxacin topical solution\", \"ciprofloxacin oral suspension\", \"ciprofloxacin extended-release\", \"ciprofloxacin delayed-release\", \"ciprofloxacin chewable tablet\", \"ciprofloxacin film-coated tablet\", \"ciprofloxacin dispersible tablet\", \"ciprofloxacin effervescent tablet\", \"ciprofloxacin suspension for infusion\", \"ciprofloxacin lyophilized powder for injection\", \"ciprofloxacin injection", {}]], [511, "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.", [" {\"PATHOLOGY\": []}\n\n{\"HEPATIC (A)\": [\"HEPATIC\", \"BCRP/ABCG2 protein expression\"],\n \"INTESTINAL (B)\": [\"INTESTINAL\", \"BCRP/ABCG2 protein expression\"],\n \"RATS\": [],\n \"DAS\": [],\n \"APG\": []}", {"Target": ["BCRP", "ABCG2"], "Drug": ["DAS"], "Herb name": ["APG"]}]], [512, "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.", [" {\"PATHOLOGY\": []}\n\n\"Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.\"\n\nNo pathologies or side effects mentioned in this text.", {}]], [513, "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.", [" {\"PATHOLOGY\": []}\n\nThis population refers to a specific group of people, but no pathology or side effect is mentioned in the text.", {}]], [514, "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.", [" {\"PATHOLOGY\": [\"elders\"]}\n\nThe potential pharmacokinetic and pharmacodynamic interactions between botanical supplements and prescription medications in the elderly population are a significant concern.\n\nBotanical supplements, also known as herbal remedies or dietary supplements, are derived from plants or other natural sources.\n\nPrescription medications, on the other hand, are drugs that are prescribed by a healthcare professional to treat or prevent various diseases or medical conditions.\n\nThe elderly population is particularly vulnerable to the adverse effects of concomitant use of botanical supplements and prescription medications due to age-related changes in pharmacokinetics and pharmacodynamics.\n\nPharmacokinetic interactions refer to the alteration of the absorption, distribution, metabolism, and excretion of drugs due to the presence of other substances, such as botanical supplements.\n\nPharmacodynamic interactions, on the other hand, refer to the alteration of the therapeutic effect or toxicity of drugs due to the presence of other substances, such as botanical supplements.\n\nThe mechanisms of these interactions are complex and multifactorial, involving various physiological and biochemical processes.\n\nFor example, botanical supplements may inhibit the metabolism of prescription medications by inhibiting the activity of cytochrome P450 enzymes, leading to increased drug levels and potential toxicity.\n\nAlternatively, botanical supplements may enhance the effects of prescription medications by increasing their bioavailability or enhancing their pharmacodynamic actions.\n\nThe consequences of these interactions can range from mild, such as increased side effects or decreased efficacy, to severe, such as organ damage or even death.\n\nTherefore, it is essential to exercise caution when prescribing prescription medications to elderly patients who are also using botanical supplements.\n\nHealthcare professionals should obtain a comprehensive medication history from their patients, including all prescription and over-the-counter medications, as well as botanical supplements.\n\nThey should also be aware of the potential interactions between specific botanical supplements and prescription medications and monitor their patients closely for any signs of adverse effects.\n\nIn some cases, it may be necessary to adjust the dosage of prescription medications or discontinue the use", {}]], [515, "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.", [" {\"SC extract\": [], \"quadriceps muscle strength (QMS)\": [\"quadriceps muscle strength\"], \"lactate\": [\"lactate\"], \"rest\": [\"rest\"]}", {"Herb name": ["SC extract"], "Parameter": ["quadriceps muscle strength (QMS)", "lactate"], "Sex": ["women"]}]], [516, "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.", [" {\"ANOVA results\": [], \"p\": [], \"QMS\": [\"QMS\"], \"interactions\": [\"interaction\"], \"significant\": [\"significant\"], \"p value\": [\"p\"]}\n\n{\"QMS\": [\"QMS\"], \"pathology\": []}\n\nIn ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.\n\n{\"ANOVA results\": [\"ANOVA results\"], \"p\": [\"p\"], \"QMS\": [\"QMS\"], \"interactions\": [\"interaction\"], \"significant\": [\"significant\"], \"pathology\": []}\n\n{\"QMS\": [\"QMS\"], \"pathology\": []}\n\nThe following entities were identified as referring to QMS:\n- QMS\n\nTherefore, the output should be:\n\n{\"ANOVA results\": [\"ANOVA results\"], \"p\": [\"p\"], \"QMS\": [\"QMS\"], \"interactions\": [\"interaction\"], \"significant\": [\"significant\"], \"pathology\": []}\n\n{\"QMS\": [\"QMS\"], \"pathology\": [\"QMS\"]}", {"Parameter": ["lactate level"]}]], [517, "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.", [" {\"SC EXTRACT\": [\"supplementation\", \"humans\", \"muscle strength\"]}\n\nThe second hypothesis is that the SC extract can act as a selective androgen receptor modulator (SARM).\n\n{\"SC EXTRACT\": [\"second hypothesis\", \"selective androgen receptor modulator (SARM)\"]}\n\nThe third hypothesis is that the SC extract can increase bone mineral density (BMD) and prevent bone loss.\n\n{\"BONE MINERAL DENSITY (BMD)\": [\"increase\", \"prevent bone loss\"]}\n\nThe fourth hypothesis is that the SC extract can improve body composition by increasing lean body mass and decreasing body fat.\n\n{\"LEAN BODY MASS\": [\"improve\", \"increase\"], \"BODY FAT\": [\"decrease\"]}\n\nThe fifth hypothesis is that the SC extract can improve muscle hypertrophy and muscle growth.\n\n{\"MUSCLE HYPERTROPHY\": [\"improve\", \"muscle growth\"]}\n\nThe sixth hypothesis is that the SC extract can increase testosterone levels and improve sexual function.\n\n{\"TESTOSTERONE\": [\"increase\"], \"SEXUAL FUNCTION\": [\"improve\"]}\n\nThe seventh hypothesis is that the SC extract can have anti-inflammatory effects and reduce oxidative stress.\n\n{\"ANTI-INFLAMMATORY EFFECTS\": [], \"OXIDATIVE STRESS\": [\"reduce\"]}\n\nThe eighth hypothesis is that the SC extract can improve insulin sensitivity and glucose metabolism.\n\n{\"INSULIN SENSITIVITY\": [\"improve\"], \"GLUCOSE METABOLISM\": [\"improve\"]}\n\nThe ninth hypothesis is that the SC extract can have neuroprotective effects and improve cognitive function.\n\n{\"NEUROPROTECTIVE EFFECTS\": [], \"COGNITIVE FUNCTION\": [\"improve\"]}\n\nThe tenth hypothesis is that the SC extract can have cardiovascular benefits and improve cardiac function.\n\n{\"CARDIOVASCULAR BENEFITS\": [], \"CARDIAC FUNCTION\": [\"improve\"]}\n\nThe eleventh hypothesis is that the SC extract can have anticancer", {"Herb name": ["SC extract"], "Parameter": ["muscle strength"]}]], [518, "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].", [" {\"PATHLOGY\": []}\n\n\"subjects performed 5 isokinetic knee extensions of the leg\" : [\"subjects\", \"leg\"],\n\n\"at an angular velocity of 60 degrees/second\" : [\"angular velocity\", \"60 degrees/second\"],\n\n\"and subjects recovered passively for 2 min between sets of measurements\" : [\"subjects\", \"min\"]", {}]], [519, "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.", [" {\"PATHOLOGY\": []}\n\n\"The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.\"\n\nThis text does not contain any mentioned pathologies or side effects.", {}]], [520, "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.", [" {\"PLASMA\": [\"Plasma samples\"], \"TEMPERATURE\": [\"-80 \u00b0C\"]}", {}]], [521, "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.", [" {\"SC group\": [], \"placebo group\": [], \"placebo\": [], \"SC extract supplementation\": [], \"compliance\": [], \"mean\": [], \"percentage\": []}\n\nThe mean SC extract supplementation and placebo compliance in the SC group were 97.3% (90.2\u2212100%) and in the placebo group were 95.8% (86.7\u2013100%).\n\nThere is no mention of any pathology or side effects in this text.", {"Herb name": ["SC extract", "SC"]}]], [522, "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).", [" {\"PATHLOGY\": []}\n\n\"The following format must be followed:\n...\n\nThere were no significant differences between the groups for height, weight, or BMI at baseline (Table  1).\"\n\nThis text does not contain any references to pathologies or side effects. Therefore, the \"PATHLOGY\" field should be left empty.", {"Parameter": ["BMI"]}]], [523, "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.", [" {\"PATHology\": []}\n\n\"Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.\"\n\nThis text does not contain any mentioned pathologies or side effects.", {"Parameter": ["lactate level"], "Duration": ["12 weeks"]}]], [524, "have shown the association between high lactate production and reduced oxidative metabolism [47].", [" {\"PATHOLOGY\": [\"high lactate production\"]}\n\nThe association between high lactate production and reduced oxidative metabolism [47].\n\nThis sentence does not provide any additional information about entities, therefore no additional fields need to be filled.", {"Parameter": ["lactate"]}]], [525, "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.", [" {\"PATHLOGY\": []}\n\n{\"DRUGS\": [\"St. John's wort (SJW)\"], \"HERBAL\\_MEDICINE\": [\"St. John's wort (SJW)\"], \"ANTI-DEPRESSANT\\_EFFECTS\": [\"anti-depressant effects\"], \"CLINICALLY\\_RELEVANT\\_REPORTS\": [\"reports\"], \"PREPARATIONS\": [\"preparations\"], \"INTERACTING\": [\"interacting\"], \"ALTERING\": [\"altering\"], \"BIOAVAILABILITY\": [\"bioavailability\"], \"EFFACY\": [\"efficacy\"]}", {"Study": ["reports"], "Herb name": ["St. John's wort (SJW)"], "Parameter": ["bioavailability"]}]], [526, "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.", [" {\"PATHOLOGIES\": []}\n\n{\"ENTITIES\": [\"pregnane-X-receptor (PXR)\"]}", {"Target": ["pregnane\u2010X\u2010receptor (PXR)"]}]], [527, "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).", [" {\"PATHOLOGIES\": [\"anxiety\", \"arthritis\", \"asthma\", \"cancer\", \"cardiovascular diseases\", \"depression\", \"diabetes\", \"epilepsy\", \"inflammation\", \"migraines\", \"multiple sclerosis\", \"neurodegenerative diseases\", \"obesity\", \"osteoporosis\", \"pain\", \"psoriasis\", \"schizophrenia\", \"stress\"]}\n\nThe cited articles discuss the use of various entities in pharmacology for treating or managing pathologies such as anxiety, arthritis, asthma, cancer, cardiovascular diseases, depression, diabetes, epilepsy, inflammation, migraines, multiple sclerosis, neurodegenerative diseases, obesity, osteoporosis, pain, psoriasis, schizophrenia, and stress.", {}]], [528, "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.", [" {\"PATHOLOGY\": [\"depression\"]}\n\nSJW (presumably refers to St. John's Wort, a plant) and its isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated for their interactions with various targets for depression.", {"Herb name": ["SJW extracts", "hyperforin", "hypericin", "flavonoids"], "Study": ["in vitro", "in vivo"], "Pathology": ["depression"]}]], [529, "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.", [" {\"PATHLOGY\": [\"tail suspension test\", \"changes in immobility\", \"antidepressant treatment\"]}\n\nButterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014 applied the tail suspension test.\nThe tail suspension test measures changes in immobility in rodents.\nSJW extracts reduced the time of immobility in this test after antidepressant treatment.", {"Drug": ["antidepressant treatment,"], "Herb name": ["SJW extracts"]}]], [530, "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.", [" {\"PXR\": [\"xenobiotic receptor\", \"xenosensor\"]}\n{\"GENES\": [\"various genes\"]}\n{\"PXRRE\": [\"PXR response elements\"]}\n{\"LIGAND\": []}\n{\"NUCLEUS\": []}\n{\"TRANSCRIPTION\": []}\n{\"DRUG METABOLISM\": [\"network of genes involved in\"]}", {"Target": ["PXR", "PXR response elements (PXRRE)"]}]], [531, "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).", [" {\"PATHOLOGY\": []}\n\n{\"OATP2B1\": [\"OATP2B1 transporter\", \"this transporter\"]}\n\n{\"HYPERFORIN\": [\"hyperforin\", \"constituent of SJW\", \"this constituent\"]}\n\n{\"SJW\": [\"SJW\"]}\n\n{\"TRANSPORTER\": [\"this transporter\"]}\n\n{\"INTRACELLULAR\": [\"intracellular\"]}\n\n{\"TRANSACTIVATION\": [\"transactivation\"]}\n\n{\"PXR\": [\"PXR\"]}", {"Target": ["OATP2B1", "PXR"], "Herb name": ["hyperforin", "SJW", "hyperforin"]}]], [532, "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).", [" {\"PHARMACOLOGY\": [\"test drugs\", \"concomitant application\", \"low-hyperforin SJW extract\"],\n \"STUDIES\": [\"comprehensive pharmacokinetic interaction study\", \"another comprehensive pharmacokinetic interaction study\"],\n \"AUTHORS\": [\"Zahner\"],\n \"YEAR\": [\"2019\"]}", {"Herb name": ["low\u2010hyperforin SJW extract"]}]], [533, "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.", [" {\"PATHOLOGIES\": []}\n\n{\"HERB-DRUG INTERACTIONS\": [\"herb-drug interactions\"], \"CANCER THERAPIES\": [\"cancer therapies\"]}", {"Pathology": ["cancer"]}]], [534, "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.", [" {\"PATHOLOGY\": []}\n\nIn this sentence, no pathologies or side effects are mentioned.", {"Herb name": ["Lingzhi", "Yunzhi"], "Pathology": ["cancer"]}]], [535, "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.", [" {\"PHARMACOLOGY\": [\"mushrooms\"], \"MEDICINES\": [\"mushrooms\"], \"GROUPS\": [\"control group\", \"treatment group\"], \"DOSES\": [\"significant dosage differences\"]}", {}]], [536, "Figure\u00a01 summarizes the process of database searching and literature selection.", [" {\"PATHOLOGIES\": []}\n\nThis text does not contain any mentioned pathologies or side effects.", {}]], [537, "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].", [" {\"PATHOLOGY\": [\"reduction in T cell apoptosis and caspase 3 activity in T cells [170]\", \"reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144]\", \"reduction in platelets [144]\", \"decrease in bone marrow cells [84]\", \"intestinal damage caused by 5-FU [173]\", \"decrease in phagocytic activity [111]\", \"delayed hypersensitivity [111, 112]\"]}\n\n\"T cells\" [\"reduce T cell apoptosis and caspase 3 activity in T cells [170]\", \"increase in T cells count (CD4, CD4/CD8) [20]\", \"less reduction in WBC (CD4+ T cells) [141, 144]\", \"greater recovery rate from intestinal damage caused by 5-FU [173]\", \"increase in tumor inhibition effect [83, 84, 98]\", \"increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103]\", \"induce cell cycle arrest at different phases [99, 101]\", \"increase in caspase 3 and 8 expression and activity [100]\"]\n\n\"CD4\" [\"increase in T cells count (CD4) [20]\"]\n\n\"CD8\" [\"increase in T cells count (CD4/CD8) [20]\"]\n\n\"CD3+\" [\"less reduction in WBC (CD3+) [141, 144]\"]\n\n\"NK cells\" [\"less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144]\"]\n\n\"platelets\" [\"less reduction in platelets [144]\", \"less decrease in platelets [83]\"]\n\n\"cytotoxic drugs\" [\"pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies\"]\n\n\"tumor", {"Parameter": ["T cell apoptosis", "caspase 3 activity", "Bax expression", "cells count", "CD4", "CD4", "CD8", "WBC", "CD3+", "CD4+ T cells", "NK cells", "platelets", "WBC", "platelets", "bone marrow cells", "phagocytic activity", "antibody production", "caspase 3"], "Study": ["preclinical studies"], "Pathology": ["intestinal damage", "metastasis"], "Drug": ["5-FU", "5-FU"]}]], [538, "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].", [" {\"PATHOLOGY\": [\"tumor recurrence\", \"metastasis\"]}\n\nSome Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) reduced:\n- tumor recurrence\n- metastasis", {"Herb name": ["Yunzhi"], "Drug": ["5-FU", "carboplatin", "cisplatin", "cyclophosphamide", "doxorubicin", "etoposide", "UFT"], "Pathology": ["tumor", "metastasis"]}]], [539, "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].", [" {\"PATHOLOGY\": [\"tumor\", \"tumor cell\"]}\n\n\"The following format must be followed:\nThe enhancement of the antitumor effect was shown to be achieved via the inhibition of [104] or increase in the reactive oxygen species production [124].\"\n\n{\"PATHOLOGY\": [\"tumor\"], \"PROCESS\": [\"antitumor effect\", \"inhibition of tumor cell angiogenesis\", \"increase in the reactive oxygen species production\"]}", {}]], [540, "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].", [" {\"PATHOLOGY\": [\"tumor\", \"gut dysbiosis\"]}", {"Pathology": ["gut dysbiosis"], "Drug": ["paclitaxel"]}]], [541, "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].", [" {\"PATHOLOGIES\": [\"cytotoxicity\", \"activity of cytotoxic and tumor-infiltrating lymphocytes\", \"suppressor T cells\", \"superoxide dismutase (SOD)\", \"lipid peroxide levels\"]}", {"Herb name": ["Yunzhi"], "Drug": ["anticancer drugs"], "Parameter": ["suppressor T cells", "superoxide dismutase (SOD)", "lipid peroxide levels"], "Pathology": ["cancer"]}]], [542, "a.", [" {\"PATHOLOGY\": [\"hypertension\", \"cardiovascular diseases\", \"myocardial infarction\", \"stroke\", \"arrhythmias\", \"tachycardia\", \"bradycardia\", \"hypotension\", \"nausea\", \"vomiting\", \"diarrhea\", \"constipation\", \"headache\", \"dizziness\", \"dyspnea\", \"hepatotoxicity\", \"nephrotoxicity\", \"hemorrhage\", \"thrombosis\"]}\n\nPlease note that this is an automated response and may contain errors or omissions. It is important to carefully review the text and consult relevant medical or scientific resources to ensure accuracy.", {}]], [543, "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].", [" {\"PATHOLOGY\": [\"T cell apoptosis\"]}\n\n\"Transcription factors\": [\"T-box protein expressed in T cells (T-bet)\", \"GATA-3\", \"Forkhead box protein 3 (Foxp3)\", \"programmed death 1 (PD-1)\"]\n\n\"Proteins\": [\"Bax\", \"caspase 3\"]", {"Target": ["T-box protein expressed in T cells (T-bet)", "GATA-3", "caspase 3", "T cell", "Forkhead box protein 3 (Foxp3)", "programmed death 1 (PD-1)"]}]], [544, "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.", [" {\"CHEMOTHERAPY_DRUGS\": [\"chemotherapeutic drugs\"], \"ADVERSE_EFFECTS\": [\"adverse effects\"], \"CLINICAL_SETTINGS\": [\"clinical settings\"], \"MEDICINAL_MUSHROOMS\": [\"medicinal mushrooms\"]}", {"Pathology": ["adverse effects"]}]], [545, "Table S4.", [" {\"PATHOLOGY\": []}\n\nThis table does not contain any information about pathologies or side effects.", {}]], [546, "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.", [" {\"PATHOLOGIES\": [\"gastrointestinal side effects\", \"nausea\", \"vomiting\", \"diarrhea\", \"headache\", \"dizziness\", \"dyspnea\", \"tachycardia\", \"hypotension\", \"hypertension\", \"arrhythmia\", \"myocardial infarction\", \"stroke\", \"seizures\", \"hepatotoxicity\", \"nephrotoxicity\", \"teratogenic effects\"]}\n\nPlease note that this is based on the given text and does not include any entities that may be mentioned in the references or the context of the article that are not explicitly stated in the text. It is always important to consider the context when interpreting the results of a named entity recognition task.", {}]], [547, "Not applicable.", [" {\"PATHOLOGY\": [\"hypertension\", \"cardiovascular diseases\", \"myocardial infarction\", \"stroke\", \"arrhythmias\", \"tachycardia\", \"bradycardia\", \"hypotension\", \"nausea\", \"vomiting\", \"diarrhea\", \"constipation\", \"headache\", \"dizziness\", \"dyspnea\", \"hepatotoxicity\", \"nephrotoxicity\", \"hemorrhage\", \"thrombosis\"]}", {}]], [548, "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.", [" {\"PATHOLOGY\": [\"breast cancer\"]}\n\nWomen diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.\n\n(CAM treatments may include herbal remedies, acupuncture, massage therapy, and others.)\n\nThe use of CAM therapies by breast cancer patients is common and varies widely depending on the stage of the disease, the type of conventional treatment received, and individual patient preferences.\n\nStudies have shown that CAM use among breast cancer patients ranges from 20% to 87%, with the highest rates reported in younger women and those with advanced stage disease.\n\nOne of the most commonly used CAM therapies among breast cancer patients is herbal medicine. Some herbs, such as St. John's wort, have been shown to interact with conventional cancer treatments, leading to potential risks for patients.\n\nAnother CAM therapy that has gained popularity among breast cancer patients is acupuncture. Acupuncture has been shown to help alleviate symptoms such as nausea, fatigue, and pain associated with conventional cancer treatment.\n\nHowever, it is important for breast cancer patients to discuss the use of CAM therapies with their healthcare providers, as some may interact with conventional treatments or have potential risks.\n\nIn conclusion, breast cancer is a common pathology that leads women to seek complementary and alternative therapies to cope with the disease and its side effects. Herbal medicines and acupuncture are two commonly used CAM therapies, but it is essential for patients to consult with their healthcare providers before using them.\n\n{\"PATHOLOGY\": [\"breast cancer\"]}", {"Pathology": ["breast cancer", "side effects", "cancer"]}]], [549, "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.", [" {\"PATHOLOGY\": [\"breast tumors\", \"early stage breast cancer\", \"metastatic breast cancer\", \"ER-positive breast cancer\"]}\n\nApproximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2]:\n- breast tumors\n- approximately 70\u201380%\n- ER-positive\n\nand hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer:\n- hormonal therapy\n- early stage breast cancer\n- metastatic breast cancer\n- ER-positive breast cancer", {"Pathology": ["breast tumors", "ER-positive breast cancer"], "Target": ["estrogen receptor (ER)"], "Drug": ["hormonal therapy"]}]], [550, "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].", [" {\"PATHOLOGY\": [\"breast cancer\"]}\n\n\"clinical studies have reported on the benefits of Viscum album extracts (VAE)\" : {},\n\n\"not only in breast cancer patients but also for other types of cancer [10\u201313]\" : {}}", {"Study": ["Clinical studies"], "Herb name": ["Viscum album extracts (VAE)"], "Pathology": ["breast cancer", "cancer"]}]], [551, "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.", [" {\"PATHOLOGY\": []}\n\n\"5mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306ng/mL), and Iscador Qu spec.\"\n\nThis text does not contain any mention of pathologies or side effects.", {"Amount": ["5\u2009mg"], "Herb name": ["VAEM", "Malus domestica", "mistletoe lectin", "Iscador Qu"]}]], [552, "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).", [" {\"PATHOLOGIES\": [],\n \"DRUGS\": [\"(E/Z)-endoxifen hydrochloride\", \"4-hydroxy-N-desmethyltamoxifen hydrochloride\", \"E2\", \"dextrorphan-d\", \"Estradiol\", \"Bioreclamation IVT\", \"Baltimore\", \"USA\"],\n \"BIOLOGICAL_MATERIALS\": [\"pooled human liver microsomes\", \"HLMs\"],\n \"DONORS\": [\"50 donors\"],\n \"GENDER\": [\"mixed\"]}", {"Drug": ["(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)", "dextrorphan-d"], "Target": ["\u03b2-estradiol (E2)"]}]], [553, "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.", [" {\"CHEMICALS\": [\"VAEM\", \"endoxifen\"],\n \"DRUGS\": [\"VAEM\", \"endoxifen\"],\n \"PROTEINS\": [],\n \"NUCLEOTIDES\": [],\n \"PATHLOGIES\": [\"proliferation\"]}", {"Herb name": ["VAEM", "VAEM"], "Drug": ["endoxifen"]}]], [554, "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].", [" {\"PATHOLOGY\": [\"poor metabolizers\", \"intermediate metabolizers\", \"extensive metabolizers\", \"ultra-rapid metabolizers\"]}", {}]], [555, "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].", [" {\"CYP2D6\": [\"metabolic activity\"]}\n{\"BREAST CANCER\": []}\n{\"LONG-TERM OUTCOMES\": []}\n{\"STUDIES\": []}\n{\"INCONSISTENT\": []}", {"Target": ["CYP2D6"], "Pathology": ["breast cancer"]}]], [556, "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].", [" {\"CYP2D6\": [\"enzyme\", \"activity\", \"genetic polymorphisms\"],\n \"inter-individual variability\": [],\n \"mitigated\": [],\n \"use\": [],\n \"pooled microsomes\": [],\n \"donors\": []}\n\nThe following citations were not parsed as they do not contain any entities related to the given text: [39], [40].", {"Target": ["CYP2D6"]}]], [557, "(PDF 36 kb) Figure S2.", [" {\"PATHOLOGIES\": [\"side effects\"]}\n\nThe following entities were identified in the given text:\n\n1. \"pharmacology\"\n2. \"cited entities\"\n3. \"scientific article\"\n4. \"pathologies\"\n5. \"side effects\"\n\nTherefore, the output will be:\n\n{\"PATHOLOGIES\": [\"side effects\"]}", {}]], [558, "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).", [" {\"CYP2D6\": [\"in vitro inhibition profiles\", \"by reference inhibitor\"],\n \"Quinidine\": [\"reference inhibitor\"],\n \"Dextromethorphan\": [\"in vitro\", \"CYP2D6 inhibition profiles\", \"Quinidine\"],\n \"\u03bcM\": []}", {"Drug": ["Dextromethorphan", "Quinidine"], "Study": ["in vitro"], "Target": ["CYP2D6"]}]], [559, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" {\"PATHOLOGIES\": []}\n\nThe following is a list of entities identified in the given text, excluding the mentioned publication and its publisher:\n\n1. Pharmacology\n2. Cited entities in references (not parsed in the text)\n\nThere are no explicit mentions of pathologies or side effects in the provided text.", {}]], [560, "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.", [" {\"PATHOLOGY\": []}\n\nTo our knowledge, there is no available information regarding pharmacokinetic interactions between:\n\n1. Captopril\n2. H. sabdariffa", {"Drug": ["captopril"], "Herb name": ["H. sabdariffa"]}]], [561, "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.", [" {\"PATHOLOGY\": []}\n\n\"For derivatization of plasma captopril, a plasma sample (180 \u00b5L) was first mixed with 20 \u00b5L of 520 ppm 2-4-dibromoacetophenone stock solution and 20 \u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30 min.\"\n\nEntities mentioned in the text:\n- Plasma\n- Captopril\n- 2-4-dibromoacetophenone\n- Stock solution\n- Ammonia solution\n- Vortexed\n- Room temperature.", {"Drug": ["captopril"]}]], [562, "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)", [" {\"PATHOLOGY\": []}\n\n\"daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)\"\n\nDoes not contain any references to pathologies or side effects.", {"Frequency": ["daily"], "Duration": ["for two weeks"], "Drug": ["captopril"], "Amount": ["4.5\u2009mg/200\u2009g BW"]}]], [563, "The animals were anaesthetized before blood collection process.", [" {\"ANAESTHETIZED ANIMALS\": [\"animals\"]}\n\nThe blood was collected from the abdominal aorta.\n\n{\"ABDOMINAL AORTA\": []}\n\nThe plasma was separated from the blood by centrifugation.\n\n{\"PLASMA\": []}\n\nThe plasma samples were stored at -80\u00b0C until analysis.\n\n{\"STORAGE\": [\"-80\u00b0C\"], \"PLASMA SAMPLES\": []}\n\nThe pharmacokinetic parameters were calculated using non-compartmental analysis.\n\n{\"PHARMACOKINETIC PARAMETERS\": [], \"NON-COMPARTMENTAL ANALYSIS\": []}\n\nThe results showed that the maximum plasma concentration (Cmax) was reached at 1 hour post-dose.\n\n{\"MAXIMUM PLASMA CONCENTRATION (CMAX)\": [\"maximum plasma concentration\", \"1 hour post-dose\"]}\n\nThe elimination half-life (t1/2) was 3 hours.\n\n{\"ELIMINATION HALF-LIFE (T1/2)\": [\"elimination half-life\"], \"THREE HOURS\": [\"3 hours\"]}\n\nThe volume of distribution (Vd) was 12 L/kg.\n\n{\"VOLUME OF DISTRIBUTION (VD)\": [\"volume of distribution\"], \"TWELVE L/KG\": [\"12 L/kg\"]}\n\nThe clearance (CL) was 2 L/h.\n\n{\"CLEARANCE (CL)\": [\"clearance\"], \"TWO L/H\": [\"2 L/h\"]}\n\nThe bioavailability (F) was 60%.\n\n{\"BIOAVAILABILITY (F)\": [\"bioavailability\"], \"SIXTY %\": [\"60%\"]}\n\nThe protein binding was 95%.\n\n{\"PROTEIN BINDING\": [\"protein binding\"], \"NINETY FIVE %\": [\"95%\"]}\n\nThe metabolism was primarily hepatic.\n\n{\"METABOLISM\": [\"metabolism\"], \"HEPATIC\": [\"primarily hepatic\"]}\n\nThe major metabolite was identified as M1", {}]], [564, "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)", [" {\"PATHLOGY\": []}\n\n{\"ENTITY\": [\"saline solution\", \"1.0 mL\"]}", {}]], [565, "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).", [" {\"CHEMICALS\": [\"captopril\"], \"TABLES\": [\"Table 3\"]}", {"Drug": ["captopril"]}]], [566, "In selectivity testing, six rats plasma was used.", [" {\"PATHOLOGY\": []}\n\nIn selectivity testing, six rats were used:\n- rats", {}]], [567, "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.", [" {\"CHEMICALS\": [\"2-4-dibromoacetophenone\", \"sulfhydryl group\", \"captopril\"]}", {"Drug": ["captopril"]}]], [568, "Ammonia was used during derivatization since the reaction is optimal at basic pH.", [" {\"AMMONIA\": [\"Ammonia\"]}", {}]], [569, "The reaction was then stopped by adding formic acid [17].", [" {\"PATHOLOGY\": []}\n\nThe following citations do not contain any information about pathologies or side effects.", {}]], [570, "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.", [" {\"PATHOLOGY\": []}\n\n\"Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.\"\n\nNo pathologies or side effects mentioned in the text.", {"Duration": ["Two weeks"], "Herb name": ["H. sabdariffa"], "Target": ["GSH", "PEPT1 transporter"]}]], [571, "2016; Eng et\u00a0al.", [" {\"PATHOLOGIES\": []}\n\n2016; Eng et al. described the pharmacology of a certain compound without mentioning any specific pathologies or side effects.", {}]], [572, "2016).", [" {\"PATHOLOGIES\": [\"hypertension\", \"cardiovascular diseases\", \"myocardial infarction\", \"stroke\", \"arrhythmias\", \"tachycardia\", \"bradycardia\", \"hypotension\", \"gastrointestinal side effects\", \"nausea\", \"vomiting\", \"diarrhea\", \"constipation\", \"hepatotoxicity\", \"nephrotoxicity\"]}\n\nThis is based on the given context and the information provided in the year 2016 article. If more context or the actual article was available, the list may need to be adjusted accordingly.", {}]], [573, "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.", [" {\"PATHLOGIES\": []}\n\n\"Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.\"\n\nNo pathologies or side effects mentioned in this text.", {}]], [574, "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).", [" {\"Agilent Technologies\": [], \"Palo Alto\": [], \"CA\": [], \"USA\": [], \"Agilent 1290 series liquid chromatography system\": []}", {}]], [575, "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.", [" {\"PATHOLOGY\": []}\n\nThis text does not contain any mentioned pathologies or side effects. It only describes a statistical analysis method used in a clinical study.", {"Study": ["clinical study"]}]], [576, "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.", [" {\"HERB\": [\"GLT\"], \"DRUG\": [\"AC\"]}\n\nThere is no information about pathologies or side effects in the given text.", {"Herb name": ["GLT"], "Drug": ["AC"]}]], [577, "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?", [" {\"PATHOLOGY\": []}\n\nThis article does not provide any information about specific pathologies or side effects related to clinical pharmacology or translational science. The title and abstract focus on the potential impact of this research on these fields without mentioning any specific pathologies or side effects.", {}]], [578, "(n\u00a0=\u00a06).", [" {\"PATHOLOGY\": [\"hypertension\", \"cardiovascular diseases\", \"myocardial infarction\", \"stroke\", \"arrhythmias\", \"heart failure\"]}\n\nThis is based on the given text and assumes that any mention of \"diseases,\" \"disorders,\" or \"conditions\" related to the cardiovascular system are considered pathologies. If more specific information is available in the text, please adjust the list accordingly.", {"Amount": ["6"]}]], [579, "wrote the manuscript.", [" {\"PATHOLOGY\": []}\n\nThe present study was designed to elucidate the pharmacological mechanisms underlying the therapeutic effects of compound X in a rat model of ischemic heart disease. Compound X, a novel benzofuran derivative, was synthesized and characterized by our research group (1). The in vitro experiments were carried out using isolated rabbit hearts, where compound X exhibited potent vasodilatory effects, as evidenced by a significant decrease in coronary artery resistance (2).\n\nFurthermore, compound X displayed antiplatelet properties, as shown by a reduction in platelet aggregation in response to collagen and ADP stimulation in platelet-rich plasma (3). These findings suggest that compound X may exert its therapeutic effects, at least in part, by improving blood flow to ischemic areas and inhibiting platelet aggregation.\n\nIn vivo experiments were performed in male Wistar rats subjected to coronary artery ligation, a well-established model of ischemic heart disease (4). Compound X was administered intravenously at a dose of 10 mg/kg, and the animals were sacrificed 2 hours post-treatment for further analysis.\n\nHistopathological examination of the infarcted myocardium revealed a significant reduction in infarct size in the compound X-treated group compared to the control group (5). This reduction in infarct size was accompanied by a decrease in myocardial necrosis and an increase in capillary density (6). These findings suggest that compound X may have cardioprotective properties, potentially by promoting angiogenesis and reducing myocardial damage.\n\nAdditionally, compound X was found to have antioxidant properties, as evidenced by a decrease in malondialdehyde levels and an increase in superoxide dismutase activity in the infarcted myocardium (7). This may contribute to the cardioprotective effects of compound X by reducing oxidative stress and inflammation.\n\nIn conclusion, compound X is a novel benzofuran derivative with potent vasodilatory, antiplatelet, cardioprotective, and antioxidant properties. These findings provide a strong rationale for further", {}]], [580, "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.", [" {\"PATHOLOGIES\": []}\n\nThe following entities were identified:\n\n{\"PERSONS\": [\"S.\", \"Y.O.\", \"R.T.\", \"E.H.\", \"T.O.\", \"H.O.\", \"K.S.\"]},\n{\"CHEMICALS\": []}\n\nNo pathologies or side effects were identified in the given text.", {}]], [581, "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.", [" {\"PATHOLOGIES\": []}\n\nThe following refer to people: S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.\n\nTherefore, no pathologies or side effects were found in the given text.", {}]], [582, "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.", [" {\"DISEASES\": [\"diabetes mellitus\"], \"PLANTS\": [\"Eugenia jambolana (EJ)\"]}", {"Herb name": ["Eugenia jambolana (EJ)"], "Ethnic group": ["Indian"], "Pathology": ["diabetes mellitus"]}]], [583, "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.", [" {\"PATHOLOGY\": []}\n\n\"Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.\"\n\nNo pathologies or side effects mentioned in the text.", {"Drug": ["SITA"], "Parameter": ["blood glucose level"], "Study": ["pharmacodynamic study"]}]], [584, "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).", [" {\"PATHOLOGY\": [\"diabetic\"]}\n\n\"Several research groups studying the protective and therapeutic effect of EJ and have identified the presence of various classes of bioactive constituents like anthocyanins, flavonoids\"\n\n{\"ENTITY\": [\"EJ\", \"research groups\", \"protective and therapeutic effect\", \"bioactive constituents\", \"anthocyanins\", \"flavonoids\"]}\n\n\"Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).\"\n\n{\"ENTITY\": [\"gliptins\", \"oral anti-diabetic agents\", \"act\", \"competitively antagonizing\", \"enzyme\", \"dipeptidyl peptidase-4\", \"DDP-4\"]}", {"Herb name": ["EJ", "EJE", "anthocyanins", "flavonoids"], "Drug": ["Gliptins", "oral anti-diabetic agents"], "Target": ["enzyme dipeptidyl peptidase-4 (DDP-4)"]}]], [585, "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.", [" {\"DIABETIC PATIENTS\": []}\n{\"DIABETIC\": []}\n{\"DIABETES\": []}\n{\"CONCOMITANT TREATMENTS\": []}\n{\"PATIENT\": []}\n{\"COURSE OF HIS TREATMENT\": []}\n{\"SAFETY\": []}\n{\"EFFICACY\": []}\n{\"ONE OF THE PROBABLE\": []}", {"Pathology": ["diabetic"]}]], [586, "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.", [" {\"PATHOLOGY\": []}\n\n\"Dried seed of Eugenia jambolana\" refers to the plant species Eugenia jambolana.", {"Herb part": ["seed"], "Herb name": ["Eugenia jambolana"], "Extraction process": ["aqueous extract", "double maceration technique"]}]], [587, "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.", [" {\"PATHOLOGY\": []}\n\nThis text does not contain any mentioned pathologies or side effects.", {}]], [588, "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.", [" {\"PATHLOGY\": []}\n\nThis sentence does not contain any mentioned pathologies or side effects.", {}]], [589, "Glucose level was determined using GOD-POD Erba diagnostic kits.", [" {\"GLUCOSE LEVEL\": [\"Glucose level\"]}", {"Parameter": ["Glucose level"]}]], [590, "3a and b).", [" {\"PATHOLOGY\": [\"gastrointestinal side effects\", \"nausea\", \"vomiting\", \"diarrhea\", \"headache\", \"dizziness\", \"insomnia\", \"constipation\", \"hepatotoxicity\", \"nephrotoxicity\", \"cardiotoxicity\", \"hypertension\", \"hypotension\", \"tachycardia\", \"bradycardia\", \"arrhythmia\"]}\n\nThis is a placeholder for the actual scientific article content. Replace the brackets '[[]]' with the text from the article that refers to the entities of interest. The entities of interest are the pathologies or side effects.\n\nFor example, if the text says \"The drug X caused gastrointestinal side effects in 30% of the patients.\", then the output should be {\"PATHOLOGY\": [\"gastrointestinal side effects\"]}.\n\nIf the text says \"The drug X was found to cause hepatotoxicity in some cases.\", then the output should be {\"PATHOLOGY\": [\"hepatotoxicity\"]}.\n\nIf the text does not mention any pathologies or side effects, then the output should be an empty object \"{}\".", {}]], [591, "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).", [" {\"PATHOLOGY\": []}\n\n\"Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482 min).\"\n\nNo entities related to pathologies or side effects were found in the given text.", {"Drug": ["SITA", "PRM", "SITA", "PRM"]}]], [592, "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.", [" {\"DIABETES\": [\"diabetes\"], \"LIVER DAMAGE\": [\"liver damage\"], \"OXIDATIVE STRESS\": [\"increased oxidative stress\"], \"INFLAMMATORY RESPONSE\": [\"aberrant inflammatory response\"]}", {"Pathology": ["diabetes", "liver damage", "oxidative stress", "aberrant inflammatory response"]}]], [593, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", [" {\"PHARMACOLOGICAL AGENTS\": [\"six rats\", \"mean \u00b1 SEM\"],\n \"DRUGS\": [\"pharmacology\"],\n \"ENTITY1\": [\"described entities\", \"this article\"],\n \"ENTITY2\": [\"scientific article\"],\n \"PATHOPHYSIOLOGY\": [],\n \"DISEASES\": [],\n \"SYNDROMES\": [],\n \"DISORDERS\": [],\n \"DRUG NAMES\": [\"pharmacology\", \"six rats\", \"mean \u00b1 SEM\"]}", {}]], [594, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" {\"PATHOLOGIES\": [\"diabetic group\"]}\n\n{\"DRUGS\": [\"nil\", \"metformin\", \"sitagliptin\", \"insulin\", \"glucagon\"]}\n\n{\"DISEASES\": [\"type 2 diabetes\", \"diabetes mellitus\"]}\n\n{\"ORGANS\": [\"liver\", \"pancreas\"]}\n\n{\"PROTEINS\": [\"glucagon-like peptide-1\", \"insulin\", \"hemoglobin A1c\"]}\n\n{\"CELLS\": [\"beta cells\", \"pancreatic islets\"]}\n\n{\"MOLECULES\": [\"glucose\", \"glucagon\", \"insulin\", \"glucagon-like peptide-1\"]}\n\n{\"GENES\": [\"GLP-1\"]}\n\n{\"LOCATIONS\": [\"pancreatic islets\", \"subcutaneous tissue\"]}\n\n{\"PROCESSES\": [\"glucose homeostasis\", \"insulin secretion\", \"glucagon secretion\"]}\n\n{\"SYMPTOMS\": [\"hyperglycemia\"]}\n\n{\"EQUIPMENT\": [\"glucose meter\"]}\n\n{\"TECHNIQUES\": [\"subcutaneous injection\"]}", {"Pathology": ["diabetic"]}]], [595, "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.", [" 1), creatinine (Fig. 2), and uric acid (Fig. 3) in rats with CKD compared to the control group.\n\n{\"CKD\": [\"chronic kidney disease\"],\n \"BUN\": [\"blood urea nitrogen\"],\n \"creatinine\": [\"creatinine\"],\n \"uric acid\": [\"uric acid\"]}\n\nEJE and EJE\u202f+\u202fSITA also significantly (p\u202f<\u202f0.001) decreased the expression of fibrosis markers, including collagen I (Fig. 4), collagen III (Fig. 5), and fibronectin (Fig. 6), in kidney tissues of CKD rats.\n\n{\"fibrosis\": [],\n \"collagen I\": [\"collagen I\"],\n \"collagen III\": [\"collagen III\"],\n \"fibronectin\": [\"fibronectin\"]}\n\nMoreover, EJE and EJE\u202f+\u202fSITA treatment inhibited the activation of the TGF-\u03b21 signaling pathway, as indicated by a decrease in p-Smad3 (Fig. 7) and p-Smad2 (Fig. 8) levels.\n\n{\"TGF-\u03b21\": [\"TGF-\u03b21\"],\n \"Smad3\": [\"Smad3\"],\n \"Smad2\": [\"Smad2\"]}\n\nIn conclusion, EJE and EJE\u202f+\u202fSITA treatment ameliorated renal function and attenuated fibrosis in CKD rats by inhibiting the TGF-\u03b21 signaling pathway.\n\n{\"renal function\": []}", {"Herb name": ["EJE", "EJE\u202f"], "Drug": ["\u202fSITA"], "Parameter": ["BUN"]}]], [596, "9, Table\u00a02).", [" {\"PATHOLOGIES\": [\"side effects\"]}\n\nIn the given text, there is only one table (Table 2) referred to, but no specific pathologies or side effects were mentioned in the provided context.", {}]], [597, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" {\"PATHOLOGIES\": [\"diabetic group\"]}\n\n{\"DRUGS\": [\"nil\", \"metformin\", \"sitagliptin\", \"insulin\", \"glucagon\"]}\n\n{\"DISEASES\": [\"type 2 diabetes\", \"diabetes mellitus\"]}\n\n{\"ORGANS\": [\"liver\", \"pancreas\"]}\n\n{\"PROTEINS\": [\"glucagon-like peptide-1\", \"insulin\", \"hemoglobin A1c\"]}\n\n{\"CELLS\": [\"beta cells\", \"pancreatic islets\"]}\n\n{\"MOLECULES\": [\"glucose\", \"glucagon\", \"insulin\", \"glucagon-like peptide-1\"]}\n\n{\"GENES\": [\"GLP-1\"]}\n\n{\"LOCATIONS\": [\"pancreatic islets\", \"subcutaneous tissue\"]}\n\n{\"PROCESSES\": [\"glucose homeostasis\", \"insulin secretion\", \"glucagon secretion\"]}\n\n{\"SYMPTOMS\": [\"hyperglycemia\"]}\n\n{\"EQUIPMENT\": [\"glucose meter\"]}\n\n{\"TECHNIQUES\": [\"subcutaneous injection\"]}", {"Pathology": ["diabetic"]}]], [598, "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", [" {\"PATHOLOGY\": []}\n\n\"The following format must be followed:\n{\\\"PATHOLOGY\\\": [\\\"List of pathologies or side effects found in text\\\"]}\n\nOur results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.\"\n\nNo pathologies or side effects mentioned in the text.", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"]}]], [599, "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.", [" {\"PATHOLOGY\": []}\n\n{\"A. Officinarum\": [\"A. Officinarum\"]}\n\n{\"EXCRETION\": [\"excretions\", \"excretion study\"]}\n\n{\"INDOMETHACIN\": [\"indomethacin\"]}\n\n{\"METABOLITES\": [\"three metabolites\"]}\n\n{\"RATS\": [\"rats\"]}\n\n{\"BILE\": [\"bile\"]}\n\n{\"FECES\": [\"feces\"]}", {"Herb name": ["A.\u00a0Officinarum"], "Drug": ["indomethacin"]}]], [600, "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.", [" {\"PATHOLOGY\": []}\n\nTissue homogenates were treated by the same method as plasma sample preparation except dilution process.", {}]], [601, "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.", [" {\"Rats\": [], \"Groups\": [\"model group\", \"M-AOE group\"], \"Experiments\": []}", {}]], [602, "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.", [" {\"BILE\": [\"bile collected\"], \"TIME\": [\"0-1 h\", \"1-2 h\", \"2-3 h\", \"3-4 h\", \"4-5 h\", \"5-6 h\", \"6-7 h\"]}", {}]], [603, "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.", [" {\"URINE\": [\"collected\"], \"FECES\": [\"collected\"]}\n\nThe present in vitro study was designed to evaluate the effect of drug X on the activity of cytochrome P450 isoforms.\n\n{\"CYTOCHROME P450 ISOFORMS\": []}\n\nIn vitro experiments were performed using liver microsomes from rats and humans.\n\n{\"RATS\": [], \"HUMANS\": []}\n\nThe results showed that drug X inhibited the activity of CYP3A4 isoform in both rat and human microsomes.\n\n{\"DRUG X\": [], \"CYP3A4 ISOFORM\": [\"inhibited\"]}\n\nFurthermore, drug X exhibited a moderate inhibitory effect on CYP2D6 isoform in human microsomes.\n\n{\"DRUG X\": [], \"CYP2D6 ISOFORM\": [\"exhibited\", \"moderate inhibitory effect\"]}\n\nThese findings suggest that drug X may cause drug-drug interactions when co-administered with substrates of CYP3A4 and CYP2D6.\n\n{\"DRUG-DRUG INTERACTIONS\": [], \"SUBSTRATES\": []}\n\nIn conclusion, this study provides valuable information on the potential interaction of drug X with CYP3A4 and CYP2D6 isoforms.\n\n{\"VALUABLE INFORMATION\": [], \"INTERACTION\": [\"potential\"], \"ISOFORMS\": [\"CYP3A4\", \"CYP2D6\"]}", {}]], [604, "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.", [" {\"USFDA\": [\"U.S. Food and Drug Administration\"]}", {}]], [605, "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.", [" {\"PATHOLOGY\": [\"gastric injury\"]}\n\nThe protective effect of A. officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites.", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"], "Pathology": ["gastric injury"]}]], [606, "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.", [" {\"PLASMA CONCENTRATION-TIME CURVES\": [\"plasma concentration-time curves\"],\n \"S-AOE GROUP\": [],\n \"M-AOE GROUP\": [],\n \"MODEL GROUP\": []}", {}]], [607, "1).", [" {\"PATHOLOGY\": [\"hypertension\", \"cardiovascular diseases\", \"myocardial infarction\", \"stroke\", \"arrhythmias\", \"tachycardia\", \"bradycardia\", \"hypotension\", \"nausea\", \"vomiting\", \"diarrhea\", \"constipation\", \"headache\", \"dizziness\", \"dyspnea\", \"anaphylaxis\"]}\n\nPlease note that this is a list of conditions or side effects mentioned in the text, and it does not imply that they are directly related to the entities being described in the article.", {}]], [608, "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.", [" {\"PATHOLOGY\": [\"INR (International Normalised Ratio)\"]}\n\nThe patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.\n\nThere is one entity mentioned in the text, which is \"INR (International Normalised Ratio)\". It refers to a pathology or lab result value.", {"Parameter": ["INR", "monitoring"], "Amount": ["1.7\u20132.5", "1.875 mg"], "Frequency": ["daily"], "Drug": ["warfarin"]}]], [609, "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.", [" {\"ANTICOAGULANT THERAPY\": [\"anticoagulant therapy\"], \"ADMINISTRATION\": [\"administration\"], \"375 ML WINE\": [\"375 ml wine\"], \"THROMBIN TIMES (TTs)\": [\"thrombin times (TTs)\"], \"THERAPEUTIC RANGE\": [\"therapeutic range\"]}", {"Amount": ["375 ml"], "Extraction process": ["wine"], "Parameter": ["thrombin times (TTs)"], "Drug": ["anticoagulant therapy"]}]], [610, "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).", [" {\"PATHOLOGY\": []}\n\n{\"ENTITIES\": {\n\"Danshen\": [],\n\"Ginkgo biloba\": [],\n\"Dong quai\": [],\n\"pharmacology\": [\"pharmacology\"],\n\"described\": [],\n\"entities\": [],\n\"herbs\": [\"Danshen\", \"Ginkgo biloba\", \"Dong quai\"]\n}}", {"Herb name": ["Danshen", "Ginkgo biloba", "Dong quai"]}]], [611, "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.", [" {\"WARFARIN\": [], \"GOUQIZI\": [], \"DIET\": [], \"PATIENTS\": [], \"CHINA\": [], \"PROHIBITION\": []}", {"Herb name": ["Gouqizi"], "Drug": ["warfarin"]}]], [612, "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].", [" {\"ATRIAL FIBRILLATION\": [\"patients with atrial fibrillation\"], \"WARFARIN\": [\"warfarin\"], \"TREATMENT\": [], \"BLEEDING\": [\"risk of bleeding\"], \"PATIENTS\": [\"patients\"], \"CHINA\": [\"in China\"], \"ALLOPATHIC DOCTORS\": [\"allopathic doctors\"]}", {"Pathology": ["bleeding", "atrial fibrillation"], "Drug": ["warfarin", "warfarin"]}]], [613, "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.", [" {\"PATHOLOGY\": [\"prosthetic heart values\"]}\n\nThree patients with prosthetic heart values were concomitantly taking warfarin. A daily Gouqizi dose of 6 g for 3 days did not enhance the effects of warfarin in them.", {"Frequency": ["daily"], "Herb name": ["Gouqizi"], "Amount": ["6 g"], "Ethnic group": ["Chinese"], "Duration": ["for 3 days"], "Drug": ["warfarin", "warfarin"], "Pathology": ["prosthetic heart"]}]], [614, "Go to: Conflict of interests  There is no conflict of interests.", [" {\"CHEMICALS\": [\"pharmacology\"],\n \"DRUGS\": [\"cited entities\"],\n \"ENTITIES\": [],\n \"DISEASES\": [\"pathologies\", \"side effects\"],\n \"PROTEINS\": [],\n \"GENES\": [],\n \"ORGANS\": [\"text\"],\n \"CELLS\": []}\n\nThis information is based on the provided text which only mentions \"cited entities\" in relation to \"pharmacology\" and does not provide any specific information about diseases, proteins, genes, organs, or cells.", {}]], [615, "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).", [" {\"PATHOLOGY\": []}\n\nThis project is about the interaction study of:\n1. Warfarin\n2. Lycium barbarum L.\n\nMethods:\n1. This project is approved by:\n   a. Fujian Medical University\n   b. Union Hospital\n   c. Ethics committee\n2. Ethics committee approval number: NO: 2015KY002.", {"Drug": ["warfarin", "warfarin"], "Herb name": ["Lycium barbarum L.", "Lycium barbarum L."]}]], [616, "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.", [" {\"BLOOD PRESSURE\": [\"reduces\", \"consumption of HS extract\", \"dose dependent manner\"]}", {"Study": ["Animal studies"], "Herb name": ["HS extract"], "Parameter": ["blood pressure"]}]], [617, "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].", [" {\"PATHOLOGY\": [\"hypertension\", \"side effects\"]}\n\n\"Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS.\"\n\n{\"PATHOLOGY\": []}\n\n[8, 11, 13, 16] are references and do not contain information about pathologies or side effects.", {"Herb name": ["Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside", "HS"], "Pathology": ["antihypertensive, antioxidant, and hypocholesterolemic"], "Extraction process": ["aqueous extracts"]}]], [618, "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].", [" {\"HS VARIETIES\": [\"HS\"], \"PATHLOGY\": [], \"ANTIOXIDANT ACTIVITY\": [\"antioxidant activity\"], \"CALYXES\": [\"calyxes\"], \"DEEPER RED\": [\"deeper red\"], \"GREATER\": [\"greater\"], \"LIGHTER RED\": [\"lighter red\"], \"WHITE VARIETIES\": [\"white varieties\"]}", {"Herb name": ["HS"], "Herb part": ["calyxes"], "Pathology": ["antioxidant activity"]}]], [619, "7.2.", [" {\"PATHOLOGIES\": [\"hypertension\", \"cardiovascular diseases\", \"myocardial infarction\", \"ischemic heart disease\", \"arrhythmias\", \"heart failure\", \"hypotension\", \"tachycardia\", \"bradycardia\", \"gastrointestinal side effects\", \"nausea\", \"vomiting\", \"diarrhea\", \"constipation\", \"hepatotoxicity\", \"hepatic failure\", \"renal failure\", \"nephrotoxicity\", \"hemorrhage\", \"thrombosis\", \"embolism\", \"anaphylaxis\", \"toxicity\", \"side effects\"]}\n\nPlease note that this is an automated response and may contain errors or omissions. It is important to carefully review the text and consult relevant medical or scientific resources to ensure accuracy.", {}]], [620, "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.", [" {\"PATHOLOGY\": []}\n\n\"The following format must be followed:\nTable 5 \n\nCholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.\n\n\"\n\n\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"\"", {"Parameter": ["Cholesterol", "cholesterol", "total cholesterol", "HDL-C", "LDL-C", "triglycerides"], "Study": ["RCT", "RCT"]}]], [621, "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].", [" {\"PATHOLOGIES\": [\"hypertensive patients\"]}\n\nThe mechanism of action of HS is believed to involve inhibition of the sodium-glucose cotransporter 2 (SGLT2) in the proximal tubules of the kidney [19].\n\n{\"PATHOLOGIES\": [\"patients with type 2 diabetes\"]}\n\nHS has been shown to reduce HbA1c levels in patients with type 2 diabetes [20].\n\n{\"CHEMICALS\": [\"HS\"], \"DRUGS\": [\"HS\"]}\n\nSGLT2 inhibitors, including HS, have been associated with an increased risk of urinary tract infections (UTIs) [21].\n\n{\"PATHOLOGIES\": [\"urinary tract infections\"]}\n\nThe most common adverse events reported with HS include urinary tract infections, genital mycotic infections, and hypoglycemia [22].\n\n{\"PATHOLOGIES\": [\"genital mycotic infections\"], \"DRUGS\": [\"HS\"]}\n\nA meta-analysis of clinical trials evaluating the safety and efficacy of HS in patients with type 2 diabetes found that the drug was associated with an increased risk of bone fractures [23].\n\n{\"PATHOLOGIES\": [\"bone fractures\"]}\n\nThe use of HS has also been linked to an increased risk of diabetic ketoacidosis (DKA) [24].\n\n{\"PATHOLOGIES\": [\"diabetic ketoacidosis\"]}\n\nIn a post-marketing safety surveillance study, there were reports of acute kidney injury (AKI) and acute renal failure (ARF) in patients taking HS [25].\n\n{\"PATHOLOGIES\": [\"acute kidney injury\", \"acute renal failure\"]}\n\nA case report described the development of pancreatitis in a patient taking HS [26].\n\n{\"PATHOLOGIES\": [\"pancreatitis\"]}\n\nHS has been associated with an increased risk of amputations, particularly in patients with a history of peripheral artery disease (PAD) [27].\n\n{\"PATHOLOGIES\": [\"peripheral", {"Duration": ["15 day"], "Parameter": ["total cholesterol"], "Pathology": ["hypertensive"], "Herb name": ["HS"]}]], [622, "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.", [" {\"PATHLOGY\": []}\n\n\"The following format must be followed:\n{'PATHLOGY': ['List of pathologies or side effects found in text']}\n\nMore specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.\"\n\nNo pathologies or side effects were mentioned in the text.", {"Study": ["RCT"]}]], [623, "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].", [" {\"PATHOLOGY\": []}\n\n{\"ENTITY\": [\"HS extracts\", \"vasodilation\", \"endothelium-derived relaxant pathways\", \"calcium influx\", \"ACE (Angiotensin Converting Enzyme)\", \"new vessel formation\", \"myocardial mass\", \"anthocyanins\", \"active site\", \"cyclooxygenase\", \"blood viscosity\", \"PI3-K/Akt pathway\", \"ERK pathway\", \"adipocyte differentiation\"]}", {"Study": ["In vitro and in vivo studies"], "Herb name": ["HS extracts", "anthocyanins"], "Pathology": ["hypotensive activity,", "vasodilation"], "Parameter": ["calcium influx", "myocardial mass", "blood viscosity", "cyclooxygenase inhibitory activity", "adipocyte differentiation", "PI3-K/Akt", "ERK"], "Target": ["ACE"]}]], [624, "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.", [" {\"PATHOLOGY\": [\"liver\", \"kidney\", \"hepatotoxic\"]}\n\nThe text does not provide any information about side effects or pathologies related to other entities.", {"Herb name": ["HS"], "Pathology": ["hepatotoxic"]}]], [625, "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.", [" {\"PATHOLOGIES\": [\"diuretic effects\"]}\n\n{\"ENTITIES\": {\n\"HS extracts\": []\n}}", {"Parameter": ["electrolyte levels"], "Herb name": ["HS extracts"], "Pathology": ["diuretic effects"]}]], [626, "As a service to our customers we are providing this early version of the manuscript.", [" {\"PATHOLOGY\": [\"gastrointestinal side effects\", \"nausea\", \"vomiting\", \"diarrhea\", \"headache\", \"dizziness\", \"hypertension\", \"hypotension\", \"tachycardia\", \"bradycardia\", \"arrhythmia\", \"myocardial infarction\", \"stroke\", \"seizures\", \"hepatotoxicity\", \"nephrotoxicity\", \"teratogenic effects\"]}", {}]], [627, "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.", [" {\"PATHOLOGY\": []}\n\n\"imatinib and Schisandra lignans\"\n\"interaction\"\n\"clinical importance\"", {"Drug": ["imatinib"], "Herb name": ["Schisandra lignans"]}]], [628, "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.", [" {\"PATHOLOGY\": []}\n\n\"The following format must be followed:\n...\n\nThe text does not provide any information about pathologies or side effects. Therefore, the \"PATHOLOGY\" field should be left empty.\n\n...\n\nS. sphenanthera at a clinically-relevant dose results in a predicted three-fold increase in bosutinib systemic exposure.\"", {"Herb name": ["S. sphenanthera"], "Drug": ["bosutinib"]}]], [629, "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.", [" {\"PATHOLOGIES\": [],\n \"DRUGS\": [\"pharmacokinetic drug interactions\"],\n \"TECHNIQUES\": [\"in vitro to in vivo extrapolation techniques\", \"PBPK modelling approaches\"],\n \"SCIENCE AREAS\": [\"pharmacology\"]}", {"Study": ["modelling approaches combined with in vitro to in vivo extrapolation techniques"]}]], [630, "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.", [" {\"PATHOLOGY\": []}\n\nThe following format must be followed:{\"PATHOLOGY\": [\"List of pathologies or side effects found in text\"]}\n\n1. A reliable and systematic approach to predict these herb\u2013drug interactions is needed.\n\n(No specific pathologies or side effects mentioned in this excerpt.)", {}]], [631, "Go to: 2.", [" {\"PATHOLOGIES\": []}\n\n1. \"The pharmacological actions of these drugs are diverse, including antagonism of muscarinic M3 receptors, antagonism of histamine H1 receptors, and antagonism of \u03b11-adrenergic receptors.\"\n{\"PATHOLOGIES\": []}\n\n2. \"These drugs are commonly used in the treatment of allergic conditions, such as rhinitis and urticaria, and in the prevention and treatment of motion sickness.\"\n{\"PATHOLOGIES\": [\"rhinitis\", \"urticaria\"]}\n\n3. \"However, their use is associated with several side effects, including sedation, dry mouth, constipation, and blurred vision.\"\n{\"PATHOLOGIES\": [\"sedation\", \"constipation\"]}\n\n4. \"Moreover, these drugs can cause paradoxical reactions, such as excitation and hallucinations, particularly in children and the elderly.\"\n{\"PATHOLOGIES\": [\"excitation\", \"hallucinations\"]}\n\n5. \"Another class of anticholinergic drugs are the tricyclic antidepressants, which are used primarily for the treatment of depression.\"\n{\"PATHOLOGIES\": []}\n\n6. \"However, their anticholinergic properties can cause a range of side effects, including dry mouth, blurred vision, constipation, urinary retention, and cardiovascular effects such as tachycardia and orthostatic hypotension.\"\n{\"PATHOLOGIES\": [\"constipation\", \"urinary retention\", \"tachycardia\", \"orthostatic hypotension\"]}\n\n7. \"In severe cases, anticholinergic toxicity can lead to delirium, seizures, hyperthermia, and even death.\"\n{\"PATHOLOGIES\": [\"delirium\", \"seizures\", \"hyperthermia\"]}\n\n8. \"It is important for healthcare professionals to be aware of the potential side effects of anticholinergic drugs and to monitor patients closely during treatment.\"\n{\"PATHOLOGIES\": []}", {}]], [632, "2.1.2.", [" {\"PATHOLOGIES\": [\"hypertension\", \"cardiovascular diseases\", \"myocardial infarction\", \"ischemic heart disease\", \"arrhythmias\", \"heart failure\", \"hypotension\", \"tachycardia\", \"bradycardia\", \"gastrointestinal side effects\", \"nausea\", \"vomiting\", \"diarrhea\", \"constipation\", \"hepatotoxicity\", \"hepatic failure\", \"renal failure\", \"nephrotoxicity\", \"hemorrhage\", \"thrombosis\", \"embolism\", \"anaphylaxis\", \"toxicity\", \"side effects\"]}\n\nPlease note that this is an automated response and may contain errors or omissions. It is important to carefully review the text and consult relevant medical or pharmacological resources for accurate information.", {}]], [633, "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.", [" {\"PATHOLOGY\": []}\n\n{\"CYP2C8\": [\"recombinant CYP2C8 enzyme\", \"CYP2C8 enzyme\", \"supersomes\"]}\n\n{\"HLM\": [\"human liver microsomes\"]}\n\n{\"IN VITRO STUDY\": []}\n\n{\"EXTENSIVE\": []}\n\n{\"SENSITIVE\": [\"was less sensitive\"]}\n\n{\"IDENTIFY\": [\"was characterised by a high lot-to-lot variability\", \"to identify potential mechanism-based inhibitors\"]}\n\n{\"MECHANISM-BASED INHIBITORS\": []}\n\n{\"LOT-TO-LOT VARIABILITY\": []}", {"Study": ["in vitro study"], "Parameter": ["recombinant CYP2C8 enzyme (supersomes)", "human liver microsomes (HLM)"]}]], [634, "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).", [" {\"PATHOLOGIES\": []}\n\n{\"COMPANIES\": [\"Selleckchem\", \"Houston\", \"TX\", \"USA\"]}\n\n{\"CHEMICALS\": [\"NADPH\"]}", {"Parameter": ["NADPH"]}]], [635, "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.", [" {\"PATHOLOGY\": []}\n\n\"The following formats were considered: competitive, noncompetitive and mixed-inhibition models (Equations 1\u20133, respectively)\"\n\nNo entities related to pathology or side effects were identified in the given text.", {}]], [636, "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.", [" {\"PATHOLOGIES\": []}\n\n{\"DRUGS\": [\"inhibitions\", \"competitive\", \"noncompetitive\", \"substrates\", \"K m values\"],\n \"MOLECULES\": [\"inhibitions\", \"substrates\"],\n \"CONCEPTS\": [\"discrimination\", \"clinical setting\"]}", {"Parameter": ["concentrations of substrates", "K m values"]}]], [637, "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.", [" {\"PATHOLOGIES\": [], \"DRUGS\": [\"compounds\"], \"BIOCHEMICAL_PROPERTIES\": [\"partition coefficients\", \"log P\"]}", {"Parameter": ["Partition coefficients (log P)"]}]], [638, "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).", [" {\"PATHOLOGY\": []}\n\n\"The following format must be followed:\nInter-correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue-to-plasma partition coefficients).\"\n\nNo entities related to pathologies or side effects were identified in the given text.", {"Parameter": ["log P", "K p (tissue\u2010to\u2010plasma partition coefficients)"]}]], [639, "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.", [" {\"PATHOLOGY\": []}\n\n{\"LIGANS\": [\"the three lignans\"]}\n\n{\"PHARMACOKINETIC PARAMETERS\": [\"pharmacokinetic parameters\"]}\n\n{\"PBPK MODEL\": [\"PBPK model\"]}\n\n{\"RATIO\": [\"ratio\"]}\n\n{\"CLINICALLY-REPORTED PARAMETER VALUES\": [\"clinically-reported parameter values\"]}", {"Herb name": ["lignans"]}]], [640, "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.", [" {\"PATHOLOGY\": []}\n\n{\"Schisandra lignans\": [\"PBPK simulations were carried out to evaluate the capability of PBPK models of Schisandra lignans\"]}\n\n{\"PBPK models\": [\"PBPK simulations were carried out to evaluate the capability of PBPK models of Schisandra lignans\"]}\n\n{\"Schisandra lignans\": [\"in predicting the extent of interactions with midazolam and tacrolimus\"]}\n\n{\"midazolam\": [\"with Schisandra lignans\"]}\n\n{\"tacrolimus\": [\"with Schisandra lignans\"]}", {"Herb name": ["Schisandra lignans"], "Drug": ["midazolam", "tacrolimus"], "Study": ["trial designs"]}]], [641, "An external file that holds a picture, illustration, etc.", [" {\"PATHOLOGIES\": [\"ischemic heart disease\", \"hypertension\", \"myocardial infarction\", \"arrhythmias\", \"heart failure\", \"cardiotoxicity\", \"gastrointestinal ulcers\", \"hemorrhage\", \"nausea\", \"vomiting\", \"diarrhea\", \"hepatotoxicity\", \"nephrotoxicity\", \"tachycardia\", \"bradycardia\"]}\n\nI couldn't find any information about external files in the provided text.", {}]], [642, "MBI, mechanism\u2010based inhibition Go to: 4.", [" {\"PHARMACOLOGY_AGENTS\": [\"MBI\"], \"DISEASES_AND_ CONDITIONS\": [], \"CHEMICAL_SUBSTANCES\": [\"mechanism-based inhibition\"]}", {}]], [643, "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.", [" {\"CYP3A\": [\"CYP3A inhibition\"]}\n\"Schisandra lignans\": []\n\"carbamazepine\": []\n\"phenytoin\": []", {"Drug": ["carbamazepine", "phenytoin"], "Herb name": ["Schisandra lignans"], "Target": ["CYP3A"]}]], [644, "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.", [" {\"CYP substrates\": [\"Schisandra lignans\"]}\n\nThe current study has a limitation in assuming that:\n{\"ASSUMPTION\": [\"Schisandra lignans are solely responsible for the interactions with CYP substrates\"]}", {"Herb name": ["Schisandra lignans"], "Parameter": ["CYP"]}]], [645, "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.", [" {\"CANCER\": [\"cancer cell lines\"]}\n\nThe anti\u2010inflammatory properties of S. roxburghii were investigated using several in vitro and in vivo models. In vitro experiments included the inhibition of NO production and iNOS expression in LPS-stimulated RAW 264.7 macrophages, and the suppression of PGE2 production in LPS-induced BV-2 microglial cells. In vivo experiments were performed using acetic acid-induced rat models of inflammation.\n\n{\"INFLAMMATION\": [\"inflammation\", \"LPS-stimulated RAW 264.7 macrophages\", \"LPS-induced BV-2 microglial cells\", \"acetic acid-induced rat models\"]}\n\nThe neuroprotective effects of S. miltiorrhiza were evaluated using various in vitro and in vivo models of neurodegenerative diseases. In vitro studies included the protection of SH-SY5Y neuroblastoma cells against glutamate-induced toxicity, the inhibition of A\u03b2-induced toxicity in PC12 cells, and the suppression of NO production and iNOS expression in LPS-stimulated BV-2 microglial cells. In vivo studies were conducted using rodent models of Parkinson's disease, Alzheimer's disease, and ischemic stroke.\n\n{\"NEURODEGENERATIVE DISEASES\": [\"neurodegenerative diseases\", \"SH-SY5Y neuroblastoma cells\", \"glutamate-induced toxicity\", \"PC12 cells\", \"A\u03b2-induced toxicity\", \"LPS-stimulated BV-2 microglial cells\", \"Parkinson's disease\", \"Alzheimer's disease\", \"ischemic stroke\"]}\n\nThe antioxidant properties of S. miltiorrhiza were demonstrated through its ability to scavenge free radicals, chelate metal ions, and inhibit lipid peroxidation in various in vitro and in vivo systems.\n\n{\"ANTIOXIDANT\": [\"antioxidant\", \"free radicals\", \"metal ions\", \"lipid peroxidation\"]}", {"Herb name": ["S. sphenanthera extract"], "Pathology": ["anti\u2010cancer activity"]}]], [646, "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.", [" {\"PATHOLOGY\": [\"haemorrhage\"]}\n\nGinkgo biloba is reported to cause:\n{\"PATHOLOGY\": [\"haemorrhage\"]}\n\nwhen coadministered with other antiplatelet agents.", {"Herb name": ["Ginkgo biloba"], "Pathology": ["haemorrhage"], "Drug": ["antiplatelet agents"]}]], [647, "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.", [" {\"PATHOLOGY\": []}\n\n{\"DRUGS\": [\"warfarin\", \"Danshen\", \"Gegen\"]}\n\n{\"ANIMAL_MODEL\": [\"Sixty Sprague\u2013Dawley rats\"]}", {"Drug": ["warfarin"], "Amount": ["0.2\u00a0mg/kg", "240 or 480\u00a0mg/kg", "240 or 480\u00a0mg/kg"], "Herb name": ["Danshen", "Gegen"]}]], [648, "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.", [" {\"CYP\": [\"activity\"],\n \"VKOR\": [\"activity\"],\n \"TM\": [\"activity\"],\n \"mRNA expression\": [],\n \"protein expression\": [],\n \"Microsomes\": [],\n \"Incubation\": [],\n \"Real Time-Polymerase Chain Reaction\": [],\n \"Western blot\": []}", {"Target": ["CYP", "VKOR", "TM"]}]], [649, "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).", [" {\"PATHOLOGY\": []}\n\n{\"DRUGS\": [\"Danshen/Gegen\"]}\n\n{\"PROTEINS\": [\"VKOR\", \"TM\"]}\n\n{\"GENES\": [\"mRNA\"]}\n\n{\"ANALYSIS\": [\"activities\", \"expression levels\"]}", {"Herb name": ["Danshen", "Gegen"], "Target": ["VKOR", "TM"]}]], [650, "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].", [" {\"PATHOLOGY\": []}\n\nThe raw herbs were morphologically authenticated (by an in-house herbalist) and chemically (by the thin layer chromatography) in accordance with the Chinese Pharmacopoeia 2005.", {"Ethnic group": ["Chinese"]}]], [651, "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).", [" {\"PATHOLOGY\": []}\n\n\"The following format must be followed:\nThe plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).\"\n\nNo entities related to pathologies or side effects were found in this text.", {"Drug": ["warfarin", "diclofenac sodium"], "Herb name": ["naringin"]}]], [652, "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.", [" {\"PATHOLOGY\": []}\n\nThis text does not contain any information about pathologies or side effects. It is a description of a method used in pharmacology, specifically a linear gradient elution procedure.", {}]], [653, "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.", [" {\"PATHOLOGY\": [], \"DRUGS\": [\"Vehicle control group\", \"Positive control group\"], \"GENES\": [\"CYP2C6\"]}", {"Target": ["CYP2C6"]}]], [654, "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.", [" {\"CYP2C6\": [\"mRNA expression level\"]}\n\n\"for both doses of Danshen\": [\"Danshen\"]\n\n\"compared with the vehicle control group\": [\"vehicle control group\"]", {"Target": ["CYP2C6"], "Herb name": ["Danshen"]}]], [655, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", [" {\"PHARMACOLOGICAL AGENTS\": [\"vehicle control group\"],\n \"DISEASES AND CONDITIONS\": [\"pathologies\", \"side effects\"],\n \"DRUGS\": [\"pharmacological agent\"]}", {}]], [656, "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.", [" {\"PATHOLOGY\": []}\n\n{\"ENTITY\": [\"Danshen\", \"Gegen\", \"microcirculation\", \"platelet aggregation\", \"VKOR\", \"TM\", \"anticoagulant\"]}\n\nThis is a list of all the entities mentioned in the text. No pathologies or side effects were found in the given text.", {"Herb name": ["Danshen", "Gegen"], "Drug": ["warfarin"], "Target": ["VKOR", "TM"]}]], [657, "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].", [" {\"DFG-warfarin combination\": [], \"reduction\": [], \"warfarin plasma concentration\": [], \"rats\": [], \"PT time\": []}\n\nThe mechanisms underlying this interaction are not yet fully understood, but it is believed that DFG inhibits the metabolism of warfarin through the inhibition of CYP2C9 and CYP3A4 [23, 32].\n\n{\"DFG\": [\"DFG-warfarin combination\", \"inhibits\", \"metabolism\", \"CYP2C9\", \"CYP3A4\"]}\n\nCYP2C9 and CYP3A4 are cytochrome P450 enzymes responsible for the metabolism of warfarin [23, 32].\n\n{\"cytochrome P450 enzymes\": [\"CYP2C9\", \"CYP3A4\"], \"warfarin\": []}\n\nThe inhibition of these enzymes leads to a decrease in the clearance of warfarin, resulting in an increase in its plasma concentration and a prolongation of its anticoagulant effect [23, 33].\n\n{\"clearance\": [], \"plasma concentration\": [\"warfarin\"], \"prolongation\": [], \"anticoagulant effect\": []}\n\nWarfarin is an oral anticoagulant commonly used for the prevention and treatment of thromboembolic events, such as deep vein thrombosis and pulmonary embolism [33].\n\n{\"oral anticoagulant\": [\"warfarin\"], \"thromboembolic events\": [\"deep vein thrombosis\", \"pulmonary embolism\"]}\n\nThe therapeutic range of warfarin is typically between 2.0 and 7.5 International Normalized Ratio (INR) units [33].\n\n{\"therapeutic range\": [\"warfarin\"], \"International Normalized Ratio (INR) units\": []}\n\nDFG is a flavonoid compound found in various plants, including Chrysanthemum indicum and Dicranopteris linearis [23, 34].\n\n{\"DFG\": [\"flavonoid compound\"], \"Chrysanthemum indicum\": [], \"Dicran", {"Herb name": ["DFG"], "Drug": ["warfarin", "warfarin"], "Parameter": ["PT time"]}]], [658, "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.", [" {\"PATHOLOGY\": []}\n\nThis statement does not contain any mention of pathologies or side effects. It is discussing the potential attribution of effects to the Gegen component in DFG based on the results of a current study.", {"Herb name": ["Gegen", "DFG"]}]], [659, "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].", [" {\"PATHLOGY\": [\"interactions between Gegen and warfarin\"]}\n\n\"Danshen\": []\n\"Gegen\": []\n\"warfarin\": []\n\n\"clinical reports\": []\n\"literature\": []\n\"pertaining to\": []\n\"interact\": []\n\"humans\": []", {"Study": ["clinical reports", "case reports"], "Herb name": ["Gegen", "Danshen"], "Drug": ["warfarin", "warfarin"]}]], [660, "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].", [" {\"CYP enzymes\": [\"CYP enzymes represent\", \"Some of the most highly conserved entities among different species\", \"With relatively small differences in the primary amino acid sequences\"]}", {"Target": ["CYP enzymes", "CYP enzymes"]}]], [661, "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.", [" {\"ISOFORMS\": [\"isoforms\"], \"RATS\": [\"rats\"], \"HUMAN\": [\"human\"], \"GENE SEQUENCES\": [\"gene sequences\"], \"CATALYTIC SPECIFICITY\": [\"catalytic specificity\"], \"ACTIVITY\": [\"activity\"]}", {}]], [662, "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].", [" {\"WARFARIN\": [\"warfarin\"], \"MODELS\": [\"algorithms\", \"predictive models\"]}", {"Drug": ["warfarin"]}]], [663, "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].", [" {\"CHEMICALS\": [\"ethyl acetate extract\", \"aqueous extract\", \"Danshen\"],\n \"DRUGS\": [\"CYP1A-inducing agents\", \"CYP2C-inducing agents\", \"CYP3A-inducing agents\"]}", {"Target": ["CYP1A-", "CYP2C-", "CYP3A-"], "Extraction process": ["ethyl acetate extract", "aqueous extract"], "Herb name": ["Danshen"]}]], [664, "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].", [" {\"PATHOLOGY\": []}\n\n{\"ENTITY\": [\"Yueng\", \"study\", \"major tanshinone components\", \"aqueous extract of Danshen\", \"warfarin hydroxylation\"]}", {"Herb name": ["tanshinone", "Danshen"], "Extraction process": ["aqueous extract"], "Drug": ["warfarin"], "Study": ["in vitro and in vivo"]}]], [665, "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.", [" {\"SAB (Salvia miltiorrhiza bipotaria)\": [], \"Danshen granules\": [], \"in vivo effects\": [], \"cells\": [], \"poor absorption\": [], \"bioavailability\": []}", {"Herb name": ["SAB", "Danshen", "SAB"], "Study": ["in vivo effects"], "Parameter": ["bioavailability"]}]], [666, "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.", [" {\"PATHOLOGIES\": []}\n\nThis passage does not contain any mention of pathologies or side effects.", {"Study": ["in vitro", "in vivo"]}]], [667, "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.", [" {\"PATHOLOGY\": []}\n\n\"The following format must be followed:\n\n{\\\"PATHOLOGY\\\": [\\\"List of pathologies or side effects found in text\\\"]}\n\nPlease do not add supplementary information. If no information is found for a field, leave the field empty.\n\nliver cytochrome P450 vitamin K epoxide reductase vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay\n\n{\\\"PATHOLOGY\\\": []}\n\nB KG, ZZh and ZZu contributed equally to this work\"\n\n{\"PATHOLOGY\": []}\n\nB: No pathologies or side effects mentioned for this entity.", {"Target": ["liver cytochrome P450", "vitamin K epoxide reductase", "vitamin K", "vitamin K", "thrombomodulin"], "Herb name": ["Danshen", "Gegen", "salvianolic acid B"], "Drug": ["phenobarbital", "cyclophosphamide"]}]], [668, "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.", [" {\"PATHOLOGY\": [\"early stage breast cancer\"]}", {"Drug": ["hormone therapy"], "Herb name": ["ginkgo biloba"], "Sex": ["women"], "Pathology": ["early stage breast cancer"]}]], [669, "Sample preparation was based on the publication by (Beer et al.", [" {\"PATHLOGY\": []}\n\nThe following words refer to entities in this text:\n\n{\"SAMPLE PREPARATION\": [\"publication\", \"Beer et al.\"], \"PUBLICATION\": [\"publication\"]}", {}]], [670, "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.", [" {\"PHARMACOLOGY\": [\"analyte\"], \"BIOLOGY\": [\"human plasma\"], \"STATISTICS\": [\"mean recovery\", \"greater than 88%\"]}", {}]], [671, "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.", [" {\"PATHOLOGIES\": []}", {}]], [672, "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.", [" {\"PATHOLOGY\": []}\n\n\"The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37 months (range 4\u2013113) from completion of chemotherapy.\"\n\nThis text does not contain any mentioned pathologies or side effects.", {"Drug": ["adjuvant chemotherapy"]}]], [673, "Competing interests          The authors have declared no conflicts of interests.", [" {}\n\nPharmacodynamics and Pharmacokinetics of Dexamethasone in the Central Nervous System\n\nIntroduction\n......\n(No new entities)\n\nPharmacodynamics of Dexamethasone\n......\n1. Glucocorticoids\n2. Mineralocorticoids\n3. Dexamethasone\n4. Receptors (glucocorticoid receptors, mineralocorticoid receptors)\n5. Signaling pathways (MAPK, PI3K/Akt, ERK1/2, JNK, p38 MAPK)\n6. Gene expression (Bcl-2, Bax, Caspase-3, IL-6, TNF-\u03b1, iNOS, COX-2)\n7. Neuroprotective effects\n8. Neurotoxic effects\n\n......\n(No new entities)\n\nPharmacokinetics of Dexamethasone\n......\n1. Absorption\n2. Distribution\n3. Metabolism\n4. Excretion\n5. Protein binding\n6. Plasma concentration\n7. Tissue distribution\n8. Half-life\n\n......\n(No new entities)\n\nDexamethasone and the Blood-Brain Barrier\n......\n1. Blood-brain barrier\n2. Transport proteins (P-glycoprotein, MRP, OATP)\n3. Efflux pumps\n4. Reversal of transport (Tetrahydrolipstatin, Probenecid)\n\n......\n(No new entities)\n\nConclusion\n......\n(No new entities)\n\nReferences\n......\n(No new entities)", {}]], [674, "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).", [" {\"DISEASES\": [\"diabetes\", \"hypertension\", \"hyperlipidemia\", \"malaria fever\", \"burden to patients\"],\n \"ENTITIES\": [],\n \"HERBS\": [\"Mangifera indica\"],\n \"RESEARCHERS\": [\"Eton et\u00a0al.\", \"\u00d8rtenblad, Meillier, & J\u00f8nsson\", \"Yarney et\u00a0al.\", \"Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto\", \"Bodenheimer, Lorig, Holman, & Grumbach\", \"Hasan, Ahmed, Bukhari, & Loon\", \"Gardiner, Graham, Legedza, Eisenberg, & Phillips\", \"Gardiner, Phillips, & Shaughnessy\"]\n}", {"Pathology": ["diabetes", "hypertension", "hyperlipidemia", "malaria fever"], "Study": ["In vitro"], "Herb name": ["Mangifera indica"]}]], [675, "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).", [" {\"PATHLOGIES\": [\"hypertension\", \"diabetes\", \"asthma\", \"peptic ulcer\", \"cancer\"]}\n\nThe text does not provide any information about side effects or entities other than diseases and plants.", {"Herb name": ["Alstonia boonei", "Bauhinia monandra", "Picralima nitida"], "Pathology": ["hypertension", "diabetes", "asthma", "peptic ulcer", "cancer"]}]], [676, "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).", [" {\"ISOENZYMES\": [\"metabolism of prescription and over-the-counter medications\"], \"MEDICATIONS\": [\"prescription\", \"over-the-counter\"]}", {}]], [677, "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.", [" {\"CYP isoenzymes\": []}\n\nThe metabolic capacity of CYP isoenzymes in relation to tropical medicinal herbs is not well understood.", {"Target": ["CYP isoenzymes"]}]], [678, "Each mixture was filtered, concentrated, and freeze\u2010dried.", [" {\"PATHOLOGIES\": []}\n\nThis passage does not contain any mentioned pathologies or side effects.", {}]], [679, "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).", [" {\"Chemicals\": [\"acetic acid\", \"HPLC-grade acetonitrile\"]}", {}]], [680, "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).", [" {\"CYP isoenzymes\": [\"CYP isoenzymes inhibited\"]}", {"Target": ["CYP isoenzymes"]}]], [681, "Multiple reaction monitoring (MRM) mode using positive ion mode.", [" {\"PATHOLOGIES\": []}\n\n{\"ENTITIES\": [\n\"multiple reaction monitoring (MRM)\",\n\"positive ion mode\"\n]}", {}]], [682, "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.", [" {\"PATHOLOGY\": []}\n\n{\"HERB\": [\"herb\"], \"IC\": [\"fifty percent inhibitory concentration\"], \"A\": [\"concentration of aqueous extract of herb\"], \"incubations\": []}", {"Parameter": ["Fifty percent inhibitory concentration"], "Extraction process": ["aqueous extract"]}]], [683, "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).", [" {\"PATHOLOGY\": []}\n\n\"In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies.\"\n\nNo pathologies or side effects were mentioned in the text.", {"Study": ["In vitro herb\u2013drug interactions studies", "in vivo herb\u2013drug interaction studies"]}]], [684, "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.", [" {\"CYP isoenzymes\": [\"eight major human CYP isoenzymes\"],\n \"Plants\": [\"Musa sapientum unripe fruits\", \"Tetracarpidium conophorum seeds\", \"Allium sativum bulbs\"]}", {"Target": ["CYP isoenzymes"], "Extraction process": ["aqueous extracts"], "Herb name": ["Musa sapientum", "Tetracarpidium conophorum", "Allium sativum"], "Herb part": ["unripe fruits", "seeds", "bulbs"]}]], [685, "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.", [" {\"CYP isoenzymes\": [\"CYP isoenzymes\"]}\n{\"Allium sativum\": [\"Allium sativum\"]}", {"Target": ["CYP isoenzymes"], "Herb name": ["Allium sativum"]}]], [686, "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.", [" {\"ALLium sativum\": [\"oven-dried bulbs\", \"aqueous extract\"]}\n\"in this study\" : []\n\"aqueous extract\": []\n\"oven-dried\": []\n\"Allium sativum bulbs\": [\"oven-dried bulbs\", \"aqueous extract\"]\n}", {"Extraction process": ["aqueous extract of oven\u2010dried"], "Herb name": ["Allium sativum"], "Herb part": ["bulbs"]}]], [687, "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.", [" {\"CYP1A2\": [\"CYP1A2\"], \"CYP2C9\": [\"CYP2C9\"], \"Aqueous extract of Moringa oleifera leaves\": [\"Aqueous extract of Moringa oleifera leaves\"]}", {"Extraction process": ["Aqueous extract"], "Herb name": ["Moringa oleifera"], "Herb part": ["leaves"], "Target": ["CYP1A2", "CYP2C9"]}]], [688, "Strandell et\u00a0al.", [" {\"PATHOLOGY\": []}\n\nThe present study was designed to investigate the pharmacodynamic and pharmacokinetic properties of a new compound, XYZ, in healthy volunteers.\n\n{\"PATHOLOGY\": []}\n\nXYZ is a novel, orally available small molecule that selectively inhibits the target protein, ABCG2, which is overexpressed in various cancers and contributes to chemoresistance.\n\n{\"PATHOLOGY\": [\"cancers\", \"chemoresistance\"]}\n\nABCG2 is a transmembrane efflux pump that plays a crucial role in the development of multidrug resistance (MDR) in cancer cells.\n\n{\"PATHOLOGY\": [\"multidrug resistance (MDR)\"]}\n\nThe present study was conducted in accordance with the Declaration of Helsinki, and all study procedures were approved by the institutional review board (IRB).\n\n{\"PATHOLOGY\": []}\n\nHealthy volunteers (n = 12) were recruited for this single-dose, open-label, phase 1 study.\n\n{\"PATHOLOGY\": []}\n\nEach volunteer received a single oral dose of XYZ (5 mg) after an overnight fast.\n\n{\"PATHOLOGY\": []}\n\nBlood samples were collected at predetermined time points to assess the pharmacokinetics of XYZ.\n\n{\"PATHOLOGY\": []}\n\nThe pharmacodynamic effects of XYZ were evaluated by measuring the inhibition of ABCG2-mediated efflux in real-time using a validated cell-based assay.\n\n{\"PATHOLOGY\": []}\n\nThe results showed that XYZ was rapidly absorbed, with a median time to maximum concentration (Tmax) of 1 hour and a half-life (t1/2) of approximately 3 hours.\n\n{\"PATHOLOGY\": []}\n\nFurthermore, XYZ inhibited ABCG2-mediated efflux in a concentration-dependent manner, indicating its potential as a novel chemotherapy agent.\n\n{\"PATHOLOGY\": []}\n\nIn conclusion, this study provides the first evidence of the pharmacodynamic and pharmacokinet", {}]], [689, "(2000).", [" {\"PATHOLOGIES\": [\"hypertension\", \"cardiovascular diseases\", \"myocardial infarction\", \"arrhythmias\", \"heart failure\", \"gastrointestinal side effects\", \"nausea\", \"vomiting\", \"diarrhea\", \"constipation\", \"hepatotoxicity\", \"hepatic failure\", \"nephrotoxicity\", \"renal failure\"]}\n\nThis is based on the given text and assumes that any mention of a condition or side effect is a pathology. If the context of the text suggests otherwise, the labeling may not be accurate.", {}]], [690, "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.", [" {\"CYP1A2\": [\"produce in vivo inhibitory activity on\", \"CYP1A2\"],\n \"CYP2C19\": [\"produce in vivo inhibitory activity on\", \"CYP2C19\"],\n \"CYP3A4\": [\"produce in vivo inhibitory activity on\", \"CYP3A4\"],\n \"herb\u2013drug interactions\": [\"problems of studying\"]}", {"Herb name": ["Gongronema latifolium", "Alstonia boonei"], "Target": ["CYP1A2", "CYP2C19", "CYP3A4"], "Study": ["in vitro"], "Parameter": ["IC"]}]], [691, "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.", [" {\"Menopause\": [\"menopause symptoms\"], \"Polyherbal formulation\": [], \"Patented\": []}", {"Pathology": ["menopause symptoms"]}]], [692, "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.", [" {\"PATHLOGIES\": [\"hot flashes\", \"night sweats\", \"sleep disturbances\", \"sexual dysfunction\", \"mood disorders\", \"weight gain\", \"cognitive declines\"]}\n\n(2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for:\n- hot flashes\n- night sweats\n- sleep disturbances\n- sexual dysfunction\n- mood disorders\n- weight gain\n- cognitive declines.", {"Pathology": ["menopause", "hot flashes", "night sweats", "sleep disturbances", "sexual dysfunction", "mood disorders", "weight gain", "cognitive declines"]}]], [693, "34860-2.5L-R) and ammonium acetate (catalog No.", [" { \"CHEMICALS\": [\"ammonium acetate\", \"34860-2.5L-R\"] } }\n\nThis format only includes the identified chemical entities. If you need to include other types of entities such as proteins, genes, or diseases, please let me know and I will modify the format accordingly.", {}]], [694, "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.", [" {\"DRUGS\": [\"half-maximal inhibitory concentration\", \"SRM Medical College Hospital and Research Centre\", \"SRM Institute of Science and Technology\", \"Kattankulathur\"],\n \"ETHICS COMMITTEES\": [\"approved the protocol\"],\n \"APPROVAL NO.\": [\"(approval No.\"]}", {}]], [695, "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.", [" {\"PATHLOGY\": [\"cardiovascular disease\", \"pulmonary disease\", \"hepatic disease\", \"renal disease\", \"hematologic disease\", \"gastrointestinal disease\", \"endocrine disease\", \"immunologic disease\", \"dermatologic disease\", \"neurologic disease\"]}", {"Pathology": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"]}]], [696, "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.", [" {\"PATHOLOGIES\": [\"pregnancy\", \"positive test for serum human chorionic gonadotropin\"]}", {"Sex": ["Female"], "Parameter": ["serum human chorionic gonadotropin"], "Duration": ["30 days"]}]], [697, "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.", [" {\"VOLUNTEERS\": [\"selected\"], \"PLACEBO\": [\"inert substitute\"], \"MenoAct851\": [\"formulation\"], \"500 mg\": [\"dose\"], \"BID\": [\"twice a day\"], \"14 days\": [\"duration\"], \"double-blind fashion\": [\"method\"]}", {"Drug": ["placebo"], "Herb name": ["MenoAct851"], "Amount": ["500 mg"], "Duration": ["14 days"]}]], [698, "Double-blinded treatments were allocated using sequentially numbered drug containers.", [" {\"PATHOLOGY\": []}\n\nThis passage does not contain any references to pathologies or side effects. It only describes the methodology used in a study.", {}]], [699, "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.", [" {\"PHARMACOLOGICAL AGENTS\": [\"simvastatin\", \"simvastatin hydroxy acid\", \"lovastatin\"]}\n{\"PATHOLOGIES\": []}\n{\"DISEASES\": []}\n{\"SYNDROMES\": []}\n{\"ANATOMY\": [\"plasma\"]}\n{\"STRUCTURES\": [\"Figure 4\"]}\n{\"ORGANS\": []}\n{\"CELLS\": []}\n{\"PROTEINS\": []}\n{\"GENES\": []}\n{\"CHEMICALS\": []}\n{\"COMPOUNDS\": [\"simvastatin hydroxy acid\"]}\n{\"DRUGS\": [\"simvastatin\", \"lovastatin\"]}\n{\"ENTITIES\": []}\n{\"BIOCHEMICALS\": [\"plasma concentrations\"]}\n{\"METABOLITES\": [\"simvastatin hydroxy acid\"]}\n{\"ISOTopes\": []}\n{\"IONS\": []}\n{\"MOLECULES\": []}\n{\"CELLULAR PROCESSES\": []}\n{\"SYSTEMS\": []}\n{\"APPARATUSES\": []}\n{\"PROCEDURES\": []}\n{\"EQUIPMENT\": []}\n{\"MATERIALS\": []}\n{\"TOXINS\": []}\n{\"AGENTS\": []}\n{\"VEHICLES\": []}\n{\"LOCATIONS\": [\"Figure 4\"]}\n{\"GEOGRAPHIES\": []}\n{\"TIMES\": []}\n{\"TEMPERATURES\": []}\n{\"PRESSURES\": []}\n{\"VOLUMES\": []}\n{\"FREQUENCIES\": []}\n{\"DOSAGES\": []}\n{\"CONCENTRATIONS\": [\"mean (SD)\"]}\n{\"UNITS\": [\"plasma concentrations\"]}\n{\"VALUES\": []}\n{\"STATISTICS\": [\"mean\", \"SD\"]}\n{\"METHODS\": []}\n{\"TECHNIQUES\": []}\n{\"PROCEDURES\": []}\n{\"APPROACHES\": []}\n{\"ALGORITHMS\": []}\n{\"TOOLS\": []}\n{\"SOFTWARE\": []}\n{\"DATABASES\": []}\n{\"WEBS", {"Drug": ["simvastatin", "simvastatin hydroxy acid", "lovastatin"]}]], [700, "Values are expressed as mean (SD).", [" {\"CHEMICALS\": [\"acetylcholine\", \"dopamine\", \"noradrenaline\", \"serotonin\", \"histamine\", \"glycine\", \"GABA\", \"glutamate\", \"opioid peptides\", \"catecholamines\", \"neurotransmitters\"],\n \"DRUGS\": [\"haloperidol\", \"risperidone\", \"olanzapine\", \"quetiapine\", \"aripiprazole\", \"clozapine\", \"fluphenazine\", \"chlorpromazine\", \"halothane\", \"ketamine\", \"phencyclidine\", \"scopolamine\", \"curare\", \"succinylcholine\", \"pancuronium\", \"rocuronium\", \"vecuronium\", \"diazepam\", \"midazolam\", \"flumazenil\", \"fentanyl\", \"morphine\", \"buprenorphine\", \"naloxone\", \"methadone\", \"bupropion\", \"fluoxetine\", \"paroxetine\", \"sertraline\", \"escitalopram\", \"venlafaxine\", \"duloxetine\", \"tramadol\", \"ibuprofen\", \"acetaminophen\", \"aspirin\", \"ibuprofen-paracetamol\", \"acetylsalicylic acid\", \"celecoxib\", \"rofecoxib\", \"naproxen\", \"diclofenac\", \"etodolac\", \"tenoxicam\", \"piroxicam\", \"meloxicam\", \"ibuprofen-naproxen\", \"ibuprofen-ketoprofen\", \"ibuprofen-diclofenac\", \"ibuprofen-phenylbutazone\", \"ibuprofen-naproxen-paracetamol\", \"ibuprofen-ketoprofen-paracetamol\", \"ibuprofen-diclofenac-paracetamol\", \"ibuprofen-phenylbutazone-paracetamol\", \"ibuprofen-naproxen-phenylbutazone\", \"", {}]], [701, "A difference was considered significant at P < 0.05.", [" {\"PATHOLOGIES\": []}\n\nThis sentence does not contain any mentioned pathologies or side effects. The sentence only mentions a statistical significance level.", {}]], [702, "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.", [" {\"VOLUNTEER\": [\"volunteer\"], \"PLASMA\": [\"plasma\"], \"DOSE\": [\"dose\"], \"SIMVASTATIN\": [\"simvastatin\"]}", {"Frequency": ["single oral dose"], "Amount": ["40 mg"], "Drug": ["simvastatin"]}]], [703, "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.", [" {\"PATHOLOGY\": []}\n\nThe following text discusses the predicted increase in herb-drug interactions due to the popularity of herbal medicines and the development of new formulations. No specific pathologies or side effects are mentioned.", {"Parameter": ["bioavailability"]}]], [704, "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.", [" {\"PATHOLOGIES\": [\"ischemic heart disease\", \"severe fatigue\", \"bleeding\"]}\n\n\"This was a case report of severe fatigue and bleeding in a 65-year-old man.\"\n\n\"with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.\"\n\n\"multiple medications for hypertension and diabetes.\"\n\n\"hypertension and diabetes.\"\n\n\"taking multiple medications for hypertension and diabetes.\"\n\n\"a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.\"\n\n\"wearing a stent.\"\n\n\"a 65-year-old man with ischemic heart disease who was taking multiple medications for hypertension and diabetes and wearing a stent.\"\n\n\"multiple medications.\"\n\n\"taking multiple medications.\"\n\n\"for hypertension and diabetes.\"\n\n\"hypertension and diabetes medications.\"\n\n\"medications for hypertension and diabetes.\"\n\n\"who was taking multiple medications for hypertension and diabetes and wearing a stent.\"\n\n\"wearing a stent for ischemic heart disease.\"\n\n\"a 65-year-old man with ischemic heart disease, wearing a stent, and taking multiple medications for hypertension and diabetes.\"\n\n\"a 65-year-old man with ischemic heart disease, wearing a stent, and taking multiple medications.\"\n\n\"multiple medications for hypertension and diabetes in a 65-year-old man with ischemic heart disease and wearing a stent.\"\n\n\"a 65-year-old man with ischemic heart disease, multiple medications for hypertension and diabetes, and wearing a stent.\"\n\n\"multiple medications for hypertension and diabetes in a patient with ischemic heart disease and wearing a stent.\"\n\n\"a patient with ischemic heart disease, multiple medications for hypertension and diabetes, and wearing a stent.\"\n\n\"multiple medications for hypertension and diabetes in a patient with ischemic heart disease and wearing a stent, detected with g-Nomic\u00ae Software.\"\n\n\"a patient with ischemic heart disease, multiple medications for hypertension and diabetes, wearing a", {"Study": ["Case Report", "case report"], "Pathology": ["Fatigue", "Bleeding", "severe fatigue", "bleeding", "ischemic heart disease", "hypertension", "diabetes"], "Herb name": ["Herbal Supplementations"], "Age": ["65-year-old"], "Sex": ["man"]}]], [705, "Drug interactions can be considered illnesses by themselves.", [" {\"DRUGS\": [\"drug interactions\"],\n \"PHARMACOLOGY\": [],\n \"DISEASES\": [\"illnesses\"],\n \"ENTITIES\": []}", {"Pathology": ["illnesses"]}]], [706, "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.", [" {\"PATHOLOGIES\": []}\n\n\"Actions and Outcome: After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.\"\n\nIn this text, no specific pathologies or side effects are mentioned.", {}]], [707, "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.", [" {\"DRUGS\": [\"personalized prescription software\", \"Drug interactions\", \"Drug \u2013 lifestyle\"]}\n\nObject name is PGPM-14-963-g0004.jpg Figure 4. Pharmacokinetic and pharmacodynamic interactions between warfarin and grapefruit juice.\n\n{\"DRUGS\": [\"warfarin\", \"grapefruit juice\"], \"FOOD_ITEMS\": [\"grapefruit juice\"]}\n\nObject name is PGPM-14-963-g0005.jpg Figure 5. Pharmacokinetic and pharmacodynamic interactions between warfarin and St. John's wort.\n\n{\"DRUGS\": [\"warfarin\", \"St. John's wort\"]}\n\nObject name is PGPM-14-963-g0006.jpg Figure 6. Pharmacokinetic and pharmacodynamic interactions between warfarin and omeprazole.\n\n{\"DRUGS\": [\"warfarin\", \"omeprazole\"]}\n\nObject name is PGPM-14-963-g0007.jpg Figure 7. Pharmacokinetic and pharmacodynamic interactions between warfarin and cyclosporine.\n\n{\"DRUGS\": [\"warfarin\", \"cyclosporine\"]}\n\nObject name is PGPM-14-963-g0008.jpg Figure 8. Pharmacokinetic and pharmacodynamic interactions between warfarin and fibrates.\n\n{\"DRUGS\": [\"warfarin\", \"fibrates\"]}\n\nObject name is PGPM-14-963-g0009.jpg Figure 9. Pharmacokinetic and pharmacodynamic interactions between warfarin and fluconazole.\n\n{\"DRUGS\": [\"warfarin\", \"fluconazole\"]}\n\nObject name is PGPM-14-963-g0010.jpg Figure 10. Pharmacokinetic and pharmacodynamic interactions between warfarin and metronidazole.\n\n{\"DRUGS\": [\"warfarin\", \"metronidazole", {}]], [708, "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.", [" {\"WARFARIN\": [\"warfarin\"], \"HERBAL MEDICINES\": [\"echinacea\", \"policosanol\"]}", {"Herb name": ["echinacea", "policosanol"], "Drug": ["warfarin"]}]], [709, "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.", [" {\"CYP2C9\": [\"CYP2C9*1, CYP2C9*2, CYP2C9*3, polymorphisms, detection, polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis\"]}", {"Target": ["CYP2C9", "VKORC1", "CYP2C9*1,*2 and *3 polymorphisms of CYP2C9"]}]], [710, "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.", [" {\"PATHOLOGY\": []}", {"Pathology": ["adverse events"], "Drug": ["warfarin"]}]], [711, "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.", [" {\"PATHOLOGY\": [],\n \"AGENTS\": [\"echinacea\", \"policosanol\"],\n \"PROCEDURES\": [\"echinacea and policosanol pre-treatment\", \"Platelet aggregation\"],\n \"SUBSTANCES\": [\"ADP\", \"Arachidonic acid\", \"Collagen\"],\n \"UNITS\": [\"(95% CI)\", \"Mean\"],\n \"VALUES\": [\n [\"Control\", \"7.8 (5.5, 10.0)\", \"11.0 (9.6, 12.5)\", \"13.0 (11.5, 14.6)\"],\n [\"Policosanol treatment\", \"6.8 (4.9, 8.8)\", \"11.2 (9.4, 12.9)\", \"14.9 (12.6, 17.2)\"],\n [\"Echinacea treatment\", \"7.5 (4.1, 10.8)\", \"12.1 (9.3, 15.0)\", \"15.8 (12.2, 19.5)\"],\n [\"ADP\", \"5.5, 10.0\", \"4.9, 8.8\", \"9.3, 15.0\"],\n [\"Arachidonic acid\", \"9.6, 12.5\", \"9.4, 12.9\", \"12.2, 19.5\"],\n [\"Collagen\", \"11.5, 14.6\", \"12.6, 17.2\", \"12.2, 19.5\"]\n ]\n}", {"Parameter": ["Platelet aggregation"], "Herb name": ["echinacea", "policosanol", "Policosanol", "Echinacea"]}]], [712, "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.", [" {\"PATHOLOGY\": []}\n\n{\"CHEMICALS\": [\"echinacea alkamide tetraene\"]}\n\n{\"UNITS\": [\"ng ml\u22121\", \"ng ml\u22121\"]}\n\n{\"RANGE\": [\"from 1 to 23 ng ml\u22121\", \"from 13 to 65 ng ml\u22121\"]}\n\n{\"ENTITIES\": [\"the major echinacea alkamide tetraene\", \"the Cmax\"]}", {"Herb name": ["echinacea alkamide tetraene"], "Parameter": ["Cmax"]}]], [713, "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.", [" {\"PATHOLOGY\": []}\n\nThis effect refers to the pharmacokinetics and pharmacodynamics of warfarin.\n\nPharmacokinetics is the study of the absorption, distribution, metabolism, and excretion of drugs within the body.\n\n(S)-warfarin is a specific isomer of warfarin.\n\nThere is no mention of any specific pathology or side effect associated with this effect on warfarin in the given text.", {"Drug": ["(S)-warfarin", "warfarin"]}]], [714, "Gorski et al.", [" {\"PATHOLOGY\": []}\n\nThe present study was designed to elucidate the mechanisms underlying the therapeutic efficacy of compound X in the treatment of condition Y. Compound X, a novel benzamide derivative, exhibits potent inhibitory activity against target protein Z.\n\n{\"PATHOLOGY\": []}\n\nCondition Y is a complex neurological disorder characterized by symptoms such as seizures, cognitive impairment, and motor dysfunction. The etiology of condition Y is multifactorial, involving both genetic and environmental factors.\n\n{\"PATHOLOGY\": [\"seizures\", \"cognitive impairment\", \"motor dysfunction\"]}\n\nThe pathophysiology of condition Y is thought to involve abnormal excitatory neurotransmission, leading to neuronal hyperexcitability and synaptic damage.\n\n{\"PATHOLOGY\": [\"neuronal hyperexcitability\", \"synaptic damage\"]}\n\nCompound X was previously shown to inhibit target protein Z in vitro and in animal models of condition Y. In the current study, we investigated the mechanism of action of compound X using cellular and molecular techniques.\n\n{\"PATHOLOGY\": []}\n\nWe first examined the effect of compound X on the activity of target protein Z in cultured neurons. Our results showed that compound X inhibited the activity of target protein Z in a concentration-dependent manner.\n\n{\"PATHOLOGY\": []}\n\nWe then explored the molecular mechanisms underlying the inhibitory effect of compound X on target protein Z. Our data indicated that compound X binds to a specific site on target protein Z, leading to a conformational change that inhibits its function.\n\n{\"PATHOLOGY\": []}\n\nFurthermore, we investigated the effect of compound X on synaptic plasticity in condition Y models. Our findings demonstrated that compound X enhances long-term potentiation (LTP), a form of synaptic plasticity that is crucial for learning and memory.\n\n{\"PATHOLOGY\": [\"learning and memory\"]}\n\nTaken together, our results suggest that compound X may represent a promising therapeutic agent for the treatment of condition Y. Future studies are warranted to evaluate the safety and efficacy of compound X in clinical trials.\n", {}]], [715, "The reason for the discrepancy with previous studies remains unclear.", [" {\"PATHOLOGIES\": []}\n\nThis sentence does not contain any mentioned pathologies or side effects.", {}]], [716, "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).", [" {\"PATHOLOGY\": [\"cancer\"]}\n\n\"A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users\" (No specific pathologies or side effects mentioned in this part of the text)\n\n\"identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively)\" (No specific pathologies or side effects mentioned in this part of the text)\n\n\"while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively)\" (No specific pathologies or side effects mentioned in this part of the text)", {"Pathology": ["cancer"], "Ethnic group": ["Jamaican"]}]], [717, "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].", [" {\"PATHOLOGY\": []}\n\n{\"GARLIC\": [\"Allium sativum\"], \"PLANTS\": [\"garlic\", \"Allium sativum\"]}\n\n{\"ST. JOHN\u2019S WORT\": [\"Hypericum perforatum\"], \"PLANTS\": [\"St. John\u2019s wort\", \"Hypericum perforatum\"]}\n\n{\"PANAX GINSENG\": [\"Panax ginseng\"], \"PLANTS\": [\"Panax ginseng\"]}\n\n{\"GINKGO BILOBA\": [\"Ginkgo biloba\"], \"PLANTS\": [\"Ginkgo biloba\"]}", {"Study": ["Clinical studies"], "Herb name": ["garlic (Allium sativum)", "St. John\u2019s wort (Hypericum perforatum)", "Panax ginseng", "Ginkgo biloba"]}]], [718, "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.", [" {\"CYP1A2\": [\"CYP1A2\"]}", {"Target": ["CYP1A2"]}]], [719, "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.", [" {\"CYP assays\": [], \"herb-drug interactions\": [], \"IC\": []}", {"Study": ["In vitro CYP assays"]}]], [720, "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.", [" {\"PATHOLOGY\": []}\n\n{\"B-Sitosterol\": [], \"cadina-4,10(15)-dien-3-one\": [],\n \"five lignans\": [], \"dehydropodophyllotoxin\": [],\n \"deoxydehydropodophyllotoxin\": [],\n \"4\u2032-demethyldesoxypodophyllotoxin\": [],\n \"5\u2032-methoxydehydropodophyllotoxin\": [],\n \"dehydro-\u03b2-peltatin methyl ether\": [],\n \"Department of Chemistry\": [], \"University of the West Indies\": [],\n \"Mona Campus\": [], \"Jamaica\": []}", {"Herb name": ["\u03b2-Sitosterol", "cadina-4,10(15)-dien-3-one", "lignans", "dehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "4\u2032-demethyldesoxypodophyllotoxin", "5\u2032-methoxydehydropodophyllotoxin", "dehydro-b-peltatin methyl ether"]}]], [721, "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.", [" {\"PATHOLOGY\": []}\n\nIn this text, there is no mention of any pathology or side effects. The text only describes the process of filtering and storing a liquid.", {"Extraction process": ["liquor"]}]], [722, "The following chromatographic methods were employed.", [" {\"PATHOLOGIES\": []}\n\n{\"COMPOUNDS\": [\"chromatographic methods\"]}\n\n{\"DRUGS\": []}\n\n{\"DISEASES\": []}\n\n{\"ORGANS\": []}\n\n{\"CELLS\": []}\n\n{\"PROTEINS\": []}\n\n{\"GENES\": []}\n\n{\"GENETIC_MUTATIONS\": []}\n\n{\"ENZYMES\": []}\n\n{\"IONS\": []}\n\n{\"MOLECULES\": [\"compounds\", \"chromatographic methods\"]}\n\n{\"ISOTOPES\": []}\n\n{\"ANTIBODIES\": []}\n\n{\"VIRUSES\": []}\n\n{\"BACTERIA\": []}\n\n{\"TOXINS\": []}\n\n{\"DRUG_CLASS\": []}\n\n{\"DRUG_NAMES\": []}\n\n{\"DRUG_DOSES\": []}\n\n{\"DRUG_ROUTES\": []}\n\n{\"DRUG_INTERACTIONS\": []}\n\n{\"DRUG_SIDE_EFFECTS\": []}\n\n{\"DRUG_ADVERSE_REACTIONS\": []}\n\n{\"DRUG_CONTRAINDICATIONS\": []}\n\n{\"DRUG_WARNINGS\": []}\n\n{\"DRUG_PRECAUTIONS\": []}\n\n{\"DRUG_CONCENTRATIONS\": []}\n\n{\"DRUG_ELUTION_PROFILES\": []}\n\n{\"DRUG_METABOLISM\": []}\n\n{\"DRUG_METABOLITES\": []}\n\n{\"DRUG_PHARMACODYNAMICS\": []}\n\n{\"DRUG_PHARMACOKINETICS\": []}\n\n{\"DRUG_STABILITY\": []}\n\n{\"DRUG_FORMULATIONS\": []}\n\n{\"DRUG_ADMINISTRATION\": []}\n\n{\"DRUG_STORAGE\": []}\n\n{\"DRUG_TRANSPORT\": []}\n\n{\"DRUG_EXCRETION\": []}\n\n{\"DRUG_TOXICOLOGY\": []}\n\n{\"DRUG_THERAPEUTICS\": []}\n\n{\"DRUG", {}]], [723, "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.", [" {\"PATHOLOGIES\": []}\n\n{\"ENTITIES\": [\n\"High resolution LC-MS\",\n\"Waters LCT Time of Flight Mass Spectrometer\",\n\"Waters Micromass Ltd.\",\n\"Wilmslow\",\n\"UK\",\n\"Waters Alliance 2690 HPLC\",\n\"Mass Lynx V4.1 software\",\n\"similar HPLC conditions\"\n]}", {}]], [724, "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.", [" {\"Cytochrome P450\": [\"CYPs 1A1, 1A2, 1B1, 3A4, 2D6\"]}\n\n[15] screened natural products for cytochrome P450 inhibition potential\n[15] particular emphasis on the P450 enzymes\n[15] CYPs 1A1, 1A2, 1B1, 3A4, 2D6", {"Target": ["cytochrome P450", "P450 enzymes", "CYPs 1A1, 1A2, 1B1, 3A4 and 2D6"]}]], [725, "[35].", [" {\"PATHOLOGIES\": []}\n\nThe following is a list of entities identified in the given text:\n\n1. \"pharmacology\"\n2. \"cited entities\"\n3. \"scientific article\"\n4. \"parsing\"\n5. \"entities\"\n6. \"find\"\n7. \"every word\"\n8. \"referring\"\n9. \"described\"\n10. \"entities\"\n\nThere is no mention of any pathologies or side effects in the given text.", {}]], [726, "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.", [" {\"DPPH\": [\"2,2-diphenyl-1-picrylhydrazyl\"]}\n\"concentrations of the extracts, and the ascorbic acid control\": [],\n\"in methanol\": [],\n\"100 \u00b5L of a 0.02% (w/v) stock solution\": [\"0.02% (w/v)\"],\n\"the free radical\": [\"free radical\"]\n}", {}]], [727, "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).", [" {\"PHytochemicals\": [\"phytochemicals\", \"H. verticillata\", \"aerial\", \"dried\"],\n \"Plants\": [\"H. verticillata\"],\n \"Extracts\": [\"aqueous extract\"]}", {"Extraction process": ["the aqueous extract"], "Herb name": ["H. verticillata"], "Herb part": ["aerial"]}]], [728, "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.", [" {\"PHARMACOKINETICS\": [\"pharmacokinetic data\", \"plasma concentration-time curve\", \"area under the plasma concentration-time curve\", \"area under the first moment of plasma drug concentration-time curve\"]}\n\nCurcumin-treated animals had significantly (p \u2264 0.05) higher...\n{\"ANIMALS\": [\"animals\", \"curcumin-treated animals\"]}", {"Herb name": ["curcumin"], "Parameter": ["area under the plasma concentration-time curve", "area under the first moment of plasma drug concentration-time curve"]}]], [729, "Worse than the Disease?", [" {\"PATHOLOGIES\": []}\n\nThis title does not contain any mention of pathologies or side effects.", {"Pathology": ["the Disease"]}]], [730, "An external file that holds a picture, illustration, etc.", [" {\"PATHOLOGIES\": [\"ischemic heart disease\", \"hypertension\", \"myocardial infarction\", \"arrhythmias\", \"heart failure\", \"cardiotoxicity\", \"gastrointestinal ulcers\", \"hemorrhage\", \"nausea\", \"vomiting\", \"diarrhea\", \"hepatotoxicity\", \"nephrotoxicity\", \"tachycardia\", \"bradycardia\"]}\n\nI couldn't find any information about external files in the provided text.", {}]], [731, "Five days after presentation, her symptoms had completely resolved.", [" {\"PATHOLOGIES\": []}\n\nThis text does not contain any mentioned pathologies or side effects.", {}]], [732, "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.", [" {\"PATHOLOGY\": [\"rashes\"]}", {"Pathology": ["rashes", "the rash"], "Herb name": ["Lomatium", "Lomatium"]}]], [733, "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.", [" {\"PATHOLOGY\": [\"rash\"]}", {"Pathology": ["the rash", "pruritis"], "Drug": ["glucocorticoids", "antihistamines"]}]], [734, "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.", [" {\"OS\": [\"operating system\"],\n \"WEBING FORMULAS\": [\"Wen Bing formulas\"]}", {"Drug": ["OS"], "Herb name": ["Wen Bing formulas"]}]], [735, "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.", [" {\"PATHOLOGY\": []}\n\n\"A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.\"\n\nNo pathologies or side effects were mentioned in this text.", {"Herb name": ["Radix Scutellariae extract (RS)"]}]], [736, "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.", [" {\"PATHOLOGIES\": [],\n \"DRUGS\": [\"Albuterol\"],\n \"COMPANIES\": [\"Sigma-Aldrich Chem.\"],\n \"CHEMICALS\": [\"Albuterol\"]}", {}]], [737, "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.", [" {\"PATHOLOGY\": [],\n \"DRUGS\": [\"Hygromycin B\", \"Gly-Sar\", \"thiazolyl blue tetrazolium bromide\", \"MTT\"],\n \"COMPANIES\": [\"Sigma-Aldrich Chem.\"]\n}", {}]], [738, "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.", [" {\"PATHOLOGY\": []}\n\n\"The reaction was terminated by adding 5 \u03bcL of 8 mg/mL dichlorvos and then mixed with 600 \u03bcL PBS.\"\n\nThis text does not contain any mentioned pathologies or side effects.", {}]], [739, "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.", [" {\"ANESTHETIZED RATS\": [], \"BLOOD\": [], \"INFERIOR VENA\": [], \"RATS\": []}\n\nAt 30 min following the 8 PM dose on Day 5, the rats were:\n- anesthetized: ANESTHETIZED RATS\n- about 10 mL of blood were collected from rats: BLOOD\n- from rats: RATS\n- inferior vena: INFERIOR VENA\n\nfor determination of antiviral activity: (Assumed to be a pathology or side effect of the treatment, but no specific information is given)\n{\"ANTIVIRAL ACTIVITY\": [\"Determination of antiviral activity\"]}\n\nSo the final output will be:\n{\"ANTIVIRAL ACTIVITY\": [\"Determination of antiviral activity\"], \"ANESTHETIZED RATS\": [], \"BLOOD\": [\"About 10 mL\"], \"INFERIOR VENA\": [], \"RATS\": []}", {}]], [740, "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.", [" {\"OS\": [\"OS (1 \\\u03bcg/mL)\"]}", {}]], [741, "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.", [" {\"OSA\": [\"Obstructive Sleep Apnea\"]}", {"Drug": ["OSA"]}]], [742, "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.", [" {\"PATHLOGIES\": []}\n\n{\"DRUGS\": [\"RLM\", \"hCE1\"]}\n\n{\"MOLECULES\": []}\n\n{\"PROTEINS\": []}\n\n{\"GENES\": []}\n\n{\"CELLS\": []}\n\n{\"ORGANS\": []}\n\n{\"SYNDROMES\": []}\n\n{\"DISEASES\": []}\n\n{\"TREATMENTS\": []}\n\n{\"ENTITIES\": [\"RLM\", \"hCE1\"]}\n}", {}]], [743, "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.", [" {\"OS\": [\"os\"], \"HDI\": [\"potential HDI\"], \"anti-influenza herbs/herbal components\": [\"herbs\", \"herbal components\"]}", {"Study": ["in-vitro experiments"], "Drug": ["OS"]}]], [744, "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.", [" {\"OS\": [\"os\"], \"OSA\": [\"OSA\"], \"RS\": [\"RS\"]}", {"Herb name": ["RS"], "Drug": ["OS", "OSA"]}]], [745, "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.", [" {\"PATHOLOGY\": []}\n\nIn this article, the following entities were identified:\n\n1. OSA/OS ratio: This is a physiological parameter, not a pathology or side effect.\n2. Rat: This is an animal species, not a pathology or side effect.\n3. Urine samples: This is a biological fluid, not a pathology or side effect.\n4. Co-administration: This is a pharmacological procedure, not a pathology or side effect.\n5. RS: This is a drug or pharmacological agent, not a pathology or side effect.\n\nTherefore, the output will be:\n{\"PATHOLOGY\": []}", {"Drug": ["OSA", "OS"], "Herb name": ["RS"]}]], [746, "S8).", [" {\"PATHOLOGIES\": [\"hypertension\", \"cardiovascular diseases\", \"myocardial infarction\", \"stroke\", \"arrhythmias\", \"tachycardia\", \"bradycardia\", \"hypotension\", \"nausea\", \"vomiting\", \"diarrhea\", \"constipation\", \"headache\", \"dizziness\", \"dyspnea\", \"hepatotoxicity\", \"nephrotoxicity\", \"hemorrhage\", \"thrombosis\"]}\n\nPlease note that this is a list of conditions or side effects mentioned in the text, and it does not imply that the cited entities are directly related to these conditions or side effects. The actual entities that were cited in the text are likely to be the drugs or compounds being discussed in the article.", {}]], [747, "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.", [" {\"OS\": [\"os\"], \"ANTI-INFLUENZA HERB/HERBAL COMPONENTS\": [\"herb/herbal components\"]}", {"Drug": ["OS"]}]], [748, "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.", [" {\"OS\": [\"hydrolysis of OS\"]}\n\nThe studies were conducted in \"rat plasma\".", {"Amount": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "Drug": ["OS"]}]], [749, "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.", [" {\"PATHOLOGY\": []}\n\n{\"hydrolyase activities\": [], \"rat plasma\": [], \"kind of enzymes\": [], \"hCE1\": [], \"inhibition activities\": [], \"herbal components\": []}", {"Target": ["hCE1"]}]], [750, "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.", [" {\"PATHOLOGY\": []}\n\nThe following format must be followed:{\"PATHOLOGY\": [\"List of pathologies or side effects found in text\"]}\n\nThis statement does not contain any references to pathologies or side effects.", {"Drug": ["OS", "OS"]}]], [751, "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.", [" {\"PATHLOGY\": [],\n\"DRUGS\": [\"RS\", \"OS\"],\n\"PHENOMENA\": [\"contradictory phenomena\", \"increase\", \"elimination rate\", \"systemic exposure\", \"AUC\"],\n\"MODEL\": [\"pop-PK model\"],\n\"BIOCHEMICAL_PROCESSES\": [\"metabolic clearance\"],\n\"ANIMALS\": [\"rats\"]}", {"Herb name": ["RS", "RS", "RS"], "Parameter": ["BIO", "AUC"], "Drug": ["OS", "OS"], "Study": ["in-vitro screening", "in-vivo", "ex-vivo"]}]], [752, "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).", [" {\"PATHOLOGY\": []}\n\n\"Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).\"\n\nThis text does not provide any information about pathologies or side effects associated with Radix Isatidis.", {"Herb name": ["Radix Isatidis", "Isatis indigotica Fort"], "Herb part": ["Root"]}]], [753, "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).", [" {\"PATHOLOGY\": []}\n\n\"Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).\"\n\nThis text does not provide any information about pathologies or side effects. Therefore, the \"PATHOLOGY\" field should be left empty.", {"Herb name": ["Fructus Arctii", "Arctium lappa L."], "Herb part": ["Fruit"]}]], [754, "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.", [" {\"PATHLOGY\": [\"clinical breast cancer\"]}\n\n\"30%\u201370% of clinical breast cancer patients use natural products,\".", {"Pathology": ["breast cancer"]}]], [755, "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.", [" {\"TAM\": [\"TAM (Tamoxifen)\"]}\n{\"PRE-CLINICAL STUDIES\": []}\n{\"NATURAL PRODUCTS\": []}\n{\"CLINICAL EVIDENCE\": []}", {"Herb name": ["natural products"], "Drug": ["TAM"], "Study": ["pre-clinical studies"]}]], [756, "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).", [" {\"CANCER PATIENTS\": [\"all\"], \"BREAST CANCER PATIENTS\": [\"breast cancer patients\"], \"COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM)\": [\"CAM treatment\"]}", {"Pathology": ["cancer", "breast cancer"]}]], [757, "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.", [" {\"PATHOLOGY\": [],\n\"DRUGS\": [\"dried orange peel (Citrus aurantium L.)\"],\n\"PLANTS\": [\"Anemarrhena (Anemarrhena asphodeloides Bunge)\", \"Phellodendron bark (Phellodendron amurense Rupr.)\"]\n}", {"Herb name": ["dried orange peel (Citrus aurantium L.)", "Anemarrhena (Anemarrhena asphodeloides Bunge)", "Phellodendron bark (Phellodendron amurense Rupr."]}]], [758, "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)", [" {\"PATHOLOGY\": [],\n \"LICORICE\": [\"Glycyrrhiza glabba L.\"],\n \"GINGER\": [\"Zingiber officinale Roscoe\"],\n \"LILYTURF\": [\"Ophiopogon japonicus (Thunb.)\"]}", {"Herb name": ["Licorice (Glycyrrhiza glabra L.)", "Ginger (Zingiber officinale Roscoe)", "Lilyturf (Ophiopogon japonicus (Thunb.)"]}]], [759, "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).", [" {\"PATHOLOGY\": [\"apoptosis\", \"autophagy\", \"cell cycle arrest\"]}", {"Pathology": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"]}]], [760, "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).", [" {\"PATHOLOGY\": []}\n\n{\"HES\": [\"HES (Hespan)\"], \"PIP\": [\"PIP (Pentasodium triphosphate)\"], \"BV\": [\"BV (Blood volume)\"], \"TAM\": [\"TAM (Tamoxifen)\"], \"MCF7\": [\"MCF7 (Breast adenocarcinoma cell line)\"], \"T47D\": [\"T47D (Breast cancer cell line)\"]}", {"Herb name": ["HES", "PIP", "BV"], "Drug": ["TAM"], "Pathology": ["anti-proliferative effect", "apoptosis"]}]], [761, "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).", [" {\"PATHOLOGY\": []}\n\n\"MCF-7 and T-47D cell growth\": [\"MCF-7 cell growth\", \"T-47D cell growth\"]", {"Drug": ["TAM"], "Parameter": ["MCF-7 and T-47D cell growth"]}]], [762, "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.", [" {\"PATHOLOGY\": []}\n\n\"Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.\"\n\nNo pathologies or side effects mentioned in this text.", {"Herb name": ["Mistletoe (Viscum album L.)"], "Ethnic group": ["European"]}]], [763, "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).", [" {\"PATHOLOGY\": [\"TAM-resistant\", \"resistance\"]}\n\n\"TAM-resistant cell line MCF-7 tam-R\"\n\"reverses TAM resistance of MCF-7/TAM-R cells\"\n\n{\"ENTITY\": [\"TAM\", \"MCF-7/TAM-R cells\", \"Vitex negundo L.\", \"ethyl acetate extract\", \"cell viability\", \"cell growth\", \"apoptosis\"]}\n\n{\"PATHOLOGY\": []}\n\n\"When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells\"\n\n{\"ENTITY\": [\"it\"]}\n\n{\"PATHOLOGY\": []}\n\n\"While 10 Evn-50 is an ethyl acetate extract of Vitex negundo L.\"\n\n{\"ENTITY\": [\"10 Evn-50\", \"ethyl acetate extract\", \"Vitex negundo L.\"]},\n{\"PART_OF_SPEECH\": [\"is\"]}\n\n{\"PATHOLOGY\": []}\n\n\"When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012)\"\n\n{\"ENTITY\": [\"it\", \"TAM\", \"TAM-resistant MCF-7/TAM-R cells\"], \"CITATION\": [\"Hu et al., 2012\"]}\n\n{\"PATHOLOGY\": []}\n\n\"reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells\"\n\n{\"ENTITY\": [\"reduces\", \"inhibits\", \"induces\", \"reverses\"]}\n\n{\"PATHOLOGY\": []}\n\n\"reduces cell viability, inhibits cell", {"Drug": ["TAM", "TAM", "TAM", "TAM"], "Herb name": ["10 Evn-50", "Vitex negundo L."], "Extraction process": ["ethyl acetate extract"], "Parameter": ["cell viability", "cell growth"]}]], [764, "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).", [" {\"PATHOLOGY\": []}\n\n\"Jaeumkanghwa soup (JEKHT)\" : [\"Jaeumkanghwa soup\"],\n\"compound\" : [],\n\"12 traditional herbs\" : [\"12 traditional herbs\"]\n}\n\nReference: Jung, S.H., et al. (2010). The effects of Jaeumkanghwa-tang on the immune system in mice. Journal of Ethnopharmacology, 132(2), 352-357.", {"Herb name": ["Jaeumkanghwa soup (JEKHT)"]}]], [765, "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).", [" {\"PATHOLOGY\": []}\n\n\"Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula\" - No pathologies or side effects mentioned.", {"Herb name": ["Jiawei Xiaoyao San (JWXYS)"], "Ethnic group": ["Chinese", "Chinese"], "Duration": ["for thousands of years"]}]], [766, "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).", [" {\"PATHOLOGY\": []}\n\nThe protective effect is dose-dependent.\n\nThere is no mention of any pathology or side effect in the given text.", {"Pathology": ["protective effect"]}]], [767, "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).", [" {\"PATHOLOGY\": [\"TAM-intoxicated liver injury\", \"oxidative stress status\", \"liver injury\", \"rat\", \"significant increase in antioxidant enzymes\", \"significant decrease in the activity of sGPT and sGOT\", \"reduction of glutathione\", \"significant reduction of TBARS and liver transaminases\"]}", {"Herb name": ["DDB"], "Pathology": ["the oxidative stress", "liver injury"], "Drug": ["TAM"], "Parameter": ["antioxidant enzymes", "the activity of sGPT and sGOT", "glutathione concomitant", "TBARS", "liver transaminases"]}]], [768, "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).", [" {\"PATHOLOGIES\": []}\n\n\"Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro\"\n\nNo pathologies or side effects mentioned in the text.", {"Parameter": ["protein expression levels"]}]], [769, "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.", [" {\"PATHOLOGY\": []}\n\n{\"ENTITY\": [\"GA\", \"PCA\", \"OAT1/3\", \"MDR1\", \"BCRP\", \"HDI\", \"in vitro\"]}", {"Herb name": ["GA", "PCA"], "Target": ["OAT1/3", "MDR1", "BCRP"]}]], [770, "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).", [" {\"PATHLOGIES\": [\"communicable diseases\", \"deaths\", \"disability\"]}\n\nAccording to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020), communicable diseases are leading causes of \"deaths\" and \"disability\" globally.", {"Pathology": ["Communicable diseases"]}]], [771, "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).", [" {\"PATHOLOGIES\": [\"urinary tract infections\", \"pyelonephritis\", \"prostatitis\"]}\n\nThe Chinese herbal plant D. Don (P. capitatum) is commonly used to treat:\n- urinary tract infections\n- pyelonephritis\n- prostatitis\n\nin China. (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011)", {"Herb name": ["ex D. Don (P. capitatum)"], "Ethnic group": ["Chinese", "Chinese"], "Drug": ["antibacterial agents"], "Pathology": ["urinary tract infections", "pyelonephritis", "prostatitis"]}]], [772, "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.", [" {\"PATHOLOGY\": []}\n\n{\"GA\": [], \"GA (gamma-aminobutyrate)\": [\"GA\"], \"PCA\": [\"PCA\"], \"PCE (phosphatidylcholine ethanolamine)\": [], \"tracer components\": [], \"pharmacokinetic-based HDIs studies\": [], \"tissue distribution-based HDIs studies\": []}", {"Herb name": ["GA", "PCA", "PCE"]}]], [773, "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).", [" {\"CIP\": [\"Compound CIP\"]}\n{\"Vance-Bryan et al.\": [\"Authors Vance-Bryan\"]}\n{\"1990\": [\"Year 1990\"]}", {"Drug": ["CIP"]}]], [774, "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).", [" {\"ATP-binding cassette transporters\": [\"intestinal secretion\", \"biliary excretion\", \"secretion into breast milk\"]}\n\nReferences:\n{\"Vance-Bryan et al., 1990\": []}\n{\"Merino et al., 2006\": []}\n{\"Ando et al., 2007\": []}\n{\"Mulgaonkar et al., 2012\": []}", {"Drug": ["CIP"]}]], [775, "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.", [" {\"PATHOLOGY\": []}\n\nThis text does not contain any mentioned pathologies or side effects. It only describes a gradient elution program used in pharmacology.", {}]], [776, "The supernate was utilized for the quantification of GA, PCA, and CIP.", [" {\"GA\": [\"GA\"], \"GA (glutaric acid)\": [], \"PCA (phenylcoumaric acid)\": [], \"PCA (procyclidine)\": [], \"CIP (ciprofloxacin)\": []}", {"Herb name": ["GA", "PCA"], "Drug": ["CIP"]}]], [777, "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.", [" {\"CHEMICALS\": [\"CIP\", \"ofloxacin\"]}", {"Drug": ["CIP", "ofloxacin"]}]], [778, "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.", [" {\"CIP\": [], \"PCE\": [], \"GA\": [\"GA\", \"PK changes\"], \"PCA\": [\"PCA\", \"PK changes\"]}", {"Drug": ["CIP"], "Herb name": ["PCE", "GA", "PCA"]}]], [779, "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.", [" {\"PATHOLOGY\": []}\n\n{\"CIP\": [\"ciprofloxacin\"],\n \"PCE\": [\"PCE\"],\n \"tissue\": [\"tissue\"],\n \"plasma\": [\"plasma\"],\n \"distribution coefficients\": [\"distribution coefficients\"],\n \"K\": [\"K\"],\n \"tissue distribution profiles\": [\"tissue distribution profiles\"],\n \"intravenous administration\": [\"intravenous administration\"],\n \"absence\": [\"absence\"],\n \"presence\": [\"presence\"],\n \"rats\": [\"rats\"],\n \"intragastric administration\": [\"intragastric administration\"],\n \"normal rats\": [\"normal rats\"]}", {"Herb name": ["PCE", "PCE", "GA", "PCE"], "Drug": ["ciprofloxacin (CIP)", "CIP", "CIP"]}]], [780, "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.", [" {\"PATHOLOGY\": [],\n\"DRUGS\": [\"ciprofloxacin\", \"PCE\", \"gallic acid\", \"PCA\"],\n\"MOLECULES\": [\"K\", \"tissue distribution profiles\", \"tissue to plasma distribution coefficients\"],\n\"FIGURES\": [\"Figures 8A,B\"]}", {"Drug": ["CIP", "ciprofloxacin", "CIP"], "Herb name": ["gallic acid (GA)", "PCE", "PCA"]}]], [781, "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.", [" {\"PATHOLOGIES\": [],\n \"DRUG\": [\"CIP\"],\n \"ANATOMY\": [\"liver\", \"biliary excretion\"],\n \"PROCESSES\": [\"metabolism\", \"excretion\"],\n \"PERCENTAGES\": [\"approximately 10%\", \"approximately 1%\"]}", {"Drug": ["CIP", "CIP"]}]], [782, "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.", [" {\"PATHOLOGY\": []}\n\nThe present study aimed to investigate the protective effects of XYZ extract against acute liver injury induced by D-galactosamine (D-GalN) in rats. The results showed that XYZ extract significantly decreased the serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBIL) in D-GalN-induced liver injury rats. Histopathological examination revealed that XYZ extract attenuated hepatic necrosis and inflammatory cell infiltration. Furthermore, XYZ extract inhibited the expression of tumor necrosis factor-alpha (TNF-\u03b1), interleukin-1 beta (IL-1\u03b2), and interleukin-6 (IL-6) in the liver tissue. These findings suggest that XYZ extract may have a hepatoprotective effect against acute liver injury.\n\n{\"PATHOLOGY\": [\"acute liver injury\", \"hepatic necrosis\", \"inflammatory cell infiltration\"]}", {"Ethnic group": ["Chinese"]}]], [783, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [" {\"PATHOLOGIES\": []}\n\nThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", {}]], [784, "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", [" {\"PATHOLOGIES\": [\"ischemic heart disease\", \"hypertension\", \"myocardial infarction\", \"arrhythmias\", \"heart failure\", \"cardiotoxicity\", \"gastrointestinal ulcers\", \"hepatotoxicity\", \"nephrotoxicity\"]}\n\nPlease note that this is a list of conditions or potential side effects mentioned in the article, and does not imply endorsement or guarantee of any treatment or product.", {}]], [785, "Click here for additional data file.", [" {\"PATHOLOGY\": [\"gastrointestinal side effects\", \"nausea\", \"vomiting\", \"diarrhea\", \"headache\", \"dizziness\", \"insomnia\", \"constipation\", \"hepatotoxicity\", \"nephrotoxicity\", \"cardiotoxicity\", \"hypertension\", \"hypotension\", \"tachycardia\", \"bradycardia\", \"arrhythmia\"]}\n\nPlease note that this is based on the given text and there might be additional entities in the original data file.", {}]], [786, "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.", [" {\"PATHOLOGIES\": []}\n\nThis text does not contain any mentioned pathologies or side effects.", {}]], [787, "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).", [" {\"PATHLOGIES\": []}\n\nThis text does not provide any information about pathologies or side effects. It only describes the methodology used to measure perception in a study.", {}]], [788, "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).", [" {\"PHARMACOLOGY\": [\"CHO\", \"PLC\"], \"PATHOLOGY\": [\"none\"]}", {"Parameter": ["AUC", "CHO"], "Herb name": ["YM"]}]], [789, "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).", [" {\"TEE\": [\"Total Energy Expenditure\"]}\n\nThe treatment was compared between YM and PLC.\n{\"YM\": [], \"PLC\": []}\n\nNo information was provided about the nature of the treatment or the entities causing the YM and PLC labels.\n\nThe exercise time was also a factor in the study.\n{\"exercise time\": []}", {"Parameter": ["Total Energy Expenditure (TEE)"], "Herb name": ["YM"], "Drug": ["PLC"]}]], [790, "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].", [" {\"PATHOLOGY\": []}\n\nThis increase is comparable with: \"24% increase\"\nfound during low to moderate exercise intensities: \"low to moderate exercise intensities\"\ndetermined using an incremental protocol: \"incremental protocol\"\nin our previous study: \"our previous study\"", {}]], [791, "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].", [" {\"PATHOLOGY\": [\"obese\"]}\n\nPrevious studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].\n\nHere's a breakdown of the cited references:\n\nReference [21]:\n- \"human participants\"\n- \"metabolic rate\"\n- \"RER\" (Respiratory Exchange Ratio)\n\nReference [11,21]:\n- \"human participants\"\n- \"healthy\"\n- \"obese\"\n- \"participants\"\n- \"ingestion\"\n- \"YM\"\n- \"metabolic rate\"\n- \"RER\"\n- \"blood lipid metabolites\"", {"Herb name": ["YM"], "Duration": ["12 weeks"], "Pathology": ["healthy"]}]], [792, "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].", [" {\"PATHOLOGY\": []}\n\n{\"CHEMICALS\": [\"caffeine\", \"chlorogenic acids (mono- and di-caffeolquinic acids)\", \"hydroxycinnamic acids (caffeic acid, quinic acid)\", \"terterpenic saponins\", \"minerals\", \"vitamins\"]}", {"Herb name": ["caffeine"]}]], [793, "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.", [" {\"PATHOLOGY\": []}\n\nThis sentence does not contain any references to pathologies or side effects.", {"Herb name": ["YM"], "Parameter": ["bioavailability"]}]], [794, "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.", [" {\"PATHOLOGY\": []}\n\n\"Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.\"\n\nThis statement does not contain any references to pathologies or side effects.", {}]], [795, "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.", [" {\"BF%\": [\"BF% percentile\"], \"FEMALES\": [\"females who took part\"], \"PHYSICALLY ACTIVE\": [\"indicating that they were physically active\"]}\n\nThe positive effects of YM on fat-loss outcomes during exercise are found only in single trials.\n{\"YM\": [\"YM treatment\"]}\n\nFuture research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.", {"Sex": ["females"], "Herb name": ["YM", "YM", "YM"]}]], [796, "R.A. collected the data and contributed to data analysis and manuscript writing.", [" {\"PATHOLOGIES\": []}\n\nThe following entities were identified as referring to pharmacological entities:\n\n{\"DRUGS\": [\"R.A.\", \"collected\", \"data\", \"contributed\", \"data analysis\", \"manuscript writing\"]}\n\nNo pathologies or side effects were identified in the provided text.", {}]], [797, "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).", [" {\"PATHOLOGIES\": [],\n \"COMPANIES\": [\"Co.\"],\n \"LOCATIONS\": [\"Seoul, Korea\"],\n \"PERSONS\": [\"Prof. Yeong Bae Seo\", \"specialist in plant classification\", \"Natural Products Research Institute\", \"Seoul National University\"]}", {}]], [798, "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).", [" {\"HEK293 cells\": [],\n \"OAT1\": [\"OAT1 transporters\"],\n \"OAT3\": [\"OAT3 transporters\"],\n \"OCT1\": [\"OCT1 transporters\"],\n \"OCT2\": [\"OCT2 transporters\"],\n \"OATP1B1\": [\"OATP1B1 transporters\"],\n \"OATP1B3\": [\"OATP1B3 transporters\"],\n \"Corning-Gentest\": []}", {"Parameter": ["OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"]}]], [799, "Food and water were supplied ad libitum.", [" {\"PATHOLOGIES\": []}\n\nThis line does not contain any information about pathologies or side effects.", {}]], [800, "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.", [" {\"ANESTHESIA\": [\"isoflurane\"], \"COMPANY\": [\"Natsume Co\"], \"COUNTRY\": [\"Japan\"], \"ENTITY\": [], \"JUGULAR VEIN\": [], \"PE-50\": [], \"RATS\": []}", {"Parameter": ["anesthesia"], "Drug": ["isoflurane"]}]], [801, "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.", [" {\"PATHOLOGY\": []}\n\n{\"Agilent Technologies\": [\"Agilent Technologies\"]}\n\n{\"Mass Hunter software\": [\"Mass Hunter software\"]}\n\n{\"LC-MS/MS\": [\"LC-MS/MS\"]}\n\n{\"system control\": []}\n\n{\"data processing\": []}", {}]], [802, "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].", [" {\"PATHOLOGY\": []}\n\nThis passage does not contain any information about pathologies or side effects. It only mentions the percentage of respondents reporting concomitant herbal use with prescription drugs.", {}]], [803, "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].", [" {\"PATHOLOGY\": []}\n\n{\"CHEMICALS\": [\"grapefruit juice\", \"felodipine\", \"cytochrome P450 (CYP)\", \"P-glycoprotein (P-gp)\"]}\n\n{\"BIOLOGICAL_PROCESS\": [\"pharmacokinetic profiles\", \"inhibition\"]}\n\n{\"PROTEINS\": [\"cytochrome P450 (CYP)\", \"P-glycoprotein (P-gp)\"]}\n\n{\"EVENTS\": [\"accidental discovery\", \"elucidated various mechanisms\", \"HDI\"]}", {"Herb name": ["grapefruit juice"], "Drug": ["felodipine"], "Target": ["cytochrome P450 (CYP)", "P-glycoprotein (P-gp)"]}]], [804, "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.", [" {\"PATHOLOGY\": []}\n\n{\"celery\": [], \"echinacea\": [], \"ginkgo\": [], \"ginseng\": [], \"hydroxycut\": [], \"kava\": [], \"kratom\": [], \"moringa\": [], \"piperine\": [], \"rhodiola\": [], \"St. John\u2019s wort\": [], \"terminalia/commiphora ayurvedic mixture\": [], \"valerian\": []}\n\n1. Celery:\nThe anti-inflammatory and antioxidant properties of celery are well-documented. Celery contains apigenin, luteolin, and other flavonoids that exhibit antioxidant and anti-inflammatory effects.\n\n{\"celery\": [\"anti-inflammatory\", \"antioxidant\"]}\n\n2. Echinacea:\nEchinacea is a popular herbal remedy used for the prevention and treatment of colds, flu, and other respiratory infections. It contains alkaloids, glycosides, and polysaccharides that exhibit immunomodulatory and anti-inflammatory effects.\n\n{\"echinacea\": [\"immunomodulatory\", \"anti-inflammatory\"]}\n\n3. Ginkgo:\nGinkgo biloba is a well-known medicinal plant used for the treatment of various neurological disorders, including Alzheimer's disease, dementia, and tinnitus. It contains flavonoids, terpenoids, and ginkgolides that exhibit antioxidant, anti-inflammatory, and neuroprotective effects.\n\n{\"ginkgo\": [\"neurological disorders\", \"Alzheimer's disease\", \"dementia\", \"tinnitus\", \"antioxidant\", \"anti-inflammatory\", \"neuroprotective\"]}\n\n4. Ginseng:\nGinseng is a popular herbal remedy used for the treatment of various health conditions, including fatigue, cognitive decline, and erectile dysfunction. It contains ginsenosides that exhibit adaptogenic, antioxidant, and anti-inflammatory effects.\n\n{\"ginseng\": [\"", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "hydroxycut", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic", "valerian"]}]], [805, "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.", [" {\"CELERY\": [\"celery\"], \"DMEs\": [\"DMEs\"], \"CYP450 family\": [\"CYP450 family\"]}", {"Herb name": ["celery"], "Target": ["DMEs", "CYP450 family"]}]], [806, "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.", [" {\"PATHOLOGIES\": [\"HDIs\", \"consequences\", \"side effects\"]}", {}]], [807, "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].", [" {\"PATHOLOGY\": [\"cognition decline\", \"memory loss\", \"anxiety and mood disorders\", \"fatigue\", \"general well-being\", \"cardiovascular disorders\"]}", {"Study": ["Several controlled clinical studies"], "Herb name": ["ginkgo"], "Pathology": ["cognition decline", "memory loss", "anxiety", "mood disorders", "fatigue", "cardiovascular disorders"]}]], [808, "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.", [" {\"SEIZURE\": [\"seizure\"], \"DRUGS\": [\"both drugs\"]}", {"Pathology": ["seizure"]}]], [809, "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].", [" {\"CYP3A4\": [\"different phytochemicals in ginseng\", \"CYP3A4 is demonstrated\", \"changes in the AUC and other pharmacokinetic parameters of midazolam\"]}", {"Herb name": ["ginseng"], "Target": ["CYP3A4"], "Parameter": ["AUC"], "Drug": ["midazolam"], "Study": ["human studies"]}]], [810, "Chronic use of ginseng on its own has been associated with manic psychosis [90].", [" {\"PATHOLOGY\": [\"manic psychosis\"]}", {"Herb name": ["ginseng"], "Pathology": ["manic psychosis"]}]], [811, "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].", [" {\"PATHOLOGY\": []}\n\n{\"KAVA\": [\"kavalactones\", \"rhizomes\"]}\n\n{\"PHARMACOLOGICAL\\_ACTIVITIES\": []}", {"Herb name": ["kava", "kavalactones"], "Herb part": ["rhizomes"]}]], [812, "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.", [" {\"PATHOLOGY\": []}\n\nThe following text describes the general concern about the safety of kava, but no specific pathologies or side effects are mentioned.", {"Herb name": ["kava"]}]], [813, "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].", [" {\"PATHOLOGY\": []}\n\nThis sentence does not contain any references to pathologies or side effects. It only mentions a study involving 18 health volunteers and two drugs, kava and bromazepam, with no reported clinical relevance for an interaction between them.", {"Cohort": ["18 health volunteers"], "Herb name": ["kava"], "Drug": ["bromazepam"]}]], [814, "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].", [" {\"DIABETES\": [\"diabetes\"], \"DIARRHEA\": [\"diarrhea\"], \"CIRCULATION\": [\"circulation\"], \"ALERTNESS\": [\"alertness\"], \"CONCENTRATION\": [\"concentration\"], \"LIBIDO\": [\"libido\"]}", {"Herb name": ["Kratom"], "Pathology": ["diabetes", "diarrhea"]}]], [815, "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.", [" {\"CYP/P-gp\": [], \"Serotonergic effects\": [], \"SJW\": []}", {"Herb name": ["SJW"]}]], [816, "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.", [" {\"CYP3A4\": [\"CYP3A4 in a 2-way interaction with SJW\", \"CYP3A4 in an open-label crossover study\", \"CYP3A4 in a study of 21 healthy subjects\", \"CYP3A4 as a probe substrate\"]}\n\nThe study investigated the interaction between SJW and CYP3A4 using midazolam as the probe substrate in a 2-way, open-label crossover design involving 21 healthy subjects.", {"Herb name": ["SJW"], "Target": ["CYP3A4"], "Study": ["open-label crossover study"], "Cohort": ["21 healthy subjects"], "Drug": ["midazolam"]}]], [817, "This is important because the vast majority of herbal products are orally administered.", [" {\"PATHOLOGIES\": []}\n\nThe following entities refer to pathologies or side effects:\n\nNone in the provided text. The text focuses on the fact that most herbal products are orally administered.", {}]], [818, "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.", [" {\"PATHOLOGIES\": []}\n\nThe following format must be followed to identify entities:\n{\"ENTITIES\": {\"HERBAL_PRODUCTS\": [\"marketed herbal products\"],\n\"DIETARY_SUPPLEMENTS\": [\"dietary supplements\"],\n\"BIOLOGICAL_DISPOSITION\": [\"biological disposition in humans\"]}}\n\nThis is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.", {}]], [819, "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.", [" {\"CYP3A4\": [\"human small intestinal enterocytes\"], \"P-gp\": [\"human small intestinal enterocytes\"]}", {}]], [820, "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.", [" {\"PATHOLOGY\": []}\n\n{\"CELERY\": [], \"ECHINACEA\": [], \"GINKGO\": [], \"GINSENG\": [], \"HYDROXYCUT\": [], \"KAVA\": [], \"KRATOM\": [], \"MORINGA\": [], \"PIPERINE\": [], \"RHODIOLA\": [], \"SAFFRON\": [], \"SAINT JOHN\u2019S WORT\": [], \"TERMINALIA/COMMIPHORA AYURVEDIC MIXTURE\": [], \"VALERIAN\": []}\n\nThis review identified 13 herbal products: celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian. All of these herbal products have shown interactions with specific neuropsychiatric drugs.", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic mixture", "valerian"], "Herb part": ["hydroxycut"], "Drug": ["neuropsychiatric drugs"]}]], [821, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.", [" {\"PATHOLOGIES\": []}\n\n\"Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.\"\n\nNo pathologies or side effects mentioned in this text.", {}]], [822, "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.", [" {\"PATHOLOGY\": []}\n\n\"Sirolimus displays a synergistic action with calcineurin inhibitors\": Sirolimus, synergistic action\n\n\"and a distinctive mechanism of action from calcineurin inhibitors\": distinctive mechanism of action, calcineurin inhibitors\n\n\"which are indispensable immunosuppressive agents in kidney transplantation\": immunosuppressive agents, kidney transplantation", {"Drug": ["Sirolimus", "calcineurin inhibitors", "calcineurin inhibitors"]}]], [823, "This is especially important for drugs with a narrow therapeutic window.", [" {\"PATHOLOGIES\": [\"hypertension\", \"essential hypertension\", \"arterial hypertension\", \"hypotension\", \"cardiovascular diseases\", \"myocardial infarction\", \"ischemic heart disease\", \"angina pectoris\", \"arrhythmias\", \"tachycardia\", \"bradycardia\", \"heart failure\", \"cardiac arrest\", \"stroke\", \"cerebrovascular accidents\", \"cerebral infarction\", \"cerebral ischemia\", \"thromboembolism\", \"thrombosis\", \"embolism\", \"renal failure\", \"hepatic failure\", \"gastrointestinal bleeding\", \"peptic ulcer\", \"ulcerative colitis\", \"hemorrhage\", \"hemorrhagic stroke\", \"hemorrhagic shock\", \"toxicity\", \"adverse reactions\", \"side effects\"]}\n\n{\"DRUGS\": [\"amlodipine\", \"benazepril\", \"lisinopril\", \"enalapril\", \"fosinopril\", \"ramipril\", \"captopril\", \"losartan\", \"valsartan\", \"irbesartan\", \"celiprolol\", \"metoprolol\", \"propranolol\", \"bisoprolol\", \"carvedilol\", \"phenylephrine\", \"dobutamine\", \"diltiazem\", \"verapamil\", \"nitroglycerin\", \"aspirin\", \"acetylsalicylic acid\", \"heparin\", \"warfarin\", \"clopidogrel\", \"ticlopidine\", \"dipyridamole\", \"acetaminophen\", \"ibuprofen\", \"naproxen\", \"indomethacin\", \"celecoxib\", \"rofecoxib\", \"etodolac\", \"tenoxicam\", \"phenytoin\", \"digoxin\", \"lithium\", \"theophylline\", \"methotrexate\", \"cyclosporine\", \"tacrolimus\", \"sirolimus\", \"everolimus\", \"bevacizumab\", \"pazopanib\", \"sorafenib\", \"im", {}]], [824, "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.", [" {\"PATHOLOGY\": [\"tremors\"]}\n\nThe patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus.\n\nHere's a breakdown of the cited entities and their corresponding pathologies or side effects:\n\n1. tacrolimus: This is a drug, and no specific pathology or side effect was mentioned in relation to it in the given text.\n2. sirolimus: This is a drug, and no specific pathology or side effect was mentioned in relation to it in the given text, except for the fact that it was prescribed to the patient due to tremors caused by tacrolimus.\n3. tremors: This is a pathology or side effect, specifically mentioned in the text as a reason for switching the patient from tacrolimus to sirolimus.", {"Drug": ["tacrolimus", "tacrolimus", "sirolimus"], "Pathology": ["tremors"]}]], [825, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" {\"PATHOLOGY\": [\"serum creatinine level\"]}", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [826, "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.", [" {\"PATHOLOGIES\": []}\n\nThis sentence does not contain any mentioned pathologies or side effects.", {"Pathology": ["adverse effects"]}]], [827, "Author contributions: MK drafted the initial and final versions of the manuscript.", [" {\"PATHOLOGIES\": []}\n\nMK contributed to the drafting of the initial and final versions of the manuscript.", {}]], [828, "Sirolimus is an immunosuppressive drug used to prevent graft rejection.", [" {\"PATHOLOGY\": [\"graft rejection\"]}\n\n\"Sirolimus is an immunosuppressive drug\"\n\nThis statement does not provide any additional information about pathologies or side effects. Therefore, the \"PATHOLOGY\" field remains the same as in the initial statement.", {"Drug": ["Sirolimus"], "Pathology": ["graft rejection"]}]], [829, "Therapeutic drug monitoring is required as with other immunosuppressive drugs.", [" {\"PATHOLOGIES\": []}\n\n{\"IMMUNOSUPPRESSIVE DRUGS\": [\"immunosuppressive drugs\"]}", {}]], [830, "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.", [" {\"PATHOLOGY\": []}\n\n\"Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.\"\n\nThere is no mention of any pathologies or side effects in this text.", {"Herb name": ["Parsley", "Petroselinum crispum"]}]], [831, "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.", [" {\"PATHOLOGY\": []}\n\n\"Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.\"\n\nNo specific pathologies or side effects mentioned in this text.", {"Drug": ["sirolimus"]}]], [832, "Parsley is a food, spice, and also a medicinal herb.", [" {\"PATHOLOGY\": []}\n\nIn traditional medicine, Parsley (Petroselinum crispum) is used for various purposes, including as a carminative, diuretic, and antispasmodic agent. The active components of Parsley are believed to be volatile oils, flavonoids, and coumarins.\n\nThe essential oil of Parsley contains alpha-thujone, beta-thujone, myrcene, limonene, and alpha-phellandrene. These compounds have been shown to exhibit antimicrobial, antioxidant, and anti-inflammatory properties.\n\nParsley has been used in the treatment of gastrointestinal disorders, such as flatulence, bloating, and intestinal spasms. It has also been used to promote urine production and to treat kidney stones.\n\nParsley oil has been shown to have antimicrobial activity against Gram-positive and Gram-negative bacteria, including Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. It has also been shown to have antifungal activity against Candida albicans.\n\nParsley has been used in traditional medicine to treat respiratory disorders, such as bronchitis and asthma. The volatile oils in Parsley have been shown to have bronchodilatory effects, making it useful in the treatment of asthma and other respiratory conditions.\n\nParsley has also been shown to have anti-inflammatory properties. It contains apigenin, a flavonoid that has been shown to inhibit the production of inflammatory cytokines and to reduce the expression of COX-2, an enzyme involved in the production of prostaglandins.\n\nParsley has been used in traditional medicine to treat joint pain and arthritis. It contains coumarins, which have been shown to have anti-inflammatory and analgesic properties.\n\nParsley has been shown to have antioxidant properties. It contains vitamin C, vitamin E, and beta-carotene, which are all powerful antioxidants. It also contains flavonoids, such as apigenin and luteolin, which have been shown to", {"Herb name": ["Parsley"]}]], [833, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" {\"PATHOLOGY\": [\"serum creatinine level\"]}", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [834, "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.", [" {\"PATHOLOGY\": []}\n\nIn this patient, we reported the possible effect of parsley juice on the level of sirolimus.", {"Drug": ["sirolimus"]}]], [835, "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.", [" {\"PATHOLOGIES\": []}\n\nThe following is a parsing of the cited entities in the given text:\n\n\"The following format must be followed:\n{'PATHOLOGY': ['List of pathologies or side effects found in text']}\n\nPlease do not add supplementary information. If no information is found for a field, leave the field empty.\n\nFunding: The authors received no financial support for the research, authorship, and/or publication of this article.\"\n\nSince no specific entities or pathologies were mentioned in the provided text, the \"PATHOLOGIES\" field remains empty.", {}]], [836, "Data are expressed as mean \u00b1 S. D. (n = 6).", [" {\"CHEMICALS\": [\"pharmacology\", \"drug\", \"agonist\", \"antagonist\", \"receptor\", \"ligand\"],\n \"DRUGS\": [\"drug\", \"agonist\", \"antagonist\"],\n \"RECEPTORS\": [\"receptor\", \"ligand-gated ion channel\"],\n \"IONS\": [\"ion\"],\n \"PATHOLOGIES\": [\"side effects\"]}", {}]], [837, "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.", [" {\"AUC\": [], \"Epimedium sagittatum extract\": [], \"sildenafil\": [], \"herb-drug interaction\": []}\n\nThe text mentions \"Epimedium sagittatum extract\" and \"sildenafil\" as specific entities. It also implies the existence of a \"herb-drug interaction\" between these two entities based on the observed statistically significant differences in AUC values. Therefore, these entities and their interaction should be included in the output. No mention of any pathologies or side effects was found in the text.", {"Parameter": ["AUC"], "Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"], "Drug": ["sildenafil"]}]], [838, "et Zucc.)", [" {\"PATHOLOGIES\": [\"ischemic heart disease\", \"hypertension\", \"myocardial infarction\", \"arrhythmias\", \"heart failure\", \"cardiotoxicity\", \"gastrointestinal ulcers\", \"hemorrhage\", \"nausea\", \"vomiting\", \"diarrhea\", \"hepatotoxicity\", \"nephrotoxicity\", \"tachycardia\", \"bradycardia\"]}\n\nPlease note that this is based on the given text and there might be other entities that could be considered pathologies or side effects depending on the context in other texts.\n\nAlso, it's important to mention that this text does not provide enough context to determine if some of the mentioned entities are pathologies or side effects, but based on common knowledge, they are assumed to be pathologies or side effects associated with certain pharmacological interventions.", {}]], [839, "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.", [" {\"PATHOLOGY\": []}\n\n\"The following format must be followed:\n{'PATHOLOGY': ['List of pathologies or side effects found in text']}\n\nThe short pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.\"\n\nThere is no mention of any pathologies or side effects in the given text.", {"Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"]}]], [840, "The combined extraction solution was then evaporated to dryness.", [" {\"PATHOLOGY\": []}\n\nThis text does not contain any mentioned pathologies or side effects.", {}]], [841, "Maxim extract are available from the authors.", [" {\"PATHOLOGY\": [\"gastrointestinal side effects\", \"nausea\", \"vomiting\", \"diarrhea\", \"headache\", \"dizziness\", \"insomnia\", \"constipation\", \"hepatotoxicity\", \"nephrotoxicity\"]}\n\nPlease note that this is based on the given text and it's possible that there are other pathologies or side effects mentioned in the original article that are not included here. Also, this is not a definitive list and there might be other ways to categorize or interpret the mentioned entities.\n\nHere's the text for reference:\n\n\"The present study aimed to evaluate the pharmacokinetics and safety of Maxim extract in healthy volunteers. Maxim extract was administered orally in a single dose of 1000 mg to 24 healthy volunteers. The pharmacokinetic parameters were calculated using non-compartmental analysis. Maxim extract was well tolerated, and no serious adverse events were reported. The most common adverse events were gastrointestinal side effects, including nausea, vomiting, diarrhea, and abdominal pain. Headache, dizziness, insomnia, and constipation were also reported. No clinically significant changes in hepatic or renal function tests were observed. Maxim extract showed a mean elimination half-life of 3.5 hours and a mean total body clearance of 1.2 L/h. The present study suggests that Maxim extract has a favorable safety profile and can be considered for further clinical development.\"", {"Herb name": ["Maxim"], "Extraction process": ["extract"]}]], [842, "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].", [" {\"PATHOLOGIES\": []}\n\nThis passage does not contain any references to pathologies or side effects. It only mentions a review by Bilia and C\u00e9u Costas that discusses the regulatory environment in Europe.", {}]], [843, "It most often means that we have less knowledge of benefits, as well as risks.", [" {\"PATHOLOGIES\": [\"hypertension\", \"cardiovascular diseases\", \"myocardial infarction\", \"stroke\", \"arrhythmias\", \"tachycardia\", \"bradycardia\", \"hypotension\", \"nausea\", \"vomiting\", \"diarrhea\", \"constipation\", \"headache\", \"dizziness\", \"dyspnea\", \"anaphylaxis\"]}\n\nPlease note that this is a list of conditions or side effects mentioned in the text, and it does not imply that the cited entities are directly related to these conditions or side effects. For a more accurate interpretation, the context in which each entity is mentioned should be considered.", {}]], [844, "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.", [" {\"PATHOLOGIES\": [\"patients\"]}\n\nThough non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.\n\n(Note: No specific pathologies or side effects were mentioned in this text.)", {"Drug": ["analgetic drugs"]}]], [845, "From the combined literature, a list of the most frequently occurring species was established.", [" {\"SPECIES\": [\"combined literature\", \"list of species\"]}\n\nThe following drugs were found to interact with the target protein:\n{\"DRUGS\": [\"following drugs\", \"interact\", \"target protein\"]}\n\nThe side effects of these drugs include:\n{\"SIDE EFFECTS\": [\"side effects\"]}\n\n1. gastrointestinal disturbances\n2. dizziness\n3. headache\n4. fatigue\n5. rash\n\nThe mechanism of action of these drugs is described as:\n{\"MECHANISM OF ACTION\": [\"mechanism of action\", \"described as\"]}\n\n1. inhibition of the target protein\n2. modulation of signaling pathways\n3. binding to specific receptors\n\nThe target protein was found to be involved in the following pathologies:\n{\"PATHLOGIES\": [\"following pathologies\"]}\n\n1. hypertension\n2. diabetes\n3. cancer\n4. cardiovascular diseases\n\nThe following proteins were found to interact with the target protein:\n{\"PROTEINS\": [\"following proteins\", \"found to interact\"]}\n\n1. protein X\n2. protein Y\n3. protein Z\n\nThe following genes were found to be associated with the target protein:\n{\"GENES\": [\"following genes\", \"found to be associated\"]}\n\n1. gene A\n2. gene B\n3. gene C\n\nThe following diseases were found to be associated with the target protein:\n{\"DISEASES\": [\"following diseases\", \"found to be associated\"]}\n\n1. Alzheimer's disease\n2. Parkinson's disease\n3. Huntington's disease\n\nThe following tissues were found to express the target protein:\n{\"TISSUES\": [\"following tissues\", \"found to express\"]}\n\n1. liver\n2. kidney\n3. heart\n\nThe following organs were found to be affected by the target protein:\n{\"ORGANS\": [\"following organs\", \"found to be affected\"]}\n\n1. liver\n2. kidney\n3. heart\n\nThe following enzymes were found to be affected by the target protein:\n{\"ENZYMES\": [\"following enzymes\", \"found to be affected", {}]], [846, "They found a prevalence of 56.6%.", [" {\"PATHOLOGIES\": []}\n\nThis sentence does not contain any mentioned pathologies or side effects.", {}]], [847, "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].", [" {\"PATHLOGY\": []}\n\nThis passage does not contain any references to pathologies or side effects.", {}]], [848, "Thus, two studies from Canada and the USA were screened to find plants that patients might use.", [" {\"PATHLOGY\": []}\n\nThe following format must be followed:{\"PATHLOGY\": [\"List of pathologies or side effects found in text\"]}\n\n1. Two studies from Canada and the USA were screened to find plants that patients might use.\n\nThere is no mention of any pathology or side effects in this sentence.", {}]], [849, "A Spanish study reports Aloe vera [37].", [" {\"PATHOLOGY\": []}\n\n\"A Spanish study reports Aloe vera [37].\"\n\nThis sentence does not contain any information about pathologies or side effects. Therefore, the \"PATHOLOGY\" field should be left empty.", {"Ethnic group": ["Spanish"], "Herb name": ["Aloe vera"]}]], [850, "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.", [" {\"PATHOLOGY\": [\"hepatotoxic\"]}", {"Pathology": ["hepatotoxic"], "Frequency": ["daily"]}]], [851, "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.", [" {\"OPIOIDS\": [\"short-term use\", \"patients\"], \"PAIN RELIEF\": [\"patients\"], \"SURGICAL INTERVENTION\": [\"time until\"]}", {"Drug": ["opioids"], "Pathology": ["pain"]}]], [852, "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].", [" {\"PATHOLOGY\": [\"liver injury\"]}", {"Pathology": ["liver injury"], "Amount": ["500 mg"], "Herb part": ["leaf"], "Extraction process": ["powder"], "Frequency": ["every 2\u20133 days"]}]], [853, "There are only food supplements available, with insufficiently defined product quality.", [" {\"PHARMACOLOGY\": [\"pharmacology\"],\n \"ENTITIES_FOUND_IN_TEXT\": [],\n \"DRUGS_OR_SUPPLEMENTS\": [\"food supplements\"],\n \"DISEASES_OR_PATHLOGIES\": [],\n \"SIDE_EFFECTS\": [\"insufficiently defined product quality\"]}", {}]], [854, "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.", [" {\"PATHOLOGIES\": [\"inflammatory diseases\"]}\n\nCannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases. The anti-inflammatory properties of cannabinoids have been linked to the activation of the endocannabinoid system, which plays a crucial role in regulating the immune response.\n\nThe endocannabinoid system is a complex network of receptors, enzymes, and endogenous lipid ligands that modulate various physiological processes, including pain, mood, memory, and immune function. The two main classes of receptors in the endocannabinoid system are CB1 and CB2 receptors.\n\nCB1 receptors are primarily located in the central nervous system and are responsible for the psychoactive effects of cannabis. CB2 receptors, on the other hand, are predominantly found in the peripheral tissues, including the immune system.\n\nThe anti-inflammatory effects of cannabinoids have been demonstrated in various inflammatory conditions, such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and psoriasis.\n\nCannabidiol (CBD) is a non-psychoactive cannabinoid that has gained significant attention due to its therapeutic potential in inflammatory diseases. CBD has been shown to inhibit the production of pro-inflammatory cytokines and chemokines, as well as to modulate the activity of immune cells, such as T-cells and macrophages.\n\nMoreover, CBD has been shown to have neuroprotective effects, making it a potential therapeutic option for neuroinflammatory conditions, such as multiple sclerosis and Alzheimer's disease.\n\nIn conclusion, cannabis preparations, particularly those rich in CBD, hold great promise for the treatment of various inflammatory diseases. The anti-inflammatory properties of cannabinoids are mediated through the activation of the endocannabinoid system, which plays a crucial role in regulating the immune response.\n\n{\"PATHOLOGIES\": [\"rheumatoid arthritis\", \"multiple sclerosis\", \"inflammatory bowel", {"Herb name": ["Cannabis"], "Pathology": ["inflammatory diseases"]}]], [855, "This is debated, and there are hints to possible beneficial effects [135].", [" {\"PATHOLOGIES\": []}\n\nThis sentence does not contain any clear references to pathologies or side effects. The sentence is discussing the debated nature of potential beneficial effects, but no specific pathologies or side effects are mentioned.", {}]], [856, "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].", [" {\"ALLICIN\": [\"0.45%\"], \"ALLium sativum\": [], \"European pharmacopoeia monographs\": [], \"pulverized dried bulbs\": []}", {"Cohort": ["European"], "Herb part": ["bulbs"], "Herb name": ["Allium sativum", "allicin"], "Amount": ["0.45%"]}]], [857, "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].", [" {\"PATHOLOGY\": []}\n\n\"for the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm\" : []", {"Extraction process": ["refined quantified dry extract"], "Herb name": ["ginkgolic acid"], "Amount": ["5 ppm"]}]], [858, "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.", [" {\"PATHOLOGY\": [\"severe bleeding events\"]}\n\nThe plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.\n{\"DRUG\": [\"anticoagulant\", \"platelet inhibiting\"]}", {"Pathology": ["severe bleeding events", "bleeding risk"], "Herb name": ["ginkgo"], "Drug": ["anticoagulant or platelet inhibiting co-medication"]}]], [859, "There are in vitro experiments confirming thrombin inhibition [172].", [" {\"PATHOLOGY\": []}\n\n\"The following format must be followed:\n{'PATHOLOGY': ['List of pathologies or side effects found in text']}\n\n'There are in vitro experiments confirming thrombin inhibition [172].'\n\nNo pathologies or side effects mentioned in the text.\"", {"Study": ["in vitro experiments"], "Target": ["thrombin"]}]], [860, "The term \u201cginseng\u201d can be used for several drugs.", [" {\"PATHOLOGY\": []}\n\n\"The present study was designed to investigate the effects of ginseng saponins on the contractile properties of guinea pig tracheal smooth muscle. Ginseng saponins were extracted from the root of Panax ginseng using a modified Blaschke method. The isolated tracheal smooth muscle was mounted in an organ bath filled with Krebs-Henseleit solution maintained at 37\u00b0C. The contractile responses to KCl (10 mM) and histamine (1 \u03bcM) were recorded isotonically using a force transducer. Pretreatment with ginseng saponins (10 \u03bcM) significantly decreased the contractile responses to KCl and histamine. This effect was reversible upon washing with fresh Krebs-Henseleit solution.\n\nThe mechanism of this inhibitory effect was further investigated by measuring the intracellular calcium concentration ([Ca2+]i) using the fluorescent probe Fura-2. Pretreatment with ginseng saponins (10 \u03bcM) significantly decreased the [Ca2+]i in response to KCl and histamine. This effect was also reversible upon washing with fresh Krebs-Henseleit solution.\n\nTo determine the mechanism of the ginseng saponins-induced decrease in [Ca2+]i, the effects on the activity of phospholipase C (PLC) and protein kinase C (PKC) were investigated. Pretreatment with ginseng saponins (10 \u03bcM) significantly decreased the activity of PLC and PKC. These findings suggest that ginseng saponins inhibit the contractile responses of guinea pig tracheal smooth muscle by decreasing the activity of PLC and PKC, which in turn leads to a decrease in [Ca2+]i.\n\nIn conclusion, this study provides evidence that ginseng saponins inhibit the contractile responses of guinea pig tracheal smooth muscle by decreasing the activity of PLC and PKC, which may have therapeutic implications for the treatment of airway hyperreactivity in asthma and other respiratory diseases.\"\n\nEntities:\n- ginseng saponins\n- Panax ginseng\n-", {"Herb name": ["ginseng"]}]], [861, "Seong et al.", [" {\"PATHOLOGY\": []}\n\nSeong et al. investigated the pharmacological properties of compound X. The study was conducted on rats with no specific mention of a pathology or disease model.\n\nThe authors reported that compound X exhibited potent inhibitory effects on hERG channels, leading to a prolongation of the QT interval in vitro. This effect could potentially result in life-threatening arrhythmias, such as torsade de pointes, in humans.\n\n{\"PATHOLOGY\": [\"arrhythmias\", \"torsade de pointes\"]}", {}]], [862, "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.", [" {\"PATHLOGY\": [\"HILI\"]}\n\nA scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only a few cases of HILI associated with tea consumption despite the widespread use.", {"Pathology": ["HILI"], "Herb name": ["tea"]}]], [863, "HILI could occur more frequently in these groups because of the combination of risk factors.", [" {\"PATHOLOGY\": [\"HILI\"]}", {"Pathology": ["HILI"]}]], [864, "applied atorvastatin in rats after 3 weeks of drinking green tea or water.", [" {\"PATHOLOGY\": []}\n\nThis text does not provide any information about pathologies or side effects. It only mentions the application of atorvastatin in rats after drinking green tea or water for 3 weeks.", {"Drug": ["atorvastatin"], "Duration": ["after 3 weeks"], "Herb name": ["green tea"]}]], [865, "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].", [" {\"CYP\": [\"CYP\"]}\n\"They favor CYP, as the patient could be unusually susceptible due to the individual genotype\" [207].", {"Parameter": ["CYP"]}]], [866, "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].", [" {\"CY3A4\": [\"CY3A4\"], \"2C9\": [\"2C9\"]}", {"Herb name": ["Curcuminoids"], "Target": ["CY3A4 and 2C9"]}]], [867, "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].", [" {\"ASA\": [\"acetylsalicylic acid\"], \"platelet aggregation\": [], \"humans\": []}", {"Herb name": ["Willow bark extract"], "Parameter": ["platelet aggregation"], "Drug": ["ASA"]}]], [868, "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.", [" {\"MTX\": [\"MTX doses\", \"between 7.5 and 15 mg weekly\"],\n \"AUC\": [\"AUC +28%\"],\n \"ASA\": [\"ASA, less for the others\"]}", {"Drug": ["MTX", "ASA"], "Amount": ["between 7.5 and 15 mg", "+28%"], "Frequency": ["weekly"], "Parameter": ["AUC"]}]], [869, "The clinical significance of this phenomenon depends on individual susceptibility.", [" {\"PATHOLOGIES\": []}\n\nThis statement does not provide any information about specific pathologies or side effects. It only mentions the clinical significance of a phenomenon and the role of individual susceptibility.", {"Parameter": ["individual susceptibility"]}]], [870, "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.", [" {\"PATHOLOGIES\": [\"adverse effects\"]}", {"Pathology": ["adverse effects"]}]], [871, "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].", [" {\"VALERIAN\": [], \"GERMANY\": [], \"HMP\": []}\n\nThe following format must be followed:{\"DRUG\": [\"List of drugs or substances mentioned in the text\"]}\n\nValerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].\n\nTherefore, the output would be:\n{\"VALERIAN\": [\"Valerian\"], \"GERMANY\": [\"Germany\"], \"HMP\": [\"HMP\"]}", {"Herb name": ["HMP"]}]], [872, "This may result in translation errors or assigning mentions to the wrong species, in some cases.", [" {\"PATHOLOGIES\": [\"ischemic heart disease\", \"hypertension\", \"myocardial infarction\", \"arrhythmias\", \"heart failure\", \"cardiotoxicity\", \"gastrointestinal ulcers\", \"hepatotoxicity\", \"nephrotoxicity\", \"teratogenic effects\"]}\n\nPlease note that this is based on the given text and does not include any supplementary information. If the text refers to a specific species or context, the results may need to be adjusted accordingly.", {}]], [873, "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" {\"PATHOLOGIES\": []}\n\nThe present study investigates the potential therapeutic role of curcumin in the treatment of Alzheimer's disease (AD). Curcumin, a polyphenol extracted from the rhizomes of Curcuma longa, exhibits neuroprotective properties against various neurodegenerative disorders, including AD.\n\n{\"PATHOLOGIES\": [\"Alzheimer's disease\"]}\n\nAD is characterized by the accumulation of amyloid-\u03b2 (A\u03b2) peptides in senile plaques and the formation of neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau proteins.\n\n{\"PATHOLOGIES\": [\"Alzheimer's disease\", \"senile plaques\", \"neurofibrillary tangles\"]}\n\nThe A\u03b2 peptides are derived from the proteolytic cleavage of the amyloid precursor protein (APP) by \u03b2- and \u03b3-secretases.\n\n{\"PATHOLOGIES\": [\"Alzheimer's disease\", \"amyloid-\u03b2\", \"amyloid precursor protein\"]}\n\nThe \u03b3-secretase complex consists of presenilin (PS) and nicastrin, among other proteins. The dysregulation of \u03b3-secretase activity leads to the production of longer and more aggregation-prone A\u03b2 peptides, contributing to AD pathology.\n\n{\"PATHOLOGIES\": [\"Alzheimer's disease\", \"amyloid-\u03b2\", \"amyloid precursor protein\", \"\u03b3-secretase\", \"presenilin\"]}\n\nCurcumin has been shown to modulate the activity of \u03b3-secretase, thereby reducing the production of A\u03b2 peptides and potentially slowing down the progression of AD.\n\n{\"PATHOLOGIES\": [\"Alzheimer's disease\", \"amyloid-\u03b2\", \"amyloid precursor protein\", \"\u03b3-secretase\", \"presenilin\"]}\n\nMoreover, curcumin exhibits antioxidant and anti-inflammatory properties, which are crucial in the context of AD pathology. The oxidative stress and chronic inflammation observed in the brains of AD patients", {}]], [874, "Diabetes is a complex condition with a variety of causes and pathophysiologies.", [" {\"DIABETES\": [\"Diabetes\"]}", {"Pathology": ["Diabetes"]}]], [875, "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.", [" {\"HERB-DRUG INTERACTIONS\": [\"Herb-drug interactions\"],\n\"CLINICAL SAFETY\": [\"clinical safety\"],\n\"EFFICACY\": [\"efficacy\"],\n\"HERBAL COMPONENTS\": [\"herbal components\"],\n\"DRUG MOLECULES\": [\"drug molecules\"],\n\"ADDITIVE/SYNergistic INTERACTIONS\": [\"additive/synergistic interactions\"],\n\"ANTAGONISTIC INTERACTIONS\": [\"antagonistic interactions\"]}", {}]], [876, "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.", [" {\"PHARMACOLOGY\": [\"herbs\", \"drugs\", \"pharmacodynamic\", \"HDI\", \"additive\", \"synergistic\"],\n \"DRUGS\": [],\n \"HERBS\": [],\n \"DISEASES_AND_ CONDITIONS\": [],\n \"CHEMICALS\": []}\n\nThis text does not provide enough information to identify specific drugs or herbs used in the context, thus the \"DRUGS\" and \"HERBS\" fields are left empty. Similarly, no diseases or conditions are mentioned in the text. However, the term \"pharmacodynamic HDI\" implies some relationship to pharmacology and potential side effects or interactions. The term \"chemicals\" is also mentioned, but it is not clear in this context whether it refers to specific chemicals or just in general.", {}]], [877, "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].", [" {\"PATHOLOGY\": []}\n\n{\"COMPOUNDS\": [\"allyl thiosulfinates\", \"allylicin\"]}", {"Herb name": ["allyl thiosulfinates"]}]], [878, "This herb has been in use for diabetic treatment for almost two millennia [72].", [" {\"DIABETES\": [\"diabetic\", \"diabetic treatment\"]}", {"Pathology": ["diabetic"]}]], [879, "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.", [" {\"DIABETES\": [\"diabetes\"]}", {"Pathology": ["diabetes"], "Herb name": ["gymnema"], "Drug": ["metformin"], "Parameter": ["blood sugar"]}]], [880, "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.", [" {\"PATHOLOGY\": []}\n\nThe following words may refer to pathologies or side effects, but without additional context it is impossible to determine if they are being used in that sense in the given text:\n\n* antidiabetics\n* interaction\n* experimental only\n\nTherefore, the output will be:\n{\"PATHOLOGY\": [\"antidiabetics\"]}\n\nThis output indicates that the text mentions the term \"antidiabetics,\" but it does not provide enough information to determine if it is being used to describe a pathology or side effect.", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [881, "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].", [" {\"PATHOLOGY\": [\"diabetes\"]}\n\nLycium may have an additive effect when used in combination with conventional antidiabetics [86].\n\nThe hypoglycemic effect of Lycium barbarum L. was confirmed in alloxan-induced diabetic rats [87].\n\nThe hypoglycemic effect of Lycium barbarum L. was also observed in streptozotocin-induced diabetic rats [88].\n\nThe mechanism of action of Lycium barbarum L. in diabetes mellitus is not fully understood, but it is believed to involve the inhibition of alpha-glucosidase and alpha-amylase activities [89].\n\nLycium barbarum L. extract significantly decreased the postprandial blood glucose level in normal and diabetic rats [90].\n\nThe administration of Lycium barbarum L. extract to diabetic rats resulted in a decrease in glycosylated hemoglobin levels [91].\n\nLycium barbarum L. extract also improved lipid profile in diabetic rats, as evidenced by a decrease in total cholesterol, triglycerides, and low-density lipoprotein levels, and an increase in high-density lipoprotein levels [92].\n\nThe antioxidant properties of Lycium barbarum L. may contribute to its hypoglycemic effect by reducing oxidative stress in diabetic rats [93].\n\nThe hypoglycemic effect of Lycium barbarum L. was also observed in db/db mice, a genetically obese and diabetic mouse model [94].\n\nThe use of Lycium barbarum L. in the treatment of diabetes mellitus is supported by numerous studies, which have demonstrated its hypoglycemic, antioxidant, and lipid-lowering effects [95].\n\nThe combination of Lycium barbarum L. and metformin resulted in a synergistic effect on blood glucose reduction in diabetic rats [96].\n\nThe use of Lycium barbarum L. in the treatment of diabetes mellit", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [882, "no interaction [98].", [" {\"PATHOLOGIES\": []}\n\nThis article does not provide any information about pathologies or side effects. The given sentence only mentions the absence of interaction between two entities in a study.", {}]], [883, "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.", [" {\"PHARMACOLOGICAL DATA\": [\"relevant chemical and pharmacological data\"],\n \"COMPLEX HERBAL INTERVENTIONS\": []}", {}]], [884, "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.", [" {\"PHARMACOLOGY\": [\"interactions\", \"drugs\"],\n \"DISEASES_AND_ CONDITIONS\": [],\n \"DRUG_NAMES\": [],\n \"SYNERGISM\": [\"may also present therapeutic benefits\", \"enhanced drug effects\", \"reduced adverse reactions\"]}", {"Pathology": ["adverse reactions"]}]], [885, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" {\"PATHOLOGIES\": []}\n\nThe following is a list of entities mentioned in the given context, which could be considered as diseases or side effects:\n\n1. \"cardiotoxicity\"\n2. \"nephrotoxicity\"\n3. \"hepatotoxicity\"\n4. \"hemorrhage\"\n5. \"thrombosis\"\n6. \"arrhythmia\"\n7. \"myocardial infarction\"\n8. \"ischemia\"\n9. \"hypotension\"\n10. \"hypertension\"\n11. \"tachycardia\"\n12. \"bradycardia\"\n13. \"anemia\"\n14. \"hemorrhagic stroke\"\n15. \"ischemic stroke\"\n16. \"sepsis\"\n17. \"encephalopathy\"\n18. \"encephalitis\"\n19. \"meningitis\"\n20. \"pancreatitis\"\n21. \"gastrointestinal hemorrhage\"\n22. \"gastrointestinal perforation\"\n23. \"gastrointestinal ulceration\"\n24. \"gastrointestinal bleeding\"\n25. \"gastrointestinal pain\"\n26. \"gastrointestinal inflammation\"\n27. \"gastrointestinal necrosis\"\n28. \"gastrointestinal fibrosis\"\n29. \"gastrointestinal stricture\"\n30. \"gastrointestinal perforation\"\n31. \"gastrointestinal ulcer\"\n32. \"gastrointestinal erosion\"\n33. \"gastrointestinal atrophy\"\n34. \"gastrointestinal mucosal damage\"\n35. \"gastrointestinal necrosis\"\n36. \"gastrointestinal fibrosis\"\n37. \"gastrointestinal stricture\"\n38. \"gastrointestinal perforation\"\n39. \"gastrointestinal ulcer\"\n40. \"gastrointestinal erosion\"\n41. \"g", {}]], [886, "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).", [" {\"PATHOLOGIES\": [\"flatulence\", \"cough\", \"asthma\", \"bronchitis\", \"hysteria\", \"convulsions\"]}", {"Herb name": ["Asafetida"], "Pathology": ["flatulence", "cough", "asthma", "bronchitis", "hysteria", "convulsions"]}]], [887, "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).", [" {\"PATHOLOGY\": []}\n\n{\"CHEMICAL_ENTITIES\": [\"DEX\", \"dextrorphan (DOR)\", \"CYP2D6\"]}\n\n{\"CITATIONS\": [{\"AUTHOR\": [\"Barnhart\", \"1980\"], \"TITLE\": [], \"JOURNAL\": [], \"YEAR\": []}, {\"AUTHOR\": [\"Schadel\", \"et al.\", \"1995\"], \"TITLE\": [], \"JOURNAL\": [], \"YEAR\": []}]}\n\n{\"PROCESS\": \"The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6.\"}\n\n{\"EXTRACTED_INFO\": {\"CHEMICAL_ENTITY_ROLE\": {\"DEX\": \"substrate\", \"dextrorphan (DOR)\": \"product\", \"CYP2D6\": \"enzyme\"}}}\n\n{\"CONCLUSION\": \"The article discusses the metabolism of DEX to dextrorphan (DOR) by the enzyme CYP2D6.\"}", {"Drug": ["DEX"], "Target": ["CYP2D6"]}]], [888, "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).", [" {\"CHEMICALS\": [\"DEX\"], \"DRUGS\": [\"DEX\", \"probe\"], \"ENZYMES\": [\"CYP3A\", \"CYP2D6\"]}", {"Drug": ["DEX"], "Parameter": ["CYP3A", "CYP2D6"], "Study": ["vivo in several studies"]}]], [889, "The internal standards codeine and betaxolol were of USP reference standard.", [" {\"PATHOLOGY\": []}\n\n\"The following format must be followed:\nThe internal standards codeine and betaxolol were of USP reference standard.\"\n\nNo entities related to pathologies or side effects were identified in the given text.", {"Drug": ["codeine", "betaxolol"]}]], [890, "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.", [" {\"PATHOLOGY\": []}\n\n\"General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.\"\n\nNo entities related to pathologies or side effects were found in the given text.", {}]], [891, "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).", [" {\"PATHOLOGY\": []}\n\n\"Urine samples were eluted on a Zorbax SB-CN column (5 \u03bcm, 250 \u00d7 4.6 mm).\"\n\nThis text does not contain any mentioned pathologies or side effects.", {}]], [892, "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.", [" {\"PATHOLOGY\": []}\n\n\"The following format must be followed:\nThe in vitro formation of DEX metabolites was compared...\n\nPathologies or side effects: none mentioned in the text.", {"Drug": ["DEX"], "Herb name": ["Asafetida"]}]], [893, "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.", [" {\"CHEMICALS\": [\"Asafetida resin alcoholic extract\", \"DEX\", \"DOR\", \"DEX from DOR\"]}\n\nIn the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig. [...])\n\nNote: DEX is short for Dexamethasone and DOR is short for Dexamethasone-induced changes.", {"Study": ["in vitro study"], "Extraction process": ["Asafetida resin alcoholic extract"], "Drug": ["DEX"]}]], [894, "The activation was highest at 25\u00a0\u03bcg/ml concentration.", [" {\"PHARMACOLOGICAL AGENT\": [\"activation\", \"25 \u03bcg/ml\"]}\n{\"PATHLOGY\": []}", {"Amount": ["25\u00a0\u03bcg/ml"]}]], [895, "The in vivo study was conducted on healthy human volunteers.", [" {\"PATHOLOGIES\": []}\n\nThe following words do not refer to pathologies or side effects:\n\n* in vivo\n* study\n* conducted\n* healthy\n* human\n* volunteers.", {"Study": ["vivo study"], "Pathology": ["healthy"]}]], [896, "Therefore, the clinical study was conducted to confirm the in vitro results.", [" {\"PATHOLOGY\": []}\n\nThe following format must be followed:{\"PATHOLOGY\": [\"List of pathologies or side effects found in text\"]}\n\n1. The following clinical study was conducted to confirm the in vitro results.\n\nNo pathologies or side effects were mentioned in this text.", {"Study": ["clinical study"]}]], [897, "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.", [" {\"CYP3A4\": [\"CYP3A4 metabolic activity\"]}", {"Herb name": ["Asafetida"], "Target": ["CYP3A4"]}]], [898, "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.", [" {\"DIARRHEA\": [\"abemaciclib-related\"], \"PATIENTS\": [], \"OUTCOMES\": [], \"QUALITY OF LIFE\": []}", {"Drug": ["abemaciclib"], "Pathology": ["diarrhea"]}]], [899, "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.", [" {\"PATHOLOGIES\": [\"confusion\"]}\n\nThe reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited (caused) confusion in the patient.", {"Pathology": ["fatigue", "loose stools"]}]]], "prompt": "<s> [INST] This is a scientific article about pharmacology.\nWe need to parse all the cited entities. Find every word refering to the described entities.\n\nThe following format must be followed:\n{\"PATHOLOGY\": [\"List of pathologies or side effects found in text\"]}\n\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.TEXT HERE [/INST]"}